Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15511682,trough,"Blood samples determined trough and peak plasma levels; levels were 27.0 +/- 9.4 microg/ml and 33.8 +/- 10.8 microg/ml, respectively, with ratios as small as 1.28 +/- 0.15.",Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15511682/),[μg] / [ml],27.0,444,DB00564,Carbamazepine
,15511682,peak plasma levels,"Blood samples determined trough and peak plasma levels; levels were 27.0 +/- 9.4 microg/ml and 33.8 +/- 10.8 microg/ml, respectively, with ratios as small as 1.28 +/- 0.15.",Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15511682/),[μg] / [ml],33.8,445,DB00564,Carbamazepine
,15511682,trough plasma levels,Seizures were not controlled in 23 of 72 patients; low trough plasma levels (approximately 15 microg/ml) were observed.,Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15511682/),[μg] / [ml],15,446,DB00564,Carbamazepine
>,15511682,peak plasma levels,Drowsiness/short attention span in five patients instigated a dosage decrease (peak plasma levels >40 microg/ml).,Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15511682/),[μg] / [ml],40,447,DB00564,Carbamazepine
,3750374,renal clearances,"The renal clearances of CBZ and of CBZ-epoxide are low (1 and 8 ml/min, respectively); both are flow dependent.",Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750374/),[ml] / [min],1,615,DB00564,Carbamazepine
,3750374,renal clearances,"The renal clearances of CBZ and of CBZ-epoxide are low (1 and 8 ml/min, respectively); both are flow dependent.",Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750374/),[ml] / [min],8,616,DB00564,Carbamazepine
,3750374,renal clearance,The renal clearance of CBZ-diol is approximately 160-350 ml/min and is independent of the urine flow.,Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750374/),[ml] / [min],160-350,617,DB00564,Carbamazepine
,3750374,Protein binding,"Protein binding of CBZ is approximately 80%, of CBZ-epoxide 50%, and of CBZ-diol 70%.",Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750374/),%,80,618,DB00564,Carbamazepine
,3750374,Protein binding,"Protein binding of CBZ is approximately 80%, of CBZ-epoxide 50%, and of CBZ-diol 70%.",Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750374/),%,50,619,DB00564,Carbamazepine
,32386241,flow rate,"Good resolution between enantiomers was achieved on a Chiralpak IA-3 column using an isocratic mobile phase (0.1% of diethyl amine in methanol), which was delivered at a flow rate of 0.8 mL/min.",Enantioselective LC-ESI-MS/MS method for quantitation of (-)-lumefantrine and (+)-lumefantrine in mice plasma and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32386241/),[ml] / [min],0.8,1063,DB00564,Carbamazepine
,32386241,m/z,"Detection and quantitation were performed using multiple reaction monitoring mode following the transitions m/z 530.27 → 512.30 and 237.00 → 194.00 for LFN enantiomers and the internal standard, respectively, in the positive-ionization mode.",Enantioselective LC-ESI-MS/MS method for quantitation of (-)-lumefantrine and (+)-lumefantrine in mice plasma and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32386241/),,530.27,1064,DB00564,Carbamazepine
,32386241,m/z,"Detection and quantitation were performed using multiple reaction monitoring mode following the transitions m/z 530.27 → 512.30 and 237.00 → 194.00 for LFN enantiomers and the internal standard, respectively, in the positive-ionization mode.",Enantioselective LC-ESI-MS/MS method for quantitation of (-)-lumefantrine and (+)-lumefantrine in mice plasma and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32386241/),,512,1065,DB00564,Carbamazepine
,32386241,m/z,"Detection and quantitation were performed using multiple reaction monitoring mode following the transitions m/z 530.27 → 512.30 and 237.00 → 194.00 for LFN enantiomers and the internal standard, respectively, in the positive-ionization mode.",Enantioselective LC-ESI-MS/MS method for quantitation of (-)-lumefantrine and (+)-lumefantrine in mice plasma and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32386241/),,237.00,1066,DB00564,Carbamazepine
,32386241,m/z,"Detection and quantitation were performed using multiple reaction monitoring mode following the transitions m/z 530.27 → 512.30 and 237.00 → 194.00 for LFN enantiomers and the internal standard, respectively, in the positive-ionization mode.",Enantioselective LC-ESI-MS/MS method for quantitation of (-)-lumefantrine and (+)-lumefantrine in mice plasma and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32386241/),,194.,1067,DB00564,Carbamazepine
,4076064,peak W-554 serum levels,"After a single 200-mg dose, peak W-554 serum levels of 2.65-4.10 mg/L were achieved in 1-4 h.",Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[mg] / [l],2.65-4.10,1357,DB00564,Carbamazepine
,4076064,Half-lives,Half-lives were 11.2-16.1 h and clearance varied from 34.2-64.6 ml/h X kg.,Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),h,11.2-16.1,1358,DB00564,Carbamazepine
,4076064,clearance,Half-lives were 11.2-16.1 h and clearance varied from 34.2-64.6 ml/h X kg.,Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[ml] / [h·kg],34.2-64.6,1359,DB00564,Carbamazepine
,4076064,apparent volume of distribution,The apparent volume of distribution was 0.726-1.046 L/kg.,Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[l] / [kg],0.726-1.046,1360,DB00564,Carbamazepine
,4076064,steady-state trough levels,"Chronic dosing at 400, 800, 1,200, and 1,600 mg/day resulted in median steady-state trough levels of 5.1, 10.2, 14.6, and 20.3 mg/L.",Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[mg] / [l],5.1,1361,DB00564,Carbamazepine
,4076064,steady-state trough levels,"Chronic dosing at 400, 800, 1,200, and 1,600 mg/day resulted in median steady-state trough levels of 5.1, 10.2, 14.6, and 20.3 mg/L.",Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[mg] / [l],10.2,1362,DB00564,Carbamazepine
,4076064,steady-state trough levels,"Chronic dosing at 400, 800, 1,200, and 1,600 mg/day resulted in median steady-state trough levels of 5.1, 10.2, 14.6, and 20.3 mg/L.",Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[mg] / [l],14.6,1363,DB00564,Carbamazepine
,4076064,steady-state trough levels,"Chronic dosing at 400, 800, 1,200, and 1,600 mg/day resulted in median steady-state trough levels of 5.1, 10.2, 14.6, and 20.3 mg/L.",Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),[mg] / [l],20.3,1364,DB00564,Carbamazepine
,4076064,Urinary excretion of unchanged,Urinary excretion of unchanged drug was 13.8-28.6% of the dose.,Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076064/),%,13.8-28.6,1365,DB00564,Carbamazepine
,20197489,plasma half-life,"By incorporating the long plasma half-life of 4βHC (~17 days) into the model, the inductive effect of 2 known inducers (carbamazepine and rifampicin) reported in the literature was adequately described.",Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197489/),d,17,1989,DB00564,Carbamazepine
,19167276,resolution factor,"Both the analytes were chromatographically separated with a resolution factor of 3.0 on a Gemini C18 (50mmx4.6mm, 5microm particle size) analytical column using 1% formic acid and methanol (50:50, v/v) as the mobile phase.",Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),,3.0,2873,DB00564,Carbamazepine
,19167276,selectivity factor (alpha),"The selectivity factor (alpha) of the column for the separation was 2.0, based on the capacity factors of 2.6 and 1.3 for (E)- and (Z)-isomers respectively.",Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),,2.0,2874,DB00564,Carbamazepine
,19167276,capacity factors,"The selectivity factor (alpha) of the column for the separation was 2.0, based on the capacity factors of 2.6 and 1.3 for (E)- and (Z)-isomers respectively.",Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),,2.6,2875,DB00564,Carbamazepine
,19167276,capacity factors,"The selectivity factor (alpha) of the column for the separation was 2.0, based on the capacity factors of 2.6 and 1.3 for (E)- and (Z)-isomers respectively.",Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),,1.3,2876,DB00564,Carbamazepine
,19167276,m,"The parent-->product ion transitions for both the isomers (m/z 306.1-->233.0) and IS (m/z 237.3-->194.2) were monitored on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring (MRM) and positive ion mode.",Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),,237.3,2877,DB00564,Carbamazepine
,19167276,process/extraction efficiency,Matrix effect was assessed by post-column analyte infusion experiment and the process/extraction efficiency found was 94.3% and 89.3% for (E)- and (Z)-isomers respectively.,Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),%,94.3,2878,DB00564,Carbamazepine
,19167276,process/extraction efficiency,Matrix effect was assessed by post-column analyte infusion experiment and the process/extraction efficiency found was 94.3% and 89.3% for (E)- and (Z)-isomers respectively.,Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),%,89.3,2879,DB00564,Carbamazepine
,2655682,elimination half-life,The mean elimination half-life was 23 h (CBZ-C) and 25 h (CBZ-CR) after dose 29 compared with a base-line value of 37 h (both P less than 0.02).,A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655682/),h,23,3281,DB00564,Carbamazepine
,2655682,elimination half-life,The mean elimination half-life was 23 h (CBZ-C) and 25 h (CBZ-CR) after dose 29 compared with a base-line value of 37 h (both P less than 0.02).,A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655682/),h,25,3282,DB00564,Carbamazepine
,2655682,elimination half-life,The mean elimination half-life was 23 h (CBZ-C) and 25 h (CBZ-CR) after dose 29 compared with a base-line value of 37 h (both P less than 0.02).,A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655682/),h,37,3283,DB00564,Carbamazepine
,16423803,AUC(0 - infinity),"However, there was no statistical significant difference (p > 0.05) in extent of bioavailability between the liquid suppository and oral suspension as indicated by the values of AUC(0 - infinity), 17.9 and 18.8 micro g x h/ml, respectively.",Thermally reversible in situ gelling carbamazepine liquid suppository. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423803/),[h·μg] / [ml],17.9,3319,DB00564,Carbamazepine
,16423803,AUC(0 - infinity),"However, there was no statistical significant difference (p > 0.05) in extent of bioavailability between the liquid suppository and oral suspension as indicated by the values of AUC(0 - infinity), 17.9 and 18.8 micro g x h/ml, respectively.",Thermally reversible in situ gelling carbamazepine liquid suppository. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423803/),[h·μg] / [ml],18.8,3320,DB00564,Carbamazepine
,30086086,CD ratio,"In 10 patients using enzyme-inducing antiepileptic drugs (AEDs), the mean CD ratio increased by 53.5% [from 1389 to 2132 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ml·ng] / [kg·mg],1389,3357,DB00564,Carbamazepine
,30086086,CD ratio,"In 10 patients using enzyme-inducing antiepileptic drugs (AEDs), the mean CD ratio increased by 53.5% [from 1389 to 2132 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ml·ng] / [kg·mg],2132,3358,DB00564,Carbamazepine
,30086086,CD ratio,"In 13 patients without enzyme-inducing AEDs, the mean CD ratio increased by 100.8% [from 3826 ng/mL to 7683 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ng] / [ml],3826,3359,DB00564,Carbamazepine
,30086086,CD ratio,"In 13 patients without enzyme-inducing AEDs, the mean CD ratio increased by 100.8% [from 3826 ng/mL to 7683 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ml·ng] / [kg·mg],7683,3360,DB00564,Carbamazepine
,17502775,trough serum concentration,The dose of carbamazepine was titrated to produce a trough serum concentration within the range of 8 to 12 mg/L.,Pharmacokinetics of aripiprazole and concomitant carbamazepine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502775/),[mg] / [l],8 to 12,3752,DB00564,Carbamazepine
,10389915,clearance,"Glioma patients had a higher clearance (1.0-18.0; median, 2.0 liters/h/m2) than lung cancer patients (0.3-5.1; median, 0.9 liters/h/m2).",Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389915/),[l] / [h·m2],1.0-18.0,4286,DB00564,Carbamazepine
,10389915,clearance,"Glioma patients had a higher clearance (1.0-18.0; median, 2.0 liters/h/m2) than lung cancer patients (0.3-5.1; median, 0.9 liters/h/m2).",Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389915/),[l] / [h·m2],2.0,4287,DB00564,Carbamazepine
,10389915,clearance,"Glioma patients had a higher clearance (1.0-18.0; median, 2.0 liters/h/m2) than lung cancer patients (0.3-5.1; median, 0.9 liters/h/m2).",Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389915/),[l] / [h·m2],0.9,4288,DB00564,Carbamazepine
,8376481,flow-rate,"The drugs and metabolites are eluted with a mobile phase containing potassium phosphate buffer-acetonitrile-methanol (110:50:30, v/v/v) at a flow-rate of 0.2 ml/min.","Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiode-array detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376481/),[ml] / [min],0.2,6438,DB00564,Carbamazepine
,8376481,recovery rates,The recovery rates range from 95.12 to 104.42%.,"Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiode-array detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376481/),%,95.12 to 104.42,6439,DB00564,Carbamazepine
,17358096,relative bioavailability,Mean relative bioavailability calculated from plasma AUCs was 8.3% (SD 5.5%) for the monohydroxy derivative and 10.8% (SD 7.3%) for oxcarbazepine.,"Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358096/),%,8.3,7018,DB00564,Carbamazepine
,17358096,relative bioavailability,Mean relative bioavailability calculated from plasma AUCs was 8.3% (SD 5.5%) for the monohydroxy derivative and 10.8% (SD 7.3%) for oxcarbazepine.,"Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358096/),%,10.8,7019,DB00564,Carbamazepine
,9578186,total area under the plasma buspirone concentration-time curve,"The total area under the plasma buspirone concentration-time curve after rifampicin was 10.4% (95% CI, 6.3-14.5%) of that after placebo (1.64+/-0.35 ng ml(-1) h vs 22.0+/-15.1 ng ml(-1) h (mean+/-s.d.); P< 0.01).",Concentrations and effects of buspirone are considerably reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[h·ng] / [ml],1.64,7058,DB00564,Carbamazepine
,9578186,total area under the plasma buspirone concentration-time curve,"The total area under the plasma buspirone concentration-time curve after rifampicin was 10.4% (95% CI, 6.3-14.5%) of that after placebo (1.64+/-0.35 ng ml(-1) h vs 22.0+/-15.1 ng ml(-1) h (mean+/-s.d.); P< 0.01).",Concentrations and effects of buspirone are considerably reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[h·ng] / [ml],22.0,7059,DB00564,Carbamazepine
,9578186,peak plasma concentration,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[ng] / [ml],6.6,7060,DB00564,Carbamazepine
,9578186,peak plasma concentration,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[ng] / [ml],0.84,7061,DB00564,Carbamazepine
,9578186,half-life,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),h,2.8,7062,DB00564,Carbamazepine
,9578186,half-life,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),h,1.3,7063,DB00564,Carbamazepine
,3268334,absorption lag time,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),h,2.07,7366,DB00564,Carbamazepine
,3268334,absorption rate constant,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),1/[h],8.328,7367,DB00564,Carbamazepine
,3268334,apparent volume of distribution,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),[l] / [kg],3.937,7368,DB00564,Carbamazepine
,3268334,oral clearance,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),[l] / [kg],2.898,7369,DB00564,Carbamazepine
,3268334,elimination rate constant,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),1/[h],0.609,7370,DB00564,Carbamazepine
,3268334,half-life,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),h,1.26,7371,DB00564,Carbamazepine
,3268334,formation rate constant,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),1/[h],0.593,7372,DB00564,Carbamazepine
,3268334,elimination rate constant,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),1/[h],0.082,7373,DB00564,Carbamazepine
,3268334,half-life,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),h,8.74,7374,DB00564,Carbamazepine
,3201523,plasma elimination half-life,Plasma kinetics of CBZ-E fitted an open one-compartment model with plasma elimination half-life of 7.4 +/- 1.8 h (mean +/- SD).,"Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3201523/),h,7.4,7410,DB00564,Carbamazepine
,3201523,clearance,The clearance was 105 +/- 17 ml/kg/h and the apparent volume of distribution 1.1 +/- 0.2 L/kg assuming complete bioavailability.,"Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3201523/),[ml] / [h·kg],105,7411,DB00564,Carbamazepine
,3201523,apparent volume of distribution,The clearance was 105 +/- 17 ml/kg/h and the apparent volume of distribution 1.1 +/- 0.2 L/kg assuming complete bioavailability.,"Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3201523/),[l] / [kg],1.1,7412,DB00564,Carbamazepine
,3201523,recovery,The recovery of trans-CBZ-diol in urine collected for 3 days was 67 +/- 9% of the given dose.,"Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3201523/),%,67,7413,DB00564,Carbamazepine
,3814762,Elimination half-lives,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,1.98,8399,DB00564,Carbamazepine
,3814762,Elimination half-lives,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,2.73,8400,DB00564,Carbamazepine
,3814762,total clearances,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],4.20,8401,DB00564,Carbamazepine
,3814762,total clearances,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.96,8402,DB00564,Carbamazepine
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,4.75,8403,DB00564,Carbamazepine
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,3.05,8404,DB00564,Carbamazepine
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],1.91,8405,DB00564,Carbamazepine
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,3.05,8406,DB00564,Carbamazepine
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,2.33,8407,DB00564,Carbamazepine
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],1.91,8408,DB00564,Carbamazepine
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.95,8409,DB00564,Carbamazepine
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.97,8410,DB00564,Carbamazepine
,24291717,recovery,Mean recovery of sec-O-glucosylhamaudol in plasma was in the range of 74.8-83.7%.,Determination of sec-O-glucosylhamaudol in rat plasma by gradient elution liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24291717/),%,74.8-83.7,8599,DB00564,Carbamazepine
,24123382,flow rate,"The separation of oxcarbazepine and the MHD enantiomers was obtained on a chiral phase Chiralcel OD-H column, using a mixture of hexane:ethanol:isopropanol (80:15:5, v/v/v) as mobile phase at a flow rate of 1.3 mL/min with a split ratio of 1:5, and quantification was performed by LC-MS/MS.",Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),[ml] / [min],1.3,9265,DB00564,Carbamazepine
,24123382,maximum plasma concentration,The maximum plasma concentration of oxcarbazepine was 1.2 µg/mL at 0.75 h.,Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),[μg] / [ml],1.2,9266,DB00564,Carbamazepine
,24123382,AUC(0-12),"The kinetic disposition of MHD is enantioselective, with a higher proportion of the S-(+)-MHD enantiomer compared to R-(-)-MHD and an AUC(0-12) S-(+)/R-(-) ratio of 5.44.",Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),,5.44,9267,DB00564,Carbamazepine
,24123382,ratio,"The kinetic disposition of MHD is enantioselective, with a higher proportion of the S-(+)-MHD enantiomer compared to R-(-)-MHD and an AUC(0-12) S-(+)/R-(-) ratio of 5.44.",Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),,5.44,9268,DB00564,Carbamazepine
,24931510,flow rate,"Enantiomeric resolution of 8PN was achieved on a Chiralpak(®) AD-RH column with an isocratic mobile phase consisting of 2-propanol and 10 mM ammonium formate (pH 8.5) (40:60, v/v) and a flow rate of 0.7 mL/min.",Enantiospecific analysis of 8-prenylnaringenin in biological fluids by liquid-chromatography-electrospray ionization mass spectrometry: application to preclinical pharmacokinetic investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931510/),[ml] / [min],0.7,9740,DB00564,Carbamazepine
,24931510,m/z,Detection was achieved using negative selective ion monitoring (SIM) of 8PN at m/z 339.15 for both enantiomers and positive SIM m/z at 237.15 for the IS.,Enantiospecific analysis of 8-prenylnaringenin in biological fluids by liquid-chromatography-electrospray ionization mass spectrometry: application to preclinical pharmacokinetic investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931510/),,237.15,9741,DB00564,Carbamazepine
,11180020,peak concentration,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],7.2,10046,DB00564,Carbamazepine
,11180020,peak concentration,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],7.6,10047,DB00564,Carbamazepine
,11180020,trough concentration,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],4.8,10048,DB00564,Carbamazepine
,11180020,trough concentration,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],4.3,10049,DB00564,Carbamazepine
,11180020,area under the plasma concentration-time curve,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[h·mg] / [l],142.4,10050,DB00564,Carbamazepine
,11180020,area under the plasma concentration-time curve,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[h·mg] / [l],143.8,10051,DB00564,Carbamazepine
,11180020,oral clearance,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[l] / [h],2.8,10052,DB00564,Carbamazepine
,11180020,oral clearance,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[l] / [h],2.9,10053,DB00564,Carbamazepine
,11180020,peak concentration,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],2,10054,DB00564,Carbamazepine
,11180020,peak concentration,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],2.1,10055,DB00564,Carbamazepine
,11180020,trough concentration,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],1.3,10056,DB00564,Carbamazepine
,11180020,trough concentration,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],1.4,10057,DB00564,Carbamazepine
,11180020,area under the plasma concentration-time curve,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[h·mg] / [l],37.5,10058,DB00564,Carbamazepine
,11180020,area under the plasma concentration-time curve,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[h·mg] / [l],41.9,10059,DB00564,Carbamazepine
,24240511,oral clearance (CL/F),"Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing ≤25 kg, >25 to <60 kg or ≥60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively.",Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240511/),[l] / [h],3.28,10753,DB00564,Carbamazepine
,24240511,oral clearance (CL/F),"Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing ≤25 kg, >25 to <60 kg or ≥60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively.",Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240511/),[l] / [h],4.23,10754,DB00564,Carbamazepine
,24240511,oral clearance (CL/F),"Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing ≤25 kg, >25 to <60 kg or ≥60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively.",Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240511/),[l] / [h],7.15,10755,DB00564,Carbamazepine
higher,17118604,sample extract recoveries,"The mean sample extract recoveries of the method were higher than 85% and 74% for finasteride and internal standard (IS), respectively.","A rapid, simple, specific liquid chromatographic-electrospray mass spectrometry method for the determination of finasteride in human plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118604/),%,85,11912,DB00564,Carbamazepine
,17118604,sample extract recoveries,"The mean sample extract recoveries of the method were higher than 85% and 74% for finasteride and internal standard (IS), respectively.","A rapid, simple, specific liquid chromatographic-electrospray mass spectrometry method for the determination of finasteride in human plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118604/),%,74,11913,DB00564,Carbamazepine
,11164700,time (Tmax),"At steady state, rufinamide reached a peak plasma concentration with a mean time (Tmax) of 3.4 h and a mean half-life (t1/2) of 7.3 h.","Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11164700/),h,3.4,11962,DB00564,Carbamazepine
,11164700,half-life (t1/2),"At steady state, rufinamide reached a peak plasma concentration with a mean time (Tmax) of 3.4 h and a mean half-life (t1/2) of 7.3 h.","Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11164700/),h,7.3,11963,DB00564,Carbamazepine
,12107617,Plasma concentrations,Plasma concentrations of risperidone and 9-hydroxyrisperidone during carbamazepine coadministration (2.5+/-3.6 ng/ml and 19.4+/-4.1 ng/ml) were significantly ( P<0.01) lower than those before carbamazepine coadministration (5.0+/-7.9 ng/ml and 34.6+/-9.8 ng/ml).,Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107617/),[ng] / [ml],2.5,11989,DB00564,Carbamazepine
,12107617,Plasma concentrations,Plasma concentrations of risperidone and 9-hydroxyrisperidone during carbamazepine coadministration (2.5+/-3.6 ng/ml and 19.4+/-4.1 ng/ml) were significantly ( P<0.01) lower than those before carbamazepine coadministration (5.0+/-7.9 ng/ml and 34.6+/-9.8 ng/ml).,Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107617/),[ng] / [ml],19.4,11990,DB00564,Carbamazepine
,12107617,Plasma concentrations,Plasma concentrations of risperidone and 9-hydroxyrisperidone during carbamazepine coadministration (2.5+/-3.6 ng/ml and 19.4+/-4.1 ng/ml) were significantly ( P<0.01) lower than those before carbamazepine coadministration (5.0+/-7.9 ng/ml and 34.6+/-9.8 ng/ml).,Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107617/),[ng] / [ml],5.0,11991,DB00564,Carbamazepine
,12107617,Plasma concentrations,Plasma concentrations of risperidone and 9-hydroxyrisperidone during carbamazepine coadministration (2.5+/-3.6 ng/ml and 19.4+/-4.1 ng/ml) were significantly ( P<0.01) lower than those before carbamazepine coadministration (5.0+/-7.9 ng/ml and 34.6+/-9.8 ng/ml).,Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107617/),[ng] / [ml],34.6,11992,DB00564,Carbamazepine
,27595590,apparent clearance,"Population PK results from 152 adolescent patients revealed a perampanel apparent clearance of 0.729L/h, consistent with previous analyses in adolescents and adults.","Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27595590/),[l] / [h],0.729,12175,DB00564,Carbamazepine
,28528287,Clearance,Clearance estimates (95% CI) were 84.9L/h (69.5-100.3) for oxcarbazepine and 2.0L/h (1.9-2.1) for both MHD enantiomers.,Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),[l] / [h],84.9,15058,DB00564,Carbamazepine
,28528287,Clearance,Clearance estimates (95% CI) were 84.9L/h (69.5-100.3) for oxcarbazepine and 2.0L/h (1.9-2.1) for both MHD enantiomers.,Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),[l] / [h],2.0,15059,DB00564,Carbamazepine
,28528287,volume of distribution,"The volume of distribution was much larger for oxcarbazepine (131L (97-165)) as compared to R-(-)- and S-(+)-MHD (23.6L (14.4-32.8) vs. 31.7L (22.5-40.9), respectively).",Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),l,131,15060,DB00564,Carbamazepine
,28528287,volume of distribution,"The volume of distribution was much larger for oxcarbazepine (131L (97-165)) as compared to R-(-)- and S-(+)-MHD (23.6L (14.4-32.8) vs. 31.7L (22.5-40.9), respectively).",Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),l,23.6,15061,DB00564,Carbamazepine
,28528287,volume of distribution,"The volume of distribution was much larger for oxcarbazepine (131L (97-165)) as compared to R-(-)- and S-(+)-MHD (23.6L (14.4-32.8) vs. 31.7L (22.5-40.9), respectively).",Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),l,31.7,15062,DB00564,Carbamazepine
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,43.3,15735,DB00564,Carbamazepine
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,14.1,15736,DB00564,Carbamazepine
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,28.9,15737,DB00564,Carbamazepine
,9342502,oral bioavailability,Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20%.,Clinical pharmacokinetics of nefazodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342502/),%,20,16638,DB00564,Carbamazepine
,16404803,Milk/maternal plasma concentration ratios,"Milk/maternal plasma concentration ratios close to 1 demonstrate extensive transfer to breast milk of many AEDs including ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and zonisamide.",Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404803/),,1,16688,DB00564,Carbamazepine
,8112245,volume of distribution (Vd),"The pharmacokinetic parameters of CBZ before and after discontinuation were volume of distribution (Vd) 1.28 +/- 0.29 versus 1.22 +/- 0.331/kg (NS), elimination half-life (t1/2) 13.7 +/- 1.67 versus 22.2 +/- 2.36 h (p < 0.001), and clearance (Cl) 1.54 +/- 0.39 versus 0.92 +/- 0.32 L/kg/day (p = 0.012).",Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112245/),1/[kg],1.28,16796,DB00564,Carbamazepine
,8112245,volume of distribution (Vd),"The pharmacokinetic parameters of CBZ before and after discontinuation were volume of distribution (Vd) 1.28 +/- 0.29 versus 1.22 +/- 0.331/kg (NS), elimination half-life (t1/2) 13.7 +/- 1.67 versus 22.2 +/- 2.36 h (p < 0.001), and clearance (Cl) 1.54 +/- 0.39 versus 0.92 +/- 0.32 L/kg/day (p = 0.012).",Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112245/),1/[kg],1.22,16797,DB00564,Carbamazepine
,8112245,elimination half-life (t1/2),"The pharmacokinetic parameters of CBZ before and after discontinuation were volume of distribution (Vd) 1.28 +/- 0.29 versus 1.22 +/- 0.331/kg (NS), elimination half-life (t1/2) 13.7 +/- 1.67 versus 22.2 +/- 2.36 h (p < 0.001), and clearance (Cl) 1.54 +/- 0.39 versus 0.92 +/- 0.32 L/kg/day (p = 0.012).",Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112245/),h,13.7,16798,DB00564,Carbamazepine
,8112245,elimination half-life (t1/2),"The pharmacokinetic parameters of CBZ before and after discontinuation were volume of distribution (Vd) 1.28 +/- 0.29 versus 1.22 +/- 0.331/kg (NS), elimination half-life (t1/2) 13.7 +/- 1.67 versus 22.2 +/- 2.36 h (p < 0.001), and clearance (Cl) 1.54 +/- 0.39 versus 0.92 +/- 0.32 L/kg/day (p = 0.012).",Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112245/),h,22.2,16799,DB00564,Carbamazepine
,8112245,clearance (Cl),"The pharmacokinetic parameters of CBZ before and after discontinuation were volume of distribution (Vd) 1.28 +/- 0.29 versus 1.22 +/- 0.331/kg (NS), elimination half-life (t1/2) 13.7 +/- 1.67 versus 22.2 +/- 2.36 h (p < 0.001), and clearance (Cl) 1.54 +/- 0.39 versus 0.92 +/- 0.32 L/kg/day (p = 0.012).",Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112245/),[l] / [d·kg],1.54,16800,DB00564,Carbamazepine
,8112245,clearance (Cl),"The pharmacokinetic parameters of CBZ before and after discontinuation were volume of distribution (Vd) 1.28 +/- 0.29 versus 1.22 +/- 0.331/kg (NS), elimination half-life (t1/2) 13.7 +/- 1.67 versus 22.2 +/- 2.36 h (p < 0.001), and clearance (Cl) 1.54 +/- 0.39 versus 0.92 +/- 0.32 L/kg/day (p = 0.012).",Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112245/),[l] / [d·kg],0.92,16801,DB00564,Carbamazepine
,8112245,t1/2,"Assuming that deinduction is a first-order process, a deinduction t1/2 of 3.84 days was obtained by log linear regression analysis.",Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112245/),d,3.84,16802,DB00564,Carbamazepine
,28623772,flow rate,Elution was achieved in gradient mode on High Resolution Chromolith RP-18e column with mobile phase comprised of acetonitrile and 0.1% (v/v) formic acid in water at the flow rate of 0.4mL/min.,"Development and validation of a highly sensitive LC-ESI-MS/MS method for estimation of IIIM-MCD-211, a novel nitrofuranyl methyl piperazine derivative with potential activity against tuberculosis: Application to drug development. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28623772/),[ml] / [min],0.4,17680,DB00564,Carbamazepine
,28623772,m,"Precursor to product ion transitions (m/z 344.5/218.4 and m/z 237.3/194.2) were used to measure analyte and IS, respectively.","Development and validation of a highly sensitive LC-ESI-MS/MS method for estimation of IIIM-MCD-211, a novel nitrofuranyl methyl piperazine derivative with potential activity against tuberculosis: Application to drug development. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28623772/),,344.5,17681,DB00564,Carbamazepine
,28623772,m,"Precursor to product ion transitions (m/z 344.5/218.4 and m/z 237.3/194.2) were used to measure analyte and IS, respectively.","Development and validation of a highly sensitive LC-ESI-MS/MS method for estimation of IIIM-MCD-211, a novel nitrofuranyl methyl piperazine derivative with potential activity against tuberculosis: Application to drug development. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28623772/),,218,17682,DB00564,Carbamazepine
,28623772,m/z,"Precursor to product ion transitions (m/z 344.5/218.4 and m/z 237.3/194.2) were used to measure analyte and IS, respectively.","Development and validation of a highly sensitive LC-ESI-MS/MS method for estimation of IIIM-MCD-211, a novel nitrofuranyl methyl piperazine derivative with potential activity against tuberculosis: Application to drug development. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28623772/),,237,17683,DB00564,Carbamazepine
,17433926,serum concentration,"The average (+/-SD) carbamazepine (CBZ) dose is 8.8 +/- 4.7 mg/kg/day, yielding a mean serum concentration of 6.3 +/- 2.2 mg/liter.",Pharmacokinetics of antiepileptic drugs in elderly nursing home residents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433926/),[mg] / [l],6.3,18536,DB00564,Carbamazepine
,2773507,CL,"Carbamazepine concentrations measured in plasma and plasma ultrafiltrates by fluorescence polarization immunoassay (f.p.i.a.) from 0 to 48 h post-dose were used to calculate CL, V, clearance of plasma unbound drug (CLunb), Vunb; mean (+/- SD) values for these were: 0.017 l/kg/h (+/- 0.004), 1.05 l/kg (+/- 0.14), 0.058 l/h/kg (+/- 0.012), and 4.28 l/kg (+/- 0.41), respectively.",The suitability of carbamazepine as a single-sample probe of human mixed function oxidase activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773507/),[l] / [h·kg],0.017,19067,DB00564,Carbamazepine
,2773507,Vunb,"Carbamazepine concentrations measured in plasma and plasma ultrafiltrates by fluorescence polarization immunoassay (f.p.i.a.) from 0 to 48 h post-dose were used to calculate CL, V, clearance of plasma unbound drug (CLunb), Vunb; mean (+/- SD) values for these were: 0.017 l/kg/h (+/- 0.004), 1.05 l/kg (+/- 0.14), 0.058 l/h/kg (+/- 0.012), and 4.28 l/kg (+/- 0.41), respectively.",The suitability of carbamazepine as a single-sample probe of human mixed function oxidase activity. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773507/),[l] / [kg],4.28,19068,DB00564,Carbamazepine
,2773507,V,"3. A value of 1.1 l/kg was used for V in calculating all single sample estimates of clearance (CL), and a value of 4.3 l/kg was used to calculate single sample estimates of clearance of plasma unbound drug (CLunb).",The suitability of carbamazepine as a single-sample probe of human mixed function oxidase activity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2773507/),[l] / [kg],1.1,19069,DB00564,Carbamazepine
,34175447,effective detection limit,The effective detection limit of this method was 1.95-1000 ng·mL-1.,"Pharmacokinetic and tissue distribution study of ZCY-15, a novel compound against Alzheimer's disease, in rats by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34175447/),[ng] / [ml],1.95-1000,19957,DB00564,Carbamazepine
,34175447,whole analysis time,The whole analysis time was 3.6 min per sample.,"Pharmacokinetic and tissue distribution study of ZCY-15, a novel compound against Alzheimer's disease, in rats by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34175447/),[min] / [sample],3.6,19958,DB00564,Carbamazepine
,9159561,total area under the plasma z,The total area under the plasma zopiclone concentration-time curve after rifampicin was 18.0% (95% CI 13.5-22.5%) of that after placebo (86.1 +/- 34.5 ng ml(-1) h vs 473 +/- 114 ng ml(-1) h (mean +/- s.d.); P<0.001).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[h·ng] / [ml],86.1,20158,DB00564,Carbamazepine
,9159561,total area under the plasma z,The total area under the plasma zopiclone concentration-time curve after rifampicin was 18.0% (95% CI 13.5-22.5%) of that after placebo (86.1 +/- 34.5 ng ml(-1) h vs 473 +/- 114 ng ml(-1) h (mean +/- s.d.); P<0.001).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[h·ng] / [ml],473,20159,DB00564,Carbamazepine
,9159561,peak plasma concentration,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[ng] / [ml],76.9,20160,DB00564,Carbamazepine
,9159561,peak plasma concentration,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[ng] / [ml],22.5,20161,DB00564,Carbamazepine
,9159561,half-life,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),h,3.8,20162,DB00564,Carbamazepine
,9159561,half-life,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),h,2.3,20163,DB00564,Carbamazepine
,9799054,AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[h·mg] / [l],292,20854,DB00564,Carbamazepine
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[h·mg] / [l],287,20855,DB00564,Carbamazepine
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0150,20856,DB00564,Carbamazepine
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0144,20857,DB00564,Carbamazepine
,9799054,rate characteristic,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0144,20858,DB00564,Carbamazepine
,8641326,clearance,"Mean (95% confidence interval) phenobarbitone clearance values were 7.6 ml x h(-1) x kg(-1) (6.2, 9.0 ml x h(-1) x kg(-1) for the monotherapy group, 5.0 ml x h(-1) x hg(-1) (4.0, 6.0 ml x h(-1) x kg(-1)) in the presence of concomitant valproate and 6.8 ml x h(-1) x kg(-1) (5.6, 8.0 ml x h(-1) x kg(-1)) in the presence of concomitant carbamazepine or phenytoin.",Determination of phenobarbitone population clearance values for South African children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641326/),[ml] / [h·kg],7.6,21193,DB00564,Carbamazepine
,8641326,clearance,"Mean (95% confidence interval) phenobarbitone clearance values were 7.6 ml x h(-1) x kg(-1) (6.2, 9.0 ml x h(-1) x kg(-1) for the monotherapy group, 5.0 ml x h(-1) x hg(-1) (4.0, 6.0 ml x h(-1) x kg(-1)) in the presence of concomitant valproate and 6.8 ml x h(-1) x kg(-1) (5.6, 8.0 ml x h(-1) x kg(-1)) in the presence of concomitant carbamazepine or phenytoin.",Determination of phenobarbitone population clearance values for South African children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641326/),[ml] / [h·hg],5.0,21194,DB00564,Carbamazepine
,8641326,clearance,"Mean (95% confidence interval) phenobarbitone clearance values were 7.6 ml x h(-1) x kg(-1) (6.2, 9.0 ml x h(-1) x kg(-1) for the monotherapy group, 5.0 ml x h(-1) x hg(-1) (4.0, 6.0 ml x h(-1) x kg(-1)) in the presence of concomitant valproate and 6.8 ml x h(-1) x kg(-1) (5.6, 8.0 ml x h(-1) x kg(-1)) in the presence of concomitant carbamazepine or phenytoin.",Determination of phenobarbitone population clearance values for South African children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641326/),[ml] / [h·kg],6.8,21195,DB00564,Carbamazepine
,11936682,recovery,"The mean recovery was 95% for carbamazepine and 101% for carbamazepine 10,11-epoxide, with a lower limit of quantification of 0.722 ng/ml for carbamazepine and 5.15 ng/ml for carbamazepine 10,11-epoxide, when using 0.5 ml plasma.","Determination of carbamazepine and carbamazepine 10,11-epoxide in human plasma by tandem liquid chromatography-mass spectrometry with electrospray ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936682/),%,95,21230,DB00564,Carbamazepine
,11936682,recovery,"The mean recovery was 95% for carbamazepine and 101% for carbamazepine 10,11-epoxide, with a lower limit of quantification of 0.722 ng/ml for carbamazepine and 5.15 ng/ml for carbamazepine 10,11-epoxide, when using 0.5 ml plasma.","Determination of carbamazepine and carbamazepine 10,11-epoxide in human plasma by tandem liquid chromatography-mass spectrometry with electrospray ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936682/),%,101,21231,DB00564,Carbamazepine
,11936682,recovery,"The mean recovery was 95% for carbamazepine and 101% for carbamazepine 10,11-epoxide, with a lower limit of quantification of 0.722 ng/ml for carbamazepine and 5.15 ng/ml for carbamazepine 10,11-epoxide, when using 0.5 ml plasma.","Determination of carbamazepine and carbamazepine 10,11-epoxide in human plasma by tandem liquid chromatography-mass spectrometry with electrospray ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936682/),ng,0.72,21232,DB00564,Carbamazepine
,11936682,recovery,"The mean recovery was 95% for carbamazepine and 101% for carbamazepine 10,11-epoxide, with a lower limit of quantification of 0.722 ng/ml for carbamazepine and 5.15 ng/ml for carbamazepine 10,11-epoxide, when using 0.5 ml plasma.","Determination of carbamazepine and carbamazepine 10,11-epoxide in human plasma by tandem liquid chromatography-mass spectrometry with electrospray ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936682/),[ng] / [ml],5.15,21233,DB00564,Carbamazepine
,11573664,elimination half-life,"The elimination half-life of vecuronium was significantly reduced in both anticonvulsant groups compared with control [control 48.2 (SD 40.3), phenytoin 23.5 (13.1), carbamazepine 18.4 (16.6) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,48.2,21612,DB00564,Carbamazepine
,11573664,elimination half-life,"The elimination half-life of vecuronium was significantly reduced in both anticonvulsant groups compared with control [control 48.2 (SD 40.3), phenytoin 23.5 (13.1), carbamazepine 18.4 (16.6) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,23.5,21613,DB00564,Carbamazepine
,11573664,elimination half-life,"The elimination half-life of vecuronium was significantly reduced in both anticonvulsant groups compared with control [control 48.2 (SD 40.3), phenytoin 23.5 (13.1), carbamazepine 18.4 (16.6) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,18.4,21614,DB00564,Carbamazepine
,11573664,clearance,"Vecuronium clearance was increased in both anticonvulsant groups [control 9.0 (3.6), phenytoin 15.1 (8.9), carbamazepine 18.8 (13.1) ml kg(-1) min(-1), 0.05<P<0.1].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),[ml] / [kg·min],9.0,21615,DB00564,Carbamazepine
,11573664,clearance,"Vecuronium clearance was increased in both anticonvulsant groups [control 9.0 (3.6), phenytoin 15.1 (8.9), carbamazepine 18.8 (13.1) ml kg(-1) min(-1), 0.05<P<0.1].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),[ml] / [kg·min],15.1,21616,DB00564,Carbamazepine
,11573664,clearance,"Vecuronium clearance was increased in both anticonvulsant groups [control 9.0 (3.6), phenytoin 15.1 (8.9), carbamazepine 18.8 (13.1) ml kg(-1) min(-1), 0.05<P<0.1].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),[ml] / [kg·min],18.8,21617,DB00564,Carbamazepine
,11573664,RI,"Children on chronic anticonvulsant therapy had a significantly shorter RI than control [control 21.8 (11), phenytoin 12.5 (8.3), carbamazepine 10.6 (5.9) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,21.8,21618,DB00564,Carbamazepine
,11573664,RI,"Children on chronic anticonvulsant therapy had a significantly shorter RI than control [control 21.8 (11), phenytoin 12.5 (8.3), carbamazepine 10.6 (5.9) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,12.5,21619,DB00564,Carbamazepine
,11573664,RI,"Children on chronic anticonvulsant therapy had a significantly shorter RI than control [control 21.8 (11), phenytoin 12.5 (8.3), carbamazepine 10.6 (5.9) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,10.6,21620,DB00564,Carbamazepine
>,22139697,Fabs,The Fabs of each form was markedly reduced with increasing of doses in species (e.g. F ( abs ) in rats ranged from > 82% to 38.4%-56.0%).,"Pharmacokinetics of carbamazepine polymorphs and dihydrate in rats, related to dogs and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139697/),%,82,22160,DB00564,Carbamazepine
,22139697,Fabs,The Fabs of each form was markedly reduced with increasing of doses in species (e.g. F ( abs ) in rats ranged from > 82% to 38.4%-56.0%).,"Pharmacokinetics of carbamazepine polymorphs and dihydrate in rats, related to dogs and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139697/),%,38.4,22161,DB00564,Carbamazepine
,22139697,Fabs,The Fabs of each form was markedly reduced with increasing of doses in species (e.g. F ( abs ) in rats ranged from > 82% to 38.4%-56.0%).,"Pharmacokinetics of carbamazepine polymorphs and dihydrate in rats, related to dogs and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139697/),%,56.0,22162,DB00564,Carbamazepine
>,22139697,F ( abs ),The Fabs of each form was markedly reduced with increasing of doses in species (e.g. F ( abs ) in rats ranged from > 82% to 38.4%-56.0%).,"Pharmacokinetics of carbamazepine polymorphs and dihydrate in rats, related to dogs and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139697/),%,82,22163,DB00564,Carbamazepine
,22139697,F ( abs ),The Fabs of each form was markedly reduced with increasing of doses in species (e.g. F ( abs ) in rats ranged from > 82% to 38.4%-56.0%).,"Pharmacokinetics of carbamazepine polymorphs and dihydrate in rats, related to dogs and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139697/),%,38.4,22164,DB00564,Carbamazepine
,22139697,F ( abs ),The Fabs of each form was markedly reduced with increasing of doses in species (e.g. F ( abs ) in rats ranged from > 82% to 38.4%-56.0%).,"Pharmacokinetics of carbamazepine polymorphs and dihydrate in rats, related to dogs and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139697/),%,56.0,22165,DB00564,Carbamazepine
,9129561,apparent oral clearance (CL/F),"In healthy subjects, stereoisomers A, C, and D showed similar kinetics, with an apparent oral clearance (CL/F) of about 4 1/2 L/hr, a half-life (t1/2) of about 10 hours, and an apparent volume of distribution (VSS/F) of about 65 L.",Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129561/),[l] / [h],4,23049,DB00564,Carbamazepine
,9129561,half-life (t1/2),"In healthy subjects, stereoisomers A, C, and D showed similar kinetics, with an apparent oral clearance (CL/F) of about 4 1/2 L/hr, a half-life (t1/2) of about 10 hours, and an apparent volume of distribution (VSS/F) of about 65 L.",Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129561/),h,10,23050,DB00564,Carbamazepine
,9129561,apparent volume of distribution (VSS/F),"In healthy subjects, stereoisomers A, C, and D showed similar kinetics, with an apparent oral clearance (CL/F) of about 4 1/2 L/hr, a half-life (t1/2) of about 10 hours, and an apparent volume of distribution (VSS/F) of about 65 L.",Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129561/),l,65,23051,DB00564,Carbamazepine
,9129561,clearance,"However, stereoisomer B showed a much higher clearance (8.7 +/- 0.9 L/hr) and a shorter t1/2 (5.8 hours).",Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129561/),[l] / [h],8.7,23052,DB00564,Carbamazepine
,9129561,t1/2,"However, stereoisomer B showed a much higher clearance (8.7 +/- 0.9 L/hr) and a shorter t1/2 (5.8 hours).",Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129561/),h,5.8,23053,DB00564,Carbamazepine
,24785428,half-life,"Perampanel is metabolized primarily via CYP3A4, yet it has a relatively long half-life of 105h; it is, therefore, recommended that perampanel be given once daily (preferably at bedtime).",The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24785428/),h,105,24632,DB00564,Carbamazepine
,2350535,area under the serum CBZ concentration-time curve,The area under the serum CBZ concentration-time curve for a dosing interval was (mean +/- s.e. mean) 146 +/- 10 mumols l-1 h on CBZ-C and 143 +/- 9 mumols l-1 h on CBZ-CHEW.,A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350535/),[h·mumols] / [l],146,26490,DB00564,Carbamazepine
,2350535,area under the serum CBZ concentration-time curve,The area under the serum CBZ concentration-time curve for a dosing interval was (mean +/- s.e. mean) 146 +/- 10 mumols l-1 h on CBZ-C and 143 +/- 9 mumols l-1 h on CBZ-CHEW.,A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350535/),[h·mumols] / [l],143,26491,DB00564,Carbamazepine
,1587063,plasma elimination half-life (t1/2),"After weight loss the mean +/- SEM plasma elimination half-life (t1/2) of carbamazepine was significantly shortened (60.3 +/- 3.1 versus 30.8 +/- 3.3 hours, p less than 0.01) and the total plasma clearance (CL) increased (20.4 +/- 1.8 versus 31.6 +/- 5.0 ml/min, p less than 0.05).",Significant weight reduction in obese subjects enhances carbamazepine elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587063/),h,60.3,28665,DB00564,Carbamazepine
,1587063,plasma elimination half-life (t1/2),"After weight loss the mean +/- SEM plasma elimination half-life (t1/2) of carbamazepine was significantly shortened (60.3 +/- 3.1 versus 30.8 +/- 3.3 hours, p less than 0.01) and the total plasma clearance (CL) increased (20.4 +/- 1.8 versus 31.6 +/- 5.0 ml/min, p less than 0.05).",Significant weight reduction in obese subjects enhances carbamazepine elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587063/),h,30.8,28666,DB00564,Carbamazepine
,1587063,total plasma clearance (CL),"After weight loss the mean +/- SEM plasma elimination half-life (t1/2) of carbamazepine was significantly shortened (60.3 +/- 3.1 versus 30.8 +/- 3.3 hours, p less than 0.01) and the total plasma clearance (CL) increased (20.4 +/- 1.8 versus 31.6 +/- 5.0 ml/min, p less than 0.05).",Significant weight reduction in obese subjects enhances carbamazepine elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587063/),[ml] / [min],20.4,28667,DB00564,Carbamazepine
,1587063,total plasma clearance (CL),"After weight loss the mean +/- SEM plasma elimination half-life (t1/2) of carbamazepine was significantly shortened (60.3 +/- 3.1 versus 30.8 +/- 3.3 hours, p less than 0.01) and the total plasma clearance (CL) increased (20.4 +/- 1.8 versus 31.6 +/- 5.0 ml/min, p less than 0.05).",Significant weight reduction in obese subjects enhances carbamazepine elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587063/),[ml] / [min],31.6,28668,DB00564,Carbamazepine
,1587063,apparent volume of distribution (Varea),"The apparent volume of distribution (Varea) decreased (106.2 +/- 9.9 versus 77.7 +/- 4.5 L, p less than 0.01); however, no difference was evident when carbamazepine Varea was corrected for body weight.",Significant weight reduction in obese subjects enhances carbamazepine elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587063/),l,106.2,28669,DB00564,Carbamazepine
,1587063,apparent volume of distribution (Varea),"The apparent volume of distribution (Varea) decreased (106.2 +/- 9.9 versus 77.7 +/- 4.5 L, p less than 0.01); however, no difference was evident when carbamazepine Varea was corrected for body weight.",Significant weight reduction in obese subjects enhances carbamazepine elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587063/),l,77.7,28670,DB00564,Carbamazepine
,18223475,Total body clearance,"Total body clearance of MDZ (33 L/kg) and intrinsic hepatic clearance (19 mL/min/kg) at steady state were both five to 10 times higher than after normal therapeutic doses, demonstrating hepatic cytochrome (CYP) 3A induction.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),[l] / [kg],33,30671,DB00564,Carbamazepine
,18223475,intrinsic hepatic clearance,"Total body clearance of MDZ (33 L/kg) and intrinsic hepatic clearance (19 mL/min/kg) at steady state were both five to 10 times higher than after normal therapeutic doses, demonstrating hepatic cytochrome (CYP) 3A induction.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),[ml] / [kg·min],19,30672,DB00564,Carbamazepine
,18223475,half-life,"Despite the high body clearance, the half-life of MDZ was in the range of 24 hours, approximately 10 times higher than after normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),h,24,30673,DB00564,Carbamazepine
,18223475,volume of distribution at steady state,"The volume of distribution at steady state was 33 L/kg, approximately 50 times higher than after normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),[l] / [kg],33,30674,DB00564,Carbamazepine
,18223475,free fraction,"The free fraction of MDZ was 58% at steady state, much higher than the 3% to 6% at normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),%,58,30675,DB00564,Carbamazepine
,18223475,free fraction,"The free fraction of MDZ was 58% at steady state, much higher than the 3% to 6% at normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),%,3,30676,DB00564,Carbamazepine
,18223475,free fraction,"The free fraction of MDZ was 58% at steady state, much higher than the 3% to 6% at normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),%,6,30677,DB00564,Carbamazepine
,29066188,retention times,"The mean retention times were 0.85±0.08, 1.20±0.15 and 2.52±0.29days in the three groups, respectively, and were significantly lower value in group A than in group B (P<0.05).",Early hemoperfusion for emergency treatment of carbamazepine poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066188/),d,0.85,30978,DB00564,Carbamazepine
,29066188,retention times,"The mean retention times were 0.85±0.08, 1.20±0.15 and 2.52±0.29days in the three groups, respectively, and were significantly lower value in group A than in group B (P<0.05).",Early hemoperfusion for emergency treatment of carbamazepine poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066188/),d,1.20,30979,DB00564,Carbamazepine
,29066188,retention times,"The mean retention times were 0.85±0.08, 1.20±0.15 and 2.52±0.29days in the three groups, respectively, and were significantly lower value in group A than in group B (P<0.05).",Early hemoperfusion for emergency treatment of carbamazepine poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066188/),d,2.52,30980,DB00564,Carbamazepine
,25383231,AUC,"In terms of AUC, there was an increase from 2471 ± 586 to 4560 ± 1396 ng·h/mL.",Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25383231/),[h·ng] / [ml],2471,31227,DB00564,Carbamazepine
,25383231,AUC,"In terms of AUC, there was an increase from 2471 ± 586 to 4560 ± 1396 ng·h/mL.",Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25383231/),[h·ng] / [ml],4560,31228,DB00564,Carbamazepine
,10653208,steady-state plasma area under the concentration-time curve (AUC),"Coadministration of nefazodone increased steady-state plasma area under the concentration-time curve (AUC) of carbamazepine from 60.77 (+/-8.44) to 74.98 (+/-12.88) microg x hr/mL (p < 0.001) and decreased the active carbamazepine-10,11-epoxide metabolite AUC concentration from 7.10 (+/-1.16) to 5.71 (+/-0.52) microg x hr/mL (p < 0.005).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·μg] / [ml],60.77,31379,DB00564,Carbamazepine
,10653208,steady-state plasma area under the concentration-time curve (AUC),"Coadministration of nefazodone increased steady-state plasma area under the concentration-time curve (AUC) of carbamazepine from 60.77 (+/-8.44) to 74.98 (+/-12.88) microg x hr/mL (p < 0.001) and decreased the active carbamazepine-10,11-epoxide metabolite AUC concentration from 7.10 (+/-1.16) to 5.71 (+/-0.52) microg x hr/mL (p < 0.005).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·μg] / [ml],74.98,31380,DB00564,Carbamazepine
,10653208,AUC concentration,"Coadministration of nefazodone increased steady-state plasma area under the concentration-time curve (AUC) of carbamazepine from 60.77 (+/-8.44) to 74.98 (+/-12.88) microg x hr/mL (p < 0.001) and decreased the active carbamazepine-10,11-epoxide metabolite AUC concentration from 7.10 (+/-1.16) to 5.71 (+/-0.52) microg x hr/mL (p < 0.005).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·μg] / [ml],7.10,31381,DB00564,Carbamazepine
,10653208,AUC concentration,"Coadministration of nefazodone increased steady-state plasma area under the concentration-time curve (AUC) of carbamazepine from 60.77 (+/-8.44) to 74.98 (+/-12.88) microg x hr/mL (p < 0.001) and decreased the active carbamazepine-10,11-epoxide metabolite AUC concentration from 7.10 (+/-1.16) to 5.71 (+/-0.52) microg x hr/mL (p < 0.005).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·μg] / [ml],5.71,31382,DB00564,Carbamazepine
,10653208,steady-state AUC,"During the combination, the steady-state AUC of nefazodone decreased from 7,326 (+/-3,768) to 542 (+/-191) ng x hr/mL, and the AUCs of its metabolites (hydroxynefazodone, meta-chlorophenylpiperazine, and triazoledione) decreased significantly as well (p < 0.001).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·ng] / [ml],"7,326",31383,DB00564,Carbamazepine
,10653208,steady-state AUC,"During the combination, the steady-state AUC of nefazodone decreased from 7,326 (+/-3,768) to 542 (+/-191) ng x hr/mL, and the AUCs of its metabolites (hydroxynefazodone, meta-chlorophenylpiperazine, and triazoledione) decreased significantly as well (p < 0.001).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·ng] / [ml],542,31384,DB00564,Carbamazepine
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],302.7,31407,DB00564,Carbamazepine
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],383.2,31408,DB00564,Carbamazepine
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],378.9,31409,DB00564,Carbamazepine
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],214.0,31410,DB00564,Carbamazepine
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1179.1,31411,DB00564,Carbamazepine
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1687.0,31412,DB00564,Carbamazepine
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],2209.5,31413,DB00564,Carbamazepine
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],381.7,31414,DB00564,Carbamazepine
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,86,31415,DB00564,Carbamazepine
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,104,31416,DB00564,Carbamazepine
,9545146,Residual variability,Residual variability was 1.8 mg/L.,Population pharmacokinetics of carbamazepine in adults with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545146/),[mg] / [l],1.8,31609,DB00564,Carbamazepine
,3596609,elimination half-lives,CBZ and CBZ-E elimination half-lives were 26 and 16.5 h respectively.,"Carbamazepine and carbamazepine-10,11-epoxide pharmacokinetics in an overdose patient. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3596609/),h,26,32865,DB00564,Carbamazepine
,3596609,elimination half-lives,CBZ and CBZ-E elimination half-lives were 26 and 16.5 h respectively.,"Carbamazepine and carbamazepine-10,11-epoxide pharmacokinetics in an overdose patient. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3596609/),h,16.5,32866,DB00564,Carbamazepine
,24765650,Є(D),"The mesoporous (pore width = 80.1233 Å) MCC was mechanically stable (Є(D) = 0.0290 J, M(F) = 8.5490 N/mm) and resilient (M(R) = 5.5040%).",In vivo and ex vivo evaluation of a multi-particulate composite construct for sustained transbuccal delivery of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24765650/),j,0.0290,33642,DB00564,Carbamazepine
,24765650,M(F),"The mesoporous (pore width = 80.1233 Å) MCC was mechanically stable (Є(D) = 0.0290 J, M(F) = 8.5490 N/mm) and resilient (M(R) = 5.5040%).",In vivo and ex vivo evaluation of a multi-particulate composite construct for sustained transbuccal delivery of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24765650/),[n] / [mm],8.5490,33643,DB00564,Carbamazepine
,24765650,M(R),"The mesoporous (pore width = 80.1233 Å) MCC was mechanically stable (Є(D) = 0.0290 J, M(F) = 8.5490 N/mm) and resilient (M(R) = 5.5040%).",In vivo and ex vivo evaluation of a multi-particulate composite construct for sustained transbuccal delivery of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24765650/),%,5.5040,33644,DB00564,Carbamazepine
,24765650,permeation,"It demonstrated distinctive controlled release (9.9800%/h), permeation enhancing (10.8730%/h), drug loading (90.0541%), and bioadhesive (ω(adh) = 0.0034 J, F(det) = 1.0751 N) capacities.",In vivo and ex vivo evaluation of a multi-particulate composite construct for sustained transbuccal delivery of carbamazepine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24765650/),[%] / [h],10.8730,33645,DB00564,Carbamazepine
,24765650,ω(adh),"It demonstrated distinctive controlled release (9.9800%/h), permeation enhancing (10.8730%/h), drug loading (90.0541%), and bioadhesive (ω(adh) = 0.0034 J, F(det) = 1.0751 N) capacities.",In vivo and ex vivo evaluation of a multi-particulate composite construct for sustained transbuccal delivery of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24765650/),j,0.0034,33646,DB00564,Carbamazepine
,24765650,F(det),"It demonstrated distinctive controlled release (9.9800%/h), permeation enhancing (10.8730%/h), drug loading (90.0541%), and bioadhesive (ω(adh) = 0.0034 J, F(det) = 1.0751 N) capacities.",In vivo and ex vivo evaluation of a multi-particulate composite construct for sustained transbuccal delivery of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24765650/),n,1.0751,33647,DB00564,Carbamazepine
,15776275,peak plasma concentration,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),[ng] / [ml],17.5,34055,DB00564,Carbamazepine
,15776275,peak plasma concentration,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),[ng] / [ml],13.9,34056,DB00564,Carbamazepine
,15776275,total area under the plasma concentration-time curve,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),[h·ng] / [ml],194.8,34057,DB00564,Carbamazepine
,15776275,total area under the plasma concentration-time curve,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),[h·ng] / [ml],105.9,34058,DB00564,Carbamazepine
,15776275,elimination half-life,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),h,11.1,34059,DB00564,Carbamazepine
,15776275,elimination half-life,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),h,6.8,34060,DB00564,Carbamazepine
,2344850,apparent volume of distribution,A two-compartment model was estimated: The apparent volume of distribution of CBZ at the steady-state (Vss) was approximately 1 L/kg.,Absolute bioavailability of carbamazepine after oral administration of a 2% syrup. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344850/),[l] / [kg],1,34295,DB00564,Carbamazepine
,10217344,CL,"The analysis showed CL = 0.067 L/hour/kg and Vd = 1.19 L/kg as the most accurate and precise set of pharmacokinetic parameters, presenting the highest percentage of clinically acceptable estimates (error < 2 microg/mL).",Predictive capacity of carbamazepine pharmacokinetic parameters in a Portuguese outpatient population. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217344/),[l] / [h·kg],0.067,34654,DB00564,Carbamazepine
,10217344,Vd,"The analysis showed CL = 0.067 L/hour/kg and Vd = 1.19 L/kg as the most accurate and precise set of pharmacokinetic parameters, presenting the highest percentage of clinically acceptable estimates (error < 2 microg/mL).",Predictive capacity of carbamazepine pharmacokinetic parameters in a Portuguese outpatient population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217344/),[l] / [kg],1.19,34655,DB00564,Carbamazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,105.15,35400,DB00564,Carbamazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,84.76,35401,DB00564,Carbamazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,94.45,35402,DB00564,Carbamazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,96.52,35403,DB00564,Carbamazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,98.62,35404,DB00564,Carbamazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,95.08,35405,DB00564,Carbamazepine
,23291439,flow rate,"The chromatographic separation was achieved on a C(18) column by using a mixture of acetonitrile-0.5% formic acid buffer (60:40, v/v) as the mobile phase at a flow rate of 0.8mL/min.",A rapid and sensitive liquid chromatography-tandem mass spectrometric assay for cycloserine in 50μL of human plasma: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23291439/),[ml] / [min],0.8,36635,DB00564,Carbamazepine
,23291439,run time,"A run time of 2.5min for each sample made it possible to analyze more number of samples in short time, thus increasing the productivity.",A rapid and sensitive liquid chromatography-tandem mass spectrometric assay for cycloserine in 50μL of human plasma: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23291439/),min,2.5,36636,DB00564,Carbamazepine
>,12959634,bioavailability,The bioavailability of the oral formulation of oxcarbazepine is high (>95%).,Clinical pharmacokinetics of oxcarbazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,95,36869,DB00564,Carbamazepine
,12959634,plasma protein binding,The plasma protein binding of MHD is about 40%.,Clinical pharmacokinetics of oxcarbazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,40,36870,DB00564,Carbamazepine
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,1-5,36871,DB00564,Carbamazepine
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,7-20,36872,DB00564,Carbamazepine
,3097715,Terminal half-lives,Terminal half-lives were 4.3 +/- 1.5 h in the patients and 4.3 +/- 1.8 h in the controls.,Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),h,4.3,37445,DB00564,Carbamazepine
,3097715,Terminal half-lives,Terminal half-lives were 4.3 +/- 1.5 h in the patients and 4.3 +/- 1.8 h in the controls.,Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),h,4.3,37446,DB00564,Carbamazepine
,3097715,Clearance,"Clearance and volume of distribution calculated after IV dosing in the patients were 124 +/- 11 ml h-1 kg-1 and 0.73 +/- 0.28 l/kg, respectively.",Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),[ml] / [h·kg],124,37447,DB00564,Carbamazepine
,3097715,volume of distribution,"Clearance and volume of distribution calculated after IV dosing in the patients were 124 +/- 11 ml h-1 kg-1 and 0.73 +/- 0.28 l/kg, respectively.",Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),[l] / [kg],0.73,37448,DB00564,Carbamazepine
,3097715,absolute oral availability,The absolute oral availability was 85 +/- 14%.,Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),%,85,37449,DB00564,Carbamazepine
,25596380,total run time,The total run time was 3.0 min and the elution of pirfenidone was at 1.39 min.,Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25596380/),min,3.0,38327,DB00564,Carbamazepine
,25596380,elution,The total run time was 3.0 min and the elution of pirfenidone was at 1.39 min.,Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25596380/),min,1.39,38328,DB00564,Carbamazepine
,25596380,recovery,Mean recovery of pirfenidone in plasma was in the range of 80.4-84.3%.,Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25596380/),%,80.4-84.3,38329,DB00564,Carbamazepine
,22406657,apparent clearance (CL/F),The apparent clearance (CL/F) of carbamazepine in this community-dwelling elderly population was estimated to be 3.59 L/h with an interindividual variability of 18.1%.,Population pharmacokinetics of carbamazepine in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406657/),[l] / [h],3.59,39143,DB00564,Carbamazepine
,22406657,volume of distribution (V/F),The volume of distribution (V/F) was estimated to be 102 L with an interindividual variability of 74.7%.,Population pharmacokinetics of carbamazepine in elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406657/),l,102,39144,DB00564,Carbamazepine
,1127587,T 1/2,"All semilogarithmic intravenous curves exhibited an irregular decay behavior in the first 3-hr period, followed by a linear disappearance phase (T 1/2 equals 1.0-2.4 hr).",Pharmacokinetics of carbamazepine in monkeys following intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127587/),h,1.0-2.4,40040,DB00564,Carbamazepine
,1127587,elimination half-life,"Oral studies also yielded a short elimination half-life (1.0-1.60 hr), which was confirmed by urinary excretion measurements.",Pharmacokinetics of carbamazepine in monkeys following intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127587/),h,1.0-1.60,40041,DB00564,Carbamazepine
,7438684,steady-state concentrations,Mean steady-state concentrations of ethosuximide declined by 17% from a preinduction (study day 10) level of 32.2 +/- 5.6 micrograms/ml to a postinduction level of 26.8 +/- 5.2 micrograms/ml on study day 28.,Kinetics of a carbamazepine-ethosuximide interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438684/),[μg] / [ml],32.2,40053,DB00564,Carbamazepine
,7438684,steady-state concentrations,Mean steady-state concentrations of ethosuximide declined by 17% from a preinduction (study day 10) level of 32.2 +/- 5.6 micrograms/ml to a postinduction level of 26.8 +/- 5.2 micrograms/ml on study day 28.,Kinetics of a carbamazepine-ethosuximide interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438684/),[μg] / [ml],26.8,40054,DB00564,Carbamazepine
,7438684,clearance,Ethosuximide clearance increased (alpha = 0.05) between study days 10 and 28 from 0.664 +/- 0.120 to 0.800 +/- 0.0154 l/hr.,Kinetics of a carbamazepine-ethosuximide interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438684/),[l] / [h],0.664,40055,DB00564,Carbamazepine
,7438684,clearance,Ethosuximide clearance increased (alpha = 0.05) between study days 10 and 28 from 0.664 +/- 0.120 to 0.800 +/- 0.0154 l/hr.,Kinetics of a carbamazepine-ethosuximide interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438684/),[l] / [h],0.800,40056,DB00564,Carbamazepine
,7438684,half-life,Ethosuximide half-life was lowered from mean - 53.7 +/- 11.5 hr (before induction) to mean = 44.6 +/- 10.7 hr (after induction); the difference between some subjects was large.,Kinetics of a carbamazepine-ethosuximide interaction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438684/),h,53.7,40057,DB00564,Carbamazepine
,7438684,half-life,Ethosuximide half-life was lowered from mean - 53.7 +/- 11.5 hr (before induction) to mean = 44.6 +/- 10.7 hr (after induction); the difference between some subjects was large.,Kinetics of a carbamazepine-ethosuximide interaction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438684/),h,44.6,40058,DB00564,Carbamazepine
,2367320,total-body clearances,"Carbamazepine total-body clearances were 15.1 +/- 3.26, 13.4 +/- 5.66, and 10.0 +/- 3.11 ml/min/kg at the 5, 10, and 20 mg/kg doses, respectively (significance of difference between the 5 and the 20 mg/kg dose = 0.06 less than P less than 0.05; Kruskal-Wallis test, Dunn's procedure).","Dose-dependent pharmacokinetics of carbamazepine in rats: determination of the formation clearance of carbamazepine-10,11-epoxide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2367320/),[ml] / [kg·min],15.1,40116,DB00564,Carbamazepine
,2367320,total-body clearances,"Carbamazepine total-body clearances were 15.1 +/- 3.26, 13.4 +/- 5.66, and 10.0 +/- 3.11 ml/min/kg at the 5, 10, and 20 mg/kg doses, respectively (significance of difference between the 5 and the 20 mg/kg dose = 0.06 less than P less than 0.05; Kruskal-Wallis test, Dunn's procedure).","Dose-dependent pharmacokinetics of carbamazepine in rats: determination of the formation clearance of carbamazepine-10,11-epoxide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2367320/),[ml] / [kg·min],13.4,40117,DB00564,Carbamazepine
,2367320,total-body clearances,"Carbamazepine total-body clearances were 15.1 +/- 3.26, 13.4 +/- 5.66, and 10.0 +/- 3.11 ml/min/kg at the 5, 10, and 20 mg/kg doses, respectively (significance of difference between the 5 and the 20 mg/kg dose = 0.06 less than P less than 0.05; Kruskal-Wallis test, Dunn's procedure).","Dose-dependent pharmacokinetics of carbamazepine in rats: determination of the formation clearance of carbamazepine-10,11-epoxide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2367320/),[ml] / [kg·min],10.0,40118,DB00564,Carbamazepine
,3608344,half-life,The half-life of nafimidone was 1.34 +/- 0.48 hours after a 100mg single dose and 1.69 +/- 0.91 hours after a 300mg single dose.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,1.34,40410,DB00564,Carbamazepine
,3608344,half-life,The half-life of nafimidone was 1.34 +/- 0.48 hours after a 100mg single dose and 1.69 +/- 0.91 hours after a 300mg single dose.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,1.69,40411,DB00564,Carbamazepine
,3608344,half-life,"However, the half-life of nafimidone alcohol increased from 2.84 +/- 0.72 hours after a 100mg single dose to 4.22 +/- 1.09 hours after a 300mg single dose (p less than 0.02).",Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,2.84,40412,DB00564,Carbamazepine
,3608344,half-life,"However, the half-life of nafimidone alcohol increased from 2.84 +/- 0.72 hours after a 100mg single dose to 4.22 +/- 1.09 hours after a 300mg single dose (p less than 0.02).",Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,4.22,40413,DB00564,Carbamazepine
,3608344,clearance,The clearance of nafimidone was 43.56 +/- 22.11 L/h/kg after a 100mg single dose and 35.51 +/- 28.93 L/h/kg after the 300mg single dose.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),[l] / [h·kg],43.56,40414,DB00564,Carbamazepine
,3608344,clearance,The clearance of nafimidone was 43.56 +/- 22.11 L/h/kg after a 100mg single dose and 35.51 +/- 28.93 L/h/kg after the 300mg single dose.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),[l] / [h·kg],35.51,40415,DB00564,Carbamazepine
,3608344,apparent volumes of distribution,The respective apparent volumes of distribution of nafimidone after single 100 and 300mg doses were 80.78 +/- 46.11 L/kg and 71.01 +/- 36.86 L/kg.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),[l] / [kg],80.78,40416,DB00564,Carbamazepine
,3608344,apparent volumes of distribution,The respective apparent volumes of distribution of nafimidone after single 100 and 300mg doses were 80.78 +/- 46.11 L/kg and 71.01 +/- 36.86 L/kg.,Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),[l] / [kg],71.01,40417,DB00564,Carbamazepine
,3608344,half-life,"After short term (9 to 10 weeks) and long term (127 to 152 weeks) maintenance therapy on nafimidone 600mg per day the half-life of nafimidone alcohol was 2.23 +/- 0.36 hours and 2.16 +/- 0.60 hours, respectively.",Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,2.23,40418,DB00564,Carbamazepine
,3608344,half-life,"After short term (9 to 10 weeks) and long term (127 to 152 weeks) maintenance therapy on nafimidone 600mg per day the half-life of nafimidone alcohol was 2.23 +/- 0.36 hours and 2.16 +/- 0.60 hours, respectively.",Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608344/),h,2.16,40419,DB00564,Carbamazepine
,1233212,half-lives,"Plasma concentrations, which were analysed by mass fragmentography, reached a maximum 1-7 hours after dosing, and then declined monoexponentially with half-lives ranging from 24 to 46 hours.",Distribution and elimination kinetics of carbamazepine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233212/),h,24 to 46,40645,DB00564,Carbamazepine
,1233212,apparent distribution volume,The apparent distribution volume ranged from 0.79 to 1.40 1/kg.,Distribution and elimination kinetics of carbamazepine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233212/),[1] / [kg],0.79 to 1.40,40646,DB00564,Carbamazepine
,7737233,A parameter,"The A parameter values are respectively 49.3, 47.2, 42.9.",Pharmacokinetics of carbamazepine. Part I: A new bioequivalency parameter based on a relative bioavailability trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7737233/),,49.3,40844,DB00564,Carbamazepine
,7737233,A parameter,"The A parameter values are respectively 49.3, 47.2, 42.9.",Pharmacokinetics of carbamazepine. Part I: A new bioequivalency parameter based on a relative bioavailability trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7737233/),,47.2,40845,DB00564,Carbamazepine
,7737233,A parameter,"The A parameter values are respectively 49.3, 47.2, 42.9.",Pharmacokinetics of carbamazepine. Part I: A new bioequivalency parameter based on a relative bioavailability trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7737233/),,42.9,40846,DB00564,Carbamazepine
,10613609,area under the serum concentration versus time curve,The area under the serum concentration versus time curve of S-10-hydroxycarbazepine was about fivefold greater than that of R-10-hydroxycarbazepine (129.8 +/- 33.1 versus 26.3 +/- 8.5 mg/L x h; P < .001).,Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613609/),[mg] / [h·l],129.8,41301,DB00564,Carbamazepine
,10613609,area under the serum concentration versus time curve,The area under the serum concentration versus time curve of S-10-hydroxycarbazepine was about fivefold greater than that of R-10-hydroxycarbazepine (129.8 +/- 33.1 versus 26.3 +/- 8.5 mg/L x h; P < .001).,Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613609/),[mg] / [h·l],26.3,41302,DB00564,Carbamazepine
,10613609,Half-lives,Half-lives did not differ significantly between the enantiomers (11.9 +/- 3.3 hours for R-10-hydroxycarbazepine versus 13.0 +/- 4.1 hours for S-10-hydroxycarbazepine).,Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613609/),h,11.9,41303,DB00564,Carbamazepine
,10613609,Half-lives,Half-lives did not differ significantly between the enantiomers (11.9 +/- 3.3 hours for R-10-hydroxycarbazepine versus 13.0 +/- 4.1 hours for S-10-hydroxycarbazepine).,Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613609/),h,13.0,41304,DB00564,Carbamazepine
,7128675,half-lives,"After IV PB distributive half-lives were 75 to 126 h, steady state volume of distribution (Vss) was 0.54 +/- 0.03 l/kg, and clearance (CL) was 3.8 +/- 0.77 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),h,75 to 126,41767,DB00564,Carbamazepine
,7128675,steady state volume of distribution (Vss),"After IV PB distributive half-lives were 75 to 126 h, steady state volume of distribution (Vss) was 0.54 +/- 0.03 l/kg, and clearance (CL) was 3.8 +/- 0.77 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[l] / [kg],0.54,41768,DB00564,Carbamazepine
,7128675,clearance (CL),"After IV PB distributive half-lives were 75 to 126 h, steady state volume of distribution (Vss) was 0.54 +/- 0.03 l/kg, and clearance (CL) was 3.8 +/- 0.77 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[ml] / [h·kg],3.8,41769,DB00564,Carbamazepine
,7128675,Absolute bioavailability,Absolute bioavailability of IM PB was 101 +/- 11%.,Kinetics of phenobarbital in normal subjects and epileptic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),%,101,41770,DB00564,Carbamazepine
,7128675,disposition half-lives,"Epileptic patients exhibited similar PB kinetics: disposition half-lives were 77 to 128 h, Vss 0.61 +/- 0.05 l/kg, and Cl 3.9 +/- 0.76 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),h,77 to 128,41771,DB00564,Carbamazepine
,7128675,Vss,"Epileptic patients exhibited similar PB kinetics: disposition half-lives were 77 to 128 h, Vss 0.61 +/- 0.05 l/kg, and Cl 3.9 +/- 0.76 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[l] / [kg],0.61,41772,DB00564,Carbamazepine
,7128675,Cl,"Epileptic patients exhibited similar PB kinetics: disposition half-lives were 77 to 128 h, Vss 0.61 +/- 0.05 l/kg, and Cl 3.9 +/- 0.76 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[ml] / [h·kg],3.9,41773,DB00564,Carbamazepine
,30179701,encapsulation efficiencies,Results showed particles in nanometric range with negative surface charge and satisfying encapsulation efficiencies (from 93.1 ± 7.6 to 95.7 ± 5.6%).,Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30179701/),%,93.1,42278,DB00564,Carbamazepine
,30179701,encapsulation efficiencies,Results showed particles in nanometric range with negative surface charge and satisfying encapsulation efficiencies (from 93.1 ± 7.6 to 95.7 ± 5.6%).,Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30179701/),%,95.7,42279,DB00564,Carbamazepine
,25770615,flow rate,"The chromatographic separation was conducted on a BEH C18 column (100 mm × 2.1 mm, 1.7 μm) with the gradient elution using a mobile phase of acetonitrile - 0.2% formic acid in water at a flow rate of 0.25 mL/min for 4 min.",Simultaneous determination of mosapride and its active des-p-fluorobenzyl and 4'-N-oxide metabolites in rat plasma using UPLC-MS/MS: an application for a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25770615/),[ml] / [min],0.25,42368,DB00564,Carbamazepine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1404,43042,DB00564,Carbamazepine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1374,43043,DB00564,Carbamazepine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1400,43044,DB00564,Carbamazepine
,18781906,trough levels,"Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],477,43045,DB00564,Carbamazepine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],240,43046,DB00564,Carbamazepine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],351,43047,DB00564,Carbamazepine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],356,43048,DB00564,Carbamazepine
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],2.9,44201,DB00564,Carbamazepine
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],5.1,44202,DB00564,Carbamazepine
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],89,44203,DB00564,Carbamazepine
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],119,44204,DB00564,Carbamazepine
,12959317,half-lives,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),h,17,44205,DB00564,Carbamazepine
,12959317,half-lives,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),h,20,44206,DB00564,Carbamazepine
,17385818,extraction recovery,The extraction recovery of andrographolide was ranged from 65.7 to 72.6%.,HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),%,65.7 to 72.6,44670,DB00564,Carbamazepine
,17385818,alpha,"The results showed that the disposition of andrographolide after intravenous administration of liposomal andrographolide conformed to a two-compartment open model with alpha = 4.75 x 10(-2) +/- 2.41 x 10(-3) min(-1), beta = 3.16 x 10(-3) +/- 1.58 x 10(-4) min(-1), V(c) = 174.67 +/- 13.97 mL, k(21) = 1.60 x 10(-2) +/- 8.12 x 10(-4) min(-1), k(10) = 9.38 x 10(-3) +/- 5.62 x 10(-4) min(-1), k(12) = 2.53 x 10(-2) +/- 1.27 x 10(-3) min(-1) and AUC(0-infinity) = 1525.47 +/- 92.35 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),1/[min],4.75 x 10(-2),44671,DB00564,Carbamazepine
,17385818,beta,"The results showed that the disposition of andrographolide after intravenous administration of liposomal andrographolide conformed to a two-compartment open model with alpha = 4.75 x 10(-2) +/- 2.41 x 10(-3) min(-1), beta = 3.16 x 10(-3) +/- 1.58 x 10(-4) min(-1), V(c) = 174.67 +/- 13.97 mL, k(21) = 1.60 x 10(-2) +/- 8.12 x 10(-4) min(-1), k(10) = 9.38 x 10(-3) +/- 5.62 x 10(-4) min(-1), k(12) = 2.53 x 10(-2) +/- 1.27 x 10(-3) min(-1) and AUC(0-infinity) = 1525.47 +/- 92.35 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),1/[min],3.16 x 10(-3),44672,DB00564,Carbamazepine
,17385818,V(c),"The results showed that the disposition of andrographolide after intravenous administration of liposomal andrographolide conformed to a two-compartment open model with alpha = 4.75 x 10(-2) +/- 2.41 x 10(-3) min(-1), beta = 3.16 x 10(-3) +/- 1.58 x 10(-4) min(-1), V(c) = 174.67 +/- 13.97 mL, k(21) = 1.60 x 10(-2) +/- 8.12 x 10(-4) min(-1), k(10) = 9.38 x 10(-3) +/- 5.62 x 10(-4) min(-1), k(12) = 2.53 x 10(-2) +/- 1.27 x 10(-3) min(-1) and AUC(0-infinity) = 1525.47 +/- 92.35 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),ml,174.67,44673,DB00564,Carbamazepine
,17385818,k(21),"The results showed that the disposition of andrographolide after intravenous administration of liposomal andrographolide conformed to a two-compartment open model with alpha = 4.75 x 10(-2) +/- 2.41 x 10(-3) min(-1), beta = 3.16 x 10(-3) +/- 1.58 x 10(-4) min(-1), V(c) = 174.67 +/- 13.97 mL, k(21) = 1.60 x 10(-2) +/- 8.12 x 10(-4) min(-1), k(10) = 9.38 x 10(-3) +/- 5.62 x 10(-4) min(-1), k(12) = 2.53 x 10(-2) +/- 1.27 x 10(-3) min(-1) and AUC(0-infinity) = 1525.47 +/- 92.35 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),1/[min],1.60 x 10(-2),44674,DB00564,Carbamazepine
,17385818,k(10),"The results showed that the disposition of andrographolide after intravenous administration of liposomal andrographolide conformed to a two-compartment open model with alpha = 4.75 x 10(-2) +/- 2.41 x 10(-3) min(-1), beta = 3.16 x 10(-3) +/- 1.58 x 10(-4) min(-1), V(c) = 174.67 +/- 13.97 mL, k(21) = 1.60 x 10(-2) +/- 8.12 x 10(-4) min(-1), k(10) = 9.38 x 10(-3) +/- 5.62 x 10(-4) min(-1), k(12) = 2.53 x 10(-2) +/- 1.27 x 10(-3) min(-1) and AUC(0-infinity) = 1525.47 +/- 92.35 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),1/[min],9.38 x 10(-3),44675,DB00564,Carbamazepine
,17385818,k(12),"The results showed that the disposition of andrographolide after intravenous administration of liposomal andrographolide conformed to a two-compartment open model with alpha = 4.75 x 10(-2) +/- 2.41 x 10(-3) min(-1), beta = 3.16 x 10(-3) +/- 1.58 x 10(-4) min(-1), V(c) = 174.67 +/- 13.97 mL, k(21) = 1.60 x 10(-2) +/- 8.12 x 10(-4) min(-1), k(10) = 9.38 x 10(-3) +/- 5.62 x 10(-4) min(-1), k(12) = 2.53 x 10(-2) +/- 1.27 x 10(-3) min(-1) and AUC(0-infinity) = 1525.47 +/- 92.35 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),1/[min],2.53 x 10(-2),44676,DB00564,Carbamazepine
,17385818,AUC(0-infinity),"The results showed that the disposition of andrographolide after intravenous administration of liposomal andrographolide conformed to a two-compartment open model with alpha = 4.75 x 10(-2) +/- 2.41 x 10(-3) min(-1), beta = 3.16 x 10(-3) +/- 1.58 x 10(-4) min(-1), V(c) = 174.67 +/- 13.97 mL, k(21) = 1.60 x 10(-2) +/- 8.12 x 10(-4) min(-1), k(10) = 9.38 x 10(-3) +/- 5.62 x 10(-4) min(-1), k(12) = 2.53 x 10(-2) +/- 1.27 x 10(-3) min(-1) and AUC(0-infinity) = 1525.47 +/- 92.35 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),[min·μg] / [ml],1525.47,44677,DB00564,Carbamazepine
,17385818,k(e),"For the intragastric administration of andrographolide tablets, the disposition of andrographolide followed a one-compartment open model with k(e) = 6.78 x 10(-3) +/- 3.53 x 10(-4) min(-1), k(a) = 3.69 x 10(-2) +/- 4.68 x 10(-3) min(-1), T(max) = 59.69 +/- 3.61 min, C(max) = 1.62 +/- 0.11 microg/mL, V(c) = 1056.90 +/- 83.42 mL, AUC(0-infinity) = 348.75 +/- 24.41 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),1/[min],6.78 x 10(-3),44678,DB00564,Carbamazepine
,17385818,k(a),"For the intragastric administration of andrographolide tablets, the disposition of andrographolide followed a one-compartment open model with k(e) = 6.78 x 10(-3) +/- 3.53 x 10(-4) min(-1), k(a) = 3.69 x 10(-2) +/- 4.68 x 10(-3) min(-1), T(max) = 59.69 +/- 3.61 min, C(max) = 1.62 +/- 0.11 microg/mL, V(c) = 1056.90 +/- 83.42 mL, AUC(0-infinity) = 348.75 +/- 24.41 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),,3.69 x 10(-2),44679,DB00564,Carbamazepine
,17385818,T(max),"For the intragastric administration of andrographolide tablets, the disposition of andrographolide followed a one-compartment open model with k(e) = 6.78 x 10(-3) +/- 3.53 x 10(-4) min(-1), k(a) = 3.69 x 10(-2) +/- 4.68 x 10(-3) min(-1), T(max) = 59.69 +/- 3.61 min, C(max) = 1.62 +/- 0.11 microg/mL, V(c) = 1056.90 +/- 83.42 mL, AUC(0-infinity) = 348.75 +/- 24.41 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),min,59.69,44680,DB00564,Carbamazepine
,17385818,C(max),"For the intragastric administration of andrographolide tablets, the disposition of andrographolide followed a one-compartment open model with k(e) = 6.78 x 10(-3) +/- 3.53 x 10(-4) min(-1), k(a) = 3.69 x 10(-2) +/- 4.68 x 10(-3) min(-1), T(max) = 59.69 +/- 3.61 min, C(max) = 1.62 +/- 0.11 microg/mL, V(c) = 1056.90 +/- 83.42 mL, AUC(0-infinity) = 348.75 +/- 24.41 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),[μg] / [ml],1.62,44681,DB00564,Carbamazepine
,17385818,V(c),"For the intragastric administration of andrographolide tablets, the disposition of andrographolide followed a one-compartment open model with k(e) = 6.78 x 10(-3) +/- 3.53 x 10(-4) min(-1), k(a) = 3.69 x 10(-2) +/- 4.68 x 10(-3) min(-1), T(max) = 59.69 +/- 3.61 min, C(max) = 1.62 +/- 0.11 microg/mL, V(c) = 1056.90 +/- 83.42 mL, AUC(0-infinity) = 348.75 +/- 24.41 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),ml,1056.90,44682,DB00564,Carbamazepine
,17385818,AUC(0-infinity),"For the intragastric administration of andrographolide tablets, the disposition of andrographolide followed a one-compartment open model with k(e) = 6.78 x 10(-3) +/- 3.53 x 10(-4) min(-1), k(a) = 3.69 x 10(-2) +/- 4.68 x 10(-3) min(-1), T(max) = 59.69 +/- 3.61 min, C(max) = 1.62 +/- 0.11 microg/mL, V(c) = 1056.90 +/- 83.42 mL, AUC(0-infinity) = 348.75 +/- 24.41 microg min/mL.",HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385818/),[min·μg] / [ml],348.75,44683,DB00564,Carbamazepine
,25156291,Tmax,"On the other hand, some pharmacokinetic parameters of BA in rat brain had obvious differences after PNS was administered, such as an increase in Tmax from 5 min to 15 min, an increase in AUC0-t and AUC0-∞ by 42.75% and 29.39%, respectively, as well as a decrease in CL by 27.95%.",Pharmacokinetics and brain distribution differences of baicalin in rat underlying the effect of Panax notoginsenosides after intravenous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25156291/),min,5,44984,DB00564,Carbamazepine
,25156291,Tmax,"On the other hand, some pharmacokinetic parameters of BA in rat brain had obvious differences after PNS was administered, such as an increase in Tmax from 5 min to 15 min, an increase in AUC0-t and AUC0-∞ by 42.75% and 29.39%, respectively, as well as a decrease in CL by 27.95%.",Pharmacokinetics and brain distribution differences of baicalin in rat underlying the effect of Panax notoginsenosides after intravenous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25156291/),min,15,44985,DB00564,Carbamazepine
,18503564,elimination half-life,"During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6-10 h.",Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503564/),h,6-10,45117,DB00564,Carbamazepine
,11042231,CL/f,"The mean values of CL/f was 6.10 l/h, of V/f was 62.0 l and of k(a) was 1.25 h(-1) for a subject of 170-cm height.",Population pharmacokinetics of tiagabine in epileptic patients on monotherapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11042231/),[l] / [h],6.10,45759,DB00564,Carbamazepine
,11042231,V/f,"The mean values of CL/f was 6.10 l/h, of V/f was 62.0 l and of k(a) was 1.25 h(-1) for a subject of 170-cm height.",Population pharmacokinetics of tiagabine in epileptic patients on monotherapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11042231/),l,62.0,45760,DB00564,Carbamazepine
,11042231,k(a),"The mean values of CL/f was 6.10 l/h, of V/f was 62.0 l and of k(a) was 1.25 h(-1) for a subject of 170-cm height.",Population pharmacokinetics of tiagabine in epileptic patients on monotherapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11042231/),1/[h],1.25,45761,DB00564,Carbamazepine
,11042231,half-life,The population half-life was 5.72 h.,Population pharmacokinetics of tiagabine in epileptic patients on monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11042231/),h,5.72,45762,DB00564,Carbamazepine
,15978311,V(i),"Median parameter estimates were V(i) (intercept) = 11.5 L (fixed); V(s) (slope) = 0.3957 L/kg (range, 0.01200-1.5730); K(i) (intercept) = 0.173 h(-1) (fixed); and K(s) (slope) = 0.004487 h(-1) . y(-1) (range, 0.0001800-0.02969).",Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978311/),l,11.5,46004,DB00564,Carbamazepine
,15978311,K(i),"Median parameter estimates were V(i) (intercept) = 11.5 L (fixed); V(s) (slope) = 0.3957 L/kg (range, 0.01200-1.5730); K(i) (intercept) = 0.173 h(-1) (fixed); and K(s) (slope) = 0.004487 h(-1) . y(-1) (range, 0.0001800-0.02969).",Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978311/),1/[h],0.173,46005,DB00564,Carbamazepine
,15978311,K(s),"Median parameter estimates were V(i) (intercept) = 11.5 L (fixed); V(s) (slope) = 0.3957 L/kg (range, 0.01200-1.5730); K(i) (intercept) = 0.173 h(-1) (fixed); and K(s) (slope) = 0.004487 h(-1) . y(-1) (range, 0.0001800-0.02969).",Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978311/),1/[h·y],0.004487,46006,DB00564,Carbamazepine
,32829132,m/z,Peak responses were detected by multiple reaction monitoring (MRM) transitions with m/z 308.0 → 264.9 for 6-O-demethylmenisporphine and m/z 237.0 → 194.1 for IS in positive-ion mode.,"Pharmacokinetics, tissue distribution and excretion of 6-O-demethylmenisporphine, a bioactive oxoisoaporphine alkaloid from Menispermi Rhizoma, as determined by a HPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32829132/),,308.0,46145,DB00564,Carbamazepine
,32829132,m/z,Peak responses were detected by multiple reaction monitoring (MRM) transitions with m/z 308.0 → 264.9 for 6-O-demethylmenisporphine and m/z 237.0 → 194.1 for IS in positive-ion mode.,"Pharmacokinetics, tissue distribution and excretion of 6-O-demethylmenisporphine, a bioactive oxoisoaporphine alkaloid from Menispermi Rhizoma, as determined by a HPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32829132/),,264.9,46146,DB00564,Carbamazepine
,32829132,m/z,Peak responses were detected by multiple reaction monitoring (MRM) transitions with m/z 308.0 → 264.9 for 6-O-demethylmenisporphine and m/z 237.0 → 194.1 for IS in positive-ion mode.,"Pharmacokinetics, tissue distribution and excretion of 6-O-demethylmenisporphine, a bioactive oxoisoaporphine alkaloid from Menispermi Rhizoma, as determined by a HPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32829132/),,237.0,46147,DB00564,Carbamazepine
,32829132,m/z,Peak responses were detected by multiple reaction monitoring (MRM) transitions with m/z 308.0 → 264.9 for 6-O-demethylmenisporphine and m/z 237.0 → 194.1 for IS in positive-ion mode.,"Pharmacokinetics, tissue distribution and excretion of 6-O-demethylmenisporphine, a bioactive oxoisoaporphine alkaloid from Menispermi Rhizoma, as determined by a HPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32829132/),,194.1,46148,DB00564,Carbamazepine
up to,32829132,oral bioavailability,"The results indicated that 6-O-demethylmenisporphine could be well absorbed into blood circulation and widely distributed in various tissues after oral dosing, the oral bioavailability was up to 51.52%.","Pharmacokinetics, tissue distribution and excretion of 6-O-demethylmenisporphine, a bioactive oxoisoaporphine alkaloid from Menispermi Rhizoma, as determined by a HPLC-MS/MS method. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32829132/),%,51.52,46149,DB00564,Carbamazepine
,1425879,unbound fraction,"The unbound fraction of phenytoin was 0.082, 0.085, and 0.077 in the control, single-dose CBZ, multi-dose CBZ phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),,0.082,46344,DB00564,Carbamazepine
,1425879,unbound fraction,"The unbound fraction of phenytoin was 0.082, 0.085, and 0.077 in the control, single-dose CBZ, multi-dose CBZ phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),,0.085,46345,DB00564,Carbamazepine
,1425879,unbound fraction,"The unbound fraction of phenytoin was 0.082, 0.085, and 0.077 in the control, single-dose CBZ, multi-dose CBZ phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),,0.077,46346,DB00564,Carbamazepine
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],276,46347,DB00564,Carbamazepine
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],237,46348,DB00564,Carbamazepine
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],176,46349,DB00564,Carbamazepine
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],22.8,46350,DB00564,Carbamazepine
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],20.5,46351,DB00564,Carbamazepine
,1425879,AUC,"The 72-h AUC of phenytoin was 276, 237, and 176 mg h.l-1 in the 3 phases, respectively, and the 72-h AUC of unbound phenytoin was 22.8, 20.5, 13.0 mg h.l-1.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),[h·mg] / [l],13.0,46352,DB00564,Carbamazepine
,1425879,apparent volume of distribution (Vz/f),"The apparent volume of distribution (Vz/f) was 89.9, 110.3, and 121.3 l in the 3 phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),l,89.9,46353,DB00564,Carbamazepine
,1425879,apparent volume of distribution (Vz/f),"The apparent volume of distribution (Vz/f) was 89.9, 110.3, and 121.3 l in the 3 phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),l,110.3,46354,DB00564,Carbamazepine
,1425879,apparent volume of distribution (Vz/f),"The apparent volume of distribution (Vz/f) was 89.9, 110.3, and 121.3 l in the 3 phases, respectively.",Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425879/),l,121.3,46355,DB00564,Carbamazepine
,33019727,Vd/F,"Male patients showed higher distribution volume (Vd/F) and oral clearance (CL/F) than female patients (median Vd/F: 52.40 L in males and 38.60 L in females, p = 0.011; median CL/F: 4.71 L/h in males and 3.91 L/h in females, p = 0.028).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),l,52.40,46556,DB00564,Carbamazepine
,33019727,Vd/F,"Male patients showed higher distribution volume (Vd/F) and oral clearance (CL/F) than female patients (median Vd/F: 52.40 L in males and 38.60 L in females, p = 0.011; median CL/F: 4.71 L/h in males and 3.91 L/h in females, p = 0.028).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),l,38.60,46557,DB00564,Carbamazepine
,33019727,CL/F,"Male patients showed higher distribution volume (Vd/F) and oral clearance (CL/F) than female patients (median Vd/F: 52.40 L in males and 38.60 L in females, p = 0.011; median CL/F: 4.71 L/h in males and 3.91 L/h in females, p = 0.028).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),[l] / [h],4.71,46558,DB00564,Carbamazepine
,33019727,CL/F,"Male patients showed higher distribution volume (Vd/F) and oral clearance (CL/F) than female patients (median Vd/F: 52.40 L in males and 38.60 L in females, p = 0.011; median CL/F: 4.71 L/h in males and 3.91 L/h in females, p = 0.028).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),[l] / [h],3.91,46559,DB00564,Carbamazepine
,33019727,Vd/F,"Carbamazepine was the co-administered antiepileptic drug that mostly affected the pharmacokinetics of levetiracetam, increasing both Vd/F (61.30 L with carbamazepine and 39.10 L without carbamazepine, p = 0.007) and CL/F (6.71 L/h with carbamazepine and 3.91 L/h without carbamazepine, p < 0.001).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),l,61.30,46560,DB00564,Carbamazepine
,33019727,Vd/F,"Carbamazepine was the co-administered antiepileptic drug that mostly affected the pharmacokinetics of levetiracetam, increasing both Vd/F (61.30 L with carbamazepine and 39.10 L without carbamazepine, p = 0.007) and CL/F (6.71 L/h with carbamazepine and 3.91 L/h without carbamazepine, p < 0.001).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),l,39.10,46561,DB00564,Carbamazepine
,33019727,CL/F,"Carbamazepine was the co-administered antiepileptic drug that mostly affected the pharmacokinetics of levetiracetam, increasing both Vd/F (61.30 L with carbamazepine and 39.10 L without carbamazepine, p = 0.007) and CL/F (6.71 L/h with carbamazepine and 3.91 L/h without carbamazepine, p < 0.001).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),[l] / [h],6.71,46562,DB00564,Carbamazepine
,33019727,CL/F,"Carbamazepine was the co-administered antiepileptic drug that mostly affected the pharmacokinetics of levetiracetam, increasing both Vd/F (61.30 L with carbamazepine and 39.10 L without carbamazepine, p = 0.007) and CL/F (6.71 L/h with carbamazepine and 3.91 L/h without carbamazepine, p < 0.001).","Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33019727/),[l] / [h],3.91,46563,DB00564,Carbamazepine
,24052066,plasma concentration,"The plasma concentration of paliperidone at baseline and with coadministration of 200, 400, and 600 mg/d were 45.8 ± 11.7, 26.9 ± 13.7, 17.1 ± 8.2, and 15.9 ± 7.6 ng/mL, respectively.",Interaction between paliperidone and carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24052066/),,26.9,47531,DB00564,Carbamazepine
,24052066,plasma concentration,"The plasma concentration of paliperidone at baseline and with coadministration of 200, 400, and 600 mg/d were 45.8 ± 11.7, 26.9 ± 13.7, 17.1 ± 8.2, and 15.9 ± 7.6 ng/mL, respectively.",Interaction between paliperidone and carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24052066/),,17.1,47532,DB00564,Carbamazepine
,24052066,plasma concentration,"The plasma concentration of paliperidone at baseline and with coadministration of 200, 400, and 600 mg/d were 45.8 ± 11.7, 26.9 ± 13.7, 17.1 ± 8.2, and 15.9 ± 7.6 ng/mL, respectively.",Interaction between paliperidone and carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24052066/),,15.9,47533,DB00564,Carbamazepine
,22476391,trough plasma concentration (C(S)),"The standardized trough plasma concentration (C(S)) of VPA was much lower in our patients with the UGT1A3*5 variant than in the wild type carriers (3.24 ± 1.05 vs. 4.68 ± 1.24 μg·kg·mL(-1)·mg(-1), P < 0.01).",Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22476391/),[kg·μg] / [mg·ml],3.24,47909,DB00564,Carbamazepine
,22476391,trough plasma concentration (C(S)),"The standardized trough plasma concentration (C(S)) of VPA was much lower in our patients with the UGT1A3*5 variant than in the wild type carriers (3.24 ± 1.05 vs. 4.68 ± 1.24 μg·kg·mL(-1)·mg(-1), P < 0.01).",Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22476391/),[kg·μg] / [mg·ml],4.68,47910,DB00564,Carbamazepine
,22321408,flow rate,"The mobile phase consisted of acetonitrile-10 mM ammonium acetate buffer solution-formic acid (35:65:0.2, v/v/v) and delivered at the flow rate of 0.25 mL/min.",Development and validation of an LC-ESI-MS/MS method for the determination of nitidine chloride in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22321408/),[ml] / [min],0.25,48343,DB00564,Carbamazepine
,29648728,relative bioavailability,"However, these statistical differences do not have practical implications and the two formulations (F(0) and F(1)) were found to be bioequivalent as the relative bioavailability of both formulations (106.9%) falls with- in the acceptable FDA set range of two bioequivalent products 80-125%.",RELATIVE BIOAVAILABILITY STUDY OF SUCCINIC ACID COCRYSTAL TABLET AND MARKETED CONVENTIONAL IMMEDIATE RELEASE TABLET FORMULATION OF CARBAMAZEPINE 200 MG IN RABBITS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29648728/),%,106.9,49300,DB00564,Carbamazepine
,29648728,relative bioavailability,"However, these statistical differences do not have practical implications and the two formulations (F(0) and F(1)) were found to be bioequivalent as the relative bioavailability of both formulations (106.9%) falls with- in the acceptable FDA set range of two bioequivalent products 80-125%.",RELATIVE BIOAVAILABILITY STUDY OF SUCCINIC ACID COCRYSTAL TABLET AND MARKETED CONVENTIONAL IMMEDIATE RELEASE TABLET FORMULATION OF CARBAMAZEPINE 200 MG IN RABBITS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29648728/),%,80-125,49301,DB00564,Carbamazepine
,10084159,peak plasma concentration,The peak plasma concentration of 1.99 +/- 0.56 micrograms.,Formulation and in vitro/in vivo investigation of carbamazepine controlled-release matrix tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084159/),μg,1.99,49591,DB00564,Carbamazepine
,10084159,AUC0-infinity,"ml-1 for Tegretol CR 200 at 15.2 +/- 8.9 h, and AUC0-infinity values of 85.2 +/- 30.8 micrograms.",Formulation and in vitro/in vivo investigation of carbamazepine controlled-release matrix tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084159/),μg,85.2,49592,DB00564,Carbamazepine
,8451779,bioavailability,"This reduction in FEL bioavailability is much smaller than that observed after co-administration of carbamazepine (CBZ) (i.e., 94%).",Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451779/),%,94,49762,DB00564,Carbamazepine
,30265980,absolute bioavailability,"Following oral administration, the absolute bioavailability was 7.04%.","Elucidation of pharmacokinetics of novel DNA ligase I inhibitor, S012-1332 in rats: Integration of in vitro and in vivo findings. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30265980/),%,7.04,51260,DB00564,Carbamazepine
,30265980,effective permeability,"The effective permeability across the intestinal membrane in in situ single pass perfusion study for S012-1332 was 5.58 ± 1.83 * 10-5 cm/sec compared to 5.99 ± 0.65 * 10-5 cm/sec for carbamazepine, with no significant difference, indicating S012-1332 has high permeability.","Elucidation of pharmacokinetics of novel DNA ligase I inhibitor, S012-1332 in rats: Integration of in vitro and in vivo findings. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30265980/),[cm] / [s],5.58,51261,DB00564,Carbamazepine
,30265980,effective permeability,"The effective permeability across the intestinal membrane in in situ single pass perfusion study for S012-1332 was 5.58 ± 1.83 * 10-5 cm/sec compared to 5.99 ± 0.65 * 10-5 cm/sec for carbamazepine, with no significant difference, indicating S012-1332 has high permeability.","Elucidation of pharmacokinetics of novel DNA ligase I inhibitor, S012-1332 in rats: Integration of in vitro and in vivo findings. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30265980/),[cm] / [s],5.99,51262,DB00564,Carbamazepine
,23316845,flow rate,"After a simple protein precipitation using methanol, LND and carbamazepine (IS) were separated on Acquity UPLC BEH™ C18 column (50 × 2.1 mm, i.d. 1.7 μm, Waters, USA) using a mobile phase consisted of acetonitrile:water:formic acid (65:35:0.1%, v/v/v) pumped at a flow rate of 0.2 mL/min.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),[ml] / [min],0.2,51317,DB00564,Carbamazepine
,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,260.1,51318,DB00564,Carbamazepine
>,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,149.0,51319,DB00564,Carbamazepine
>,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,237.0,51320,DB00564,Carbamazepine
>,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,179.0,51321,DB00564,Carbamazepine
,26818624,saliva/plasma MHD ratio,"The saliva/plasma MHD ratio was around 0.71 and had no significant difference with age, gender, and combined medications.",Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818624/),,0.71,51461,DB00564,Carbamazepine
,12823575,CL/F,"Compared with corresponding controls, mean CBZ CL/F values were 23% and 24% lower, respectively, in the groups of elderly patients receiving monotherapy (57.1 +/- 20.6 vs. 74.6 +/- 28.3 ml/h/kg; p < 0.0001) and PB comedication (74.7 +/- 25.5 vs. 98.7 +/- 34.9 ml/h/kg; p < 0.01).",Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823575/),[ml] / [h·kg],57.1,51545,DB00564,Carbamazepine
,12823575,CL/F,"Compared with corresponding controls, mean CBZ CL/F values were 23% and 24% lower, respectively, in the groups of elderly patients receiving monotherapy (57.1 +/- 20.6 vs. 74.6 +/- 28.3 ml/h/kg; p < 0.0001) and PB comedication (74.7 +/- 25.5 vs. 98.7 +/- 34.9 ml/h/kg; p < 0.01).",Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823575/),[ml] / [h·kg],74.6,51546,DB00564,Carbamazepine
,12823575,CL/F,"Compared with corresponding controls, mean CBZ CL/F values were 23% and 24% lower, respectively, in the groups of elderly patients receiving monotherapy (57.1 +/- 20.6 vs. 74.6 +/- 28.3 ml/h/kg; p < 0.0001) and PB comedication (74.7 +/- 25.5 vs. 98.7 +/- 34.9 ml/h/kg; p < 0.01).",Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823575/),[ml] / [h·kg],74.7,51547,DB00564,Carbamazepine
,12823575,CL/F,"Compared with corresponding controls, mean CBZ CL/F values were 23% and 24% lower, respectively, in the groups of elderly patients receiving monotherapy (57.1 +/- 20.6 vs. 74.6 +/- 28.3 ml/h/kg; p < 0.0001) and PB comedication (74.7 +/- 25.5 vs. 98.7 +/- 34.9 ml/h/kg; p < 0.01).",Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823575/),[ml] / [h·kg],98.7,51548,DB00564,Carbamazepine
,6403891,accumulation half-life,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),h,49.7,52153,DB00564,Carbamazepine
,6403891,time to steady state,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),d,10.4,52154,DB00564,Carbamazepine
,6403891,elimination half-life,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),h,72.2,52155,DB00564,Carbamazepine
,29169112,free fraction at the time of peak plasma concentration,"The free fraction at the time of peak plasma concentration of OXC was 0.27 for OXC, 0.37 for S-(+)-MHD and 0.42 for R-(-)-MHD.",Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29169112/),,0.27,52378,DB00564,Carbamazepine
,29169112,free fraction at the time of peak plasma concentration,"The free fraction at the time of peak plasma concentration of OXC was 0.27 for OXC, 0.37 for S-(+)-MHD and 0.42 for R-(-)-MHD.",Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29169112/),,0.37,52379,DB00564,Carbamazepine
,29169112,free fraction at the time of peak plasma concentration,"The free fraction at the time of peak plasma concentration of OXC was 0.27 for OXC, 0.37 for S-(+)-MHD and 0.42 for R-(-)-MHD.",Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29169112/),,0.42,52380,DB00564,Carbamazepine
,22271001,C(max),"The C(max) (µg·ml⁻¹, 8.13/3.65) and t(max) (h, 1.83/0.92) were increased more than two-fold and the AUC₀₋₂₄ (µg·h·ml⁻¹, 20.09/8.19) was 2.5 times that of the values obtained under fasting conditions.",Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271001/),-1,8.13,53202,DB00564,Carbamazepine
,22271001,C(max),"The C(max) (µg·ml⁻¹, 8.13/3.65) and t(max) (h, 1.83/0.92) were increased more than two-fold and the AUC₀₋₂₄ (µg·h·ml⁻¹, 20.09/8.19) was 2.5 times that of the values obtained under fasting conditions.",Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271001/),-1,3.65,53203,DB00564,Carbamazepine
,22271001,t(max),"The C(max) (µg·ml⁻¹, 8.13/3.65) and t(max) (h, 1.83/0.92) were increased more than two-fold and the AUC₀₋₂₄ (µg·h·ml⁻¹, 20.09/8.19) was 2.5 times that of the values obtained under fasting conditions.",Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271001/),h,1.83,53204,DB00564,Carbamazepine
,22271001,t(max),"The C(max) (µg·ml⁻¹, 8.13/3.65) and t(max) (h, 1.83/0.92) were increased more than two-fold and the AUC₀₋₂₄ (µg·h·ml⁻¹, 20.09/8.19) was 2.5 times that of the values obtained under fasting conditions.",Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271001/),h,0.92,53205,DB00564,Carbamazepine
,22271001,AUC₀₋₂₄,"The C(max) (µg·ml⁻¹, 8.13/3.65) and t(max) (h, 1.83/0.92) were increased more than two-fold and the AUC₀₋₂₄ (µg·h·ml⁻¹, 20.09/8.19) was 2.5 times that of the values obtained under fasting conditions.",Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271001/),h·ml⁻¹·μg,20.09,53206,DB00564,Carbamazepine
,22271001,AUC₀₋₂₄,"The C(max) (µg·ml⁻¹, 8.13/3.65) and t(max) (h, 1.83/0.92) were increased more than two-fold and the AUC₀₋₂₄ (µg·h·ml⁻¹, 20.09/8.19) was 2.5 times that of the values obtained under fasting conditions.",Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271001/),h·ml⁻¹·μg,8.19,53207,DB00564,Carbamazepine
,22271001,bioavailability,"The bioavailability of the tablets under fasting conditions was 91.2%, but increased to 223.5%, 182.8% and 148.4% in the Co-food, 0.5 h before food and 2 h after food groups, respectively (p < 0.05).",Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271001/),%,91.2,53208,DB00564,Carbamazepine
,22271001,bioavailability,"The bioavailability of the tablets under fasting conditions was 91.2%, but increased to 223.5%, 182.8% and 148.4% in the Co-food, 0.5 h before food and 2 h after food groups, respectively (p < 0.05).",Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271001/),%,223.5,53209,DB00564,Carbamazepine
,22271001,bioavailability,"The bioavailability of the tablets under fasting conditions was 91.2%, but increased to 223.5%, 182.8% and 148.4% in the Co-food, 0.5 h before food and 2 h after food groups, respectively (p < 0.05).",Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271001/),%,182.8,53210,DB00564,Carbamazepine
,22271001,bioavailability,"The bioavailability of the tablets under fasting conditions was 91.2%, but increased to 223.5%, 182.8% and 148.4% in the Co-food, 0.5 h before food and 2 h after food groups, respectively (p < 0.05).",Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271001/),%,148.4,53211,DB00564,Carbamazepine
,1628595,blood,Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,16.7,53367,DB00564,Carbamazepine
,1628595,blood,Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,11.2,53368,DB00564,Carbamazepine
,1628595,brain elimination half-lives (t1/2),Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,22.4,53369,DB00564,Carbamazepine
,1628595,brain elimination half-lives (t1/2),Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,11.2,53370,DB00564,Carbamazepine
,1628595,brain elimination half-lives (t1/2),Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,14.7,53371,DB00564,Carbamazepine
,22171585,CL/F,"Eslicarbazepine CL/F was affected by bodyweight, dose of carbamazepine (D(CAR)) and co-administration of barbiturates or phenytoin (AED(PB)), as predicted by the equation CL/F = (2.36 + 0.00149 • D(CAR) + 1.41 • AED(PB)) • (weight/70)0.75, which means that CL/F is 2.36 L/h for a subject with a bodyweight of 70 kg and without concomitant carbamazepine and barbiturates/phenytoin.","Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22171585/),[l] / [h],2.36,53544,DB00564,Carbamazepine
,627139,saliva/plasma ratio,The saliva/plasma ratio for CBZ concentration was 0.26 +/- 0.01 (SD).,"Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627139/),,0.26,53852,DB00564,Carbamazepine
,627139,binding,"Since CBZ binding to plasma proteins is in the order of 76%, saliva CBZ concentration seems to reflect the unbound fraction of the drug in plasma.","Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627139/),%,76,53853,DB00564,Carbamazepine
,3992620,elimination half-life,Analysis of simultaneous plasma CBZ and CBZ-EP concentration-time data by iterative curve fitting to a one-compartment linear model permitted the calculation of elimination kinetic parameters of the CBZ-EP; the mean elimination half-life was 6.9 +/- 2.7 h.,Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3992620/),h,6.9,54101,DB00564,Carbamazepine
,26924357,maximal encapsulation,Nano-spherical OX-emulsomes with maximal encapsulation of 96.75% were generated.,Identifying lipidic emulsomes for improved oxcarbazepine brain targeting: In vitro and rat in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26924357/),,96,54358,DB00564,Carbamazepine
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB00564,Carbamazepine
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB00564,Carbamazepine
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB00564,Carbamazepine
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB00564,Carbamazepine
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB00564,Carbamazepine
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,58.4,55481,DB00564,Carbamazepine
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,57.4,55482,DB00564,Carbamazepine
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,50.2,55483,DB00564,Carbamazepine
lower,24050973,brain/plasma ratios,"All the test compounds presented brain/plasma ratios lower than 1.0, suggesting that the blood-brain barrier restricts drug entry into the brain.","Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24050973/),,1.0,56614,DB00564,Carbamazepine
>,24050973,brain/plasma ratios,"In agreement with in vitro studies already performed within our research group, CBZ, CBZ-10,11-epoxide and oxcarbazepine exhibited the highest brain/plasma ratios (>0.50), followed by eslicarbazepine, R-licarbazepine, trans-diol and BIA 2-024 (ratios within 0.05-0.50).","Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24050973/),,0.50,56615,DB00564,Carbamazepine
,12405865,bioavailability,Methadone has a mean bioavailability of around 75% (range 36-100%).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,75,57243,DB00564,Carbamazepine
,12405865,free fraction,"Its mean free fraction is around 13%, with a 4-fold interindividual variation.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,13,57244,DB00564,Carbamazepine
,12405865,volume of distribution,Its volume of distribution is about 4 L/kg (range 2-13 L/kg).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [kg],4,57245,DB00564,Carbamazepine
,12405865,Total body clearance,"Total body clearance is about 0.095 L/min, with wide interindividual variation (range 0.02-2 L/min).",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [min],0.095,57246,DB00564,Carbamazepine
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,22,57247,DB00564,Carbamazepine
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,5,57248,DB00564,Carbamazepine
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],400,57249,DB00564,Carbamazepine
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],250,57250,DB00564,Carbamazepine
sooner,9834004,time of maximum plasma concentration,"In vivo fraction absorbed plots indicated that the three generic formulations were absorbed more rapidly than the innovator product, and the mean time of maximum plasma concentration was 6-7 hr sooner for the generic formulations.",The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834004/),h,6-7,58537,DB00564,Carbamazepine
,33217013,total clearance,"A 1-compartment PK model with first-order absorption and elimination best described the parent carbamazepine data, with a total clearance of 1.96 L/h, central distribution volume of 164 L and absorption rate constant of 0.45 h-1 .",Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217013/),[l] / [h],1.96,58761,DB00564,Carbamazepine
,33217013,central distribution volume,"A 1-compartment PK model with first-order absorption and elimination best described the parent carbamazepine data, with a total clearance of 1.96 L/h, central distribution volume of 164 L and absorption rate constant of 0.45 h-1 .",Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217013/),l,164,58762,DB00564,Carbamazepine
,33217013,absorption rate constant,"A 1-compartment PK model with first-order absorption and elimination best described the parent carbamazepine data, with a total clearance of 1.96 L/h, central distribution volume of 164 L and absorption rate constant of 0.45 h-1 .",Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33217013/),1/[h],0.45,58763,DB00564,Carbamazepine
,14639056,CL/F,"In particular, CL/F values in children aged less than 10 years (112 +/- 82 mL/kg/h, mean +/- SD, n = 14) were almost three times as high as those observed in patients aged >15 to 30 years (42 +/- 16 mL/kg/h, n = 17), whereas the CL/F value in children aged 10 to 15 years (66 +/- 22 mL/kg/h, n = 11) was intermediate between those found in the two other age groups.","Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639056/),[ml] / [h·kg],112,60607,DB00564,Carbamazepine
,14639056,CL/F,"In particular, CL/F values in children aged less than 10 years (112 +/- 82 mL/kg/h, mean +/- SD, n = 14) were almost three times as high as those observed in patients aged >15 to 30 years (42 +/- 16 mL/kg/h, n = 17), whereas the CL/F value in children aged 10 to 15 years (66 +/- 22 mL/kg/h, n = 11) was intermediate between those found in the two other age groups.","Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639056/),[ml] / [h·kg],42,60608,DB00564,Carbamazepine
,14639056,CL/F,"In particular, CL/F values in children aged less than 10 years (112 +/- 82 mL/kg/h, mean +/- SD, n = 14) were almost three times as high as those observed in patients aged >15 to 30 years (42 +/- 16 mL/kg/h, n = 17), whereas the CL/F value in children aged 10 to 15 years (66 +/- 22 mL/kg/h, n = 11) was intermediate between those found in the two other age groups.","Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639056/),[ml] / [h·kg],66,60609,DB00564,Carbamazepine
,17711537,half-life,"Rapid development of tolerance was demonstrated for most neurological adverse effects, with a characteristic half-life of 02.29 h and an initial EC50 of 2.33 mg l(-1).",Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17711537/),h,02.29,60758,DB00564,Carbamazepine
,17711537,EC50,"Rapid development of tolerance was demonstrated for most neurological adverse effects, with a characteristic half-life of 02.29 h and an initial EC50 of 2.33 mg l(-1).",Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17711537/),[mg] / [l],2.33,60759,DB00564,Carbamazepine
,14673555,CL,The population CL as estimated by base model (no covariates) was 0.581 l h(-1) with inter-individual variability (C.V. %) of 17.4% and SD of residual error was 6.82 mg l(-1).,Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14673555/),[l] / [h],0.581,61129,DB00564,Carbamazepine
,31222537,apparent clearance (CL/F),"Average parameter estimates for valproic acid apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.14 L/h and 37.7 L (fixed), respectively.",Estimation of apparent clearance of valproic acid in adult Saudi patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222537/),[l] / [h],0.14,63153,DB00564,Carbamazepine
,31222537,apparent volume of distribution (V/F),"Average parameter estimates for valproic acid apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.14 L/h and 37.7 L (fixed), respectively.",Estimation of apparent clearance of valproic acid in adult Saudi patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222537/),l,37.7,63154,DB00564,Carbamazepine
,12576167,concentration at 1h (C(1h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],2.1,63306,DB00564,Carbamazepine
,12576167,concentration at 12h (C(12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],0.8,63307,DB00564,Carbamazepine
,12576167,area under the curve from 0 to 12h (AUC(0-12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],17.1,63308,DB00564,Carbamazepine
,12576167,half-life (t(1/2)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),h,8.1,63309,DB00564,Carbamazepine
,12576167,apparent oral clearance (CL/F),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),1/[mlmin],0.97,63310,DB00564,Carbamazepine
,9536449,apparent oral clearance,"Carbamazepine significantly (p < .001) increased the apparent oral clearance (0.90 +/- 0.21 vs. 2.13 +/- 0.54 ml/min/kg) and shortened the elimination half-life (17.1 +/- 4.9 vs. 7.7 +/- 1.7 h), with no significant effect on the peak plasma concentration (11.7 +/- 1.5 vs. 13.0 +/- 3.5 ng/ml).",Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536449/),[ml] / [kg·min],0.90,64015,DB00564,Carbamazepine
,9536449,apparent oral clearance,"Carbamazepine significantly (p < .001) increased the apparent oral clearance (0.90 +/- 0.21 vs. 2.13 +/- 0.54 ml/min/kg) and shortened the elimination half-life (17.1 +/- 4.9 vs. 7.7 +/- 1.7 h), with no significant effect on the peak plasma concentration (11.7 +/- 1.5 vs. 13.0 +/- 3.5 ng/ml).",Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536449/),[ml] / [kg·min],2.13,64016,DB00564,Carbamazepine
,9536449,elimination half-life,"Carbamazepine significantly (p < .001) increased the apparent oral clearance (0.90 +/- 0.21 vs. 2.13 +/- 0.54 ml/min/kg) and shortened the elimination half-life (17.1 +/- 4.9 vs. 7.7 +/- 1.7 h), with no significant effect on the peak plasma concentration (11.7 +/- 1.5 vs. 13.0 +/- 3.5 ng/ml).",Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536449/),h,17.1,64017,DB00564,Carbamazepine
,9536449,elimination half-life,"Carbamazepine significantly (p < .001) increased the apparent oral clearance (0.90 +/- 0.21 vs. 2.13 +/- 0.54 ml/min/kg) and shortened the elimination half-life (17.1 +/- 4.9 vs. 7.7 +/- 1.7 h), with no significant effect on the peak plasma concentration (11.7 +/- 1.5 vs. 13.0 +/- 3.5 ng/ml).",Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536449/),h,7.7,64018,DB00564,Carbamazepine
,9536449,peak plasma concentration,"Carbamazepine significantly (p < .001) increased the apparent oral clearance (0.90 +/- 0.21 vs. 2.13 +/- 0.54 ml/min/kg) and shortened the elimination half-life (17.1 +/- 4.9 vs. 7.7 +/- 1.7 h), with no significant effect on the peak plasma concentration (11.7 +/- 1.5 vs. 13.0 +/- 3.5 ng/ml).",Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536449/),[ng] / [ml],11.7,64019,DB00564,Carbamazepine
,9536449,peak plasma concentration,"Carbamazepine significantly (p < .001) increased the apparent oral clearance (0.90 +/- 0.21 vs. 2.13 +/- 0.54 ml/min/kg) and shortened the elimination half-life (17.1 +/- 4.9 vs. 7.7 +/- 1.7 h), with no significant effect on the peak plasma concentration (11.7 +/- 1.5 vs. 13.0 +/- 3.5 ng/ml).",Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536449/),[ng] / [ml],13.0,64020,DB00564,Carbamazepine
,15730534,CL/F,PB CL/F values were significantly lower in elderly patients than in controls (3.2 +/- 0.8 vs. 4.1 +/- 1.2 ml/h/kg; p < 0.0001).,Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730534/),[ml] / [h·kg],3.2,65549,DB00564,Carbamazepine
,15730534,CL/F,PB CL/F values were significantly lower in elderly patients than in controls (3.2 +/- 0.8 vs. 4.1 +/- 1.2 ml/h/kg; p < 0.0001).,Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730534/),[ml] / [h·kg],4.1,65550,DB00564,Carbamazepine
less,24732215,t1/2,"The results showed that after intravenous administration of CX, it was mainly distributed in blood and eliminated quickly, t1/2 was less than 1h.",Development of LC-MS determination method and back-propagation ANN pharmacokinetic model of corynoxeine in rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24732215/),h,1,66223,DB00564,Carbamazepine
,26514967,AUC(0-12),The kinetic disposition of MHD was enantioselective with plasma accumulation (AUC(0-12) S-(+)/R-(-) ratio of 4.38) and lower fraction unbound (0.37 vs 0.42) of the S-(+)-MHD enantiomer.,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),,4.38,66710,DB00564,Carbamazepine
,26514967,fraction unbound,The kinetic disposition of MHD was enantioselective with plasma accumulation (AUC(0-12) S-(+)/R-(-) ratio of 4.38) and lower fraction unbound (0.37 vs 0.42) of the S-(+)-MHD enantiomer.,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),,0.37,66711,DB00564,Carbamazepine
,26514967,fraction unbound,The kinetic disposition of MHD was enantioselective with plasma accumulation (AUC(0-12) S-(+)/R-(-) ratio of 4.38) and lower fraction unbound (0.37 vs 0.42) of the S-(+)-MHD enantiomer.,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),,0.42,66712,DB00564,Carbamazepine
,26514967,mean residence time,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),h,4.91,66713,DB00564,Carbamazepine
,26514967,mean residence time,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),h,4.20,66714,DB00564,Carbamazepine
,26514967,apparent volume of distribution,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[l] / [kg],4.72,66715,DB00564,Carbamazepine
,26514967,apparent volume of distribution,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[l] / [kg],3.15,66716,DB00564,Carbamazepine
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],2.65,66717,DB00564,Carbamazepine
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],2.98,66718,DB00564,Carbamazepine
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],10.15,66719,DB00564,Carbamazepine
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],11.60,66720,DB00564,Carbamazepine
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],1.98,66721,DB00564,Carbamazepine
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],2.18,66722,DB00564,Carbamazepine
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],8.10,66723,DB00564,Carbamazepine
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],8.83,66724,DB00564,Carbamazepine
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],23.79,66725,DB00564,Carbamazepine
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],26.19,66726,DB00564,Carbamazepine
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],97.87,66727,DB00564,Carbamazepine
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],108.35,66728,DB00564,Carbamazepine
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,34.4,67748,DB00564,Carbamazepine
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,50.2,67749,DB00564,Carbamazepine
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,5.1,67750,DB00564,Carbamazepine
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,11.4,67751,DB00564,Carbamazepine
,3595702,clearance,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [h·kg],2.99,67752,DB00564,Carbamazepine
,3595702,clearance,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [h·kg],1.60,67753,DB00564,Carbamazepine
,3595702,volume of distribution,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [kg],126,67754,DB00564,Carbamazepine
,3595702,volume of distribution,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [kg],106,67755,DB00564,Carbamazepine
,3595702,unbound fraction,The unbound fraction of chlorpropamide in serum was also higher in the patients (5.7%) than in the healthy subjects (4.4%).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),%,5.7,67756,DB00564,Carbamazepine
,3595702,unbound fraction,The unbound fraction of chlorpropamide in serum was also higher in the patients (5.7%) than in the healthy subjects (4.4%).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),%,4.4,67757,DB00564,Carbamazepine
,7571921,Serum drug concentrations,Serum drug concentrations were therapeutically optimal (6-8 mg/ml) only in one third of children.,[Therapeutic drug monitoring and the pharmacokinetics of carbamazepine in children with a convulsive syndrome]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571921/),,6,67804,DB00564,Carbamazepine
,24023446,retention time,"Warfarin, 7-hydroxy warfarin and carbamazepine (internal standard) were separated on a C18 column and had the retention time 3.6 min, 2.9 min and 5.9 min, respectively.",Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023446/),min,3.6,69579,DB00564,Carbamazepine
,24023446,retention time,"Warfarin, 7-hydroxy warfarin and carbamazepine (internal standard) were separated on a C18 column and had the retention time 3.6 min, 2.9 min and 5.9 min, respectively.",Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023446/),min,2.9,69580,DB00564,Carbamazepine
,24023446,retention time,"Warfarin, 7-hydroxy warfarin and carbamazepine (internal standard) were separated on a C18 column and had the retention time 3.6 min, 2.9 min and 5.9 min, respectively.",Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023446/),min,5.9,69581,DB00564,Carbamazepine
,24023446,extraction recovery,The extraction recovery was found to be ≃85%.,Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023446/),%,≃85,69582,DB00564,Carbamazepine
,7916169,elimination half-lives,"After withdrawal of sulthiame in 11 patients, short elimination half-lives (8.65 +/- 3.10 h) were estimated.",Pharmacokinetics of sulthiame in epileptic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7916169/),h,8.65,69627,DB00564,Carbamazepine
,9332885,oral clearance,"Overall, CBZ oral clearance was unchanged following the introduction of LTG (5.58 +/- 1.60 vs. 5.81 +/- 1.74 1/h, P = 0.630).",Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332885/),[1] / [h],5.58,69746,DB00564,Carbamazepine
,9332885,oral clearance,"Overall, CBZ oral clearance was unchanged following the introduction of LTG (5.58 +/- 1.60 vs. 5.81 +/- 1.74 1/h, P = 0.630).",Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332885/),[1] / [h],5.81,69747,DB00564,Carbamazepine
,9332885,to,"Likewise, CBZE to CBZ serum concentration ratios were not significantly different (0.241 +/- 0.082 vs. 0.232 +/- 0.082, P = 0.782).",Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332885/),,0.241,69748,DB00564,Carbamazepine
,9332885,serum concentration ratios,"Likewise, CBZE to CBZ serum concentration ratios were not significantly different (0.241 +/- 0.082 vs. 0.232 +/- 0.082, P = 0.782).",Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332885/),,0.241,69749,DB00564,Carbamazepine
,9332885,serum concentration ratios,"Likewise, CBZE to CBZ serum concentration ratios were not significantly different (0.241 +/- 0.082 vs. 0.232 +/- 0.082, P = 0.782).",Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332885/),,0.232,69750,DB00564,Carbamazepine
,890949,saliva/plasma ratio,The saliva/plasma ratio for carbamazepine was 0.26 +/- 0.02 (S.D.).,Relationship between carbamazepine concentrations in plasma and saliva in man as determined by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/890949/),,0.26,70603,DB00564,Carbamazepine
,26751267,total C/D ratio,"The interindividual pharmacokinetic variability was extensive, as illustrated by a 100-fold variability in serum concentration compared with dose (total C/D ratio 0.03-3.29 µmol·L·mg).",Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751267/),l·mg·μM,0.03-3.29,70769,DB00564,Carbamazepine
,688725,turnover half-lives,Apparent enzyme(s) turnover half-lives ranged between 1 and 6 days.,Time-course of interaction between carbamazepine and clonazepam in normal man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688725/),d,1 and 6,70995,DB00564,Carbamazepine
,3446773,absolute bioavailabilities,"The kinetic parameters of disposition for CBZ and EPO were calculated by the method of Wagner, assuming the absolute bioavailabilities of CBZ and EPO to be 1.0 and 0.81, respectively.",Pharmacokinetic study of carbamazepine and its epoxide metabolite in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3446773/),,1.0,72742,DB00564,Carbamazepine
,3446773,absolute bioavailabilities,"The kinetic parameters of disposition for CBZ and EPO were calculated by the method of Wagner, assuming the absolute bioavailabilities of CBZ and EPO to be 1.0 and 0.81, respectively.",Pharmacokinetic study of carbamazepine and its epoxide metabolite in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3446773/),,0.81,72743,DB00564,Carbamazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.32,73970,DB00564,Carbamazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.34,73971,DB00564,Carbamazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.45,73972,DB00564,Carbamazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.46,73973,DB00564,Carbamazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.52,73974,DB00564,Carbamazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.53,73975,DB00564,Carbamazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.54,73976,DB00564,Carbamazepine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.52,74496,DB00564,Carbamazepine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.17,74497,DB00564,Carbamazepine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.803,74498,DB00564,Carbamazepine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.636,74499,DB00564,Carbamazepine
,29403791,flow rate,The reconstituted samples were chromatographed on a Alltima HP C18 column by using a 60:40 (v/v) mixture of acetonitrile and 10 mM ammonium acetate (pH 3.0) as the mobile phase at a flow rate of 1.1 mL/min.,"Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403791/),[ml] / [min],1.1,74796,DB00564,Carbamazepine
,29403791,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 plasma samples per day.,"Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403791/),min,2.5,74797,DB00564,Carbamazepine
,2710641,peak/mean trough carbamazepine-serum concentration ratio,The mean peak/mean trough carbamazepine-serum concentration ratio was slightly lower after the intake of divitabs in comparison to normal formulation: 1.14 +/- 0.447 versus 1.23 +/- 0.545 (mean +/- SD).,A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients. Preliminary pharmacokinetic results. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710641/),,1.14,75374,DB00564,Carbamazepine
,2710641,peak/mean trough carbamazepine-serum concentration ratio,The mean peak/mean trough carbamazepine-serum concentration ratio was slightly lower after the intake of divitabs in comparison to normal formulation: 1.14 +/- 0.447 versus 1.23 +/- 0.545 (mean +/- SD).,A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients. Preliminary pharmacokinetic results. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710641/),,1.23,75375,DB00564,Carbamazepine
at least,2710641,peak/trough carbamazepine-serum level ratios,"In patients with peak/trough carbamazepine-serum level ratios of at least 1.30 after the intake of normal formulation, divitabs had a significant advantage.",A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients. Preliminary pharmacokinetic results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710641/),,1.30,75376,DB00564,Carbamazepine
,20433250,particle size,The mean particle size of S-SMEDDS formulation after dispersion was about 33.7?,Studies on preparation of carbamazepine (CBZ) supersaturatable self-microemulsifying (S-SMEDDS) formulation and relative bioavailability in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20433250/),?,33.7,75742,DB00564,Carbamazepine
,20433250,AUC(0?t),"In pharmacokinetic parameters of S-SMEDDS formulation, AUC(0?t) and C(max) were 9.83???2.47??g?ml(?1)?h and 4.96???1.16??g?ml(?1), compared to the conventional tablet which were 1.67???1.19??g?ml(?1)?h and 0.74???0.19??g?ml(?1), respectively.",Studies on preparation of carbamazepine (CBZ) supersaturatable self-microemulsifying (S-SMEDDS) formulation and relative bioavailability in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20433250/),?,9.83,75743,DB00564,Carbamazepine
,20433250,AUC(0?t),"In pharmacokinetic parameters of S-SMEDDS formulation, AUC(0?t) and C(max) were 9.83???2.47??g?ml(?1)?h and 4.96???1.16??g?ml(?1), compared to the conventional tablet which were 1.67???1.19??g?ml(?1)?h and 0.74???0.19??g?ml(?1), respectively.",Studies on preparation of carbamazepine (CBZ) supersaturatable self-microemulsifying (S-SMEDDS) formulation and relative bioavailability in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20433250/),?,1.67,75744,DB00564,Carbamazepine
,20433250,C(max),"In pharmacokinetic parameters of S-SMEDDS formulation, AUC(0?t) and C(max) were 9.83???2.47??g?ml(?1)?h and 4.96???1.16??g?ml(?1), compared to the conventional tablet which were 1.67???1.19??g?ml(?1)?h and 0.74???0.19??g?ml(?1), respectively.",Studies on preparation of carbamazepine (CBZ) supersaturatable self-microemulsifying (S-SMEDDS) formulation and relative bioavailability in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20433250/),?,4.96,75745,DB00564,Carbamazepine
,20433250,C(max),"In pharmacokinetic parameters of S-SMEDDS formulation, AUC(0?t) and C(max) were 9.83???2.47??g?ml(?1)?h and 4.96???1.16??g?ml(?1), compared to the conventional tablet which were 1.67???1.19??g?ml(?1)?h and 0.74???0.19??g?ml(?1), respectively.",Studies on preparation of carbamazepine (CBZ) supersaturatable self-microemulsifying (S-SMEDDS) formulation and relative bioavailability in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20433250/),?,0.74,75746,DB00564,Carbamazepine
,15371980,Oral absorption,"Oral absorption of talinolol was significantly lower after carbamazepine comedication (53.2% +/- 15.5% versus 62.1% +/- 13.0%, P =.018), and renal clearance and metabolic clearance were significantly increased, correlated in each case with MDR1 mRNA ( r = 0.612, P =.020, and r = 0.554, P =.040, respectively) and MRP2 mRNA ( r = 0.596, P =.025, and r = 0.565, P =.035, respectively).",Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371980/),%,53.2,76506,DB00564,Carbamazepine
,15371980,Oral absorption,"Oral absorption of talinolol was significantly lower after carbamazepine comedication (53.2% +/- 15.5% versus 62.1% +/- 13.0%, P =.018), and renal clearance and metabolic clearance were significantly increased, correlated in each case with MDR1 mRNA ( r = 0.612, P =.020, and r = 0.554, P =.040, respectively) and MRP2 mRNA ( r = 0.596, P =.025, and r = 0.565, P =.035, respectively).",Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371980/),%,62.1,76507,DB00564,Carbamazepine
,20606310,Volume of distribution,Volume of distribution of topiramate was 0.518 l/kg.,A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606310/),[l] / [kg],0.518,78908,DB00564,Carbamazepine
,20606310,oral clearance,"For a typical patient oral clearance was estimated at 1.47 l/h, with interindividual variability of 39.2%.",A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606310/),[l] / [h],1.47,78909,DB00564,Carbamazepine
< or =,11145056,absolute recovery,The absolute recovery of the analyte in brain and plasma samples was < or = 90%.,"Determination of the enaminone DM5, an anti-epileptic agent, in mouse plasma and brain tissue by high-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145056/),%,90,79604,DB00564,Carbamazepine
,17116022,oral clearance,"When RWJ-333369 was administered with CBZ, its mean (SD) oral clearance increased from 3.2 L/h to 4.9 L/h and consequently its mean half-life was shortened from 10.4 (1.9) h to 7.4 (1.2) h, and mean AUCss and C(max) were reduced by 37% and 30%, respectively.",Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17116022/),[l] / [h],3.2,79724,DB00564,Carbamazepine
,17116022,oral clearance,"When RWJ-333369 was administered with CBZ, its mean (SD) oral clearance increased from 3.2 L/h to 4.9 L/h and consequently its mean half-life was shortened from 10.4 (1.9) h to 7.4 (1.2) h, and mean AUCss and C(max) were reduced by 37% and 30%, respectively.",Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17116022/),[l] / [h],4.9,79725,DB00564,Carbamazepine
,17116022,half-life,"When RWJ-333369 was administered with CBZ, its mean (SD) oral clearance increased from 3.2 L/h to 4.9 L/h and consequently its mean half-life was shortened from 10.4 (1.9) h to 7.4 (1.2) h, and mean AUCss and C(max) were reduced by 37% and 30%, respectively.",Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17116022/),h,10.4,79726,DB00564,Carbamazepine
,17116022,half-life,"When RWJ-333369 was administered with CBZ, its mean (SD) oral clearance increased from 3.2 L/h to 4.9 L/h and consequently its mean half-life was shortened from 10.4 (1.9) h to 7.4 (1.2) h, and mean AUCss and C(max) were reduced by 37% and 30%, respectively.",Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17116022/),h,7.4,79727,DB00564,Carbamazepine
,8119045,bioavailability,The bioavailability of the oral formulation is about 98%.,Lamotrigine clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),%,98,80086,DB00564,Carbamazepine
,8119045,plasma protein binding,The degree of plasma protein binding is 56%.,Lamotrigine clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),%,56,80087,DB00564,Carbamazepine
,8119045,half-lives,Mean half-lives of lamotrigine in healthy volunteers (single and multiple doses) as well as in epileptic patients receiving lamotrigine monotherapy range from 22.8 to 37.4 hours.,Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,22.8 to 37.4,80088,DB00564,Carbamazepine
,8119045,half-life,"Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours).",Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,13.5 to 15,80089,DB00564,Carbamazepine
,8119045,half-life,"Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours).",Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,48.3 to 59,80090,DB00564,Carbamazepine
,28600961,LOD,"The calibration curves were found to be linear in concentration range of 1.98-2000ng/mL (r2≥0.995) having LOD and LLOQ of 0.80 and 1.98ng/mL, respectively.",UPLC-MS/MS assay for identification and quantification of brivaracetam in plasma sample: Application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28600961/),,0,80550,DB00564,Carbamazepine
,8120112,peak height,Linear relationships between the amount of drug and peak height were confirmed at 1-20 micrograms/ml in serum for carbamazepine and 5-40 micrograms/ml in serum for phenytoin and phenobarbital.,Simple and accurate high-performance liquid chromatographic method for the measurement of three antiepileptics in therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120112/),,1,80668,DB00564,Carbamazepine
,8120112,peak height,Linear relationships between the amount of drug and peak height were confirmed at 1-20 micrograms/ml in serum for carbamazepine and 5-40 micrograms/ml in serum for phenytoin and phenobarbital.,Simple and accurate high-performance liquid chromatographic method for the measurement of three antiepileptics in therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120112/),,5-40,80669,DB00564,Carbamazepine
,9832379,ED50,"Valproate, at its ED50 of 280 mg/kg against maximal electroshock, produced motor impairment.","LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832379/),[mg] / [kg],280,81809,DB00564,Carbamazepine
,17971810,half-lives,"The half-lives of CYP3A4 and CYP1A2 were estimated to be 70 and 105 h, respectively.","Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17971810/),h,70,81949,DB00564,Carbamazepine
,17971810,half-lives,"The half-lives of CYP3A4 and CYP1A2 were estimated to be 70 and 105 h, respectively.","Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17971810/),h,105,81950,DB00564,Carbamazepine
,11103752,elimination half-life,The elimination half-life of repaglinide was shortened from 1.5 to 1.1 hours (P < .01).,Rifampin decreases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),h,1.5,82164,DB00564,Carbamazepine
,11103752,elimination half-life,The elimination half-life of repaglinide was shortened from 1.5 to 1.1 hours (P < .01).,Rifampin decreases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),h,1.1,82165,DB00564,Carbamazepine
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],0.94,82166,DB00564,Carbamazepine
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],-,82167,DB00564,Carbamazepine
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],0.23,82168,DB00564,Carbamazepine
,25220641,Ka,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),1/[h],0.83,82170,DB00564,Carbamazepine
,25220641,Vd,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [kg],0.67,82171,DB00564,Carbamazepine
,25220641,CL,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [h·kg],0.035,82172,DB00564,Carbamazepine
,25220641,MP,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.01,82173,DB00564,Carbamazepine
,25220641,MAE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.46,82174,DB00564,Carbamazepine
,25220641,MSE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),,0.39,82175,DB00564,Carbamazepine
,2089056,resolution,Calculated resolution of 2H10 CBZ from CBZ and of 2H10 PHT from PHT were 1.3.,Simultaneous separation and determination (in serum) of phenytoin and carbamazepine and their deuterated analogues by high-performance liquid chromatography--ultraviolet detection for tracer studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2089056/),,1.3,83183,DB00564,Carbamazepine
,25495693,bioavailability,"After oral ingestion, perampanel is rapidly absorbed and peak plasma concentrations occur 0.5-2.5 h later; its bioavailability is ~100%.",The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),%,100,83917,DB00564,Carbamazepine
,25495693,apparent terminal half-life,"In healthy volunteers, the apparent terminal half-life is ~105 h, whereas the calculated effective half-life is 48 h.",The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),h,105,83918,DB00564,Carbamazepine
,25495693,effective half-life,"In healthy volunteers, the apparent terminal half-life is ~105 h, whereas the calculated effective half-life is 48 h.",The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),h,48,83919,DB00564,Carbamazepine
,25495693,half-life,"In healthy volunteers prescribed carbamazepine, half-life decreases to 25 h.",The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),h,25,83920,DB00564,Carbamazepine
,25495693,Clearance,Clearance values are not significantly different in adolescents (~13.0 ml/min) and the elderly (~10.5 ml/min) compared with adults (10.9 ml/min).,The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),[ml] / [min],13.0,83921,DB00564,Carbamazepine
,25495693,Clearance,Clearance values are not significantly different in adolescents (~13.0 ml/min) and the elderly (~10.5 ml/min) compared with adults (10.9 ml/min).,The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),[ml] / [min],10.5,83922,DB00564,Carbamazepine
,25495693,Clearance,Clearance values are not significantly different in adolescents (~13.0 ml/min) and the elderly (~10.5 ml/min) compared with adults (10.9 ml/min).,The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495693/),[ml] / [min],10.9,83923,DB00564,Carbamazepine
,9114913,Cmin,"2. Overall, trough serum drug concentrations (Cmin) were lower with once daily dosing (Cmin: b.d. 7.5 mg l-1, o.d. 6.5 mg l-1, P < 0.05, 95% CI of the difference -1.3 to -0.1), but no significant differences were found in average (Cav) or peak (Cmax) concentrations, AUC values or fluctuations in CBZ concentrations.",Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114913/),[mg] / [l],7.5,84470,DB00564,Carbamazepine
,9114913,Cmin,"2. Overall, trough serum drug concentrations (Cmin) were lower with once daily dosing (Cmin: b.d. 7.5 mg l-1, o.d. 6.5 mg l-1, P < 0.05, 95% CI of the difference -1.3 to -0.1), but no significant differences were found in average (Cav) or peak (Cmax) concentrations, AUC values or fluctuations in CBZ concentrations.",Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114913/),[mg] / [l],6.5,84471,DB00564,Carbamazepine
,8799524,half-lives,"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),h,29.0,85129,DB00564,Carbamazepine
,8799524,half-lives,"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),h,53.7,85130,DB00564,Carbamazepine
,8799524,apparent oral clearance (CL/F),"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[ml] / [h·kg],15.3,85131,DB00564,Carbamazepine
,8799524,apparent oral clearance (CL/F),"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[ml] / [h·kg],9.2,85132,DB00564,Carbamazepine
,8799524,apparent volume of distribution (V/F),"The apparent volume of distribution (V/F) of ethosuximide was slightly lower in the patients than in controls (0.6 +/- 0.1 vs 0.7 +/- 0.1 l kg-1, P < 0.05).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[l] / [kg],0.6,85133,DB00564,Carbamazepine
,8799524,apparent volume of distribution (V/F),"The apparent volume of distribution (V/F) of ethosuximide was slightly lower in the patients than in controls (0.6 +/- 0.1 vs 0.7 +/- 0.1 l kg-1, P < 0.05).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[l] / [kg],0.7,85134,DB00564,Carbamazepine
,422308,maximum concentrations,"5. Absorption was generally delayed by about half an hour, the maximum concentrations ranging from 3.14 to 10 microgram.",Pharmacokinetics of carbamazepine in the neonate and in the child. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/422308/),μg,3.14 to 10,86079,DB00564,Carbamazepine
,422308,half-life for absorption,The mean half-life for absorption was 1.42 +/- 0.34 hr.,Pharmacokinetics of carbamazepine in the neonate and in the child. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/422308/),h,1.42,86080,DB00564,Carbamazepine
,422308,half-life for elimination,The mean half-life for elimination was 8.76 +/- 0.85 hr.,Pharmacokinetics of carbamazepine in the neonate and in the child. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/422308/),h,8.76,86081,DB00564,Carbamazepine
,20205992,elimination half-life,"Its elimination half-life is very long, around 60 h.",[Therapeutic drug monitoring of zonisamide]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20205992/),h,60,86087,DB00564,Carbamazepine
,8205132,volume of distribution (V),"The volume of distribution (V) was estimated to be 1.27 l/kg in a typical 33-kg patient, assuming that the bioavailability of orally administered zonisamide is 100%.",Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205132/),[l] / [kg],1.27,86252,DB00564,Carbamazepine
,8205132,bioavailability,"The volume of distribution (V) was estimated to be 1.27 l/kg in a typical 33-kg patient, assuming that the bioavailability of orally administered zonisamide is 100%.",Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205132/),%,100,86253,DB00564,Carbamazepine
,8205132,maximal daily dose to be cleared (Vmax),"The maximal daily dose to be cleared (Vmax) and the concentration giving half maximal clearance (a Michaelis-Menten constant) was 27.6 mg/d/kg and 45.9 micrograms/ml, respectively.",Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205132/),[mg] / [d·kg],27.6,86254,DB00564,Carbamazepine
,8205132,concentration giving,"The maximal daily dose to be cleared (Vmax) and the concentration giving half maximal clearance (a Michaelis-Menten constant) was 27.6 mg/d/kg and 45.9 micrograms/ml, respectively.",Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205132/),[mg] / [d·kg],27.6,86255,DB00564,Carbamazepine
,8205132,half maximal clearance (a Michaelis-Menten constant),"The maximal daily dose to be cleared (Vmax) and the concentration giving half maximal clearance (a Michaelis-Menten constant) was 27.6 mg/d/kg and 45.9 micrograms/ml, respectively.",Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205132/),[μg] / [ml],45.9,86256,DB00564,Carbamazepine
,18043476,CL/F,The population estimate of CL/F from the base model was 5.14 L/h with interindividual variability of 50.20%.,Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043476/),[l] / [h],5.14,86360,DB00564,Carbamazepine
,18175970,flow rate,"Chromatographic separation was achieved isocratically on a C18 reversed-phase column within 3.0 min, using a mobile phase of acetonitrile-10 mM ammonium formate (90 : 10 v/v) at a flow rate of 0.3 ml/min.",Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),[ml] / [min],0.3,87504,DB00564,Carbamazepine
>,18175970,m/z,Quantitation was achieved using multiple reaction monitoring (MRM) scan at MRM transitions m/z 253>208 and m/z 281>86 for OXB and the IS respectively.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),,253,87505,DB00564,Carbamazepine
>,18175970,m/z,Quantitation was achieved using multiple reaction monitoring (MRM) scan at MRM transitions m/z 253>208 and m/z 281>86 for OXB and the IS respectively.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),,208,87506,DB00564,Carbamazepine
>,18175970,m/z 281,Quantitation was achieved using multiple reaction monitoring (MRM) scan at MRM transitions m/z 253>208 and m/z 281>86 for OXB and the IS respectively.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),,86,87507,DB00564,Carbamazepine
,18175970,recoveries,Analytical recoveries of OXB from spiked human plasma were in the range of 74.9 to 76.3%.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),%,74.9 to 76.3,87508,DB00564,Carbamazepine
,32534880,trough,"Based on this model, we proposed dosage regimens to achieve trough lamotrigine concentrations within reference interval (2.5-15 mg/L).",Dosing Recommendations Based on Population Pharmacokinetics of Lamotrigine in Mexican Adult Patients With Epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534880/),mg,2.5-15,88099,DB00564,Carbamazepine
,20845455,t(1/2),"The in vivo elimination of N-Gly-CBZ following IV administration in rats was biphasic in nature with a t(1/2) of about 1.1 min, which was very similar to the t(1/2) for appearance of CBZ.",In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845455/),min,1.1,88889,DB00564,Carbamazepine
,20845455,relative AUC ratio,The mean value for the relative AUC ratio for CBZ from N-Gly-CBZ and CBZ from a cyclodextrin solution showed that N-Gly-CBZ delivered a (± SD) 98 ± 16% (± SD) equivalent dose of CBZ in six rats.,In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845455/),,98,88890,DB00564,Carbamazepine
,20845455,overall absolute oral bioavailability,The overall absolute oral bioavailability of CBZ from N-Gly-CBZ was determined to be 41 ± 14% in three rats.,In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845455/),%,41,88891,DB00564,Carbamazepine
,20845455,relative oral bioavailability,The relative oral bioavailability of CBZ from N-Gly-CBZ compared to an oral CBZ control was 1.72 ± 0.54.,In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845455/),,1.72,88892,DB00564,Carbamazepine
,17270398,t(max),"Levetiracetam was rapidly absorbed following oral dosing, with median t(max) of 0.5 h.",Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270398/),h,0.5,91035,DB00564,Carbamazepine
,17270398,t(1/2),Dose proportional increases were observed for C(max) and AUC((0-12)) over the dose range; t(1/2) was 4.9 h.,Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270398/),h,4.9,91036,DB00564,Carbamazepine
,22714390,m/z,"The precursor to the product ion transition for TWo8 derivatives and for the internal standard (carbamazepine) was m/z 776.4 → 387.2 and 237.4 → 194.4, respectively.",Enantioselective LC/ESI-MS/MS analysis and pharmacokinetic and tissue distribution study of (2RS)-1-(7-methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22714390/),,776.4,91255,DB00564,Carbamazepine
,22714390,m/z,"The precursor to the product ion transition for TWo8 derivatives and for the internal standard (carbamazepine) was m/z 776.4 → 387.2 and 237.4 → 194.4, respectively.",Enantioselective LC/ESI-MS/MS analysis and pharmacokinetic and tissue distribution study of (2RS)-1-(7-methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22714390/),,387.2,91256,DB00564,Carbamazepine
,22714390,m/z,"The precursor to the product ion transition for TWo8 derivatives and for the internal standard (carbamazepine) was m/z 776.4 → 387.2 and 237.4 → 194.4, respectively.",Enantioselective LC/ESI-MS/MS analysis and pharmacokinetic and tissue distribution study of (2RS)-1-(7-methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22714390/),,237.4,91257,DB00564,Carbamazepine
,22714390,terminal half-lives,"The terminal half-lives of (-)-(S)-TWo8 and (+)-(R)-TWo8 were 3.2 and 3.9 h, respectively.",Enantioselective LC/ESI-MS/MS analysis and pharmacokinetic and tissue distribution study of (2RS)-1-(7-methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22714390/),h,3.2,91258,DB00564,Carbamazepine
,22714390,terminal half-lives,"The terminal half-lives of (-)-(S)-TWo8 and (+)-(R)-TWo8 were 3.2 and 3.9 h, respectively.",Enantioselective LC/ESI-MS/MS analysis and pharmacokinetic and tissue distribution study of (2RS)-1-(7-methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22714390/),h,3.9,91259,DB00564,Carbamazepine
,12784320,AUC(0-alpha),"The results showed that the pharmacokinetic parameters C(max), AUC and t(1/2) were not statistically different when HEPP was administered alone and with CBZ, (AUC(0-alpha) 82.86+/-19.40 vs 83.24+/-12.56 microg h ml(-1); t( 1 2 beta) 3.40+/-0.29 vs 3.36+/-0.45 h; C(max) 18.93+/-2.99 vs 19.79+/-2.68 microg ml(-1) and T(max) 1.27+/-0.16 vs 1.22+/-0.11 h for HEPP alone and HEPP plus CBZ respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),[h·μg] / [ml],82.86,91351,DB00564,Carbamazepine
,12784320,AUC(0-alpha),"The results showed that the pharmacokinetic parameters C(max), AUC and t(1/2) were not statistically different when HEPP was administered alone and with CBZ, (AUC(0-alpha) 82.86+/-19.40 vs 83.24+/-12.56 microg h ml(-1); t( 1 2 beta) 3.40+/-0.29 vs 3.36+/-0.45 h; C(max) 18.93+/-2.99 vs 19.79+/-2.68 microg ml(-1) and T(max) 1.27+/-0.16 vs 1.22+/-0.11 h for HEPP alone and HEPP plus CBZ respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),[h·μg] / [ml],83.24,91352,DB00564,Carbamazepine
,12784320,t( 1 2 beta),"The results showed that the pharmacokinetic parameters C(max), AUC and t(1/2) were not statistically different when HEPP was administered alone and with CBZ, (AUC(0-alpha) 82.86+/-19.40 vs 83.24+/-12.56 microg h ml(-1); t( 1 2 beta) 3.40+/-0.29 vs 3.36+/-0.45 h; C(max) 18.93+/-2.99 vs 19.79+/-2.68 microg ml(-1) and T(max) 1.27+/-0.16 vs 1.22+/-0.11 h for HEPP alone and HEPP plus CBZ respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),h,3.40,91353,DB00564,Carbamazepine
,12784320,t( 1 2 beta),"The results showed that the pharmacokinetic parameters C(max), AUC and t(1/2) were not statistically different when HEPP was administered alone and with CBZ, (AUC(0-alpha) 82.86+/-19.40 vs 83.24+/-12.56 microg h ml(-1); t( 1 2 beta) 3.40+/-0.29 vs 3.36+/-0.45 h; C(max) 18.93+/-2.99 vs 19.79+/-2.68 microg ml(-1) and T(max) 1.27+/-0.16 vs 1.22+/-0.11 h for HEPP alone and HEPP plus CBZ respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),h,3.36,91354,DB00564,Carbamazepine
,12784320,C(max),"The results showed that the pharmacokinetic parameters C(max), AUC and t(1/2) were not statistically different when HEPP was administered alone and with CBZ, (AUC(0-alpha) 82.86+/-19.40 vs 83.24+/-12.56 microg h ml(-1); t( 1 2 beta) 3.40+/-0.29 vs 3.36+/-0.45 h; C(max) 18.93+/-2.99 vs 19.79+/-2.68 microg ml(-1) and T(max) 1.27+/-0.16 vs 1.22+/-0.11 h for HEPP alone and HEPP plus CBZ respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),[μg] / [ml],18.93,91355,DB00564,Carbamazepine
,12784320,C(max),"The results showed that the pharmacokinetic parameters C(max), AUC and t(1/2) were not statistically different when HEPP was administered alone and with CBZ, (AUC(0-alpha) 82.86+/-19.40 vs 83.24+/-12.56 microg h ml(-1); t( 1 2 beta) 3.40+/-0.29 vs 3.36+/-0.45 h; C(max) 18.93+/-2.99 vs 19.79+/-2.68 microg ml(-1) and T(max) 1.27+/-0.16 vs 1.22+/-0.11 h for HEPP alone and HEPP plus CBZ respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),[μg] / [ml],19.79,91356,DB00564,Carbamazepine
,12784320,T(max),"The results showed that the pharmacokinetic parameters C(max), AUC and t(1/2) were not statistically different when HEPP was administered alone and with CBZ, (AUC(0-alpha) 82.86+/-19.40 vs 83.24+/-12.56 microg h ml(-1); t( 1 2 beta) 3.40+/-0.29 vs 3.36+/-0.45 h; C(max) 18.93+/-2.99 vs 19.79+/-2.68 microg ml(-1) and T(max) 1.27+/-0.16 vs 1.22+/-0.11 h for HEPP alone and HEPP plus CBZ respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),h,1.27,91357,DB00564,Carbamazepine
,12784320,T(max),"The results showed that the pharmacokinetic parameters C(max), AUC and t(1/2) were not statistically different when HEPP was administered alone and with CBZ, (AUC(0-alpha) 82.86+/-19.40 vs 83.24+/-12.56 microg h ml(-1); t( 1 2 beta) 3.40+/-0.29 vs 3.36+/-0.45 h; C(max) 18.93+/-2.99 vs 19.79+/-2.68 microg ml(-1) and T(max) 1.27+/-0.16 vs 1.22+/-0.11 h for HEPP alone and HEPP plus CBZ respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),h,1.22,91358,DB00564,Carbamazepine
,12784320,AUC(0-inf),"Evaluation of the pharmacokinetic parameters of CBZ showed, AUC(0-inf) 61.5+/-21.7 vs 67.4+/-23.8 microg h ml(-1); t(12) 4.60+/-1.54 vs 4.41+/-1.35 h; C(max) 8.45+/-3.83 vs 8.70+/-2.59 microg ml(-1) when the drug was administered alone and CBZ plus HEPP, respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),[h·μg] / [ml],61.5,91359,DB00564,Carbamazepine
,12784320,AUC(0-inf),"Evaluation of the pharmacokinetic parameters of CBZ showed, AUC(0-inf) 61.5+/-21.7 vs 67.4+/-23.8 microg h ml(-1); t(12) 4.60+/-1.54 vs 4.41+/-1.35 h; C(max) 8.45+/-3.83 vs 8.70+/-2.59 microg ml(-1) when the drug was administered alone and CBZ plus HEPP, respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),[h·μg] / [ml],67.4,91360,DB00564,Carbamazepine
,12784320,t(12),"Evaluation of the pharmacokinetic parameters of CBZ showed, AUC(0-inf) 61.5+/-21.7 vs 67.4+/-23.8 microg h ml(-1); t(12) 4.60+/-1.54 vs 4.41+/-1.35 h; C(max) 8.45+/-3.83 vs 8.70+/-2.59 microg ml(-1) when the drug was administered alone and CBZ plus HEPP, respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),h,4.60,91361,DB00564,Carbamazepine
,12784320,t(12),"Evaluation of the pharmacokinetic parameters of CBZ showed, AUC(0-inf) 61.5+/-21.7 vs 67.4+/-23.8 microg h ml(-1); t(12) 4.60+/-1.54 vs 4.41+/-1.35 h; C(max) 8.45+/-3.83 vs 8.70+/-2.59 microg ml(-1) when the drug was administered alone and CBZ plus HEPP, respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),h,4.41,91362,DB00564,Carbamazepine
,12784320,C(max),"Evaluation of the pharmacokinetic parameters of CBZ showed, AUC(0-inf) 61.5+/-21.7 vs 67.4+/-23.8 microg h ml(-1); t(12) 4.60+/-1.54 vs 4.41+/-1.35 h; C(max) 8.45+/-3.83 vs 8.70+/-2.59 microg ml(-1) when the drug was administered alone and CBZ plus HEPP, respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),[μg] / [ml],8.45,91363,DB00564,Carbamazepine
,12784320,C(max),"Evaluation of the pharmacokinetic parameters of CBZ showed, AUC(0-inf) 61.5+/-21.7 vs 67.4+/-23.8 microg h ml(-1); t(12) 4.60+/-1.54 vs 4.41+/-1.35 h; C(max) 8.45+/-3.83 vs 8.70+/-2.59 microg ml(-1) when the drug was administered alone and CBZ plus HEPP, respectively.","Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784320/),[μg] / [ml],8.70,91364,DB00564,Carbamazepine
,3130892,steady-state concentration,"2 VPA alone had no effect on antipyrine clearance, urinary 6 beta-hydroxycortisol excretion and a battery of psychomotor function tests after 3 days' treatment despite achieving a mean steady-state concentration (90 +/- 6 mg 1(-1)) well within the target range (50-100 mg 1(-1)) for the drug.",Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3130892/),mg,90,92013,DB00564,Carbamazepine
,3130892,steady-state concentration,"2 VPA alone had no effect on antipyrine clearance, urinary 6 beta-hydroxycortisol excretion and a battery of psychomotor function tests after 3 days' treatment despite achieving a mean steady-state concentration (90 +/- 6 mg 1(-1)) well within the target range (50-100 mg 1(-1)) for the drug.",Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3130892/),mg,50-100,92014,DB00564,Carbamazepine
,3576660,Cmax,A statistically significant higher Cmax (3.81 +/- 81 vs. 4.64 +/- .80 mg/L) was observed with the chewable tablet formulation but was not thought to be clinically relevant.,A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576660/),[mg] / [l],3.81,92033,DB00564,Carbamazepine
,3576660,Cmax,A statistically significant higher Cmax (3.81 +/- 81 vs. 4.64 +/- .80 mg/L) was observed with the chewable tablet formulation but was not thought to be clinically relevant.,A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576660/),[mg] / [l],4.64,92034,DB00564,Carbamazepine
,3576660,Ke,"No significant differences between formulations for Ke (0.022 +/- 0.007 vs. 0.025 +/- 0.008 h-1 h), Tmax (7.49 +/- 2.69 vs.",A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576660/),[h] / [h],0.022,92035,DB00564,Carbamazepine
,3576660,Ke,"No significant differences between formulations for Ke (0.022 +/- 0.007 vs. 0.025 +/- 0.008 h-1 h), Tmax (7.49 +/- 2.69 vs.",A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576660/),[h] / [h],0.025,92036,DB00564,Carbamazepine
,3576660,Tmax,"No significant differences between formulations for Ke (0.022 +/- 0.007 vs. 0.025 +/- 0.008 h-1 h), Tmax (7.49 +/- 2.69 vs.",A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576660/),,7.49,92037,DB00564,Carbamazepine
,3576660,AUC 48 h,"6.04 +/- 2.7 h), AUC 48 h (119 +/- 22 vs. 133 +/- 13 mg/h/L), or AUCO--infinity ( 221 +/- 40 vs.",A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576660/),[mg] / [h·l],119,92038,DB00564,Carbamazepine
,3576660,AUC 48 h,"6.04 +/- 2.7 h), AUC 48 h (119 +/- 22 vs. 133 +/- 13 mg/h/L), or AUCO--infinity ( 221 +/- 40 vs.",A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576660/),[mg] / [h·l],133,92039,DB00564,Carbamazepine
,3576660,AUCO--infinity,"6.04 +/- 2.7 h), AUC 48 h (119 +/- 22 vs. 133 +/- 13 mg/h/L), or AUCO--infinity ( 221 +/- 40 vs.",A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576660/),,221,92040,DB00564,Carbamazepine
,3576660,relative bioavailability,The relative bioavailability using the tablet as the standard formulation was (0.92 +/- 0.22).,A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576660/),,0.92,92041,DB00564,Carbamazepine
,7377892,elimination half-life,Plasma concentrations declined with an elimination half-life of 1.5 hr.,Pharmacokinetics of carbamazepine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),h,1.5,92213,DB00564,Carbamazepine
,7377892,half-life,"The concentrations of the epoxide remained high as long as plasma concentrations of carbamazepine were above 2--4 nmole/ml, then they fell with an average half-life of 2.2 hr.",Pharmacokinetics of carbamazepine in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),h,2.2,92214,DB00564,Carbamazepine
,7377892,Binding,4. Binding to serum proteins was about 70% for carbamazepine and 40% for the epoxide in dog serum; slightly higher values were found for human serum.,Pharmacokinetics of carbamazepine in the dog. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),%,70,92215,DB00564,Carbamazepine
,7377892,Binding,4. Binding to serum proteins was about 70% for carbamazepine and 40% for the epoxide in dog serum; slightly higher values were found for human serum.,Pharmacokinetics of carbamazepine in the dog. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),%,40,92216,DB00564,Carbamazepine
,32782230,CD ratio,"The mean baseline CD ratio of perampanel was 1,247 ng/mL/mg/kg which increased markedly over time after discontinuation of carbamazepine, with a mean CD ratio at Weeks 1-2, Weeks 3-4, and Weeks 5-8 of 2,683, 3,914, and 4,220, respectively.",Changes in serum perampanel concentration profile after discontinuation of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32782230/),[ng] / [kg·mg·ml],"1,247",93261,DB00564,Carbamazepine
,32782230,CD ratio,"The mean baseline CD ratio of perampanel was 1,247 ng/mL/mg/kg which increased markedly over time after discontinuation of carbamazepine, with a mean CD ratio at Weeks 1-2, Weeks 3-4, and Weeks 5-8 of 2,683, 3,914, and 4,220, respectively.",Changes in serum perampanel concentration profile after discontinuation of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32782230/),,"2,683",93262,DB00564,Carbamazepine
,32782230,CD ratio,"The mean baseline CD ratio of perampanel was 1,247 ng/mL/mg/kg which increased markedly over time after discontinuation of carbamazepine, with a mean CD ratio at Weeks 1-2, Weeks 3-4, and Weeks 5-8 of 2,683, 3,914, and 4,220, respectively.",Changes in serum perampanel concentration profile after discontinuation of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32782230/),,"3,914",93263,DB00564,Carbamazepine
,32782230,CD ratio,"The mean baseline CD ratio of perampanel was 1,247 ng/mL/mg/kg which increased markedly over time after discontinuation of carbamazepine, with a mean CD ratio at Weeks 1-2, Weeks 3-4, and Weeks 5-8 of 2,683, 3,914, and 4,220, respectively.",Changes in serum perampanel concentration profile after discontinuation of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32782230/),,"4,220",93264,DB00564,Carbamazepine
>,15301575,bioavailability,"After oral ingestion, levetiracetam is rapidly absorbed, with peak concentration occurring after 1.3 hours, and its bioavailability is >95%.",Clinical pharmacokinetics of levetiracetam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),%,95,93302,DB00564,Carbamazepine
,15301575,volume of distribution,Levetiracetam is not bound to plasma proteins and has a volume of distribution of 0.5-0.7 L/kg.,Clinical pharmacokinetics of levetiracetam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),[l] / [kg],0.5-0.7,93303,DB00564,Carbamazepine
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,6-8,93304,DB00564,Carbamazepine
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,5-7,93305,DB00564,Carbamazepine
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,10-11,93306,DB00564,Carbamazepine
,1563339,bioavailability,The mean bioavailability of CBZ from Neurotol slow was 11% (P = 0.002) higher than from Tegretol Retard.,Comparative bioavailability of carbamazepine from two slow-release preparations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563339/),%,11,93483,DB00564,Carbamazepine
,952573,total body clearance (TBC),"Attempts were made to relate pharmacokinetic properties of carbamazepine to its effect on pentobarbital sleeping time and on protection against electroshock, after acute and repeated administration: --it was found that male rats eliminate carbamazepine faster than females: the total body clearance (TBC) was 16 ml/min/kg and 9.4 ml/min/kg, respectively.","Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952573/),[ml] / [kg·min],16,94553,DB00564,Carbamazepine
,952573,total body clearance (TBC),"Attempts were made to relate pharmacokinetic properties of carbamazepine to its effect on pentobarbital sleeping time and on protection against electroshock, after acute and repeated administration: --it was found that male rats eliminate carbamazepine faster than females: the total body clearance (TBC) was 16 ml/min/kg and 9.4 ml/min/kg, respectively.","Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952573/),[ml] / [kg·min],9.4,94554,DB00564,Carbamazepine
,16225101,plasma half-life (T(1/2)),During the HP procedure the mean CBZ plasma half-life (T(1/2)) was 6.67 h and 12.66 h.,"[Carbamazepine ""CR""--clinical picture of intoxication: the kinetics of extracorporeal elimination]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16225101/),h,6.67,95400,DB00564,Carbamazepine
,16225101,plasma half-life (T(1/2)),During the HP procedure the mean CBZ plasma half-life (T(1/2)) was 6.67 h and 12.66 h.,"[Carbamazepine ""CR""--clinical picture of intoxication: the kinetics of extracorporeal elimination]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16225101/),h,12.66,95401,DB00564,Carbamazepine
,16225101,clearances,The mean charcoal column clearances (with blood flow 180 ml/min) were 77.2 and 108.9 ml/min.,"[Carbamazepine ""CR""--clinical picture of intoxication: the kinetics of extracorporeal elimination]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16225101/),[ml] / [min],180,95402,DB00564,Carbamazepine
,16225101,clearances,The mean charcoal column clearances (with blood flow 180 ml/min) were 77.2 and 108.9 ml/min.,"[Carbamazepine ""CR""--clinical picture of intoxication: the kinetics of extracorporeal elimination]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16225101/),[ml] / [min],77.2,95403,DB00564,Carbamazepine
,16225101,clearances,The mean charcoal column clearances (with blood flow 180 ml/min) were 77.2 and 108.9 ml/min.,"[Carbamazepine ""CR""--clinical picture of intoxication: the kinetics of extracorporeal elimination]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16225101/),[ml] / [min],108.9,95404,DB00564,Carbamazepine
,16225101,blood flow,The mean charcoal column clearances (with blood flow 180 ml/min) were 77.2 and 108.9 ml/min.,"[Carbamazepine ""CR""--clinical picture of intoxication: the kinetics of extracorporeal elimination]. ",Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16225101/),[ml] / [min],180,95405,DB00564,Carbamazepine
,16225101,blood flow,The mean charcoal column clearances (with blood flow 180 ml/min) were 77.2 and 108.9 ml/min.,"[Carbamazepine ""CR""--clinical picture of intoxication: the kinetics of extracorporeal elimination]. ",Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16225101/),[ml] / [min],77.2,95406,DB00564,Carbamazepine
,16225101,blood flow,The mean charcoal column clearances (with blood flow 180 ml/min) were 77.2 and 108.9 ml/min.,"[Carbamazepine ""CR""--clinical picture of intoxication: the kinetics of extracorporeal elimination]. ",Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16225101/),[ml] / [min],108.9,95407,DB00564,Carbamazepine
,16388199,AUC(0-infinity),"The increase in AUC(0-infinity) (22.78 +/- 4.71 to 63.10 +/- 12.29), Cmax (2.76 +/- 0.77 to 7.02 +/- 1.08), Tmax (2.83 +/- 0.17 to 4.16 +/- 0.40) was statistically significant when artemether was given along with carbamazepine (p < 0.05).","Effects of artemisinin, artemether, arteether on the pharmacokinetics of carbamazepine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16388199/),,22.78,95532,DB00564,Carbamazepine
,16388199,AUC(0-infinity),"The increase in AUC(0-infinity) (22.78 +/- 4.71 to 63.10 +/- 12.29), Cmax (2.76 +/- 0.77 to 7.02 +/- 1.08), Tmax (2.83 +/- 0.17 to 4.16 +/- 0.40) was statistically significant when artemether was given along with carbamazepine (p < 0.05).","Effects of artemisinin, artemether, arteether on the pharmacokinetics of carbamazepine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16388199/),,63.10,95533,DB00564,Carbamazepine
,16388199,Cmax,"The increase in AUC(0-infinity) (22.78 +/- 4.71 to 63.10 +/- 12.29), Cmax (2.76 +/- 0.77 to 7.02 +/- 1.08), Tmax (2.83 +/- 0.17 to 4.16 +/- 0.40) was statistically significant when artemether was given along with carbamazepine (p < 0.05).","Effects of artemisinin, artemether, arteether on the pharmacokinetics of carbamazepine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16388199/),,2.76,95534,DB00564,Carbamazepine
,16388199,Cmax,"The increase in AUC(0-infinity) (22.78 +/- 4.71 to 63.10 +/- 12.29), Cmax (2.76 +/- 0.77 to 7.02 +/- 1.08), Tmax (2.83 +/- 0.17 to 4.16 +/- 0.40) was statistically significant when artemether was given along with carbamazepine (p < 0.05).","Effects of artemisinin, artemether, arteether on the pharmacokinetics of carbamazepine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16388199/),,7.02,95535,DB00564,Carbamazepine
,16388199,Tmax,"The increase in AUC(0-infinity) (22.78 +/- 4.71 to 63.10 +/- 12.29), Cmax (2.76 +/- 0.77 to 7.02 +/- 1.08), Tmax (2.83 +/- 0.17 to 4.16 +/- 0.40) was statistically significant when artemether was given along with carbamazepine (p < 0.05).","Effects of artemisinin, artemether, arteether on the pharmacokinetics of carbamazepine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16388199/),,2.83,95536,DB00564,Carbamazepine
,16388199,Tmax,"The increase in AUC(0-infinity) (22.78 +/- 4.71 to 63.10 +/- 12.29), Cmax (2.76 +/- 0.77 to 7.02 +/- 1.08), Tmax (2.83 +/- 0.17 to 4.16 +/- 0.40) was statistically significant when artemether was given along with carbamazepine (p < 0.05).","Effects of artemisinin, artemether, arteether on the pharmacokinetics of carbamazepine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16388199/),,4.16,95537,DB00564,Carbamazepine
,6485876,clearance rate,"The carbamazepine hemoperfusion clearance rate was 80-90 ml/min, but due to a probable ongoing absorption from the gut the effect of hemoperfusion was limited.",Charcoal hemoperfusion for treatment of serious carbamazepine poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6485876/),[ml] / [min],80-90,95617,DB00564,Carbamazepine
,20508296,biological half-life,"The average biological half-life of carbamazepine in non-addicted epileptics was 41.5 h, 43.5 h for alcohol-dependent patients during abstinency, and 38.6 in abused patients.",Carbamazepine intoxication in alcohol dependent epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508296/),h,41.5,96189,DB00564,Carbamazepine
,20508296,biological half-life,"The average biological half-life of carbamazepine in non-addicted epileptics was 41.5 h, 43.5 h for alcohol-dependent patients during abstinency, and 38.6 in abused patients.",Carbamazepine intoxication in alcohol dependent epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508296/),h,43.5,96190,DB00564,Carbamazepine
,20508296,biological half-life,"The average biological half-life of carbamazepine in non-addicted epileptics was 41.5 h, 43.5 h for alcohol-dependent patients during abstinency, and 38.6 in abused patients.",Carbamazepine intoxication in alcohol dependent epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508296/),,38.6,96191,DB00564,Carbamazepine
,30782258,bioavailability,"Furthermore, the extent of bioavailability (110.6 %) for the generic moclobemide tablets if compared to Aurorix tablets is not significantly different.",Bioavailability of moclobemide from two formulation tablets in healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782258/),%,110.6,97234,DB00564,Carbamazepine
,22278332,Absolute clearance,Absolute clearance (l/hr/kg) was significantly lower in men (0.039 ± 0.017) than in women (0.049 ± 0.018; P = 0.007) and in African Americans (0.039 ± 0.017) when compared with Caucasians (0.048 ± 0.018; P = 0.019).,Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278332/),[l] / [h·kg],0.039,98081,DB00564,Carbamazepine
,22278332,Absolute clearance,Absolute clearance (l/hr/kg) was significantly lower in men (0.039 ± 0.017) than in women (0.049 ± 0.018; P = 0.007) and in African Americans (0.039 ± 0.017) when compared with Caucasians (0.048 ± 0.018; P = 0.019).,Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278332/),[l] / [h·kg],0.049,98082,DB00564,Carbamazepine
,22278332,Absolute clearance,Absolute clearance (l/hr/kg) was significantly lower in men (0.039 ± 0.017) than in women (0.049 ± 0.018; P = 0.007) and in African Americans (0.039 ± 0.017) when compared with Caucasians (0.048 ± 0.018; P = 0.019).,Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278332/),[l] / [h·kg],0.048,98083,DB00564,Carbamazepine
,22278332,absolute bioavailability,The absolute bioavailability was 0.78.,Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278332/),,0.78,98084,DB00564,Carbamazepine
,1572759,relative bioavailability,"The following relative bioavailability values were obtained: A/B: AUC = 87% (83%, 92%), MRT = 106% (103%, 109%), HVD = 109% (105%, 113%).",Investigations into the relative bioavailability of carbamazepine after single oral administration of three test batches of a carbamazepine-containing sustained release formulation in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572759/),%,87,98518,DB00564,Carbamazepine
,1572759,relative bioavailability,"The following relative bioavailability values were obtained: A/B: AUC = 87% (83%, 92%), MRT = 106% (103%, 109%), HVD = 109% (105%, 113%).",Investigations into the relative bioavailability of carbamazepine after single oral administration of three test batches of a carbamazepine-containing sustained release formulation in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572759/),%,83,98519,DB00564,Carbamazepine
,1572759,relative bioavailability,"The following relative bioavailability values were obtained: A/B: AUC = 87% (83%, 92%), MRT = 106% (103%, 109%), HVD = 109% (105%, 113%).",Investigations into the relative bioavailability of carbamazepine after single oral administration of three test batches of a carbamazepine-containing sustained release formulation in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572759/),%,92,98520,DB00564,Carbamazepine
,1572759,relative bioavailability,"The following relative bioavailability values were obtained: A/B: AUC = 87% (83%, 92%), MRT = 106% (103%, 109%), HVD = 109% (105%, 113%).",Investigations into the relative bioavailability of carbamazepine after single oral administration of three test batches of a carbamazepine-containing sustained release formulation in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572759/),%,106,98521,DB00564,Carbamazepine
,1572759,relative bioavailability,"The following relative bioavailability values were obtained: A/B: AUC = 87% (83%, 92%), MRT = 106% (103%, 109%), HVD = 109% (105%, 113%).",Investigations into the relative bioavailability of carbamazepine after single oral administration of three test batches of a carbamazepine-containing sustained release formulation in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572759/),%,109,98522,DB00564,Carbamazepine
,1572759,relative bioavailability,"The following relative bioavailability values were obtained: A/B: AUC = 87% (83%, 92%), MRT = 106% (103%, 109%), HVD = 109% (105%, 113%).",Investigations into the relative bioavailability of carbamazepine after single oral administration of three test batches of a carbamazepine-containing sustained release formulation in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572759/),%,109,98523,DB00564,Carbamazepine
,1572759,relative bioavailability,"The following relative bioavailability values were obtained: A/B: AUC = 87% (83%, 92%), MRT = 106% (103%, 109%), HVD = 109% (105%, 113%).",Investigations into the relative bioavailability of carbamazepine after single oral administration of three test batches of a carbamazepine-containing sustained release formulation in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572759/),%,113,98524,DB00564,Carbamazepine
,12207869,first order elimination rate constant (K(10)),"For CBZ, the fitted parameters were: the first order elimination rate constant (K(10)) 0.024 and 0.022 hr(-1), t(1/2) 27.3 and 30.3 hr, volume of central compartment (V(1) ) 1.119 and 1.160 L/kg, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),1/[hr],0.024,98794,DB00564,Carbamazepine
,12207869,first order elimination rate constant (K(10)),"For CBZ, the fitted parameters were: the first order elimination rate constant (K(10)) 0.024 and 0.022 hr(-1), t(1/2) 27.3 and 30.3 hr, volume of central compartment (V(1) ) 1.119 and 1.160 L/kg, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),1/[hr],0.022,98795,DB00564,Carbamazepine
,12207869,t(1/2),"For CBZ, the fitted parameters were: the first order elimination rate constant (K(10)) 0.024 and 0.022 hr(-1), t(1/2) 27.3 and 30.3 hr, volume of central compartment (V(1) ) 1.119 and 1.160 L/kg, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),h,27.3,98796,DB00564,Carbamazepine
,12207869,t(1/2),"For CBZ, the fitted parameters were: the first order elimination rate constant (K(10)) 0.024 and 0.022 hr(-1), t(1/2) 27.3 and 30.3 hr, volume of central compartment (V(1) ) 1.119 and 1.160 L/kg, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),h,30.3,98797,DB00564,Carbamazepine
,12207869,volume of central compartment (V(1) ),"For CBZ, the fitted parameters were: the first order elimination rate constant (K(10)) 0.024 and 0.022 hr(-1), t(1/2) 27.3 and 30.3 hr, volume of central compartment (V(1) ) 1.119 and 1.160 L/kg, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),[l] / [kg],1.119,98798,DB00564,Carbamazepine
,12207869,volume of central compartment (V(1) ),"For CBZ, the fitted parameters were: the first order elimination rate constant (K(10)) 0.024 and 0.022 hr(-1), t(1/2) 27.3 and 30.3 hr, volume of central compartment (V(1) ) 1.119 and 1.160 L/kg, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),[l] / [kg],1.160,98799,DB00564,Carbamazepine
,12207869,first order elimination rate constant (K (30) ),"For CBZ-E, the fitted parameters were: the first order elimination rate constant (K (30) ) 0.128 and 0.157 hr (-1), t (1/2) 6.1 and 5.1 hr, volume of central compartment (V (3) ) 0.728 and 0.644 L/kg, V (max) 0.085 and 0.076 mg/hr/kg, K (m) 28.639 and 33.138 mg/mL, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),-1·h,0.128,98800,DB00564,Carbamazepine
,12207869,first order elimination rate constant (K (30) ),"For CBZ-E, the fitted parameters were: the first order elimination rate constant (K (30) ) 0.128 and 0.157 hr (-1), t (1/2) 6.1 and 5.1 hr, volume of central compartment (V (3) ) 0.728 and 0.644 L/kg, V (max) 0.085 and 0.076 mg/hr/kg, K (m) 28.639 and 33.138 mg/mL, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),-1·h,0.157,98801,DB00564,Carbamazepine
,12207869,t (1/2),"For CBZ-E, the fitted parameters were: the first order elimination rate constant (K (30) ) 0.128 and 0.157 hr (-1), t (1/2) 6.1 and 5.1 hr, volume of central compartment (V (3) ) 0.728 and 0.644 L/kg, V (max) 0.085 and 0.076 mg/hr/kg, K (m) 28.639 and 33.138 mg/mL, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),h,6.1,98802,DB00564,Carbamazepine
,12207869,t (1/2),"For CBZ-E, the fitted parameters were: the first order elimination rate constant (K (30) ) 0.128 and 0.157 hr (-1), t (1/2) 6.1 and 5.1 hr, volume of central compartment (V (3) ) 0.728 and 0.644 L/kg, V (max) 0.085 and 0.076 mg/hr/kg, K (m) 28.639 and 33.138 mg/mL, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),h,5.1,98803,DB00564,Carbamazepine
,12207869,volume of central compartment (V (3) ),"For CBZ-E, the fitted parameters were: the first order elimination rate constant (K (30) ) 0.128 and 0.157 hr (-1), t (1/2) 6.1 and 5.1 hr, volume of central compartment (V (3) ) 0.728 and 0.644 L/kg, V (max) 0.085 and 0.076 mg/hr/kg, K (m) 28.639 and 33.138 mg/mL, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),[l] / [kg],0.728,98804,DB00564,Carbamazepine
,12207869,volume of central compartment (V (3) ),"For CBZ-E, the fitted parameters were: the first order elimination rate constant (K (30) ) 0.128 and 0.157 hr (-1), t (1/2) 6.1 and 5.1 hr, volume of central compartment (V (3) ) 0.728 and 0.644 L/kg, V (max) 0.085 and 0.076 mg/hr/kg, K (m) 28.639 and 33.138 mg/mL, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),[l] / [kg],0.644,98805,DB00564,Carbamazepine
,12207869,V (max),"For CBZ-E, the fitted parameters were: the first order elimination rate constant (K (30) ) 0.128 and 0.157 hr (-1), t (1/2) 6.1 and 5.1 hr, volume of central compartment (V (3) ) 0.728 and 0.644 L/kg, V (max) 0.085 and 0.076 mg/hr/kg, K (m) 28.639 and 33.138 mg/mL, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),[mg] / [h·kg],0.085,98806,DB00564,Carbamazepine
,12207869,V (max),"For CBZ-E, the fitted parameters were: the first order elimination rate constant (K (30) ) 0.128 and 0.157 hr (-1), t (1/2) 6.1 and 5.1 hr, volume of central compartment (V (3) ) 0.728 and 0.644 L/kg, V (max) 0.085 and 0.076 mg/hr/kg, K (m) 28.639 and 33.138 mg/mL, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),[mg] / [h·kg],0.076,98807,DB00564,Carbamazepine
,12207869,K (m),"For CBZ-E, the fitted parameters were: the first order elimination rate constant (K (30) ) 0.128 and 0.157 hr (-1), t (1/2) 6.1 and 5.1 hr, volume of central compartment (V (3) ) 0.728 and 0.644 L/kg, V (max) 0.085 and 0.076 mg/hr/kg, K (m) 28.639 and 33.138 mg/mL, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),[mg] / [ml],28.639,98808,DB00564,Carbamazepine
,12207869,K (m),"For CBZ-E, the fitted parameters were: the first order elimination rate constant (K (30) ) 0.128 and 0.157 hr (-1), t (1/2) 6.1 and 5.1 hr, volume of central compartment (V (3) ) 0.728 and 0.644 L/kg, V (max) 0.085 and 0.076 mg/hr/kg, K (m) 28.639 and 33.138 mg/mL, for Carbatrol and Tegretol-XR, respectively.",Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207869/),[mg] / [ml],33.138,98809,DB00564,Carbamazepine
,6766389,absolute bioavailability,"The absolute bioavailability was 38% from formulation A, 81% from formulation B and 82% from formulation C.",Intramuscular absorption of carbamazepine in rhesus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6766389/),%,38,99301,DB00564,Carbamazepine
,6766389,absolute bioavailability,"The absolute bioavailability was 38% from formulation A, 81% from formulation B and 82% from formulation C.",Intramuscular absorption of carbamazepine in rhesus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6766389/),%,81,99302,DB00564,Carbamazepine
,6766389,absolute bioavailability,"The absolute bioavailability was 38% from formulation A, 81% from formulation B and 82% from formulation C.",Intramuscular absorption of carbamazepine in rhesus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6766389/),%,82,99303,DB00564,Carbamazepine
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,2.8,99721,DB00564,Carbamazepine
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,13,99722,DB00564,Carbamazepine
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,29,99723,DB00564,Carbamazepine
,26194841,total run time,"After sample preparation by a simple liquid-liquid extraction, chromatography was performed on an Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 µm particle size) and total run time was 2.0 min.",Determination and Pharmacokinetic Study of Apatinib in Rat Plasma by UPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26194841/),min,2.0,100447,DB00564,Carbamazepine
>,26194841,Recoveries,Recoveries of apatinib and IS were >80%.,Determination and Pharmacokinetic Study of Apatinib in Rat Plasma by UPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26194841/),%,80,100448,DB00564,Carbamazepine
,689797,relative bioavailability,"By comparing the areas under the various curves for each volunteer, the relative bioavailability of one of the carbamazepines in relation to the other one was found of approximately 70%.",The relative bioavailability and pharmacokinetics of carbamazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/689797/),%,70,100862,DB00564,Carbamazepine
,1888646,Peak serum CBZ concentrations,"2. Peak serum CBZ concentrations (mean +/- s.e. mean) were lower (CBZ 11.4 +/- 0.4 mg l-1; CBZ-CR 10.4 +/- 0.5 mg l-1; P less than 0.01) and times to peak longer (CBZ 3.6 +/- 0.5 h, CBZ-CR 5.2 +/- 0.7 h, P less than 0.01) during CBZ-CR treatment.","Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888646/),[mg] / [l],11.4,100890,DB00564,Carbamazepine
,1888646,Peak serum CBZ concentrations,"2. Peak serum CBZ concentrations (mean +/- s.e. mean) were lower (CBZ 11.4 +/- 0.4 mg l-1; CBZ-CR 10.4 +/- 0.5 mg l-1; P less than 0.01) and times to peak longer (CBZ 3.6 +/- 0.5 h, CBZ-CR 5.2 +/- 0.7 h, P less than 0.01) during CBZ-CR treatment.","Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888646/),[mg] / [l],10.4,100891,DB00564,Carbamazepine
,1888646,times to peak,"2. Peak serum CBZ concentrations (mean +/- s.e. mean) were lower (CBZ 11.4 +/- 0.4 mg l-1; CBZ-CR 10.4 +/- 0.5 mg l-1; P less than 0.01) and times to peak longer (CBZ 3.6 +/- 0.5 h, CBZ-CR 5.2 +/- 0.7 h, P less than 0.01) during CBZ-CR treatment.","Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888646/),h,3.6,100892,DB00564,Carbamazepine
,1888646,times to peak,"2. Peak serum CBZ concentrations (mean +/- s.e. mean) were lower (CBZ 11.4 +/- 0.4 mg l-1; CBZ-CR 10.4 +/- 0.5 mg l-1; P less than 0.01) and times to peak longer (CBZ 3.6 +/- 0.5 h, CBZ-CR 5.2 +/- 0.7 h, P less than 0.01) during CBZ-CR treatment.","Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888646/),h,5.2,100893,DB00564,Carbamazepine
,25132417,flow rate,"The rat plasma samples (100 μL) were injected directly onto pre-column, where RIP was retained and pre-concentrated, while proteins were washed to waste using a methanol-water (5:95) as the mobile phase at a flow rate of 1 mL/min.",Determination of rifampicin in rat plasma by modified large-volume direct injection RAM-HPLC and its application to a pharmcokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25132417/),[ml] / [min],1,101163,DB00564,Carbamazepine
,25132417,flow rate,"Then, by rotation of the switching valve at 5 min, the RIP were eluted from the pre-column and transferred to an Luna C18 analytical column by the chromatographic mobile phase consisting of methanol-acetonitrile-10 mm ammonium format (60:5:35) at a flow rate of 1 mL/min.",Determination of rifampicin in rat plasma by modified large-volume direct injection RAM-HPLC and its application to a pharmcokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25132417/),[ml] / [min],1,101164,DB00564,Carbamazepine
,25132417,total analytical run time,The total analytical run time was 15 min with UV detection wavelength at 254 nm.,Determination of rifampicin in rat plasma by modified large-volume direct injection RAM-HPLC and its application to a pharmcokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25132417/),min,15,101165,DB00564,Carbamazepine
,25132417,recoveries,The recoveries were in the range of from 99.98-113.66% for plasma.,Determination of rifampicin in rat plasma by modified large-volume direct injection RAM-HPLC and its application to a pharmcokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25132417/),%,99.98-113.66,101166,DB00564,Carbamazepine
,15907629,flow rate,"The chromatographic separation was achieved within 5 min using a C(8) (150 mm x 2.1mm) 5 microm column with a mobile phase composed of water/acetonitrile/acetic acid (69.5:30:0.5, v/v/v) at a flow rate of 0.4 ml/min.",Liquid chromatography/tandem mass spectrometry for the determination of carbamazepine and its main metabolite in rat plasma utilizing an automated blood sampling system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907629/),[ml] / [min],0.4,101667,DB00564,Carbamazepine
over,15907629,extraction recovery,The extraction recovery of analytes from rat plasma was over 87%.,Liquid chromatography/tandem mass spectrometry for the determination of carbamazepine and its main metabolite in rat plasma utilizing an automated blood sampling system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907629/),%,87,101668,DB00564,Carbamazepine
,26342165,total run time,The total run time was 3.0min and the elution of songorine was at 1.68min.,Determination of songorine in rat plasma by UPLC-MS/MS: Assay development and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342165/),min,3.0,102267,DB00564,Carbamazepine
,26342165,elution,The total run time was 3.0min and the elution of songorine was at 1.68min.,Determination of songorine in rat plasma by UPLC-MS/MS: Assay development and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342165/),min,1.68,102268,DB00564,Carbamazepine
,26342165,recovery,Mean recovery of songorine in plasma was in the range of 75.2-87.5%.,Determination of songorine in rat plasma by UPLC-MS/MS: Assay development and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342165/),%,75.2-87.5,102269,DB00564,Carbamazepine
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],1.38,102510,DB00564,Carbamazepine
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],2.16,102511,DB00564,Carbamazepine
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],2.72,102512,DB00564,Carbamazepine
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],3.02,102513,DB00564,Carbamazepine
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],2.67,102514,DB00564,Carbamazepine
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],1.22,102515,DB00564,Carbamazepine
,17723537,flow rate,Its flow rate was 1 ml min(-1).,Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),[ml] / [min],1,102785,DB00564,Carbamazepine
,17723537,elution time,"The elution time for nifedipine and carbamazepine was approximately 12 and 8 min, respectively.",Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),min,12,102786,DB00564,Carbamazepine
,17723537,elution time,"The elution time for nifedipine and carbamazepine was approximately 12 and 8 min, respectively.",Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),min,8,102787,DB00564,Carbamazepine
,17723537,Limits of detection,"Limits of detection and quantification in plasma were 0.5 and 1.5 ng ml(-1), respectively.",Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),[ng] / [ml],0.5,102788,DB00564,Carbamazepine
,17723537,Limits of detection,"Limits of detection and quantification in plasma were 0.5 and 1.5 ng ml(-1), respectively.",Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),[ng] / [ml],1.5,102789,DB00564,Carbamazepine
greater,17723537,Recovery,Recovery was greater than 98%.,Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),%,98,102790,DB00564,Carbamazepine
,16197654,Plasma drug concentrations,"Plasma drug concentrations after 24 hours without medication were 4.1 mg/L for CBZ-ERC, 8 mg/L for 600 mg OXC, and 16 mg/L for 1200 mg OXC.",Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197654/),[mg] / [l],4.1,103001,DB00564,Carbamazepine
,16197654,Plasma drug concentrations,"Plasma drug concentrations after 24 hours without medication were 4.1 mg/L for CBZ-ERC, 8 mg/L for 600 mg OXC, and 16 mg/L for 1200 mg OXC.",Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197654/),[mg] / [l],8,103002,DB00564,Carbamazepine
,16197654,Plasma drug concentrations,"Plasma drug concentrations after 24 hours without medication were 4.1 mg/L for CBZ-ERC, 8 mg/L for 600 mg OXC, and 16 mg/L for 1200 mg OXC.",Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197654/),[mg] / [l],16,103003,DB00564,Carbamazepine
,16197654,steady-state trough,"If a patient was to take only a single dose 24 hours late, it would take 24 hours to reach steady-state trough values for CBZ-ERC, 36 hours for 600 mg OXC, and 2 days for 1200 mg OXC.",Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197654/),h,36,103004,DB00564,Carbamazepine
,16197654,steady-state trough,"If a patient was to take only a single dose 24 hours late, it would take 24 hours to reach steady-state trough values for CBZ-ERC, 36 hours for 600 mg OXC, and 2 days for 1200 mg OXC.",Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197654/),d,2,103005,DB00564,Carbamazepine
,8992022,peak concentrations,Plasma concentrations reached peak concentrations of 2.4-8.8 micrograms/mliter at about 1.5 h and declined with an elimination half-life of approximately 4 h.,Pharmacokinetics of oxcarbazepine in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992022/),[μg] / [mliter],2.4-8.8,103112,DB00564,Carbamazepine
,8992022,elimination half-life,Plasma concentrations reached peak concentrations of 2.4-8.8 micrograms/mliter at about 1.5 h and declined with an elimination half-life of approximately 4 h.,Pharmacokinetics of oxcarbazepine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992022/),h,4,103113,DB00564,Carbamazepine
,8992022,terminal half-life,"Plasma concentrations showed a pronounced decline from day 3, and the terminal half-life decreased to 2 h and 1 h.",Pharmacokinetics of oxcarbazepine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992022/),h,2,103114,DB00564,Carbamazepine
,8992022,terminal half-life,"Plasma concentrations showed a pronounced decline from day 3, and the terminal half-life decreased to 2 h and 1 h.",Pharmacokinetics of oxcarbazepine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992022/),h,1,103115,DB00564,Carbamazepine
,9757152,steady peak concentration,"Compared with water, grapefruit significantly increased the steady peak concentration (6.55 versus 9.20 microgram/mL), trough concentration (4.51 versus 6.28 microgram/mL), and area under the plasma concentration-time curve (43.99 versus 61.95 micrograms.h/mL) of carbamazepine.",Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757152/),[μg] / [ml],6.55,103382,DB00564,Carbamazepine
,9757152,steady peak concentration,"Compared with water, grapefruit significantly increased the steady peak concentration (6.55 versus 9.20 microgram/mL), trough concentration (4.51 versus 6.28 microgram/mL), and area under the plasma concentration-time curve (43.99 versus 61.95 micrograms.h/mL) of carbamazepine.",Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757152/),[μg] / [ml],9.20,103383,DB00564,Carbamazepine
,9757152,trough concentration,"Compared with water, grapefruit significantly increased the steady peak concentration (6.55 versus 9.20 microgram/mL), trough concentration (4.51 versus 6.28 microgram/mL), and area under the plasma concentration-time curve (43.99 versus 61.95 micrograms.h/mL) of carbamazepine.",Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757152/),[μg] / [ml],4.51,103384,DB00564,Carbamazepine
,9757152,trough concentration,"Compared with water, grapefruit significantly increased the steady peak concentration (6.55 versus 9.20 microgram/mL), trough concentration (4.51 versus 6.28 microgram/mL), and area under the plasma concentration-time curve (43.99 versus 61.95 micrograms.h/mL) of carbamazepine.",Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757152/),[μg] / [ml],6.28,103385,DB00564,Carbamazepine
,9757152,area under the plasma concentration-time curve,"Compared with water, grapefruit significantly increased the steady peak concentration (6.55 versus 9.20 microgram/mL), trough concentration (4.51 versus 6.28 microgram/mL), and area under the plasma concentration-time curve (43.99 versus 61.95 micrograms.h/mL) of carbamazepine.",Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757152/),[h·μg] / [ml],43.99,103386,DB00564,Carbamazepine
,9757152,area under the plasma concentration-time curve,"Compared with water, grapefruit significantly increased the steady peak concentration (6.55 versus 9.20 microgram/mL), trough concentration (4.51 versus 6.28 microgram/mL), and area under the plasma concentration-time curve (43.99 versus 61.95 micrograms.h/mL) of carbamazepine.",Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757152/),[h·μg] / [ml],61.95,103387,DB00564,Carbamazepine
,15811,hepatic clearance,The mean hepatic clearance of carbamazepine was 0.28 ml per min per g of liver corresponding to a mean extraction ratio of 0.16 and a mean intrinsic clearance of 0.33 ml per min g of liver.,"Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),[ml] / [g·min],0.28,103576,DB00564,Carbamazepine
,15811,extraction ratio,The mean hepatic clearance of carbamazepine was 0.28 ml per min per g of liver corresponding to a mean extraction ratio of 0.16 and a mean intrinsic clearance of 0.33 ml per min g of liver.,"Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),,0.16,103577,DB00564,Carbamazepine
,15811,intrinsic clearance,The mean hepatic clearance of carbamazepine was 0.28 ml per min per g of liver corresponding to a mean extraction ratio of 0.16 and a mean intrinsic clearance of 0.33 ml per min g of liver.,"Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),[ml] / [g·min],0.33,103578,DB00564,Carbamazepine
,15811,extraction ratio,"In phenobarbital-pretreated rats, there was an approximately 40% increase in the hepatic clearance due to a concomitant increase in the mean extraction ratio from 0.16 to 0.26.","Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),,0.16,103579,DB00564,Carbamazepine
,15811,extraction ratio,"In phenobarbital-pretreated rats, there was an approximately 40% increase in the hepatic clearance due to a concomitant increase in the mean extraction ratio from 0.16 to 0.26.","Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),,0.26,103580,DB00564,Carbamazepine
,15811,extraction ratio,The mean extraction ratio of the epoxide in this situation was only 0.016 and it was unaffected by prior treatment of the rats with phenobarbital.,"Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),,0.016,103581,DB00564,Carbamazepine
,12076842,Cl(o),"In a subset analysis of completers, LTG Cl(o) determined prior to withdrawal of the inducers was significantly greater in patients (n=28) on LTG+PHT (160% increase) than in those (n=48) receiving LTG+CBZ (62% increase): 1.77+/-0.77 vs. 1.06+/-0.41 ml/min/kg, respectively, p=0.017.",Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12076842/),[ml] / [kg·min],1.77,103868,DB00564,Carbamazepine
,12076842,Cl(o),"In a subset analysis of completers, LTG Cl(o) determined prior to withdrawal of the inducers was significantly greater in patients (n=28) on LTG+PHT (160% increase) than in those (n=48) receiving LTG+CBZ (62% increase): 1.77+/-0.77 vs. 1.06+/-0.41 ml/min/kg, respectively, p=0.017.",Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12076842/),[ml] / [kg·min],1.06,103869,DB00564,Carbamazepine
,797496,half-life,It has a relatively long half-life (in adults 2 to 3 days; in children shorter).,Clinical pharmacokinetics of anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/797496/),d,2 to 3,104851,DB00564,Carbamazepine
,24831712,AUC,"However, there is a statistical pharmacokinetics difference between lapatinib in the lapatinib group and co-administration group, when co-oral administration MS-275 with lapatinib, AUC increased from 2375.5 to 9900.3 ng/mL h (p < 0.05), Cmax increased from 538.0 to 2578.2 ng/mL (p < 0.01), CL decreased from 6.2 to 1.7 L/h/kg (p < 0.01).",Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24831712/),[ng] / [h·ml],2375.5,104853,DB00564,Carbamazepine
,24831712,AUC,"However, there is a statistical pharmacokinetics difference between lapatinib in the lapatinib group and co-administration group, when co-oral administration MS-275 with lapatinib, AUC increased from 2375.5 to 9900.3 ng/mL h (p < 0.05), Cmax increased from 538.0 to 2578.2 ng/mL (p < 0.01), CL decreased from 6.2 to 1.7 L/h/kg (p < 0.01).",Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24831712/),[ng] / [h·ml],9900.3,104854,DB00564,Carbamazepine
,24831712,Cmax,"However, there is a statistical pharmacokinetics difference between lapatinib in the lapatinib group and co-administration group, when co-oral administration MS-275 with lapatinib, AUC increased from 2375.5 to 9900.3 ng/mL h (p < 0.05), Cmax increased from 538.0 to 2578.2 ng/mL (p < 0.01), CL decreased from 6.2 to 1.7 L/h/kg (p < 0.01).",Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24831712/),[ng] / [ml],538.0,104855,DB00564,Carbamazepine
,24831712,Cmax,"However, there is a statistical pharmacokinetics difference between lapatinib in the lapatinib group and co-administration group, when co-oral administration MS-275 with lapatinib, AUC increased from 2375.5 to 9900.3 ng/mL h (p < 0.05), Cmax increased from 538.0 to 2578.2 ng/mL (p < 0.01), CL decreased from 6.2 to 1.7 L/h/kg (p < 0.01).",Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24831712/),[ng] / [ml],2578.2,104856,DB00564,Carbamazepine
,24831712,CL,"However, there is a statistical pharmacokinetics difference between lapatinib in the lapatinib group and co-administration group, when co-oral administration MS-275 with lapatinib, AUC increased from 2375.5 to 9900.3 ng/mL h (p < 0.05), Cmax increased from 538.0 to 2578.2 ng/mL (p < 0.01), CL decreased from 6.2 to 1.7 L/h/kg (p < 0.01).",Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24831712/),[l] / [h·kg],6.2,104857,DB00564,Carbamazepine
,24831712,CL,"However, there is a statistical pharmacokinetics difference between lapatinib in the lapatinib group and co-administration group, when co-oral administration MS-275 with lapatinib, AUC increased from 2375.5 to 9900.3 ng/mL h (p < 0.05), Cmax increased from 538.0 to 2578.2 ng/mL (p < 0.01), CL decreased from 6.2 to 1.7 L/h/kg (p < 0.01).",Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24831712/),[l] / [h·kg],1.7,104858,DB00564,Carbamazepine
,15286095,t(max),"Median maximum plasma concentrations of the major metabolite (licarbazepine, (+/-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide) were attained (t(max)) at 2 to 3 h postdose; thereafter, plasma concentrations declined with a mean apparent terminal half-life of 9 to 13 h following repeated dosing.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),h,2 to 3,105427,DB00564,Carbamazepine
,15286095,apparent terminal half-life,"Median maximum plasma concentrations of the major metabolite (licarbazepine, (+/-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide) were attained (t(max)) at 2 to 3 h postdose; thereafter, plasma concentrations declined with a mean apparent terminal half-life of 9 to 13 h following repeated dosing.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),h,9 to 13,105428,DB00564,Carbamazepine
,15286095,extent of accumulation (R(O),"Licarbazepine accumulated in plasma following repeated administration of BIA 2-093; the mean extent of accumulation (R(O), calculated from AUC(0-tau) (day 8)/AUC(0-tau) (day 1)) was 3.0 after repeated, twice-daily dosing and 1.4 to 1.7 after once-daily dosing.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),,3.0,105429,DB00564,Carbamazepine
,15286095,extent of accumulation (R(O),"Licarbazepine accumulated in plasma following repeated administration of BIA 2-093; the mean extent of accumulation (R(O), calculated from AUC(0-tau) (day 8)/AUC(0-tau) (day 1)) was 3.0 after repeated, twice-daily dosing and 1.4 to 1.7 after once-daily dosing.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),,1.4 to 1.7,105430,DB00564,Carbamazepine
,15286095,half-life,"Steady-state plasma licarbazepine concentrations were attained at 4 to 5 days of once- or twice-daily dosing, consistent with an effective half-life on the order of 20 to 24 h.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),h,20 to 24,105431,DB00564,Carbamazepine
,15286095,renal clearance,"The mean renal clearance of licarbazepine from plasma was approximately 20 to 30 mL/min, which is low compared with the glomerular filtration rate.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),[ml] / [min],20 to 30,105432,DB00564,Carbamazepine
,15286095,total amount,The total amount of licarbazepine recovered in urine was approximately 20% within 12 h postdose and 40% within 24 h postdose.,"Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),%,20,105433,DB00564,Carbamazepine
,15286095,total amount,The total amount of licarbazepine recovered in urine was approximately 20% within 12 h postdose and 40% within 24 h postdose.,"Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),%,40,105434,DB00564,Carbamazepine
,25339590,Relative bioavailability,Relative bioavailability of carbamazepine after administration of nanoemulsion was 160% compared to unmodified substance.,Experimental investigation of pharmacodynamics and pharmacokinetics of carbamazepine nanoemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25339590/),%,160,105602,DB00564,Carbamazepine
over,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,30,106800,DB00564,Carbamazepine
,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,5-7,106801,DB00564,Carbamazepine
,27611096,flow rate,"Chromatographic separation was performed on a Waters ACQUITY UPLC® HSS C18 column (2.1mm×50mm, 1.8μm) with a gradient mobile phase consisting of acetonitrile-water (containing 0.1% formic acid) as mobile phase at a flow rate of 0.2mL/min.",Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611096/),[ml] / [min],0.2,107189,DB00564,Carbamazepine
,27611096,m/,The quantification was performed by multiple reactions monitoring mode with m/z 367.99→195.89 for prucalopride and m/z 236.97→194.04 for carbamazepine on a Waters Xevo TQD mass spectrometry equipped with electrospray ionization (ESI) source.,Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611096/),,367.99,107190,DB00564,Carbamazepine
,27611096,m/,The quantification was performed by multiple reactions monitoring mode with m/z 367.99→195.89 for prucalopride and m/z 236.97→194.04 for carbamazepine on a Waters Xevo TQD mass spectrometry equipped with electrospray ionization (ESI) source.,Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611096/),,195.89,107191,DB00564,Carbamazepine
,27611096,m/z,The quantification was performed by multiple reactions monitoring mode with m/z 367.99→195.89 for prucalopride and m/z 236.97→194.04 for carbamazepine on a Waters Xevo TQD mass spectrometry equipped with electrospray ionization (ESI) source.,Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611096/),,236.97,107192,DB00564,Carbamazepine
,27611096,m/z,The quantification was performed by multiple reactions monitoring mode with m/z 367.99→195.89 for prucalopride and m/z 236.97→194.04 for carbamazepine on a Waters Xevo TQD mass spectrometry equipped with electrospray ionization (ESI) source.,Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611096/),,194.04,107193,DB00564,Carbamazepine
more,27611096,recoveries,The recoveries obtained for prucalopride were more than 85%.,Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611096/),%,85,107194,DB00564,Carbamazepine
,27611096,time to reach peak concentration (Tmax),"The pharmacokinetic parameters were demonstrated as followed: the time to reach peak concentration (Tmax) was 1.0h, and the peak concentration (Cmax) was 21.71±4.28ng/mL, the half-life (t1/2) was 18.21±0.69h, and the area under the curve (AUC) was 59.30±9.43ngh/mL.",Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611096/),h,1.0,107195,DB00564,Carbamazepine
,27611096,peak concentration (Cmax),"The pharmacokinetic parameters were demonstrated as followed: the time to reach peak concentration (Tmax) was 1.0h, and the peak concentration (Cmax) was 21.71±4.28ng/mL, the half-life (t1/2) was 18.21±0.69h, and the area under the curve (AUC) was 59.30±9.43ngh/mL.",Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611096/),[ng] / [ml],21.71,107196,DB00564,Carbamazepine
,27611096,half-life (t1/2),"The pharmacokinetic parameters were demonstrated as followed: the time to reach peak concentration (Tmax) was 1.0h, and the peak concentration (Cmax) was 21.71±4.28ng/mL, the half-life (t1/2) was 18.21±0.69h, and the area under the curve (AUC) was 59.30±9.43ngh/mL.",Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611096/),h,18.21,107197,DB00564,Carbamazepine
,27611096,area under the curve (AUC),"The pharmacokinetic parameters were demonstrated as followed: the time to reach peak concentration (Tmax) was 1.0h, and the peak concentration (Cmax) was 21.71±4.28ng/mL, the half-life (t1/2) was 18.21±0.69h, and the area under the curve (AUC) was 59.30±9.43ngh/mL.",Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611096/),[ngh] / [ml],59.30,107198,DB00564,Carbamazepine
,26555147,plasma levels,Patients resistant to CBZ treatment showed increased dosage of CBZ (657 ± 285 vs 489 ± 231 mg/day; P<0.001) but also increased plasma levels of CBZ (9.84 ± 4.37 vs 7.41 ± 3.43 μg/mL; P<0.001) compared to patients responsive to CBZ treatment.,"Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555147/),,9.84,108205,DB00564,Carbamazepine
,26555147,plasma levels,Patients resistant to CBZ treatment showed increased dosage of CBZ (657 ± 285 vs 489 ± 231 mg/day; P<0.001) but also increased plasma levels of CBZ (9.84 ± 4.37 vs 7.41 ± 3.43 μg/mL; P<0.001) compared to patients responsive to CBZ treatment.,"Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555147/),,7.41,108206,DB00564,Carbamazepine
,3504397,plasma elimination half-life (T1/2),Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,14,108309,DB00564,Carbamazepine
,3504397,T1/2,Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,24,108310,DB00564,Carbamazepine
,3504397,T1/2,Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10).,Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504397/),h,30,108311,DB00564,Carbamazepine
,12973408,volume of distribution,"The volume of distribution is 0.6-0.8 l/kg, suggesting distribution into total body water.",Pharmacokinetics and metabolism of topiramate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973408/),[l] / [kg],0.6-0.8,108482,DB00564,Carbamazepine
,30426526,Rs,LDP and DDP resolved with good baseline separation (Rs = 4.45) on a Chiralpak IG-3 column.,Enantioselective LC-ESI-MS/MS determination of dropropizine enantiomers in rat plasma and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30426526/),,4.45,108949,DB00564,Carbamazepine
,30426526,flow rate,The mobile phase consisted of methanol with 0.05% diethylamine pumped at a flow rate of 0.5 mL/min.,Enantioselective LC-ESI-MS/MS determination of dropropizine enantiomers in rat plasma and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30426526/),[ml] / [min],0.5,108950,DB00564,Carbamazepine
,30826570,TID20,The experimentally determined TID20 value for TP427 was 11.71 mg/kg.,"New derivative of 1,2,4-triazole-3-thione (TP427) potentiates the anticonvulsant action of valproate, but not that of carbamazepine, phenytoin or phenobarbital in the mouse tonic-clonic seizure model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30826570/),[mg] / [kg],11.71,109717,DB00564,Carbamazepine
,18330250,flow rate,"Cinnamic acid was separated on a Kromasil C18 column (250 mm x 4.6 mm, 5 microm) eluted with a mobile phase of methanol-acetonitrile-water-glacial acetic acid (25:20:55:0.3) at a flow rate of 1.0 mL x min(-1) and room temperature with UV detection at 278 nm, carbamazepine as internal standard.",[Determination of cinnamic acid in rat plasma after oral administration of subing orally disintegrating tablets and study of its pharmacokinetics behavior]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330250/),[ml] / [min],1.0,109820,DB00564,Carbamazepine
,18330250,extraction recovery,"The LOQ was 4.0 ng x mL(-1), the mean extraction recovery of the spiked samples at low, middle and high levels was 86.4%, while the mean method recovery was 100.3%.",[Determination of cinnamic acid in rat plasma after oral administration of subing orally disintegrating tablets and study of its pharmacokinetics behavior]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330250/),%,86.4,109821,DB00564,Carbamazepine
,18330250,method recovery,"The LOQ was 4.0 ng x mL(-1), the mean extraction recovery of the spiked samples at low, middle and high levels was 86.4%, while the mean method recovery was 100.3%.",[Determination of cinnamic acid in rat plasma after oral administration of subing orally disintegrating tablets and study of its pharmacokinetics behavior]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330250/),%,100.3,109822,DB00564,Carbamazepine
,22674769,flow rate,"Chromatographic separation was achieved on a Zorbax XDB-Phenyl (4.6 × 75 mm, 3.5 µm) column using an isocratic mobile phase (5 mm ammonium acetate:methanol, 20:80, v/v) at a flow rate of 0.8 mL/min with a total run time of 2.2 min.",Simultaneous determination of carisoprodol and aspirin in human plasma using liquid chromatography-tandem mass spectrometry in polarity switch mode: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22674769/),[ml] / [min],0.8,110441,DB00564,Carbamazepine
,22674769,total run time,"Chromatographic separation was achieved on a Zorbax XDB-Phenyl (4.6 × 75 mm, 3.5 µm) column using an isocratic mobile phase (5 mm ammonium acetate:methanol, 20:80, v/v) at a flow rate of 0.8 mL/min with a total run time of 2.2 min.",Simultaneous determination of carisoprodol and aspirin in human plasma using liquid chromatography-tandem mass spectrometry in polarity switch mode: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22674769/),min,2.2,110442,DB00564,Carbamazepine
,19160725,clearance,The population mean values of phenobarbitone clearance obtained were 0.250 litres/day/kg for children on phenobarbitone only and 0.208 litres/day/ kg for those on concomitant CBZ or PTO.,Determination of phenobarbitone population clearance values for physically and mentally handicapped Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160725/),[l] / [d·kg],0.250,111732,DB00564,Carbamazepine
,19160725,clearance,The population mean values of phenobarbitone clearance obtained were 0.250 litres/day/kg for children on phenobarbitone only and 0.208 litres/day/ kg for those on concomitant CBZ or PTO.,Determination of phenobarbitone population clearance values for physically and mentally handicapped Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160725/),[l] / [·d·kg],0.208,111733,DB00564,Carbamazepine
,22660444,Clearance (CL),Clearance (CL) was estimated to be 2.27 L/h with inter-individual variability (IIV) of 29 CV%.,Population pharmacokinetics of lamotrigine in Indian epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22660444/),[l] / [h],2.27,111841,DB00564,Carbamazepine
,22660444,Volume of distribution (V),Volume of distribution (V) was estimated to be 53.6 L (31 CV% IIV).,Population pharmacokinetics of lamotrigine in Indian epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22660444/),l,53.6,111842,DB00564,Carbamazepine
,1954073,gastric emptying,"3. The Oros was taken after breakfast and gastric emptying occurred between 1.1- greater than h post-dosing (median, 5.3 h).",Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954073/),h,1.1- greater than,112300,DB00564,Carbamazepine
,1954073,gastric emptying,"3. The Oros was taken after breakfast and gastric emptying occurred between 1.1- greater than h post-dosing (median, 5.3 h).",Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954073/),h,5.3,112301,DB00564,Carbamazepine
,1954073,Small intestinal transit times,"Small intestinal transit times ranged from 1.5- greater than 3.6 h, with a median of 2.2 h.",Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954073/),h,2.2,112302,DB00564,Carbamazepine
,1954073,total transit time,"There were wide individual variations in colonic transit, and the total transit time ranged from 10-60 h (median, 22 h).",Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954073/),h,22,112303,DB00564,Carbamazepine
,1954073,dose normalised AUC ratio,"4. Relative systemic bioavailability of CBZ from the Oros was reduced compared with that from the suspension (mean dose normalised AUC ratio = 0.69 +/- 0.17; mean dose-normalised AUC ratio = 0.85 +/- 0.13, allowing for actual release from the Oros system).",Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954073/),,0.69,112304,DB00564,Carbamazepine
,1954073,dose-normalised AUC ratio,"4. Relative systemic bioavailability of CBZ from the Oros was reduced compared with that from the suspension (mean dose normalised AUC ratio = 0.69 +/- 0.17; mean dose-normalised AUC ratio = 0.85 +/- 0.13, allowing for actual release from the Oros system).",Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954073/),,0.85,112305,DB00564,Carbamazepine
,19566114,rate constant,"The estimated rate constant for enzyme degradation was 0.00805 h-1, corresponding to a half-life of the combined enzymes of 86.1 hours (3.6 days).",Characterization of the time course of carbamazepine deinduction by an enzyme turnover model. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566114/),1/[h],0.00805,112501,DB00564,Carbamazepine
,19566114,half-life,"The estimated rate constant for enzyme degradation was 0.00805 h-1, corresponding to a half-life of the combined enzymes of 86.1 hours (3.6 days).",Characterization of the time course of carbamazepine deinduction by an enzyme turnover model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566114/),h,86.1,112502,DB00564,Carbamazepine
,19566114,half-life,"The estimated rate constant for enzyme degradation was 0.00805 h-1, corresponding to a half-life of the combined enzymes of 86.1 hours (3.6 days).",Characterization of the time course of carbamazepine deinduction by an enzyme turnover model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566114/),d,3.6,112503,DB00564,Carbamazepine
,15634033,volume of distribution at steady state,"Mean (%CV) population pharmacokinetic parameter estimates for delavirdine were: volume of distribution at steady state 67.6 (100) L, intrinsic oral clearance 19.8 (64) L/h, concentration at half the maximum velocity of metabolism (V(max)) 6.3 (69) micromol/L and first order oral clearance 0.57 (86) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),l,67.6,112615,DB00564,Carbamazepine
,15634033,intrinsic oral clearance,"Mean (%CV) population pharmacokinetic parameter estimates for delavirdine were: volume of distribution at steady state 67.6 (100) L, intrinsic oral clearance 19.8 (64) L/h, concentration at half the maximum velocity of metabolism (V(max)) 6.3 (69) micromol/L and first order oral clearance 0.57 (86) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),[l] / [h],19.8,112616,DB00564,Carbamazepine
,15634033,concentration at half the maximum velocity of metabolism (V(max)),"Mean (%CV) population pharmacokinetic parameter estimates for delavirdine were: volume of distribution at steady state 67.6 (100) L, intrinsic oral clearance 19.8 (64) L/h, concentration at half the maximum velocity of metabolism (V(max)) 6.3 (69) micromol/L and first order oral clearance 0.57 (86) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),[μM] / [l],6.3,112617,DB00564,Carbamazepine
,15634033,first order oral clearance,"Mean (%CV) population pharmacokinetic parameter estimates for delavirdine were: volume of distribution at steady state 67.6 (100) L, intrinsic oral clearance 19.8 (64) L/h, concentration at half the maximum velocity of metabolism (V(max)) 6.3 (69) micromol/L and first order oral clearance 0.57 (86) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),[l] / [h],0.57,112618,DB00564,Carbamazepine
,15634033,apparent volume of distribution,"For N-delavirdine, the mean (%CV) apparent volume of distribution was 24.7 (75) L and apparent clearance 29.7 (42) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),l,24.7,112619,DB00564,Carbamazepine
,15634033,apparent clearance,"For N-delavirdine, the mean (%CV) apparent volume of distribution was 24.7 (75) L and apparent clearance 29.7 (42) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),[l] / [h],29.7,112620,DB00564,Carbamazepine
,15634033,V(max),The mean V(max) was 1376 (68) mg/day.,Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),[mg] / [d],1376,112621,DB00564,Carbamazepine
,21455427,AUC(0-24),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,22.78,113108,DB00564,Carbamazepine
,21455427,AUC(0-24),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,10.46,113109,DB00564,Carbamazepine
,21455427,C(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,2.76,113110,DB00564,Carbamazepine
,21455427,C(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,1.412,113111,DB00564,Carbamazepine
,21455427,T(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,2.83,113112,DB00564,Carbamazepine
,21455427,T(max),"The decrease in AUC(0-24) (22.78 ± 4.71 to 10.46 ± 2.29), C(max) (2.76 ± 0.77 to 1.412±1.08), T(max) (2.83 ± 0.17 to 3 ± 0.40) was statistically significant (P < 0.05) when esomeprazole was given along with carbamazepine.",Effect of esomeprazole on the pharmacokinetics of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21455427/),,3,113113,DB00564,Carbamazepine
,6891250,tmax,"(+)-catechin caused a delayed absorption of carbamazepine (40 mg/kg p.o.), as evidenced by a shift of tmax from 2 h in controls to 6 h in (+)-catechin-treated animals.",[Effect of (+)-catechin on the pharmacokinetics of carbamazepine in rabbits]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891250/),h,2,113392,DB00564,Carbamazepine
,6891250,tmax,"(+)-catechin caused a delayed absorption of carbamazepine (40 mg/kg p.o.), as evidenced by a shift of tmax from 2 h in controls to 6 h in (+)-catechin-treated animals.",[Effect of (+)-catechin on the pharmacokinetics of carbamazepine in rabbits]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891250/),h,6,113393,DB00564,Carbamazepine
,6891250,tmax,Repeated oral administration of carbamazepine (10 mg/kg p.o.) for 5 days showed no differences in the maximum concentrations at the expected tmax (2 h) for controls and (+)-catechin-treated animals.,[Effect of (+)-catechin on the pharmacokinetics of carbamazepine in rabbits]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891250/),h,2,113394,DB00564,Carbamazepine
,17573925,CL,Mean LEV CL differed significantly between older (46.5 ml/h/kg) and younger adults (78.3 ml/h/kg).,Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17573925/),[ml] / [h·kg],46.5,113565,DB00564,Carbamazepine
,17573925,CL,Mean LEV CL differed significantly between older (46.5 ml/h/kg) and younger adults (78.3 ml/h/kg).,Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17573925/),[ml] / [h·kg],78.3,113566,DB00564,Carbamazepine
,15673889,clearance,"The clearance of cisatracurium was significantly faster in Group A when compared with Group C (7.12 +/- 1.87 versus 5.72 +/- 0.70 L . kg(-1) . min(-1), P = 0.01).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[l] / [kg·min],7.12,113790,DB00564,Carbamazepine
,15673889,clearance,"The clearance of cisatracurium was significantly faster in Group A when compared with Group C (7.12 +/- 1.87 versus 5.72 +/- 0.70 L . kg(-1) . min(-1), P = 0.01).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[l] / [kg·min],5.72,113791,DB00564,Carbamazepine
,15673889,Cp(ss)95,"The Cp(ss)95 was also significantly larger in Group A (191 +/- 45 versus 159 +/- 36 ng/mL, P = 0.04).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[ng] / [ml],191,113792,DB00564,Carbamazepine
,15673889,Cp(ss)95,"The Cp(ss)95 was also significantly larger in Group A (191 +/- 45 versus 159 +/- 36 ng/mL, P = 0.04).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[ng] / [ml],159,113793,DB00564,Carbamazepine
,14691614,half-life,"The mean peak concentrations of both simvastatin and simvastatin acid were reduced by 68% ( P<0.01), and half-life of simvastatin acid was shortened from 5.9+/-0.3 h to 3.7+/-0.5 h ( P<0.01) by carbamazepine.",Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14691614/),h,5.9,113992,DB00564,Carbamazepine
,14691614,half-life,"The mean peak concentrations of both simvastatin and simvastatin acid were reduced by 68% ( P<0.01), and half-life of simvastatin acid was shortened from 5.9+/-0.3 h to 3.7+/-0.5 h ( P<0.01) by carbamazepine.",Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14691614/),h,3.7,113993,DB00564,Carbamazepine
up to,6143468,time to the steady-state,"Due to the long half-life of phenobarbital its plasma concentrations change slowly, and time to the steady-state may be up to 30 days, if no loading dose is given.",Pharmacokinetics of antiepileptic drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),d,30,115019,DB00564,Carbamazepine
,6143468,half-lives,"Diazepam, clonazepam and nitrazepam are largely bound to plasma proteins and extensively metabolized with the half-lives of 20 to 60 hours.",Pharmacokinetics of antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),h,20 to 60,115020,DB00564,Carbamazepine
,10477323,AUC(0-infinity),"From this IVIVC and the requirements for bioequivalence (AUC(0-infinity): 0.8-1.25 and C(max) : 0.75-1.35; 90% confidence interval), a specification for dissolution testing in SLS was calculated as follows: 'after 20 minutes, 34-99% dissolved'.",In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10477323/),,0.8-1.25,115103,DB00564,Carbamazepine
,10477323,C(max),"From this IVIVC and the requirements for bioequivalence (AUC(0-infinity): 0.8-1.25 and C(max) : 0.75-1.35; 90% confidence interval), a specification for dissolution testing in SLS was calculated as follows: 'after 20 minutes, 34-99% dissolved'.",In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10477323/),,0.75-1.35,115104,DB00564,Carbamazepine
,19841161,relative bioavailability,"The AUC(tau,ss) and C(max,ss) point estimates (combined vs sole treatment) showed relative bioavailability of approximately 100% for both drugs.",No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841161/),%,100,115475,DB00564,Carbamazepine
,9008266,bound concentration,"The mean bound concentration ranged from 37 to 40%; however, an affinity of MHD to red corpuscles was found.",The distribution of 10-hydroxy carbazepine in blood compartments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9008266/),%,37 to 40,115665,DB00564,Carbamazepine
,8254493,time to reach maximum concentration,"The area under the curve of concentration versus time for the complex was 5.6 times greater than the tablet, whereas the mean time to reach maximum concentration for the tablet was 1.4 hours versus 0.5 hours for the complex.",Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8254493/),h,1.4,116040,DB00564,Carbamazepine
,8254493,time to reach maximum concentration,"The area under the curve of concentration versus time for the complex was 5.6 times greater than the tablet, whereas the mean time to reach maximum concentration for the tablet was 1.4 hours versus 0.5 hours for the complex.",Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8254493/),h,0.5,116041,DB00564,Carbamazepine
,23891703,Volume of distribution,Volume of distribution of TPM was estimated at 0.575 l/kg.,Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [kg],0.575,116785,DB00564,Carbamazepine
,23891703,CL/F,"Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ.",Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [h],2.46,116786,DB00564,Carbamazepine
,12507057,elimination half-life,The elimination half-life was calculated to be 5.14 hours.,A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507057/),h,5.14,117772,DB00564,Carbamazepine
,6144486,clearance,Concomitant cimetidine administration produced a decrease in carbamazepine clearance (liters/hr/kg) (0.68 +/- 0.037 vs. 0.41 +/- 0.091; p less than 0.002) which was accompanied by an increase in carbamazepine half-life (hr) (1.1 +/- 0.16 vs. 2.0 +/- 0.37; p less than 0.003).,Inhibition of carbamazepine metabolism by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[l] / [h·kg],0.68,118368,DB00564,Carbamazepine
,6144486,clearance,Concomitant cimetidine administration produced a decrease in carbamazepine clearance (liters/hr/kg) (0.68 +/- 0.037 vs. 0.41 +/- 0.091; p less than 0.002) which was accompanied by an increase in carbamazepine half-life (hr) (1.1 +/- 0.16 vs. 2.0 +/- 0.37; p less than 0.003).,Inhibition of carbamazepine metabolism by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[l] / [h·kg],0.41,118369,DB00564,Carbamazepine
,6144486,half-life,Concomitant cimetidine administration produced a decrease in carbamazepine clearance (liters/hr/kg) (0.68 +/- 0.037 vs. 0.41 +/- 0.091; p less than 0.002) which was accompanied by an increase in carbamazepine half-life (hr) (1.1 +/- 0.16 vs. 2.0 +/- 0.37; p less than 0.003).,Inhibition of carbamazepine metabolism by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),h,1.1,118370,DB00564,Carbamazepine
,6144486,half-life,Concomitant cimetidine administration produced a decrease in carbamazepine clearance (liters/hr/kg) (0.68 +/- 0.037 vs. 0.41 +/- 0.091; p less than 0.002) which was accompanied by an increase in carbamazepine half-life (hr) (1.1 +/- 0.16 vs. 2.0 +/- 0.37; p less than 0.003).,Inhibition of carbamazepine metabolism by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),h,2.0,118371,DB00564,Carbamazepine
,6144486,volume of distribution at steady-state,No cimetidine-induced alterations in the volume of distribution at steady-state (liters/kg) occurred (1.1 +/- 0.14 vs. 1.2 +/- 0.04; NS).,Inhibition of carbamazepine metabolism by cimetidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[l] / [kg],1.1,118372,DB00564,Carbamazepine
,6144486,volume of distribution at steady-state,No cimetidine-induced alterations in the volume of distribution at steady-state (liters/kg) occurred (1.1 +/- 0.14 vs. 1.2 +/- 0.04; NS).,Inhibition of carbamazepine metabolism by cimetidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[l] / [kg],1.2,118373,DB00564,Carbamazepine
,6144486,area under the plasma concentration-time curve,"A reduction in the partial area under the plasma concentration-time curve for carbamazepine-10, 11-epoxide (mg X hr/liter) (28 +/- 2.5 vs. 18 +/- 3.7; p less than 0.002) with cimetidine treatment suggests that a portion of the reduction in carbamazepine clearance may be the result of cimetidine-induced inhibition of epoxide formation.",Inhibition of carbamazepine metabolism by cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[h·mg] / [l],28,118374,DB00564,Carbamazepine
,6144486,area under the plasma concentration-time curve,"A reduction in the partial area under the plasma concentration-time curve for carbamazepine-10, 11-epoxide (mg X hr/liter) (28 +/- 2.5 vs. 18 +/- 3.7; p less than 0.002) with cimetidine treatment suggests that a portion of the reduction in carbamazepine clearance may be the result of cimetidine-induced inhibition of epoxide formation.",Inhibition of carbamazepine metabolism by cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144486/),[h·mg] / [l],18,118375,DB00564,Carbamazepine
,14594524,elimination half-life,"The model was used to simulate plasma CBZ concentrations following multiple doses given every 12 h to hypothetical long-term CBZ-treated patients, with the CBZ elimination half-life set to 13.7 h to account for enzymatic autoinduction.",Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14594524/),h,13.7,118759,DB00564,Carbamazepine
,14594524,trough,"Predicted plasma CBZ concentrations in this simulation fell from a trough of approximately 6.4 microg/ml only to 4 microg/ml after 24 h without medication, and only to 2.5 microg/ml after 36 h without medication.",Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14594524/),[μg] / [ml],6.4,118760,DB00564,Carbamazepine
,14594524,trough,"Predicted plasma CBZ concentrations in this simulation fell from a trough of approximately 6.4 microg/ml only to 4 microg/ml after 24 h without medication, and only to 2.5 microg/ml after 36 h without medication.",Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14594524/),,4,118761,DB00564,Carbamazepine
,25986188,IC50,"In vitro hydrolysis of carbamazepine-epoxide in human hepatocytes was inhibited by brivaracetam, with an IC50 of 8.2μM.",Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25986188/),μM,8.2,119129,DB00564,Carbamazepine
,19855315,peak plasma concentration,"Carbamazepine pretreatment significantly altered fexofenadine pharmacokinetics, decreasing the mean (+/- standard deviation) peak plasma concentration from 176.6 (+/- 82.1) ng/mL to 103.2 (+/- 33.6) ng/mL (P < 0.01) and the area under the plasma concentration-time curve from 1058.4 (+/- 528.7) ng/h/mL to 604.8 (+/- 255.9) ng/h/mL (P < 0.01) without changing the elimination half-life.",Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19855315/),[ng] / [ml],176.6,119423,DB00564,Carbamazepine
,19855315,peak plasma concentration,"Carbamazepine pretreatment significantly altered fexofenadine pharmacokinetics, decreasing the mean (+/- standard deviation) peak plasma concentration from 176.6 (+/- 82.1) ng/mL to 103.2 (+/- 33.6) ng/mL (P < 0.01) and the area under the plasma concentration-time curve from 1058.4 (+/- 528.7) ng/h/mL to 604.8 (+/- 255.9) ng/h/mL (P < 0.01) without changing the elimination half-life.",Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19855315/),[ng] / [ml],103.2,119424,DB00564,Carbamazepine
,19855315,area under the plasma concentration-time curve,"Carbamazepine pretreatment significantly altered fexofenadine pharmacokinetics, decreasing the mean (+/- standard deviation) peak plasma concentration from 176.6 (+/- 82.1) ng/mL to 103.2 (+/- 33.6) ng/mL (P < 0.01) and the area under the plasma concentration-time curve from 1058.4 (+/- 528.7) ng/h/mL to 604.8 (+/- 255.9) ng/h/mL (P < 0.01) without changing the elimination half-life.",Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19855315/),[ng] / [h·ml],1058.4,119425,DB00564,Carbamazepine
,19855315,area under the plasma concentration-time curve,"Carbamazepine pretreatment significantly altered fexofenadine pharmacokinetics, decreasing the mean (+/- standard deviation) peak plasma concentration from 176.6 (+/- 82.1) ng/mL to 103.2 (+/- 33.6) ng/mL (P < 0.01) and the area under the plasma concentration-time curve from 1058.4 (+/- 528.7) ng/h/mL to 604.8 (+/- 255.9) ng/h/mL (P < 0.01) without changing the elimination half-life.",Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19855315/),[ng] / [h·ml],604.8,119426,DB00564,Carbamazepine
,32330998,Cmax,"The integrated pharmacokinetic parameters Cmax , Tmax , and t1/2 were 81.54 ± 9.62 ng/mL, 1.00 ± 0.21 h, and 3.26 ± 1.14 h, respectively.",UPLC-MS/MS simultaneous determination of seven active ingredients of Yaobitong capsule in rat plasma and its integrated pharmacokinetic application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32330998/),[ng] / [ml],81.54,121304,DB00564,Carbamazepine
,32330998,Tmax,"The integrated pharmacokinetic parameters Cmax , Tmax , and t1/2 were 81.54 ± 9.62 ng/mL, 1.00 ± 0.21 h, and 3.26 ± 1.14 h, respectively.",UPLC-MS/MS simultaneous determination of seven active ingredients of Yaobitong capsule in rat plasma and its integrated pharmacokinetic application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32330998/),h,1.00,121305,DB00564,Carbamazepine
,32330998,t1/2,"The integrated pharmacokinetic parameters Cmax , Tmax , and t1/2 were 81.54 ± 9.62 ng/mL, 1.00 ± 0.21 h, and 3.26 ± 1.14 h, respectively.",UPLC-MS/MS simultaneous determination of seven active ingredients of Yaobitong capsule in rat plasma and its integrated pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32330998/),h,3.26,121306,DB00564,Carbamazepine
,33171342,concentration,"In 206 patients, the seizure reduction from baseline was > 50 % and the median perampanel concentration was 351 ng/mL (interquartile range, 191-603 ng/mL).","Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33171342/),,35,122290,DB00564,Carbamazepine
,7030746,elimination half-life,The elimination half-life varied from 15.15 hours at 16.00h to 10.48 hours at 22.00h.,Circadian effect on carbamazepine kinetics in rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7030746/),h,15.15,122929,DB00564,Carbamazepine
,7030746,elimination half-life,The elimination half-life varied from 15.15 hours at 16.00h to 10.48 hours at 22.00h.,Circadian effect on carbamazepine kinetics in rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7030746/),h,10.48,122930,DB00564,Carbamazepine
more,25636663,Recoveries,Recoveries were more than 75.3% and matrix effects were not significant.,"Simultaneous determination of liensinine, isoliensinine and neferine in rat plasma by UPLC-MS/MS and application of the technique to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25636663/),%,75.3,125325,DB00564,Carbamazepine
,31077428,m/,Ketamine enantiomers were detected by mass spectrometry with multiple reaction monitoring mode using the transitions of m/z 238.3 → 125.9 for the analytes and m/z 237.1 → 194.1 for carbamazepine (internal standard).,Enantioselective determination of ketamine in dog plasma by chiral liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077428/),,238.3,125677,DB00564,Carbamazepine
,31077428,m/,Ketamine enantiomers were detected by mass spectrometry with multiple reaction monitoring mode using the transitions of m/z 238.3 → 125.9 for the analytes and m/z 237.1 → 194.1 for carbamazepine (internal standard).,Enantioselective determination of ketamine in dog plasma by chiral liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077428/),,125.9,125678,DB00564,Carbamazepine
,31077428,m/,Ketamine enantiomers were detected by mass spectrometry with multiple reaction monitoring mode using the transitions of m/z 238.3 → 125.9 for the analytes and m/z 237.1 → 194.1 for carbamazepine (internal standard).,Enantioselective determination of ketamine in dog plasma by chiral liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077428/),,237.1,125679,DB00564,Carbamazepine
,31077428,m/,Ketamine enantiomers were detected by mass spectrometry with multiple reaction monitoring mode using the transitions of m/z 238.3 → 125.9 for the analytes and m/z 237.1 → 194.1 for carbamazepine (internal standard).,Enantioselective determination of ketamine in dog plasma by chiral liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077428/),,194.1,125680,DB00564,Carbamazepine
,29637542,AUCss,"Based on published clinical data, an AUCss value of 1,000 pg/ml.h was selected as the threshold for breakthrough bleeding.",Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29637542/),[pg] / [h·ml],"1,000",125794,DB00564,Carbamazepine
,9607957,Elimination rate constants,"Elimination rate constants calculated using partial area analysis are 0.087 +/- 0.015 (h-1) and 0.056 +/- 0.014 (h-1) for CBZE and CBZD, respectively.",A partial area difference analysis for estimating elimination rate constants and distribution volumes of metabolites. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607957/),1/[h],0.087,126307,DB00564,Carbamazepine
,9607957,Elimination rate constants,"Elimination rate constants calculated using partial area analysis are 0.087 +/- 0.015 (h-1) and 0.056 +/- 0.014 (h-1) for CBZE and CBZD, respectively.",A partial area difference analysis for estimating elimination rate constants and distribution volumes of metabolites. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607957/),1/[h],0.056,126308,DB00564,Carbamazepine
,9607957,half-life,"These correspond to an average half-life of 8.0 h for CBZE and 12.4 h for CBZD, which suggest elimination-rate-limited disappearance of CBZD.",A partial area difference analysis for estimating elimination rate constants and distribution volumes of metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607957/),h,8.0,126309,DB00564,Carbamazepine
,9607957,half-life,"These correspond to an average half-life of 8.0 h for CBZE and 12.4 h for CBZD, which suggest elimination-rate-limited disappearance of CBZD.",A partial area difference analysis for estimating elimination rate constants and distribution volumes of metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607957/),h,12.4,126310,DB00564,Carbamazepine
,9607957,Volumes of distribution,"Volumes of distribution of CBZE and CBZD are also estimated to be 0.57 +/- 0.11 L/kg and 0.76 +/- 0.24 L/kg, respectively.",A partial area difference analysis for estimating elimination rate constants and distribution volumes of metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607957/),[l] / [kg],0.57,126311,DB00564,Carbamazepine
,9607957,Volumes of distribution,"Volumes of distribution of CBZE and CBZD are also estimated to be 0.57 +/- 0.11 L/kg and 0.76 +/- 0.24 L/kg, respectively.",A partial area difference analysis for estimating elimination rate constants and distribution volumes of metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607957/),[l] / [kg],0.76,126312,DB00564,Carbamazepine
,25151742,trough concentrations,Seven sampling designs were investigated using various number of trough concentrations per individual ranging from 1-4.,[Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25151742/),,1-4,126413,DB00564,Carbamazepine
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],16 to 28,126871,DB00564,Carbamazepine
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],7.4 to 14,126872,DB00564,Carbamazepine
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],18 to 26,126873,DB00564,Carbamazepine
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],260 to 335,126874,DB00564,Carbamazepine
,475429,half-lives,"The saliva CBZ half-lives in 2 children were 7.3 and 12.7 hours, and the apparent volumes of distribution (saliva) were 1.6 and 1.5 l/kg respectively.",Carbamazepine dose-frequency requirement in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/475429/),h,7.3,127322,DB00564,Carbamazepine
,475429,half-lives,"The saliva CBZ half-lives in 2 children were 7.3 and 12.7 hours, and the apparent volumes of distribution (saliva) were 1.6 and 1.5 l/kg respectively.",Carbamazepine dose-frequency requirement in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/475429/),h,12.7,127323,DB00564,Carbamazepine
,475429,apparent volumes of distribution (saliva),"The saliva CBZ half-lives in 2 children were 7.3 and 12.7 hours, and the apparent volumes of distribution (saliva) were 1.6 and 1.5 l/kg respectively.",Carbamazepine dose-frequency requirement in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/475429/),[l] / [kg],1.6,127324,DB00564,Carbamazepine
,475429,apparent volumes of distribution (saliva),"The saliva CBZ half-lives in 2 children were 7.3 and 12.7 hours, and the apparent volumes of distribution (saliva) were 1.6 and 1.5 l/kg respectively.",Carbamazepine dose-frequency requirement in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/475429/),[l] / [kg],1.5,127325,DB00564,Carbamazepine
,6439443,elimination half-life,"Mean elimination half-life was 8.21 +/- 3.13 hours, mean apparent volume of distribution 0.1868 +/- 0.0641 L/kg and mean plasma clearance 0.0177 +/- 0.0099 L/kg/hour.",Steady-state valproate pharmacokinetics during long term therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6439443/),h,8.21,127741,DB00564,Carbamazepine
,6439443,apparent volume of distribution,"Mean elimination half-life was 8.21 +/- 3.13 hours, mean apparent volume of distribution 0.1868 +/- 0.0641 L/kg and mean plasma clearance 0.0177 +/- 0.0099 L/kg/hour.",Steady-state valproate pharmacokinetics during long term therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6439443/),[l] / [kg],0.1868,127742,DB00564,Carbamazepine
,6439443,plasma clearance,"Mean elimination half-life was 8.21 +/- 3.13 hours, mean apparent volume of distribution 0.1868 +/- 0.0641 L/kg and mean plasma clearance 0.0177 +/- 0.0099 L/kg/hour.",Steady-state valproate pharmacokinetics during long term therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6439443/),[l] / [h·kg],0.0177,127743,DB00564,Carbamazepine
,29951541,m/,"Multiple reaction monitoring (MRM) modes of m/z 238.1 → 179.1 for ketamine, m/z 385.3 → 159.8 for rhynchophylline, and m/z 237.3 → 194.3 for carbamazepine (IS) were utilized to conduct quantitative analysis.",Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29951541/),,238.,128253,DB00564,Carbamazepine
,29951541,m/,"Multiple reaction monitoring (MRM) modes of m/z 238.1 → 179.1 for ketamine, m/z 385.3 → 159.8 for rhynchophylline, and m/z 237.3 → 194.3 for carbamazepine (IS) were utilized to conduct quantitative analysis.",Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29951541/),,179.1,128254,DB00564,Carbamazepine
,29951541,m/z,"Multiple reaction monitoring (MRM) modes of m/z 238.1 → 179.1 for ketamine, m/z 385.3 → 159.8 for rhynchophylline, and m/z 237.3 → 194.3 for carbamazepine (IS) were utilized to conduct quantitative analysis.",Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29951541/),,385.3,128255,DB00564,Carbamazepine
,29951541,m/z,"Multiple reaction monitoring (MRM) modes of m/z 238.1 → 179.1 for ketamine, m/z 385.3 → 159.8 for rhynchophylline, and m/z 237.3 → 194.3 for carbamazepine (IS) were utilized to conduct quantitative analysis.",Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29951541/),,159.8,128256,DB00564,Carbamazepine
,29951541,m/,"Multiple reaction monitoring (MRM) modes of m/z 238.1 → 179.1 for ketamine, m/z 385.3 → 159.8 for rhynchophylline, and m/z 237.3 → 194.3 for carbamazepine (IS) were utilized to conduct quantitative analysis.",Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29951541/),,237.3,128257,DB00564,Carbamazepine
,15010199,Maximum time (T(max)),"Maximum time (T(max)) for CBZ was reached at 2.72+/-0.71 h and for CBZ-E, it was 3.60+/-0.79 h.","Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010199/),h,2.72,128259,DB00564,Carbamazepine
,15010199,Maximum time (T(max)),"Maximum time (T(max)) for CBZ was reached at 2.72+/-0.71 h and for CBZ-E, it was 3.60+/-0.79 h.","Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010199/),h,3.60,128260,DB00564,Carbamazepine
,15010199,C(max),"C(max) for CBZ was 7.30+/-2.30 microg/mL, while C(min) for CBZ was 6.30+/-2.49.","Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010199/),[μg] / [ml],7.30,128261,DB00564,Carbamazepine
,15010199,C(min),"C(max) for CBZ was 7.30+/-2.30 microg/mL, while C(min) for CBZ was 6.30+/-2.49.","Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010199/),,6.30,128262,DB00564,Carbamazepine
,15010199,Maximum serum,"Maximum serum values for CBZ-E were 1.01+/-0.57, equivalent to 13.80% of CBZ; t(12) value for CBZ and CBZ-E was 18.20 and 16.10 h, respectively.","Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010199/),,1.01,128263,DB00564,Carbamazepine
,15010199,t(12),"Maximum serum values for CBZ-E were 1.01+/-0.57, equivalent to 13.80% of CBZ; t(12) value for CBZ and CBZ-E was 18.20 and 16.10 h, respectively.","Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010199/),h,18.20,128264,DB00564,Carbamazepine
,15010199,t(12),"Maximum serum values for CBZ-E were 1.01+/-0.57, equivalent to 13.80% of CBZ; t(12) value for CBZ and CBZ-E was 18.20 and 16.10 h, respectively.","Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010199/),h,16.10,128265,DB00564,Carbamazepine
,15010199,AUC,"AUC values for CBZ and metabolite were 70.33+/-17.10 microg/L/h and 9.20+/-2.50 microg/L/h, respectively.","Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010199/),[μg] / [h·l],70.33,128266,DB00564,Carbamazepine
,15010199,AUC,"AUC values for CBZ and metabolite were 70.33+/-17.10 microg/L/h and 9.20+/-2.50 microg/L/h, respectively.","Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010199/),[μg] / [h·l],9.20,128267,DB00564,Carbamazepine
,15010199,clearance,"CBZ and CBZ-E clearance did not show differences and were 0.37 mL/kg/min and 0.40 mL/kg/min, respectively.","Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010199/),[ml] / [kg·min],0.37,128268,DB00564,Carbamazepine
,15010199,clearance,"CBZ and CBZ-E clearance did not show differences and were 0.37 mL/kg/min and 0.40 mL/kg/min, respectively.","Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010199/),[ml] / [kg·min],0.40,128269,DB00564,Carbamazepine
,2043285,half-life,"The pharmacokinetic profile in children is similar to that in adults, but the half-life in long term paediatric therapy is between 6 and 12 hours, compared with 15 hours in adults.",Risk-benefit assessment of carbamazepine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2043285/),h,6 and 12,128489,DB00564,Carbamazepine
,2043285,half-life,"The pharmacokinetic profile in children is similar to that in adults, but the half-life in long term paediatric therapy is between 6 and 12 hours, compared with 15 hours in adults.",Risk-benefit assessment of carbamazepine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2043285/),h,15,128490,DB00564,Carbamazepine
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],6.1,128709,DB00564,Carbamazepine
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],2.1,128710,DB00564,Carbamazepine
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],3.1,128711,DB00564,Carbamazepine
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],2.4,128712,DB00564,Carbamazepine
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.8,128713,DB00564,Carbamazepine
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.3,128714,DB00564,Carbamazepine
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.4,128715,DB00564,Carbamazepine
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,8.0,128716,DB00564,Carbamazepine
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,3.8,128717,DB00564,Carbamazepine
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,4.1,128718,DB00564,Carbamazepine
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,4.9,128719,DB00564,Carbamazepine
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],1.8,128720,DB00564,Carbamazepine
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.4,128721,DB00564,Carbamazepine
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.6,128722,DB00564,Carbamazepine
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.5,128723,DB00564,Carbamazepine
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.2,128724,DB00564,Carbamazepine
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.06,128725,DB00564,Carbamazepine
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.1,128726,DB00564,Carbamazepine
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,4.3,128727,DB00564,Carbamazepine
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,1.9,128728,DB00564,Carbamazepine
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,2.2,128729,DB00564,Carbamazepine
,1542148,half-life,The mean half-life of carbamazepine was as follows: a) Acute vs. Acute-On-Chronic overdose: 8.63 h vs. 12.01 h (p less than 0.05); b) No Activated Charcoal vs. 30-50 g Activated Charcoal vs. 60-90 g Activated Charcoal: 23.3 h vs. 10.17 h vs. 7.21 h (p less than 0.05); c) No Activated Charcoal vs. 2-3 doses vs. 7-12 doses: 23.3 h vs. 8.96 h vs 7.55 h (ns).,Carbamazepine overdose--the effects of multiple dose activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1542148/),h,8.63,128991,DB00564,Carbamazepine
,1542148,half-life,The mean half-life of carbamazepine was as follows: a) Acute vs. Acute-On-Chronic overdose: 8.63 h vs. 12.01 h (p less than 0.05); b) No Activated Charcoal vs. 30-50 g Activated Charcoal vs. 60-90 g Activated Charcoal: 23.3 h vs. 10.17 h vs. 7.21 h (p less than 0.05); c) No Activated Charcoal vs. 2-3 doses vs. 7-12 doses: 23.3 h vs. 8.96 h vs 7.55 h (ns).,Carbamazepine overdose--the effects of multiple dose activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1542148/),h,12.01,128992,DB00564,Carbamazepine
,1542148,half-life,The mean half-life of carbamazepine was as follows: a) Acute vs. Acute-On-Chronic overdose: 8.63 h vs. 12.01 h (p less than 0.05); b) No Activated Charcoal vs. 30-50 g Activated Charcoal vs. 60-90 g Activated Charcoal: 23.3 h vs. 10.17 h vs. 7.21 h (p less than 0.05); c) No Activated Charcoal vs. 2-3 doses vs. 7-12 doses: 23.3 h vs. 8.96 h vs 7.55 h (ns).,Carbamazepine overdose--the effects of multiple dose activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1542148/),h,23.3,128993,DB00564,Carbamazepine
,1542148,half-life,The mean half-life of carbamazepine was as follows: a) Acute vs. Acute-On-Chronic overdose: 8.63 h vs. 12.01 h (p less than 0.05); b) No Activated Charcoal vs. 30-50 g Activated Charcoal vs. 60-90 g Activated Charcoal: 23.3 h vs. 10.17 h vs. 7.21 h (p less than 0.05); c) No Activated Charcoal vs. 2-3 doses vs. 7-12 doses: 23.3 h vs. 8.96 h vs 7.55 h (ns).,Carbamazepine overdose--the effects of multiple dose activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1542148/),h,10.17,128994,DB00564,Carbamazepine
,1542148,half-life,The mean half-life of carbamazepine was as follows: a) Acute vs. Acute-On-Chronic overdose: 8.63 h vs. 12.01 h (p less than 0.05); b) No Activated Charcoal vs. 30-50 g Activated Charcoal vs. 60-90 g Activated Charcoal: 23.3 h vs. 10.17 h vs. 7.21 h (p less than 0.05); c) No Activated Charcoal vs. 2-3 doses vs. 7-12 doses: 23.3 h vs. 8.96 h vs 7.55 h (ns).,Carbamazepine overdose--the effects of multiple dose activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1542148/),h,7.21,128995,DB00564,Carbamazepine
,1542148,half-life,The mean half-life of carbamazepine was as follows: a) Acute vs. Acute-On-Chronic overdose: 8.63 h vs. 12.01 h (p less than 0.05); b) No Activated Charcoal vs. 30-50 g Activated Charcoal vs. 60-90 g Activated Charcoal: 23.3 h vs. 10.17 h vs. 7.21 h (p less than 0.05); c) No Activated Charcoal vs. 2-3 doses vs. 7-12 doses: 23.3 h vs. 8.96 h vs 7.55 h (ns).,Carbamazepine overdose--the effects of multiple dose activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1542148/),h,8.96,128996,DB00564,Carbamazepine
,1542148,half-life,The mean half-life of carbamazepine was as follows: a) Acute vs. Acute-On-Chronic overdose: 8.63 h vs. 12.01 h (p less than 0.05); b) No Activated Charcoal vs. 30-50 g Activated Charcoal vs. 60-90 g Activated Charcoal: 23.3 h vs. 10.17 h vs. 7.21 h (p less than 0.05); c) No Activated Charcoal vs. 2-3 doses vs. 7-12 doses: 23.3 h vs. 8.96 h vs 7.55 h (ns).,Carbamazepine overdose--the effects of multiple dose activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1542148/),h,7.55,128997,DB00564,Carbamazepine
,16940857,half-life,"The median decreases in the NVP half-life were 18.8, 19.0, and 16.9 hours, respectively.",Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940857/),h,19.0,129028,DB00564,Carbamazepine
,16940857,half-life,"The median decreases in the NVP half-life were 18.8, 19.0, and 16.9 hours, respectively.",Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940857/),h,16.9,129029,DB00564,Carbamazepine
,10511917,half-life,"Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),h,33,129674,DB00564,Carbamazepine
,10511917,apparent plasma clearance,"The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),[l] / [h],26,129675,DB00564,Carbamazepine
,1773780,peak plasma concentrations,"In an open dose-escalating study, LTG 240 mg produced peak plasma concentrations of around 3 micrograms/mg with no significant adverse events.",Clinical pharmacology of lamotrigine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773780/),[μg] / [mg],3,130119,DB00564,Carbamazepine
,1773780,half-life,"Subsequent pharmacokinetic studies revealed complete oral absorption, first-order kinetics with a mean half-life of approximately 1 day, and elimination mainly as a glucuronide in the urine.",Clinical pharmacology of lamotrigine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773780/),d,1,130120,DB00564,Carbamazepine
,8557788,flow rate,The eluting solvent was 20% acetonitrile in water at a flow rate of 1.5 ml/min and the detector was monitored at 215 nm.,Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557788/),[ml] / [min],1.5,130568,DB00564,Carbamazepine
,8557788,detection limit,"The detection limit of OXC and 10-hydroxycarbazepine was 50 and 20 ng/ml, respectively.",Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557788/),[ng] / [ml],50,130569,DB00564,Carbamazepine
,8557788,detection limit,"The detection limit of OXC and 10-hydroxycarbazepine was 50 and 20 ng/ml, respectively.",Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557788/),[ng] / [ml],20,130570,DB00564,Carbamazepine
,8557788,relative,The relative and absolute recoveries varied between 71.4% and 104.0%.,Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557788/),%,71.4,130571,DB00564,Carbamazepine
,8557788,absolute recoveries,The relative and absolute recoveries varied between 71.4% and 104.0%.,Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557788/),%,104.0,130572,DB00564,Carbamazepine
,28165818,bioavailability,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[h·μg] / [ml],1441.711,130599,DB00564,Carbamazepine
,28165818,bioavailability,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[μg] / [ml],137.518,130600,DB00564,Carbamazepine
,28165818,bioavailability,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[h·μg] / [ml],321.011,130601,DB00564,Carbamazepine
,28165818,bioavailability,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[μg] / [ml],38.673,130602,DB00564,Carbamazepine
,28165818,AUC,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[h·μg] / [ml],321.011,130603,DB00564,Carbamazepine
,28165818,AUC,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[μg] / [ml],38.673,130604,DB00564,Carbamazepine
,28165818,Cpmax,"The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively).",Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28165818/),[μg] / [ml],38.673,130605,DB00564,Carbamazepine
,25972738,Cmax,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[μg] / [ml],4.33,131119,DB00564,Carbamazepine
,25972738,Cmax,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[μg] / [ml],4.76,131120,DB00564,Carbamazepine
,25972738,tmax,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),h,2.91,131121,DB00564,Carbamazepine
,25972738,tmax,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),h,3.6,131122,DB00564,Carbamazepine
,25972738,total area under the curve AUC0-t,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[h·μg] / [ml],64.90,131123,DB00564,Carbamazepine
,25972738,total area under the curve AUC0-t,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[h·μg] / [ml],102.90,131124,DB00564,Carbamazepine
,25972738,AUC0-∞,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[h·μg] / [ml],74.0,131125,DB00564,Carbamazepine
,25972738,AUC0-∞,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),[h·μg] / [ml],124.3,131126,DB00564,Carbamazepine
,25972738,t ½,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),h,14.10,131127,DB00564,Carbamazepine
,25972738,t ½,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),h,16.43,131128,DB00564,Carbamazepine
,25972738,elimination rate constant ke,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),1/[h],0.050,131129,DB00564,Carbamazepine
,25972738,elimination rate constant ke,"Cmax, the mean peak plasma concentration was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 μg·h/ml versus 102.90 ± 66.9 μg·h/ml, AUC0-∞ was 74.0 ± 52.6 μg·h/ml versus 124.3 ± 85 μg·h/mL, t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h(-1) versus 0.057 ± 0.049 h(-1), respectively.",The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25972738/),1/[h],0.057,131130,DB00564,Carbamazepine
,25808507,flow rate,"The plasma (0.05 mL) or urine (0.2 mL) samples were extracted by liquid-liquid extraction with ethyl acetate and separated on an Eclipse Plus C18 column (100 × 4.6 mm, 3.5 μm) with a mobile phase consisting of acetonitrile and 0.1% formic acid water (60:40, v/v) at a flow rate of 0.7 mL/min.",Development and validation of a liquid chromatography with tandem mass spectrometry method for the quantification of vitisin B in rat plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808507/),[ml] / [min],0.7,133716,DB00564,Carbamazepine
,26567546,flow rate,"After the extraction of samples by protein precipitation, both lorcaserin and IS were separated on an Acquity BEH™ C18 (50 × 2.1 mm, 1.7 µm) column using a mobile phase consisting of acetonitrile-10 mM ammonium acetate-formic acid (85:15:0.1, v/v/v) at a flow rate of 0.25 mL/min.",A Validated UPLC-MS-MS Assay for the Rapid Determination of Lorcaserin in Plasma and Brain Tissue Samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26567546/),[ml] / [min],0.25,134130,DB00564,Carbamazepine
,26567546,m/z,"The MS-MS ion transitions were monitored at m/z 195.99 > 143.91 for lorcaserin and m/z 237.00 > 178.97 for IS, respectively.",A Validated UPLC-MS-MS Assay for the Rapid Determination of Lorcaserin in Plasma and Brain Tissue Samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26567546/),,195.99,134131,DB00564,Carbamazepine
>,26567546,m/z,"The MS-MS ion transitions were monitored at m/z 195.99 > 143.91 for lorcaserin and m/z 237.00 > 178.97 for IS, respectively.",A Validated UPLC-MS-MS Assay for the Rapid Determination of Lorcaserin in Plasma and Brain Tissue Samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26567546/),,143.91,134132,DB00564,Carbamazepine
>,26567546,m/z,"The MS-MS ion transitions were monitored at m/z 195.99 > 143.91 for lorcaserin and m/z 237.00 > 178.97 for IS, respectively.",A Validated UPLC-MS-MS Assay for the Rapid Determination of Lorcaserin in Plasma and Brain Tissue Samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26567546/),,237.00,134133,DB00564,Carbamazepine
>,26567546,m/z,"The MS-MS ion transitions were monitored at m/z 195.99 > 143.91 for lorcaserin and m/z 237.00 > 178.97 for IS, respectively.",A Validated UPLC-MS-MS Assay for the Rapid Determination of Lorcaserin in Plasma and Brain Tissue Samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26567546/),,178.97,134134,DB00564,Carbamazepine
,9050802,plasma elimination half-life,"Intravenous administration of an aqueous carbamazepine x 2-hydroxypropyl-beta-cyclodextrin (CBZ x HPbetaCD) complex at a CBZ dose of 20 mg/kg was well tolerated and generated high initial drug levels that fell monoexponentially as a function of time, yielding a plasma elimination half-life of 38 min.",Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9050802/),min,38,134449,DB00564,Carbamazepine
<,9050802,maximum CBZ concentrations (C(max)),"Oral administration of tablets gave erratic and slow absorption, leading to maximum CBZ concentrations (C(max)) of <2 microg/mL, which were manifested only at 2.5 h after drug dosing.",Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9050802/),[μg] / [ml],2,134450,DB00564,Carbamazepine
,9050802,absolute bioavailability,The absolute bioavailability of CBZ from the tablets was approximately 25%.,Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9050802/),%,25,134451,DB00564,Carbamazepine
,9527647,ED50,"4-amino-(2-methyl-4-aminophenyl)benzamide (4A-2M4A-PB) gave anti maximal electroshock seizures ED50 of 63 micromol/kg (15.4 mg/kg) and a TD50 of 676 micromol/kg (163 mg/kg), yielding a PI of 10.7; the potency is similar to that of the 4-amino-(2-methyl-3-aminophenyl)phthalimide (4A-2M3A-PP), superior to that of 4-amino-(2,6-dimethylphenyl)phthalimide (4A-2,6-DMPP), close to that of phenytoin and carbamazepine and inferior to that of ameltolide.",Anticonvulsant profile of 4-amino-(2-methyl-4-aminophenyl)benzamide in mice and rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527647/),[μM] / [kg],63,134606,DB00564,Carbamazepine
,9527647,TD50,"4-amino-(2-methyl-4-aminophenyl)benzamide (4A-2M4A-PB) gave anti maximal electroshock seizures ED50 of 63 micromol/kg (15.4 mg/kg) and a TD50 of 676 micromol/kg (163 mg/kg), yielding a PI of 10.7; the potency is similar to that of the 4-amino-(2-methyl-3-aminophenyl)phthalimide (4A-2M3A-PP), superior to that of 4-amino-(2,6-dimethylphenyl)phthalimide (4A-2,6-DMPP), close to that of phenytoin and carbamazepine and inferior to that of ameltolide.",Anticonvulsant profile of 4-amino-(2-methyl-4-aminophenyl)benzamide in mice and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527647/),[μM] / [kg],676,134607,DB00564,Carbamazepine
,9527647,ED50,"4A-2M4A-PB with an ED50 of 41[28-60] micromol/kg (9.9 mg/kg) is as active after oral administration to rats as carbamazepine, more active than ameltolide, 4-A-2M3A-PP and phenytoin and slightly less active than the 4A-2,6-DMPP.",Anticonvulsant profile of 4-amino-(2-methyl-4-aminophenyl)benzamide in mice and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527647/),[μM] / [kg],41,134608,DB00564,Carbamazepine
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],4.41,134944,DB00564,Carbamazepine
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],7.23,134945,DB00564,Carbamazepine
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],4.87,134946,DB00564,Carbamazepine
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],17.30,134947,DB00564,Carbamazepine
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],20.08,134948,DB00564,Carbamazepine
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],20.49,134949,DB00564,Carbamazepine
,26865186,half-life,"The half-life of retigabine in plasma was 2.5 h, with appreciable concentrations reached in the brain within 1 h of administration.",Profile of retigabine-induced neuronal apoptosis in the developing rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865186/),h,2.5,135025,DB00564,Carbamazepine
,2804994,clearances (dose/AUC),"On these days, the mean (+/- SD) LTG clearances (dose/AUC) were 0.0436 +/- 0.0171, 0.0468 +/- 0.0093, and 0.0575 +/- 0.0160 L/h/kg, respectively.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[l] / [h·kg],0.0436,135251,DB00564,Carbamazepine
,2804994,clearances (dose/AUC),"On these days, the mean (+/- SD) LTG clearances (dose/AUC) were 0.0436 +/- 0.0171, 0.0468 +/- 0.0093, and 0.0575 +/- 0.0160 L/h/kg, respectively.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[l] / [h·kg],0.0468,135252,DB00564,Carbamazepine
,2804994,clearances (dose/AUC),"On these days, the mean (+/- SD) LTG clearances (dose/AUC) were 0.0436 +/- 0.0171, 0.0468 +/- 0.0093, and 0.0575 +/- 0.0160 L/h/kg, respectively.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[l] / [h·kg],0.0575,135253,DB00564,Carbamazepine
,2804994,trough levels,"In conclusion, when given for long periods of time (9.5 months to 2 years), LTG was well tolerated in doses up to 400 mg/day and mean trough levels of 3.0 +/- 0.6 microgram/ml; LTG has a favorable pharmacokinetic profile and appears to exhibit first-order linear kinetics during long-term chronic dosing; LTG shows preliminary evidence of efficacy during long-term administration; and to date, our patients represent the longest reported experience of continuous and closely monitored LTG therapy in the literature.","Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804994/),[μg] / [ml],3.0,135254,DB00564,Carbamazepine
,8156973,half-life,MHD is eliminated with a half-life of about 8-10 h.,Clinical pharmacology and pharmacokinetics of oxcarbazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156973/),h,8-10,135672,DB00564,Carbamazepine
,30636182,clearance (CL/F),"The typical values for MHD clearance (CL/F), distribution volume (V/F) and absorption rate constant (Ka) were 3.25 L/h/70 kg, 151.41 L/70 kg and 0.598 h-1 , respectively.",Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636182/),[l] / [70·h·kg],3.25,136555,DB00564,Carbamazepine
,30636182,distribution volume (V/F),"The typical values for MHD clearance (CL/F), distribution volume (V/F) and absorption rate constant (Ka) were 3.25 L/h/70 kg, 151.41 L/70 kg and 0.598 h-1 , respectively.",Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636182/),[l] / [70·kg],151.41,136556,DB00564,Carbamazepine
,30636182,absorption rate constant (Ka),"The typical values for MHD clearance (CL/F), distribution volume (V/F) and absorption rate constant (Ka) were 3.25 L/h/70 kg, 151.41 L/70 kg and 0.598 h-1 , respectively.",Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636182/),1/[h],0.598,136557,DB00564,Carbamazepine
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.045-0.070,137436,DB00564,Carbamazepine
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.028,137437,DB00564,Carbamazepine
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.014,137438,DB00564,Carbamazepine
,8991789,half-lives,The harmonic mean half-lives of 3.8 to 4.9 h were remarkably constant across dosages and shorter than those of historical control subjects not taking enzyme-inducing AEDs suggesting that epilepsy patients not taking enzyme-inducing AEDs may require lower tiagabine.,Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991789/),h,3.8 to 4.9,138431,DB00564,Carbamazepine
,31749700,m/z,"Trepibutone and carbamazepine (internal standard, IS) were quantified using multiple reaction monitoring (MRM) mode with the transitions of m/z 311.09→265.08 and m/z 237.06→194.08, respectively.",Pharmacokinetics and Metabolite Profiling of Trepibutone in Rats Using Ultra-High Performance Liquid Chromatography Combined With Hybrid Quadrupole-Orbitrap and Triple Quadrupole Mass Spectrometers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31749700/),,311.09,138672,DB00564,Carbamazepine
,31749700,m/z,"Trepibutone and carbamazepine (internal standard, IS) were quantified using multiple reaction monitoring (MRM) mode with the transitions of m/z 311.09→265.08 and m/z 237.06→194.08, respectively.",Pharmacokinetics and Metabolite Profiling of Trepibutone in Rats Using Ultra-High Performance Liquid Chromatography Combined With Hybrid Quadrupole-Orbitrap and Triple Quadrupole Mass Spectrometers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31749700/),,265.08,138673,DB00564,Carbamazepine
,31749700,m/z,"Trepibutone and carbamazepine (internal standard, IS) were quantified using multiple reaction monitoring (MRM) mode with the transitions of m/z 311.09→265.08 and m/z 237.06→194.08, respectively.",Pharmacokinetics and Metabolite Profiling of Trepibutone in Rats Using Ultra-High Performance Liquid Chromatography Combined With Hybrid Quadrupole-Orbitrap and Triple Quadrupole Mass Spectrometers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31749700/),,237.06,138674,DB00564,Carbamazepine
,31749700,m/z,"Trepibutone and carbamazepine (internal standard, IS) were quantified using multiple reaction monitoring (MRM) mode with the transitions of m/z 311.09→265.08 and m/z 237.06→194.08, respectively.",Pharmacokinetics and Metabolite Profiling of Trepibutone in Rats Using Ultra-High Performance Liquid Chromatography Combined With Hybrid Quadrupole-Orbitrap and Triple Quadrupole Mass Spectrometers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31749700/),,194.08,138675,DB00564,Carbamazepine
,3191893,apparent clearance,"Following a single dose, mean values (and ranges) for apparent clearance, volume distribution, and elimination half-life (t1/2) were 0.504 L/h/kg (0.086-1.119), 12,431 L (1,959-20,920), and 308 h (61-506), respectively.",Pharmacokinetic profile of flunarizine after single and multiple dosing in epileptic patients receiving comedication. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191893/),[l] / [h·kg],0.504,140423,DB00564,Carbamazepine
,3191893,elimination half-life (t1/2),"Following a single dose, mean values (and ranges) for apparent clearance, volume distribution, and elimination half-life (t1/2) were 0.504 L/h/kg (0.086-1.119), 12,431 L (1,959-20,920), and 308 h (61-506), respectively.",Pharmacokinetic profile of flunarizine after single and multiple dosing in epileptic patients receiving comedication. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191893/),h,308,140424,DB00564,Carbamazepine
,1777370,half-lives,"3. Nimodipine half-lives were shorter in enzyme-induced patients than in controls (3.9 +/- 2.0 h vs 9.1 +/- 3.4 h, means +/- s.d., P less than 0.01), but this difference could be artifactual since in the patients drug concentrations declined rapidly below the limit of assay, thus preventing identification of a possible slower terminal phase.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,3.9,140864,DB00564,Carbamazepine
,1777370,half-lives,"3. Nimodipine half-lives were shorter in enzyme-induced patients than in controls (3.9 +/- 2.0 h vs 9.1 +/- 3.4 h, means +/- s.d., P less than 0.01), but this difference could be artifactual since in the patients drug concentrations declined rapidly below the limit of assay, thus preventing identification of a possible slower terminal phase.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,9.1,140865,DB00564,Carbamazepine
,1777370,half-lives,"In valproate-treated patients, half-lives (8.2 +/- 1.8 h) were similar to those found in controls.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,8.2,140866,DB00564,Carbamazepine
,30449206,concentration/dose (C/D) ratio,Using the paliperidone concentration/dose (C/D) ratio as a measure of clearance provided a weighted mean of 7.7 ng/ml per mg/day among 69 patients from three steady-state PP1M studies (twice as high as oral paliperidone).,A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30449206/),[ng] / [d·mg·ml],7.7,141549,DB00564,Carbamazepine
,30449206,clearance,Using the paliperidone concentration/dose (C/D) ratio as a measure of clearance provided a weighted mean of 7.7 ng/ml per mg/day among 69 patients from three steady-state PP1M studies (twice as high as oral paliperidone).,A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30449206/),[ng] / [d·mg·ml],7.7,141550,DB00564,Carbamazepine
,12952496,apparent terminal half-life,"Maximum plasma concentrations (C(max)) of BIA 2-005 and oxcarbazepine were reached, respectively, at 0.75-4h and 6h postdose, after which they declined with an approximate mean apparent terminal half-life of 8-17h and 7-12h, respectively.","Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12952496/),h,8-17,141848,DB00564,Carbamazepine
,12952496,apparent terminal half-life,"Maximum plasma concentrations (C(max)) of BIA 2-005 and oxcarbazepine were reached, respectively, at 0.75-4h and 6h postdose, after which they declined with an approximate mean apparent terminal half-life of 8-17h and 7-12h, respectively.","Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12952496/),h,7-12,141849,DB00564,Carbamazepine
,12952496,Renal clearance,"Renal clearance of BIA 2-005 (20 mL/min) appeared to be constant over the dose range studied, indicating that the dose-dependent urinary recovery was due either to increased formation of BIA 2-005 with increasing dose level or to decreased non-renal elimination of the metabolite.","Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12952496/),[ml] / [min],20,141850,DB00564,Carbamazepine
,19076986,AUC,"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[h·mg] / [l],7.794,141913,DB00564,Carbamazepine
,19076986,AUC,"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[h·mg] / [l],5.038,141914,DB00564,Carbamazepine
,19076986,C(max),"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],1.911,141915,DB00564,Carbamazepine
,19076986,C(max),"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],1.383,141916,DB00564,Carbamazepine
,19076986,oral clearance,"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[kg(-·l] / [h],0,141917,DB00564,Carbamazepine
,19076986,through concentrations,"MCB through concentrations were also decreased, on average by 41% (from 0.950 to 0.559 mg l(-1); 95% CI -0.77479, -0.03301; P < 0.05).",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],0.950,141918,DB00564,Carbamazepine
,19076986,through concentrations,"MCB through concentrations were also decreased, on average by 41% (from 0.950 to 0.559 mg l(-1); 95% CI -0.77479, -0.03301; P < 0.05).",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],0.559,141919,DB00564,Carbamazepine
,26342166,flow rate,"The analyte and IS were separated on an Acquity UPLC BEH C18 column (2.1mm×50mm, 1.7μm) with the mobile phase of acetonitrile and 0.1% formic acid in water with gradient elution at a flow rate of 0.40mL/min.",Simultaneous determination of nintedanib and its metabolite BIBF 1202 in different tissues of mice by UPLC-MS/MS and its application in drug tissue distribution study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342166/),[ml] / [min],0.40,142432,DB00564,Carbamazepine
,17616250,flow rate,"The chromatographic separation was performed by isocratic elution with water/methanol (88:12, v/v), pumped at a flow rate of 0.7 mL min(-1), on a LichroCART 250-4 ChiraDex (beta-cyclodextrin, 5 microm) column at 30 degrees C.","Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R-licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17616250/),[ml] / [min],0.7,142710,DB00564,Carbamazepine
,761426,kabs,"3. Calculated mean absorption and elimination parameters for carbamazepine were as follows: kabs = 0.1081 h-1, (s.d. = 0.0289); Tmax = 23.39 h, (s.d. = 8.66); k = 0.0191 h-1, (s.d. = 0.0033); VD = 0.989 1/kg, (s.d. = 0.159); and clearance = 0.0185 1/kg h, (s.d. = 0.0015).",The comparative bioavailability of carbamazepine in 100 mg and 200 mg tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761426/),1/[h],0.1081,145922,DB00564,Carbamazepine
,761426,Tmax,"3. Calculated mean absorption and elimination parameters for carbamazepine were as follows: kabs = 0.1081 h-1, (s.d. = 0.0289); Tmax = 23.39 h, (s.d. = 8.66); k = 0.0191 h-1, (s.d. = 0.0033); VD = 0.989 1/kg, (s.d. = 0.159); and clearance = 0.0185 1/kg h, (s.d. = 0.0015).",The comparative bioavailability of carbamazepine in 100 mg and 200 mg tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761426/),h,23.39,145923,DB00564,Carbamazepine
,761426,k,"3. Calculated mean absorption and elimination parameters for carbamazepine were as follows: kabs = 0.1081 h-1, (s.d. = 0.0289); Tmax = 23.39 h, (s.d. = 8.66); k = 0.0191 h-1, (s.d. = 0.0033); VD = 0.989 1/kg, (s.d. = 0.159); and clearance = 0.0185 1/kg h, (s.d. = 0.0015).",The comparative bioavailability of carbamazepine in 100 mg and 200 mg tablets. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761426/),1/[h],0.0191,145924,DB00564,Carbamazepine
,761426,VD,"3. Calculated mean absorption and elimination parameters for carbamazepine were as follows: kabs = 0.1081 h-1, (s.d. = 0.0289); Tmax = 23.39 h, (s.d. = 8.66); k = 0.0191 h-1, (s.d. = 0.0033); VD = 0.989 1/kg, (s.d. = 0.159); and clearance = 0.0185 1/kg h, (s.d. = 0.0015).",The comparative bioavailability of carbamazepine in 100 mg and 200 mg tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761426/),[1] / [kg],0.989,145925,DB00564,Carbamazepine
,761426,clearance,"3. Calculated mean absorption and elimination parameters for carbamazepine were as follows: kabs = 0.1081 h-1, (s.d. = 0.0289); Tmax = 23.39 h, (s.d. = 8.66); k = 0.0191 h-1, (s.d. = 0.0033); VD = 0.989 1/kg, (s.d. = 0.159); and clearance = 0.0185 1/kg h, (s.d. = 0.0015).",The comparative bioavailability of carbamazepine in 100 mg and 200 mg tablets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761426/),[1] / [h·kg],0.0185,145926,DB00564,Carbamazepine
,32714422,C max,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),[μM] / [l],20,146255,DB00564,Carbamazepine
,32714422,C max,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),[μM] / [l],11,146256,DB00564,Carbamazepine
,32714422,AUC0⟶24,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),[h·μM] / [l],347,146257,DB00564,Carbamazepine
,32714422,AUC0⟶24,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),[h·μM] / [l],170,146258,DB00564,Carbamazepine
,32714422,K e,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),1/[h],0.28,146259,DB00564,Carbamazepine
,32714422,K e,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),1/[h],0.41,146260,DB00564,Carbamazepine
,32714422,t 1/2,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),h,2.3,146261,DB00564,Carbamazepine
,32714422,t 1/2,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),h,1.7,146262,DB00564,Carbamazepine
,17898646,volume,"Both volume and absorption rate constant were fixed (14 L and 1 hr, respectively).",Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898646/),l,14,146382,DB00564,Carbamazepine
,17898646,absorption rate constant,"Both volume and absorption rate constant were fixed (14 L and 1 hr, respectively).",Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898646/),h,1,146383,DB00564,Carbamazepine
,17898646,CL/F,The population CL/F was 0.843 L/hr.,Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898646/),[l] / [h],0.843,146384,DB00564,Carbamazepine
at,1635933,peak/trough carbamazepine serum level ratios,"However, all patients with peak/trough carbamazepine serum level ratios of at least 1.30 after the intake of the normal tablet-form (n = 9) showed a smaller peak/trough ratio during the Divitabs period.",A comparison of carbamazepine Divitabs and a normal carbamazepine preparation in psychiatric and oligophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635933/),,1.30,147081,DB00564,Carbamazepine
,8983936,peak plasma concentration,The peak plasma concentration of 3.96-8.25 mg/l was reached 4-24 h after drug administration.,Pharmacokinetics of carbamazepine derived from a new tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983936/),[mg] / [l],3.96-8.25,147273,DB00564,Carbamazepine
,8983936,terminal phase half-life,The terminal phase half-life was 22.19-39.61 h and a systemic clearance was 1.05-2.06 l/h.,Pharmacokinetics of carbamazepine derived from a new tablet formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983936/),h,22.19-39.61,147274,DB00564,Carbamazepine
,8983936,systemic clearance,The terminal phase half-life was 22.19-39.61 h and a systemic clearance was 1.05-2.06 l/h.,Pharmacokinetics of carbamazepine derived from a new tablet formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983936/),[l] / [h],1.05-2.06,147275,DB00564,Carbamazepine
,8983936,systemic availability,The systemic availability was 97.8-98.9% and the elimination of the drug on its first-pass through the liver was 1.13-2.20%.,Pharmacokinetics of carbamazepine derived from a new tablet formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983936/),%,97.8-98.9,147276,DB00564,Carbamazepine
,8983936,elimination,The systemic availability was 97.8-98.9% and the elimination of the drug on its first-pass through the liver was 1.13-2.20%.,Pharmacokinetics of carbamazepine derived from a new tablet formulation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983936/),%,1.13-2.20,147277,DB00564,Carbamazepine
,21497708,AUC(0-∞),"Differences in the mean AUC(0-∞) were 12.7 (4.4) and 14.2 (6.6) ng/mL/h in pomegranate juice and control groups, respectively (geometric mean ratio: 1.02 [95% CI, 0.95-1.09]; P = 0.40).","Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21497708/),[ng] / [h·ml],12.7,147494,DB00564,Carbamazepine
,21497708,AUC(0-∞),"Differences in the mean AUC(0-∞) were 12.7 (4.4) and 14.2 (6.6) ng/mL/h in pomegranate juice and control groups, respectively (geometric mean ratio: 1.02 [95% CI, 0.95-1.09]; P = 0.40).","Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21497708/),[ng] / [h·ml],14.2,147495,DB00564,Carbamazepine
,21497708,C(max),"Differences in C(max) for midazolam did not reach the level of statistical significance (5.1 [1.7] vs 5.0 [2.0] ng/mL, geometric mean ratio: 0.95 [95% CI, 0.79-1.11]; P = 0.68).","Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21497708/),[ng] / [ml],5.1,147496,DB00564,Carbamazepine
,21497708,C(max),"Differences in C(max) for midazolam did not reach the level of statistical significance (5.1 [1.7] vs 5.0 [2.0] ng/mL, geometric mean ratio: 0.95 [95% CI, 0.79-1.11]; P = 0.68).","Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21497708/),[ng] / [ml],5.0,147497,DB00564,Carbamazepine
,8453849,log metabolic ratio,"In 110 healthy white adults, the log metabolic ratio ranged from 1.28 to 2.05 (mean +/- SD, 1.68 +/- 0.155).",Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453849/),,1.28 to 2.05,147593,DB00564,Carbamazepine
,8453849,log metabolic ratio,"In 110 healthy white adults, the log metabolic ratio ranged from 1.28 to 2.05 (mean +/- SD, 1.68 +/- 0.155).",Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453849/),,1.68,147594,DB00564,Carbamazepine
,8056699,area under the plasma concentration versus time curve (AUC),"On day 7, the area under the plasma concentration versus time curve (AUC) varied fourfold (3263 to 12776 nmol.h/L) between individuals.",Plasma pentamidine concentrations vary between individuals with Pneumocystis carinii pneumonia and the drug is actively secreted by the kidney. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8056699/),[h·nM] / [l],3263 to 12776,147692,DB00564,Carbamazepine
,27561183,recovery,The recovery of trelagliptin ranged from 87.8% to 93.7%.,A rapid and sensitive UHPLC-MS/MS assay for the determination of trelagliptin in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27561183/),%,87.8,149172,DB00564,Carbamazepine
,27561183,recovery,The recovery of trelagliptin ranged from 87.8% to 93.7%.,A rapid and sensitive UHPLC-MS/MS assay for the determination of trelagliptin in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27561183/),%,93.7,149173,DB00564,Carbamazepine
,6185649,plasma half-life,"The mean plasma half-life of valproate, using a one-compartment model, was 10.9 +/- 1.3 h (mean +/- SD).",Plasma concentrations of valproate during maintenance therapy in epileptic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6185649/),h,10.9,149798,DB00564,Carbamazepine
,7604141,apparent oral clearance,"Compared with a control session, treatment with CBZ caused a marked increase in DMI apparent oral clearance (from 1.05 +/- 0.40 to 1.38 +/- 0.52 1 h per kg, means +/- SD, P < 0.01) and a significant shortening in DMI half-life (from 22.1 +/- 3.5 to 17.8 +/- 3.5 h, P < 0.01).",The effect of carbamazepine on the 2-hydroxylation of desipramine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604141/),[1·h] / [kg],1.05,150283,DB00564,Carbamazepine
,7604141,apparent oral clearance,"Compared with a control session, treatment with CBZ caused a marked increase in DMI apparent oral clearance (from 1.05 +/- 0.40 to 1.38 +/- 0.52 1 h per kg, means +/- SD, P < 0.01) and a significant shortening in DMI half-life (from 22.1 +/- 3.5 to 17.8 +/- 3.5 h, P < 0.01).",The effect of carbamazepine on the 2-hydroxylation of desipramine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604141/),[1·h] / [kg],1.38,150284,DB00564,Carbamazepine
,7604141,half-life,"Compared with a control session, treatment with CBZ caused a marked increase in DMI apparent oral clearance (from 1.05 +/- 0.40 to 1.38 +/- 0.52 1 h per kg, means +/- SD, P < 0.01) and a significant shortening in DMI half-life (from 22.1 +/- 3.5 to 17.8 +/- 3.5 h, P < 0.01).",The effect of carbamazepine on the 2-hydroxylation of desipramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604141/),h,22.1,150285,DB00564,Carbamazepine
,7604141,half-life,"Compared with a control session, treatment with CBZ caused a marked increase in DMI apparent oral clearance (from 1.05 +/- 0.40 to 1.38 +/- 0.52 1 h per kg, means +/- SD, P < 0.01) and a significant shortening in DMI half-life (from 22.1 +/- 3.5 to 17.8 +/- 3.5 h, P < 0.01).",The effect of carbamazepine on the 2-hydroxylation of desipramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604141/),h,17.8,150286,DB00564,Carbamazepine
,34286279,drug content,"The drug content of carbamazepine in CPH pectin formulations A and B was 95% and 96%, respectively.",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),,95,151380,DB00564,Carbamazepine
,34286279,AUC0⟶36,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),[h·μg] / [ml],176.20,151381,DB00564,Carbamazepine
,34286279,C max,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),[μg] / [ml],8.45,151382,DB00564,Carbamazepine
,34286279,T max,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),h,12,151383,DB00564,Carbamazepine
,34286279,t 1/2,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),h,13.75,151384,DB00564,Carbamazepine
,34286279,AUC0⟶36,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),[h·μg] / [ml],155,151385,DB00564,Carbamazepine
,34286279,C max,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),[μg] / [ml],8.24,151386,DB00564,Carbamazepine
,34286279,T max,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),h,8.0,151387,DB00564,Carbamazepine
,34286279,t 1/2,"AUC0⟶36 (176.20 ± 7.97 µg.h/mL), C max (8.45 ± 0.71 μg/mL), T max (12 ± 1.28 h), and t 1/2 (13.75 ± 3.28 h) of formulation A showed a moderately enhanced and comparable pharmacokinetic profile to Tegretol CR® (AUC0⟶36: 155 ± 7.15 µg.h/mL, C max: 8.24 ± 0.45 μg/mL, T max: 8.0 ± 2.23 h, and t 1/2: 13.51 ± 2.87 h).",A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286279/),h,13.51,151388,DB00564,Carbamazepine
,8038465,trough concentrations,Phenobarbital dosage was subsequently reduced to 150 mg/d; this resulted in phenobarbital trough concentrations of 60 micrograms/mL.,Potential pharmacokinetic interaction between felbamate and phenobarbital. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8038465/),[μg] / [ml],60,152050,DB00564,Carbamazepine
,8987182,t1/2 beta,"Pharmacokinetic data reported a mean t1/2 beta of 9.5 h, shorter than the reference value of 18-54 h (p < 0.05), and a mean CLB of 103.13 ml/ min/kg, higher than the reference of 75.01 ml/min/ kg (p < 0.05).",Carbamazepine poisoning in adolescent suicide attempters. Effectiveness of multiple-dose activated charcoal in enhancing carbamazepine elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987182/),h,9.5,152329,DB00564,Carbamazepine
,8987182,t1/2 beta,"Pharmacokinetic data reported a mean t1/2 beta of 9.5 h, shorter than the reference value of 18-54 h (p < 0.05), and a mean CLB of 103.13 ml/ min/kg, higher than the reference of 75.01 ml/min/ kg (p < 0.05).",Carbamazepine poisoning in adolescent suicide attempters. Effectiveness of multiple-dose activated charcoal in enhancing carbamazepine elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987182/),h,18-54,152330,DB00564,Carbamazepine
,8987182,CLB,"Pharmacokinetic data reported a mean t1/2 beta of 9.5 h, shorter than the reference value of 18-54 h (p < 0.05), and a mean CLB of 103.13 ml/ min/kg, higher than the reference of 75.01 ml/min/ kg (p < 0.05).",Carbamazepine poisoning in adolescent suicide attempters. Effectiveness of multiple-dose activated charcoal in enhancing carbamazepine elimination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987182/),[ml] / [kg·min],103.13,152331,DB00564,Carbamazepine
,8987182,CLB,"Pharmacokinetic data reported a mean t1/2 beta of 9.5 h, shorter than the reference value of 18-54 h (p < 0.05), and a mean CLB of 103.13 ml/ min/kg, higher than the reference of 75.01 ml/min/ kg (p < 0.05).",Carbamazepine poisoning in adolescent suicide attempters. Effectiveness of multiple-dose activated charcoal in enhancing carbamazepine elimination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987182/),[ml] / [·kg·min],75.01,152332,DB00564,Carbamazepine
,8987182,CBZ,"Initial mean CBZ levels of 27.9 decreased to 0.82 microgram/ml (97% of elimination, p < 0.05).",Carbamazepine poisoning in adolescent suicide attempters. Effectiveness of multiple-dose activated charcoal in enhancing carbamazepine elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987182/),,27.9,152333,DB00564,Carbamazepine
,8987182,CBZ,"Initial mean CBZ levels of 27.9 decreased to 0.82 microgram/ml (97% of elimination, p < 0.05).",Carbamazepine poisoning in adolescent suicide attempters. Effectiveness of multiple-dose activated charcoal in enhancing carbamazepine elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987182/),[μg] / [ml],0.82,152334,DB00564,Carbamazepine
,34303214,flow rate,"The mobile phase consists of acetonitrile and 0.5 mM ammonium acetate in water, and these compounds were well separated at a gradient elution program with flow rate of 0.35 mL/min.",Simultaneous determination of twenty-five compounds with anti-inflammatory activity in Spatholobi Caulis by using an optimized UFLC-MS/MS method: An application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34303214/),[ml] / [min],0.35,152424,DB00564,Carbamazepine
,34303214,IC50,"Isoflavones, especially compounds 20-22 (The IC50 of which were 22.75 μM, 21.11 μM and 48.29 μM, respectively.) might be the important constituents for anti-inflammatory activity of SPC.",Simultaneous determination of twenty-five compounds with anti-inflammatory activity in Spatholobi Caulis by using an optimized UFLC-MS/MS method: An application to pharmacokinetic study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34303214/),μM,22.75,152425,DB00564,Carbamazepine
,34303214,IC50,"Isoflavones, especially compounds 20-22 (The IC50 of which were 22.75 μM, 21.11 μM and 48.29 μM, respectively.) might be the important constituents for anti-inflammatory activity of SPC.",Simultaneous determination of twenty-five compounds with anti-inflammatory activity in Spatholobi Caulis by using an optimized UFLC-MS/MS method: An application to pharmacokinetic study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34303214/),μM,21.11,152426,DB00564,Carbamazepine
,34303214,IC50,"Isoflavones, especially compounds 20-22 (The IC50 of which were 22.75 μM, 21.11 μM and 48.29 μM, respectively.) might be the important constituents for anti-inflammatory activity of SPC.",Simultaneous determination of twenty-five compounds with anti-inflammatory activity in Spatholobi Caulis by using an optimized UFLC-MS/MS method: An application to pharmacokinetic study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34303214/),μM,48.29,152427,DB00564,Carbamazepine
,21098143,peak plasma concentrations (C(max)),"In the 2 periods of treatments, the mean peak plasma concentrations (C(max)) were 59 ng/mL (zolpidem alone) and 35 ng/mL (zolpidem after pretreatment with carbamazepine).",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),[ng] / [ml],59,152963,DB00564,Carbamazepine
,21098143,peak plasma concentrations (C(max)),"In the 2 periods of treatments, the mean peak plasma concentrations (C(max)) were 59 ng/mL (zolpidem alone) and 35 ng/mL (zolpidem after pretreatment with carbamazepine).",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),[ng] / [ml],35,152964,DB00564,Carbamazepine
,21098143,t(max),"The t(max), times taken to reach C(max), were 0.9 hours and 1.0 hour, respectively, and the total areas under the curve (AUC(0-∞)) were 234.9 ng·h/mL and 101.5 ng·h/mL, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),h,0.9,152965,DB00564,Carbamazepine
,21098143,t(max),"The t(max), times taken to reach C(max), were 0.9 hours and 1.0 hour, respectively, and the total areas under the curve (AUC(0-∞)) were 234.9 ng·h/mL and 101.5 ng·h/mL, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),h,1.0,152966,DB00564,Carbamazepine
,21098143,total areas under the curve (AUC(0-∞)),"The t(max), times taken to reach C(max), were 0.9 hours and 1.0 hour, respectively, and the total areas under the curve (AUC(0-∞)) were 234.9 ng·h/mL and 101.5 ng·h/mL, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),[h·ng] / [ml],234.9,152967,DB00564,Carbamazepine
,21098143,total areas under the curve (AUC(0-∞)),"The t(max), times taken to reach C(max), were 0.9 hours and 1.0 hour, respectively, and the total areas under the curve (AUC(0-∞)) were 234.9 ng·h/mL and 101.5 ng·h/mL, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),[h·ng] / [ml],101.5,152968,DB00564,Carbamazepine
,21098143,half-life,"The half-life of zolpidem was 2.3 and 1.6 hours, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),h,2.3,152969,DB00564,Carbamazepine
,21098143,half-life,"The half-life of zolpidem was 2.3 and 1.6 hours, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),h,1.6,152970,DB00564,Carbamazepine
,24562047,concentration,"Analysis of variance showed a correlation of dose with LCM concentrations (r = 0.53, P < 0.001), and women had statistically higher mean LCM concentration than did men, 37.2 ± 23.6 versus 26.8 ± 12.9 μmol/L (P = 0.001).","Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24562047/),,26,153175,DB00564,Carbamazepine
,17099560,bioavailability,Its mean bioavailability is around 75%.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,75,153478,DB00564,Carbamazepine
,17099560,volume of distribution,Its volume of distribution is of around 4 L/kg.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[l] / [kg],4,153479,DB00564,Carbamazepine
,17099560,half-life elimination,The value of half-life elimination is of around 22 hours.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),h,22,153480,DB00564,Carbamazepine
,17099560,bioavibility,"Thus, bioavibility ranges from 36 to 100%.",[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,36 to 100,153481,DB00564,Carbamazepine
,17099560,plasmatic target,The methadone plasmatic target value of 400 microg/ml can be recommended for therapeutic drug monitoring.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[μg] / [ml],400,153482,DB00564,Carbamazepine
,1418866,ED50s,"Specifically, after 14 days of aminophylline treatment, ED50s for carbamazepine and diphenylhydantoin were 26 and 19 mg/kg, respectively.",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],26,153843,DB00564,Carbamazepine
,1418866,ED50s,"Specifically, after 14 days of aminophylline treatment, ED50s for carbamazepine and diphenylhydantoin were 26 and 19 mg/kg, respectively.",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],19,153844,DB00564,Carbamazepine
,1418866,ED50s,"These ED50s were significantly elevated compared to values determined after acute aminophylline treatment (21.2 and 14.9 mg/kg, respectively).",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],21.2,153845,DB00564,Carbamazepine
,1418866,ED50s,"These ED50s were significantly elevated compared to values determined after acute aminophylline treatment (21.2 and 14.9 mg/kg, respectively).",Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418866/),[mg] / [kg],14.9,153846,DB00564,Carbamazepine
,3691011,maximum serum concentration,"Mean values of maximum serum concentration and absorption rate constant were significantly greater for the unflavored suspension (5.7 mg/L [24 mumol/L] and 0.832 hr-1, respectively) than for the tablet (4.9 mg/L [20.8 mumol/L] and 0.266 hr-1, respectively).",Palatability and relative bioavailability of an extemporaneous carbamazepine oral suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691011/),[mg] / [l],5.7,153949,DB00564,Carbamazepine
,3691011,maximum serum concentration,"Mean values of maximum serum concentration and absorption rate constant were significantly greater for the unflavored suspension (5.7 mg/L [24 mumol/L] and 0.832 hr-1, respectively) than for the tablet (4.9 mg/L [20.8 mumol/L] and 0.266 hr-1, respectively).",Palatability and relative bioavailability of an extemporaneous carbamazepine oral suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691011/),[mg] / [l],4.9,153950,DB00564,Carbamazepine
,3691011,absorption rate constant,"Mean values of maximum serum concentration and absorption rate constant were significantly greater for the unflavored suspension (5.7 mg/L [24 mumol/L] and 0.832 hr-1, respectively) than for the tablet (4.9 mg/L [20.8 mumol/L] and 0.266 hr-1, respectively).",Palatability and relative bioavailability of an extemporaneous carbamazepine oral suspension. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691011/),1/[h],0.832,153951,DB00564,Carbamazepine
,3691011,absorption rate constant,"Mean values of maximum serum concentration and absorption rate constant were significantly greater for the unflavored suspension (5.7 mg/L [24 mumol/L] and 0.832 hr-1, respectively) than for the tablet (4.9 mg/L [20.8 mumol/L] and 0.266 hr-1, respectively).",Palatability and relative bioavailability of an extemporaneous carbamazepine oral suspension. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691011/),1/[h],0.266,153952,DB00564,Carbamazepine
,3691011,time to maximum concentration,The mean time to maximum concentration was significantly shorter after suspension administration (3.87 hours) than after tablet administration (11.8 hours).,Palatability and relative bioavailability of an extemporaneous carbamazepine oral suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691011/),h,3.87,153953,DB00564,Carbamazepine
,3691011,time to maximum concentration,The mean time to maximum concentration was significantly shorter after suspension administration (3.87 hours) than after tablet administration (11.8 hours).,Palatability and relative bioavailability of an extemporaneous carbamazepine oral suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691011/),h,11.8,153954,DB00564,Carbamazepine
,3691011,bioavailability,The mean (+/- S.D.) bioavailability of the suspension relative to the tablet was 94.46% +/- 20.42 (range 76.35-132.72%).,Palatability and relative bioavailability of an extemporaneous carbamazepine oral suspension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691011/),%,94.46,153955,DB00564,Carbamazepine
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,292.2,154091,DB00564,Carbamazepine
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,163.2,154092,DB00564,Carbamazepine
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,237.1,154093,DB00564,Carbamazepine
,9109895,Dose-normalized Cmax,"Dose-normalized Cmax was higher in children taking valproate (18.2 +/- 5.0 ng/mL/mg) than in the induced children (14.8 +/- 6.9 ng/mL/mg), but the difference was not statistically significant.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ng] / [mg·ml],18.2,155190,DB00564,Carbamazepine
,9109895,Dose-normalized Cmax,"Dose-normalized Cmax was higher in children taking valproate (18.2 +/- 5.0 ng/mL/mg) than in the induced children (14.8 +/- 6.9 ng/mL/mg), but the difference was not statistically significant.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ng] / [mg·ml],14.8,155191,DB00564,Carbamazepine
,9109895,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time was significantly higher (p = 0.002) in children taking valproate (176.5 +/- 54.7 ng.hr/mL/mg) than in induced children (92.4 +/- 56.7 ng.hr/mL/mg).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[h·ng] / [mg·ml],176.5,155192,DB00564,Carbamazepine
,9109895,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time was significantly higher (p = 0.002) in children taking valproate (176.5 +/- 54.7 ng.hr/mL/mg) than in induced children (92.4 +/- 56.7 ng.hr/mL/mg).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[h·ng] / [mg·ml],92.4,155193,DB00564,Carbamazepine
,9109895,oral clearance,"Similarly, oral clearance in the children taking valproate (96 +/- 39 mL/min) was half that of the induced children (207 +/- 91 mL/min).",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ml] / [min],96,155194,DB00564,Carbamazepine
,9109895,oral clearance,"Similarly, oral clearance in the children taking valproate (96 +/- 39 mL/min) was half that of the induced children (207 +/- 91 mL/min).",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ml] / [min],207,155195,DB00564,Carbamazepine
,9109895,Half-life,"Half-life in children taking valproate (5.7 hr) was almost twice that for the induced children (3.2 hr), and the elimination rate constant was significantly lower (p < 0.02) for the children taking valproate than for the induced children.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),h,5.7,155196,DB00564,Carbamazepine
,9109895,Half-life,"Half-life in children taking valproate (5.7 hr) was almost twice that for the induced children (3.2 hr), and the elimination rate constant was significantly lower (p < 0.02) for the children taking valproate than for the induced children.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),h,3.2,155197,DB00564,Carbamazepine
,9109895,Volume of distribution,Volume of distribution was similar in the children taking valproate (52 +/- 9 L) and the induced children (59 +/- 29 L).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),l,52,155198,DB00564,Carbamazepine
,9109895,Volume of distribution,Volume of distribution was similar in the children taking valproate (52 +/- 9 L) and the induced children (59 +/- 29 L).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),l,59,155199,DB00564,Carbamazepine
,8404751,plasma FNR concentration,"After an 8-week baseline period, a single-dose pharmacokinetic study was performed for each patient to calculate a loading dose and maintenance dosage necessary to achieve a target plasma FNR concentration of 30 ng/ml.",Increasing plasma concentration tolerability study of flunarizine in comedicated epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8404751/),[ng] / [ml],30,155293,DB00564,Carbamazepine
,1742552,flow rate,Chromatographic separation of oxcarbazepine and its metabolites was achieved using a mobile phase consisting of acetonitrile/methanol/water (13:25:62 by volume) at a flow rate of 1.2 mL/min in conjunction with a Waters Associates Nova-Pak C18 column.,Solid phase extraction of oxcarbazepine and its metabolites from plasma for analysis by high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742552/),[ml] / [min],1.2,155968,DB00564,Carbamazepine
,21416779,CL/F,"RESULTS; Population estimates of CL/F and V/F for VPA were 0.022 +/- 0.013 L/h and 0.217 +/- 0.134 L/kg, respectively.",Effect of treatment and additional disease on pharmacokinetic of valproic acid in children with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21416779/),[l] / [h],0.022,156722,DB00564,Carbamazepine
,21416779,V/F,"RESULTS; Population estimates of CL/F and V/F for VPA were 0.022 +/- 0.013 L/h and 0.217 +/- 0.134 L/kg, respectively.",Effect of treatment and additional disease on pharmacokinetic of valproic acid in children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21416779/),[l] / [kg],0.217,156723,DB00564,Carbamazepine
,2015172,Elimination half-lives,4. Elimination half-lives (mean +/- s.e. mean) of 10-OH-CZ were unaltered by 2 weeks' therapy with OXC (before 11.3 +/- 1.1 h; after 13.9 +/- 3 h).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),h,11.3,156873,DB00564,Carbamazepine
,2015172,Elimination half-lives,4. Elimination half-lives (mean +/- s.e. mean) of 10-OH-CZ were unaltered by 2 weeks' therapy with OXC (before 11.3 +/- 1.1 h; after 13.9 +/- 3 h).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),h,13.9,156874,DB00564,Carbamazepine
,2015172,Trough plasma concentrations,Trough plasma concentrations of 10-OH-CZ at steady-state (31 +/- 2.2 mumol l-1) were higher than predicted (16.5 +/- 4 mumol l-1).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),[μM] / [l],31,156875,DB00564,Carbamazepine
,2015172,Trough plasma concentrations,Trough plasma concentrations of 10-OH-CZ at steady-state (31 +/- 2.2 mumol l-1) were higher than predicted (16.5 +/- 4 mumol l-1).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),[μM] / [l],16.5,156876,DB00564,Carbamazepine
,11097146,elimination half-life,The mean (+/- SEM) elimination half-life of CBZ was 33.0+/-1.8 h after pretreatment with placebo and 30.1+/-2.0 h after a one-week-pretreatment with LTG (NS).,Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),h,33.0,157177,DB00564,Carbamazepine
,11097146,elimination half-life,The mean (+/- SEM) elimination half-life of CBZ was 33.0+/-1.8 h after pretreatment with placebo and 30.1+/-2.0 h after a one-week-pretreatment with LTG (NS).,Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),h,30.1,157178,DB00564,Carbamazepine
,11097146,area under the serum concentration curve to infinity (AUC),The area under the serum concentration curve to infinity (AUC) of CBZ was 638+/-45 micromol/l after placebo and 624+/-53 micromol/l after LTG (NS).,Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),[μM] / [l],638,157179,DB00564,Carbamazepine
,11097146,area under the serum concentration curve to infinity (AUC),The area under the serum concentration curve to infinity (AUC) of CBZ was 638+/-45 micromol/l after placebo and 624+/-53 micromol/l after LTG (NS).,Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),[μM] / [l],624,157180,DB00564,Carbamazepine
,11097146,peak serum concentration,"Changes in the peak serum concentration, from 9.0+/-0.3 micromol/l to 9.2+/-0.4 micromol/l (LTG), and in the time to peak serum concentration, from 9.3+/-1.1 h to 9.1+/-1.2 h (LTG), were also not significant.",Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),[μM] / [l],9.0,157181,DB00564,Carbamazepine
,11097146,peak serum concentration,"Changes in the peak serum concentration, from 9.0+/-0.3 micromol/l to 9.2+/-0.4 micromol/l (LTG), and in the time to peak serum concentration, from 9.3+/-1.1 h to 9.1+/-1.2 h (LTG), were also not significant.",Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),[μM] / [l],9.2,157182,DB00564,Carbamazepine
,11097146,time to peak serum concentration,"Changes in the peak serum concentration, from 9.0+/-0.3 micromol/l to 9.2+/-0.4 micromol/l (LTG), and in the time to peak serum concentration, from 9.3+/-1.1 h to 9.1+/-1.2 h (LTG), were also not significant.",Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),h,9.3,157183,DB00564,Carbamazepine
,11097146,time to peak serum concentration,"Changes in the peak serum concentration, from 9.0+/-0.3 micromol/l to 9.2+/-0.4 micromol/l (LTG), and in the time to peak serum concentration, from 9.3+/-1.1 h to 9.1+/-1.2 h (LTG), were also not significant.",Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097146/),h,9.1,157184,DB00564,Carbamazepine
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],12.1,157653,DB00564,Carbamazepine
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],8,157654,DB00564,Carbamazepine
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],18,157655,DB00564,Carbamazepine
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],11,157656,DB00564,Carbamazepine
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],253,157657,DB00564,Carbamazepine
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],249,157658,DB00564,Carbamazepine
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],10,157659,DB00564,Carbamazepine
,21676154,half-life,"The CBZ half-life during CVVHD was 14.7 hours, compared with the patient's endogenous half-life of 30.8 hours.",Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21676154/),h,14.7,158219,DB00564,Carbamazepine
,21676154,half-life,"The CBZ half-life during CVVHD was 14.7 hours, compared with the patient's endogenous half-life of 30.8 hours.",Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21676154/),h,30.8,158220,DB00564,Carbamazepine
,21676154,half-life,The CBZ-epoxide half-life was 3.2 hours during HD.,Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21676154/),h,3.2,158221,DB00564,Carbamazepine
,9099448,AUC,"The mean predicted AUC of flunarizine was 1230 +/- 717 ng h mL-1, whereas the observed AUC was 1203 +/- 900 ng h mL-1.",A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[h·ng] / [ml],1230,159481,DB00564,Carbamazepine
,9099448,AUC,"The mean predicted AUC of flunarizine was 1230 +/- 717 ng h mL-1, whereas the observed AUC was 1203 +/- 900 ng h mL-1.",A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[h·ng] / [ml],1203,159482,DB00564,Carbamazepine
,9099448,Cmax,The mean predicted Cmax of flunarizine was 86 +/- 32 ng mL-1 as compared to an observed mean Cmax of 90 +/- 42 ng mL-1.,A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[ng] / [ml],86,159483,DB00564,Carbamazepine
,9099448,Cmax,The mean predicted Cmax of flunarizine was 86 +/- 32 ng mL-1 as compared to an observed mean Cmax of 90 +/- 42 ng mL-1.,A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[ng] / [ml],90,159484,DB00564,Carbamazepine
,25132315,flow rate,Detection was performed in the multiple reaction monitoring mode using electrospray ionization in the positive ion mode at a flow rate of 0.3 mL/min and a run time of 8 min.,LC-MS/MS analysis of Gegen Qinlian Decoction and its pharmacokinetics after oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25132315/),[ml] / [min],0.3,159940,DB00564,Carbamazepine
,25132315,run time,Detection was performed in the multiple reaction monitoring mode using electrospray ionization in the positive ion mode at a flow rate of 0.3 mL/min and a run time of 8 min.,LC-MS/MS analysis of Gegen Qinlian Decoction and its pharmacokinetics after oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25132315/),min,8,159941,DB00564,Carbamazepine
,29175782,Cmax,"Pharmacokinetic studies (PK) in rabbits demonstrated that formulation F7-X (1% cocrystal, 1% HPMC-AS and 2% Polyvinyl carpolactam-polyvinyl acetatepolyethylene glycol graft co-polymer®) caused almost 6fold improvement in AUC0-72 (***P k 0.05) as well as much higher Cmax of 4.73μ.mL-1 to that of 1.07μ.",Improved in vitro and in vivo performance of carbamazepine enabled by using a succinic acid cocrystal in a stable suspension formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175782/),[μ] / [ml],4.73,160541,DB00564,Carbamazepine
,29175782,Cmax,"Pharmacokinetic studies (PK) in rabbits demonstrated that formulation F7-X (1% cocrystal, 1% HPMC-AS and 2% Polyvinyl carpolactam-polyvinyl acetatepolyethylene glycol graft co-polymer®) caused almost 6fold improvement in AUC0-72 (***P k 0.05) as well as much higher Cmax of 4.73μ.mL-1 to that of 1.07μ.",Improved in vitro and in vivo performance of carbamazepine enabled by using a succinic acid cocrystal in a stable suspension formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175782/),μ,1.07,160542,DB00564,Carbamazepine
,29175782,Cmax,Cmax of reference formulation observed was 3.9μmL-1.,Improved in vitro and in vivo performance of carbamazepine enabled by using a succinic acid cocrystal in a stable suspension formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175782/),1/[μml],3.9,160543,DB00564,Carbamazepine
,1649676,half-lives,"The average CBZ half-lives in single- and multiple-dose phases were 50.1 +/- 12.1 (mean +/- SD) hours and 26.1 +/- 4.2 hours and the clearances were 16.4 +/- 3.3 ml/kg/h and 45.3 +/- 23.4 ml/kg/h respectively, both with significant differences (p less than 0.005).",Metabolism of carbamazepine: evidence of autoinduction in Chinese. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1649676/),h,50.1,160641,DB00564,Carbamazepine
,1649676,half-lives,"The average CBZ half-lives in single- and multiple-dose phases were 50.1 +/- 12.1 (mean +/- SD) hours and 26.1 +/- 4.2 hours and the clearances were 16.4 +/- 3.3 ml/kg/h and 45.3 +/- 23.4 ml/kg/h respectively, both with significant differences (p less than 0.005).",Metabolism of carbamazepine: evidence of autoinduction in Chinese. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1649676/),h,26.1,160642,DB00564,Carbamazepine
,1649676,clearances,"The average CBZ half-lives in single- and multiple-dose phases were 50.1 +/- 12.1 (mean +/- SD) hours and 26.1 +/- 4.2 hours and the clearances were 16.4 +/- 3.3 ml/kg/h and 45.3 +/- 23.4 ml/kg/h respectively, both with significant differences (p less than 0.005).",Metabolism of carbamazepine: evidence of autoinduction in Chinese. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1649676/),[ml] / [h·kg],16.4,160643,DB00564,Carbamazepine
,1649676,clearances,"The average CBZ half-lives in single- and multiple-dose phases were 50.1 +/- 12.1 (mean +/- SD) hours and 26.1 +/- 4.2 hours and the clearances were 16.4 +/- 3.3 ml/kg/h and 45.3 +/- 23.4 ml/kg/h respectively, both with significant differences (p less than 0.005).",Metabolism of carbamazepine: evidence of autoinduction in Chinese. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1649676/),[ml] / [h·kg],45.3,160644,DB00564,Carbamazepine
,21883329,CL,"The POP estimate for CL was 3·5 L/h with coefficient of variation value of 2·6%, which was consistent with literature data.",Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883329/),[l] / [h],3·5,161484,DB00564,Carbamazepine
,4085354,area under the plasma concentration-time curve,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),[h·μg] / [ml],324.2,161820,DB00564,Carbamazepine
,4085354,area under the plasma concentration-time curve,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),[h·μg] / [ml],326.3,161821,DB00564,Carbamazepine
,4085354,elimination half-life,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),h,32.2,161822,DB00564,Carbamazepine
,4085354,elimination half-life,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),h,31.7,161823,DB00564,Carbamazepine
,760753,oral bioavailability,"3 The oral bioavailability (mean +/- s.e. mean) was significantly lower in the epileptic patients than in the normal subjects (0.77 +/- 0.03 and 0.89 +/- 0.02 respectively, P less than 0.01), whereas the urinary excretion total (free+conjugated) paracetamol was almost identical in the two groups.",Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760753/),,0.77,162430,DB00564,Carbamazepine
,760753,oral bioavailability,"3 The oral bioavailability (mean +/- s.e. mean) was significantly lower in the epileptic patients than in the normal subjects (0.77 +/- 0.03 and 0.89 +/- 0.02 respectively, P less than 0.01), whereas the urinary excretion total (free+conjugated) paracetamol was almost identical in the two groups.",Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760753/),,0.89,162431,DB00564,Carbamazepine
,29694732,T1/2,"Fingolimod Cmax was reduced by 18% and AUCinf by 40%, as was T1/2 (106 vs 163 hours).",Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29694732/),h,106,162527,DB00564,Carbamazepine
,29694732,T1/2,"Fingolimod Cmax was reduced by 18% and AUCinf by 40%, as was T1/2 (106 vs 163 hours).",Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29694732/),h,163,162528,DB00564,Carbamazepine
,10589373,oral bioavailability,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),%,52 to 55,162570,DB00564,Carbamazepine
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],1.01 to 1.52,162571,DB00564,Carbamazepine
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],2.41 to 2.85,162572,DB00564,Carbamazepine
,10589373,elimination half-life,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),h,3.3 to 4.9,162573,DB00564,Carbamazepine
,10589373,total body clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],29.2 to 58.1,162574,DB00564,Carbamazepine
,10589373,renal clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],6.7 to 12.8,162575,DB00564,Carbamazepine
,32029960,plasma concentration,"Patients inheriting CYP3A5*3/*3 variant (nonexpressers) had an increased plasma concentration of CBZ (4.86 μg/ml) when compared to patients inheriting either CYP3A5*1/*1 or CYP3A5*1/*3 (expressers) (4.3 μg/ml, P = 0.004).",Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32029960/),,4,162912,DB00564,Carbamazepine
higher,20457547,extraction recovery,The mean extraction recovery was higher than 83% for finasteride and 84% for the IS.,Rapid determination of finasteride in human plasma by UPLC-MS/MS and its application to clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20457547/),%,83,163595,DB00564,Carbamazepine
,20457547,extraction recovery,The mean extraction recovery was higher than 83% for finasteride and 84% for the IS.,Rapid determination of finasteride in human plasma by UPLC-MS/MS and its application to clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20457547/),%,84,163596,DB00564,Carbamazepine
,16791583,log10,The mean log10(omeprazole/omeprazole sulfone) ratio was 0.18 3 h after intake of omeprazole alone.,Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791583/),,0.18,164111,DB00564,Carbamazepine
,3391153,epoxide to parent ratio,"The CBZ epoxide to parent ratio increased to 0.46 and 0.39, respectively during FBM treatment.",Felbamate increases phenytoin but decreases carbamazepine concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391153/),,0.46,164545,DB00564,Carbamazepine
,3391153,epoxide to parent ratio,"The CBZ epoxide to parent ratio increased to 0.46 and 0.39, respectively during FBM treatment.",Felbamate increases phenytoin but decreases carbamazepine concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391153/),,0.39,164546,DB00564,Carbamazepine
,10778590,Cmax,"The mean Cmax, Tmax and t1/2a for Tegretol 200 were: 2.17 +/- 0.42 mcg/mL, 11.67 +/- 6.37 h and 2.72 +/- 1.87 h; for Zen-200 were 3.10 +/- 0.05 mcg/mL, 3.50 +/- 2.11 h and 0.76 +/- 0.76 h respectively.",Comparison of absorption rate and bioavailability of two brands of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778590/),[mcg] / [ml],2.17,165661,DB00564,Carbamazepine
,10778590,Tmax,"The mean Cmax, Tmax and t1/2a for Tegretol 200 were: 2.17 +/- 0.42 mcg/mL, 11.67 +/- 6.37 h and 2.72 +/- 1.87 h; for Zen-200 were 3.10 +/- 0.05 mcg/mL, 3.50 +/- 2.11 h and 0.76 +/- 0.76 h respectively.",Comparison of absorption rate and bioavailability of two brands of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778590/),h,11.67,165662,DB00564,Carbamazepine
,10778590,Tmax,"The mean Cmax, Tmax and t1/2a for Tegretol 200 were: 2.17 +/- 0.42 mcg/mL, 11.67 +/- 6.37 h and 2.72 +/- 1.87 h; for Zen-200 were 3.10 +/- 0.05 mcg/mL, 3.50 +/- 2.11 h and 0.76 +/- 0.76 h respectively.",Comparison of absorption rate and bioavailability of two brands of carbamazepine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778590/),h,3.50,165663,DB00564,Carbamazepine
,10778590,t1/2a,"The mean Cmax, Tmax and t1/2a for Tegretol 200 were: 2.17 +/- 0.42 mcg/mL, 11.67 +/- 6.37 h and 2.72 +/- 1.87 h; for Zen-200 were 3.10 +/- 0.05 mcg/mL, 3.50 +/- 2.11 h and 0.76 +/- 0.76 h respectively.",Comparison of absorption rate and bioavailability of two brands of carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778590/),h,2.72,165664,DB00564,Carbamazepine
,10778590,t1/2a,"The mean Cmax, Tmax and t1/2a for Tegretol 200 were: 2.17 +/- 0.42 mcg/mL, 11.67 +/- 6.37 h and 2.72 +/- 1.87 h; for Zen-200 were 3.10 +/- 0.05 mcg/mL, 3.50 +/- 2.11 h and 0.76 +/- 0.76 h respectively.",Comparison of absorption rate and bioavailability of two brands of carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778590/),h,3.50,165665,DB00564,Carbamazepine
,10778590,t1/2a,"The mean Cmax, Tmax and t1/2a for Tegretol 200 were: 2.17 +/- 0.42 mcg/mL, 11.67 +/- 6.37 h and 2.72 +/- 1.87 h; for Zen-200 were 3.10 +/- 0.05 mcg/mL, 3.50 +/- 2.11 h and 0.76 +/- 0.76 h respectively.",Comparison of absorption rate and bioavailability of two brands of carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778590/),h,0.76,165666,DB00564,Carbamazepine
,10778590,AUC (0-96 h),However AUC (0-96 h) value of 150.16 +/- 27.13 mcg/ml.h after Zen-200 was not statistically significant as compared to 128.68 +/- 20.22 mcg/ml.h after Tegretol 200.,Comparison of absorption rate and bioavailability of two brands of carbamazepine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778590/),[mcg] / [h·ml],150.16,165667,DB00564,Carbamazepine
,10778590,AUC (0-96 h),However AUC (0-96 h) value of 150.16 +/- 27.13 mcg/ml.h after Zen-200 was not statistically significant as compared to 128.68 +/- 20.22 mcg/ml.h after Tegretol 200.,Comparison of absorption rate and bioavailability of two brands of carbamazepine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778590/),[mcg] / [h·ml],128.68,165668,DB00564,Carbamazepine
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,6.3,165985,DB00564,Carbamazepine
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.2,165986,DB00564,Carbamazepine
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.5,165987,DB00564,Carbamazepine
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.6,165988,DB00564,Carbamazepine
,29745750,flow rate,The chromatographic separation was conducted on an Acquity UPLC BEH™ C18 column with an optimum mobile phase of 10 mM ammonium acetate buffer and 0.1% formic acid in acetonitrile (30:70 v/v) at a flow rate of 0.3 ml/min.,UPLC/MS-MS assay development for estimation of mozavaptan in plasma and its pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29745750/),[ml] / [min],0.3,166710,DB00564,Carbamazepine
,25939097,flow rate,"The analyte and IS were separated on an Acquity UPLC BEH C18 column (2.1mm×50mm, 1.7μm) with the mobile phase of acetonitrile and 0.1% formic acid in water with gradient elution at a flow rate of 0.40ml/min.",Quantification of liensinine in rat plasma using ultra-performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939097/),[ml] / [min],0.40,167256,DB00564,Carbamazepine
,25939097,injection volume,The injection volume was 6μl.,Quantification of liensinine in rat plasma using ultra-performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939097/),μl,6,167257,DB00564,Carbamazepine
,25939097,matrix,The matrix effect was 93.8-107.4% for liensinine.,Quantification of liensinine in rat plasma using ultra-performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939097/),,93.8-107.4,167258,DB00564,Carbamazepine
,25939097,recovery,The recovery ranged from 76.2 to 86.8%.,Quantification of liensinine in rat plasma using ultra-performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939097/),%,76.2 to 86.8,167259,DB00564,Carbamazepine
,25939097,t1/2,"The pharmacokinetic parameters were demonstrated as followed: t1/2 was 8.2±3.3h, Cmax was 668.4±156.9ng/ml, and AUC0→∞ was 1802.9±466.4ng/mlh.",Quantification of liensinine in rat plasma using ultra-performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939097/),h,8.2,167260,DB00564,Carbamazepine
,25939097,Cmax,"The pharmacokinetic parameters were demonstrated as followed: t1/2 was 8.2±3.3h, Cmax was 668.4±156.9ng/ml, and AUC0→∞ was 1802.9±466.4ng/mlh.",Quantification of liensinine in rat plasma using ultra-performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939097/),[ng] / [ml],668.4,167261,DB00564,Carbamazepine
,25939097,AUC0→∞,"The pharmacokinetic parameters were demonstrated as followed: t1/2 was 8.2±3.3h, Cmax was 668.4±156.9ng/ml, and AUC0→∞ was 1802.9±466.4ng/mlh.",Quantification of liensinine in rat plasma using ultra-performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939097/),[ng] / [mlh],1802.9,167262,DB00564,Carbamazepine
,33447943,apparent clearance,The median value of apparent clearance for children (0.074 L/h/kg [range 0.038-0.079]) was higher than that for adults (0.054 L/h/kg [range 0.039-0.061]).,Population Pharmacokinetics of Levetiracetam: A Systematic Review. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33447943/),[l] / [h·kg],0.074,169024,DB00564,Carbamazepine
,33447943,apparent clearance,The median value of apparent clearance for children (0.074 L/h/kg [range 0.038-0.079]) was higher than that for adults (0.054 L/h/kg [range 0.039-0.061]).,Population Pharmacokinetics of Levetiracetam: A Systematic Review. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33447943/),[l] / [h·kg],0.054,169025,DB00564,Carbamazepine
,9626375,Maximum serum carbamazepine concentrations,"Maximum serum carbamazepine concentrations ranged from 7.10 to 9.92 mg/L, area under the concentration-versus-time curve from 54.85 to 82.23 micrograms.hr/L, and terminal elimination half-life from 14.05 to 15.71 hours.",Feasibility and pharmacokinetics of carbamazepine oral loading doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626375/),[mg] / [l],7.10 to 9.92,169039,DB00564,Carbamazepine
,9626375,area under the concentration-versus-time curve,"Maximum serum carbamazepine concentrations ranged from 7.10 to 9.92 mg/L, area under the concentration-versus-time curve from 54.85 to 82.23 micrograms.hr/L, and terminal elimination half-life from 14.05 to 15.71 hours.",Feasibility and pharmacokinetics of carbamazepine oral loading doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626375/),[h·μg] / [l],54.85 to 82.23,169040,DB00564,Carbamazepine
,9626375,terminal elimination half-life,"Maximum serum carbamazepine concentrations ranged from 7.10 to 9.92 mg/L, area under the concentration-versus-time curve from 54.85 to 82.23 micrograms.hr/L, and terminal elimination half-life from 14.05 to 15.71 hours.",Feasibility and pharmacokinetics of carbamazepine oral loading doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626375/),h,14.05 to 15.71,169041,DB00564,Carbamazepine
,14651727,Vmax,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),[nM] / [min·nmol],10.3,170324,DB00564,Carbamazepine
,14651727,apparent Km,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μm,362,170325,DB00564,Carbamazepine
,14651727,Vmax,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),[nM] / [min·nmol],1.17,170326,DB00564,Carbamazepine
,14651727,apparent Km,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μm,119,170327,DB00564,Carbamazepine
,14651727,Vmax,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),[nM] / [min·nmol],0.669,170328,DB00564,Carbamazepine
,14651727,apparent Km,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μm,757,170329,DB00564,Carbamazepine
,14651727,IC50,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μM,14,170330,DB00564,Carbamazepine
,14651727,IC50,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μM,5.1,170331,DB00564,Carbamazepine
,14651727,IC50,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μM,37,170332,DB00564,Carbamazepine
,14651727,apparent Ki,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μm,3.7,170333,DB00564,Carbamazepine
,14651727,apparent Ki,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μm,2.5,170334,DB00564,Carbamazepine
,14651727,apparent Ki,"Carbamazepine biotransformation to its 10,11-epoxide by human liver microsomes (Vmax = 10.3 nmol min(-1) nmol(-1) P450, apparent Km = 362 microm), cDNA-expressed CYP3A4 (Vmax = 1.17 nmol min(-1) nmol(-1) P450, apparent Km = 119 microm) and CYP2C8 (Vmax = 0.669 nmol min(-1) nmol(-1) P450, apparent Km = 757 microm) was inhibited by stiripentol (IC50 14, 5.1, 37 microM and apparent Ki 3.7, 2.5, 35 microm, respectively).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μm,35,170335,DB00564,Carbamazepine
,14651727,Vmax,"Saquinavir biotransformation to its major metabolite M7 by human liver microsomes (Vmax = 5.7 nmol min(-1) nmol(-1) P450, apparent Km = 0.79 microm) was inhibited by stiripentol (IC50 163 microM, apparent Ki 86 microm).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),[nM] / [min·nmol],5.7,170336,DB00564,Carbamazepine
,14651727,apparent Km,"Saquinavir biotransformation to its major metabolite M7 by human liver microsomes (Vmax = 5.7 nmol min(-1) nmol(-1) P450, apparent Km = 0.79 microm) was inhibited by stiripentol (IC50 163 microM, apparent Ki 86 microm).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μm,0.79,170337,DB00564,Carbamazepine
,14651727,IC50,"Saquinavir biotransformation to its major metabolite M7 by human liver microsomes (Vmax = 5.7 nmol min(-1) nmol(-1) P450, apparent Km = 0.79 microm) was inhibited by stiripentol (IC50 163 microM, apparent Ki 86 microm).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μM,163,170338,DB00564,Carbamazepine
,14651727,apparent Ki,"Saquinavir biotransformation to its major metabolite M7 by human liver microsomes (Vmax = 5.7 nmol min(-1) nmol(-1) P450, apparent Km = 0.79 microm) was inhibited by stiripentol (IC50 163 microM, apparent Ki 86 microm).",Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μm,86,170339,DB00564,Carbamazepine
,14651727,apparent Ki,The in vivo apparent Ki for stiripentol ranged from 10.5 to 41.4 microm.,Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14651727/),μm,10.5 to 41.4,170340,DB00564,Carbamazepine
,23995050,maximum Cl/F,"Age was a significant factor contributing to pharmacokinetic variability in individuals using LTG, OXC, and CBZ with increasing clearance as a function of bioavailability (Cl/F) over age 18, a maximum Cl/F at 33years (CBZ) and 36 years (LTG and OXC), and a gradual decrease of Cl/F towards older age.",The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23995050/),years,33,170622,DB00564,Carbamazepine
,23995050,maximum Cl/F,"Age was a significant factor contributing to pharmacokinetic variability in individuals using LTG, OXC, and CBZ with increasing clearance as a function of bioavailability (Cl/F) over age 18, a maximum Cl/F at 33years (CBZ) and 36 years (LTG and OXC), and a gradual decrease of Cl/F towards older age.",The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23995050/),years,36,170623,DB00564,Carbamazepine
,7875188,oral clearance,"The mean oral clearance of CBZ increased from 1.48 to 1.74 l.h-1 (difference 0.26 l.h-1, 95% confidence interval 0.11 to 0.41 l.h-1) and the mean percentage urinary recovery of the amount of CBZ eliminated increased from 41.8% to 44.6% (difference 2.8%, 95% confidence interval 0.5 to 5%) between the two studies 5 days apart.",Early stage autoinduction of carbamazepine metabolism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875188/),[l] / [h],1.48,170775,DB00564,Carbamazepine
,7875188,oral clearance,"The mean oral clearance of CBZ increased from 1.48 to 1.74 l.h-1 (difference 0.26 l.h-1, 95% confidence interval 0.11 to 0.41 l.h-1) and the mean percentage urinary recovery of the amount of CBZ eliminated increased from 41.8% to 44.6% (difference 2.8%, 95% confidence interval 0.5 to 5%) between the two studies 5 days apart.",Early stage autoinduction of carbamazepine metabolism in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875188/),[l] / [h],1.74,170776,DB00564,Carbamazepine
,27509066,m/z,"Detection was by positive electrospray ionization (ESI+) in multiple reaction monitoring mode monitoring the quantifier transitions m/z 191.4 → m/z 148.3 for cis-4,4'-DMAR and m/z 259.3 → m/z 194.2 for carbamazepine (internal standard).","A validated, sensitive HPLC-MS/MS method for quantification of cis-para-methyl-4-methylaminorex (cis-4,4'-DMAR) in rat and human plasma: application to pharmacokinetic studies in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27509066/),,259.3,171043,DB00564,Carbamazepine
,27509066,t1/2,"After an intravenous dose of 1 mg/kg, plasma levels declined rapidly (≥80% in 4 h), followed by a slow elimination phase (t1/2 of 5.14 ± 0.65 h).","A validated, sensitive HPLC-MS/MS method for quantification of cis-para-methyl-4-methylaminorex (cis-4,4'-DMAR) in rat and human plasma: application to pharmacokinetic studies in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27509066/),h,5.14,171044,DB00564,Carbamazepine
,27509066,tmax,Absorption was rapid after intraperitoneal injection (tmax = 15 min) with a rapid decline thereafter; Cmax and AUC0-240min showed dose-proportionality over the dose range 1-10 mg/kg.,"A validated, sensitive HPLC-MS/MS method for quantification of cis-para-methyl-4-methylaminorex (cis-4,4'-DMAR) in rat and human plasma: application to pharmacokinetic studies in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27509066/),min,15,171045,DB00564,Carbamazepine
,7988100,terminal elimination half-life,"Following administration of single doses, fluvoxamine shows a biphasic elimination with a mean terminal elimination half-life of about 15 to 20 hours.",Clinical pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988100/),h,15 to 20,171285,DB00564,Carbamazepine
,19954714,clearance,"Typical mean value of lamotrigine clearance, estimated by the base model (without covariates), in our population was 1.15 l h-1.",Population pharmacokinetics of lamotrigine in patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954714/),[l] / [h],1.15,171748,DB00564,Carbamazepine
,2694113,Vd (L),"The final models for felbamate clearance and volume of distribution (Vd) were as follows: Cl(L/hr) = 2.43 + 0.429*CDCR/240, Vd (L) = 51.","Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2694113/),,51,171864,DB00564,Carbamazepine
,7667170,trough C,"Even though the mean daily dosage of CsA was consistently higher in the carbamazepine group than in the control group (16.2 mg/kg/24 hrs vs 10.8 mg/kg/24 hrs, respectively), the predose trough CsA blood concentrations were significantly lower in the carbamazepine group (57 ng/ml vs 162 ng/ml, respectively; p = 0.0023).",Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667170/),[ng] / [ml],57,172083,DB00564,Carbamazepine
,7667170,trough C,"Even though the mean daily dosage of CsA was consistently higher in the carbamazepine group than in the control group (16.2 mg/kg/24 hrs vs 10.8 mg/kg/24 hrs, respectively), the predose trough CsA blood concentrations were significantly lower in the carbamazepine group (57 ng/ml vs 162 ng/ml, respectively; p = 0.0023).",Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667170/),[ng] / [ml],162,172084,DB00564,Carbamazepine
,7667170,blood concentrations,"Even though the mean daily dosage of CsA was consistently higher in the carbamazepine group than in the control group (16.2 mg/kg/24 hrs vs 10.8 mg/kg/24 hrs, respectively), the predose trough CsA blood concentrations were significantly lower in the carbamazepine group (57 ng/ml vs 162 ng/ml, respectively; p = 0.0023).",Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667170/),[ng] / [ml],57,172085,DB00564,Carbamazepine
,7667170,blood concentrations,"Even though the mean daily dosage of CsA was consistently higher in the carbamazepine group than in the control group (16.2 mg/kg/24 hrs vs 10.8 mg/kg/24 hrs, respectively), the predose trough CsA blood concentrations were significantly lower in the carbamazepine group (57 ng/ml vs 162 ng/ml, respectively; p = 0.0023).",Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667170/),[ng] / [ml],162,172086,DB00564,Carbamazepine
,29171002,apparent clearance (CL/F),"In the absence of antiepileptic drugs (AEDs) affecting perampanel PK, estimated perampanel apparent clearance (CL/F) was 0.668 L/h (all subjects) and 0.682 L/h (adolescent subjects).",Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29171002/),[l] / [h],0.668,172319,DB00564,Carbamazepine
,29171002,apparent clearance (CL/F),"In the absence of antiepileptic drugs (AEDs) affecting perampanel PK, estimated perampanel apparent clearance (CL/F) was 0.668 L/h (all subjects) and 0.682 L/h (adolescent subjects).",Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29171002/),[l] / [h],0.682,172320,DB00564,Carbamazepine
,18200330,CL,Typical mean value of CL of VPA estimated by the base model in our population was 0.368 l h(-1).,Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18200330/),[l] / [h],0.368,173865,DB00564,Carbamazepine
,11401423,rate (Tmax,"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),h,8.58,174080,DB00564,Carbamazepine
,11401423,rate (Tmax,"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),h,5.66,174081,DB00564,Carbamazepine
,11401423,K(a),"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),1/[h],0.47,174082,DB00564,Carbamazepine
,11401423,K(a),"PTX reduced the rate (Tmax, 8.58 +/- 2.64 vs 5.66 +/- 1.44 h; K(a); 0.47 +/- 0.14 vs 0.72 +/- 0.19 h(-1)), but not the extent of CBZ absorption at 22:00 h treatment.",Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401423/),1/[h],0.72,174083,DB00564,Carbamazepine
,3734137,half-life,"The half-life of this CBZ-D4 dose in the two patients (20 and 26 hr, respectively) was similar to the post-steady-state half-life of CBZ (23 hr in both patients) measured later.",Pharmacokinetics: time-dependent changes--autoinduction of carbamazepine epoxidation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3734137/),h,20,174540,DB00564,Carbamazepine
,3734137,half-life,"The half-life of this CBZ-D4 dose in the two patients (20 and 26 hr, respectively) was similar to the post-steady-state half-life of CBZ (23 hr in both patients) measured later.",Pharmacokinetics: time-dependent changes--autoinduction of carbamazepine epoxidation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3734137/),h,26,174541,DB00564,Carbamazepine
,3734137,post-steady-state half-life,"The half-life of this CBZ-D4 dose in the two patients (20 and 26 hr, respectively) was similar to the post-steady-state half-life of CBZ (23 hr in both patients) measured later.",Pharmacokinetics: time-dependent changes--autoinduction of carbamazepine epoxidation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3734137/),h,23,174542,DB00564,Carbamazepine
,3734137,half-life,"A single dose of CBZ given one week after the last maintenance dose had a longer half-life (46 and 45 hr, respectively), which probably is close to the disposition of the drug before starting the treatment with CBZ.",Pharmacokinetics: time-dependent changes--autoinduction of carbamazepine epoxidation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3734137/),h,46,174543,DB00564,Carbamazepine
,3734137,half-life,"A single dose of CBZ given one week after the last maintenance dose had a longer half-life (46 and 45 hr, respectively), which probably is close to the disposition of the drug before starting the treatment with CBZ.",Pharmacokinetics: time-dependent changes--autoinduction of carbamazepine epoxidation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3734137/),h,45,174544,DB00564,Carbamazepine
,28771787,trough concentration (Ctrough ),A parent-metabolite population pharmacokinetic model in children was developed to evaluate the consistency between the recommended paediatric doses and the reference range for trough concentration (Ctrough ) of MHD (3-35 mg l-1 ).,Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[mg] / [l],3-35,176046,DB00564,Carbamazepine
,28771787,Ctrough,The probability to obtain Ctrough between 3-35 mg l-1 was determined by Monte Carlo simulations for doses ranging from 10 to 90 mg kg-1 day-1 .,Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[mg] / [l],3-35,176047,DB00564,Carbamazepine
,28771787,clearance,"Typical values for oxcarbazepine clearance, central and peripheral distribution volume and distribution clearance were 140 l h-1 70 kg-1 , 337 l 70 kg-1 , 60.7 l and 62.5 l h-1 , respectively.",Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[l] / [70·h·kg],140,176048,DB00564,Carbamazepine
,28771787,peripheral distribution volume,"Typical values for oxcarbazepine clearance, central and peripheral distribution volume and distribution clearance were 140 l h-1 70 kg-1 , 337 l 70 kg-1 , 60.7 l and 62.5 l h-1 , respectively.",Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[l] / [70·kg],337,176049,DB00564,Carbamazepine
,28771787,peripheral distribution volume,"Typical values for oxcarbazepine clearance, central and peripheral distribution volume and distribution clearance were 140 l h-1 70 kg-1 , 337 l 70 kg-1 , 60.7 l and 62.5 l h-1 , respectively.",Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),l,60.7,176050,DB00564,Carbamazepine
,28771787,distribution clearance,"Typical values for oxcarbazepine clearance, central and peripheral distribution volume and distribution clearance were 140 l h-1 70 kg-1 , 337 l 70 kg-1 , 60.7 l and 62.5 l h-1 , respectively.",Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[l] / [h],62.5,176051,DB00564,Carbamazepine
,28771787,clearance,Typical values for MHD clearance and distribution volume were 4.11 l h-1 70 kg-1 and 54.8 l 70 kg-1 respectively.,Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[l] / [70·h·kg],4.11,176052,DB00564,Carbamazepine
,28771787,distribution volume,Typical values for MHD clearance and distribution volume were 4.11 l h-1 70 kg-1 and 54.8 l 70 kg-1 respectively.,Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[l] / [70·kg],54.8,176053,DB00564,Carbamazepine
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],19.8,176121,DB00564,Carbamazepine
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],54.6,176122,DB00564,Carbamazepine
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],113.3,176123,DB00564,Carbamazepine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,1.9,176124,DB00564,Carbamazepine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,3.3,176125,DB00564,Carbamazepine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,4.0,176126,DB00564,Carbamazepine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,23,176127,DB00564,Carbamazepine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,32,176128,DB00564,Carbamazepine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,24,176129,DB00564,Carbamazepine
,598420,kabs,The following values were obtained for various pharmacokinetic parameters: kabs = 0.176 +/- 0.209 h-1; k = 0.0203 +/- 0.0055 h-1; T1/2 = 37.5 +/- 13.1 h; VD = 0.825 +/- 0.1041 .,The pharmacokinetics of carbamazepine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598420/),1/[h],0.176,176144,DB00564,Carbamazepine
,598420,k,The following values were obtained for various pharmacokinetic parameters: kabs = 0.176 +/- 0.209 h-1; k = 0.0203 +/- 0.0055 h-1; T1/2 = 37.5 +/- 13.1 h; VD = 0.825 +/- 0.1041 .,The pharmacokinetics of carbamazepine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598420/),1/[h],0.0203,176145,DB00564,Carbamazepine
,598420,T1/2,The following values were obtained for various pharmacokinetic parameters: kabs = 0.176 +/- 0.209 h-1; k = 0.0203 +/- 0.0055 h-1; T1/2 = 37.5 +/- 13.1 h; VD = 0.825 +/- 0.1041 .,The pharmacokinetics of carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598420/),h,37.5,176146,DB00564,Carbamazepine
,598420,VD,The following values were obtained for various pharmacokinetic parameters: kabs = 0.176 +/- 0.209 h-1; k = 0.0203 +/- 0.0055 h-1; T1/2 = 37.5 +/- 13.1 h; VD = 0.825 +/- 0.1041 .,The pharmacokinetics of carbamazepine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598420/),,0.825,176147,DB00564,Carbamazepine
,598420,Clearance,KG-1; Clearance = 0.0163 +/- 0.0061 1 . kg-1.,The pharmacokinetics of carbamazepine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598420/),[1] / [kg],0.0163,176148,DB00564,Carbamazepine
,3136790,half-life,VPM caused a prolongation of the CBZ-E half-life from 6.4 +/- 1.4 to 20.5 +/- 6.3 h and decreased CBZ-E clearance from 73.5 +/- 20.0 to 23.5 +/- 4.0 ml h-1 kg-1 (P less than 0.01).,"Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3136790/),h,6.4,176963,DB00564,Carbamazepine
,3136790,half-life,VPM caused a prolongation of the CBZ-E half-life from 6.4 +/- 1.4 to 20.5 +/- 6.3 h and decreased CBZ-E clearance from 73.5 +/- 20.0 to 23.5 +/- 4.0 ml h-1 kg-1 (P less than 0.01).,"Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3136790/),h,20.5,176964,DB00564,Carbamazepine
,3136790,clearance,VPM caused a prolongation of the CBZ-E half-life from 6.4 +/- 1.4 to 20.5 +/- 6.3 h and decreased CBZ-E clearance from 73.5 +/- 20.0 to 23.5 +/- 4.0 ml h-1 kg-1 (P less than 0.01).,"Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3136790/),[ml] / [h·kg],73.5,176965,DB00564,Carbamazepine
,3136790,clearance,VPM caused a prolongation of the CBZ-E half-life from 6.4 +/- 1.4 to 20.5 +/- 6.3 h and decreased CBZ-E clearance from 73.5 +/- 20.0 to 23.5 +/- 4.0 ml h-1 kg-1 (P less than 0.01).,"Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3136790/),[ml] / [h·kg],23.5,176966,DB00564,Carbamazepine
,11436701,clearance (Cl/F),"The mean MHD clearance (Cl/F) calculated was 4.05 +/- 1.69 l/h, with a coefficient variation of 41%.",[Pharmacokinetic variability of oxcarbazepine in epileptic patients]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11436701/),[l] / [h],4.05,177429,DB00564,Carbamazepine
,11436701,half-life,The half-life of MHD was 10.50 +/- 3.17 hours.,[Pharmacokinetic variability of oxcarbazepine in epileptic patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11436701/),h,10.50,177430,DB00564,Carbamazepine
,1446959,MRT,"The following values were found for relative bioavailability: T/R: AUC = 109.6 (101.5-116.5)%, MRT = 96.4 (92.0-100.4)%, HVD = 92.4 (85.0-97.8)%.",Investigation of the bioequivalence of two carbamazepine sustained-release formulations in healthy subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1446959/),%,96.4,179642,DB00564,Carbamazepine
,8602663,recovery times to T(1),"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,28.1,180814,DB00564,Carbamazepine
,8602663,recovery times to T(1),"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,47.3,180815,DB00564,Carbamazepine
,8602663,T(1) 25% to T(1) 75% recovery index,"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,7.6,180816,DB00564,Carbamazepine
,8602663,T(1) 25% to T(1) 75% recovery index,"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,21.9,180817,DB00564,Carbamazepine
,8602663,Clearance,"Clearance was 9.0 +/- 1.2 ml x kg-1 x min-1 versus 3.8 +/- 0.3 in the control group (P=0.003), whereas no changes in volumes of distribution at steady-state were observed.",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),[ml] / [kg·min],9.0,180818,DB00564,Carbamazepine
,8602663,Clearance,"Clearance was 9.0 +/- 1.2 ml x kg-1 x min-1 versus 3.8 +/- 0.3 in the control group (P=0.003), whereas no changes in volumes of distribution at steady-state were observed.",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),,3.8,180819,DB00564,Carbamazepine
,8602663,mean residence time,"Therefore, the mean residence time was halved (17.8 +/- 2.5 vs. 31.9 +/- 2.5 min in control subjects; P=0.001).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,17.8,180820,DB00564,Carbamazepine
,8602663,mean residence time,"Therefore, the mean residence time was halved (17.8 +/- 2.5 vs. 31.9 +/- 2.5 min in control subjects; P=0.001).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,31.9,180821,DB00564,Carbamazepine
,8877605,Elimination half-life,Elimination half-life was 24.5 hours.,Treatment of neonatal seizures with carbamazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877605/),h,24.5,180871,DB00564,Carbamazepine
more,26088709,Recoveries,Recoveries of caudatin and IS were more than 80% and matrix effects were not significant.,Determination of Caudatin in Rat Plasma by UPLC-MS/MS: Application to a Preclinical Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26088709/),%,80,181559,DB00564,Carbamazepine
,7859804,apparent elimination half-life,The apparent elimination half-life of the monohydroxy-metabolite [19 (SD 3) h] in these patients was about twice that in healthy subjects.,The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859804/),h,19,181564,DB00564,Carbamazepine
,30877932,gradient elution flow,Chromatographic separation was achieved by using a Waters BEH C18 column and involving the optimized mobile phase of 0.1% formic acid aqueous solution and acetonitrile with gradient elution flow of 0.20 ml/min.,A validated UHPLC-MS/MS method for measurement of pharmacokinetics and tissue distribution of trolline in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30877932/),[ml] / [min],0.20,182778,DB00564,Carbamazepine
,31806398,IC50,"The IC50 values of compounds 7, 12 and 13 were 42.81, 20.55 and 22.74 μM.",Simultaneous characterisation of multiple Mahonia fortunei bioactive compounds in rat plasma by UPLC-MS/MS for application in pharmacokinetic studies and anti-inflammatory activity in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806398/),μM,42.81,183442,DB00564,Carbamazepine
,31806398,IC50,"The IC50 values of compounds 7, 12 and 13 were 42.81, 20.55 and 22.74 μM.",Simultaneous characterisation of multiple Mahonia fortunei bioactive compounds in rat plasma by UPLC-MS/MS for application in pharmacokinetic studies and anti-inflammatory activity in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806398/),μM,20.55,183443,DB00564,Carbamazepine
,31806398,IC50,"The IC50 values of compounds 7, 12 and 13 were 42.81, 20.55 and 22.74 μM.",Simultaneous characterisation of multiple Mahonia fortunei bioactive compounds in rat plasma by UPLC-MS/MS for application in pharmacokinetic studies and anti-inflammatory activity in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806398/),μM,22.74,183444,DB00564,Carbamazepine
,3266736,elimination half-life,The elimination half-life of the untreated control group (n = 27) was 4.62 h.,Effects of drugs on aminophylline elimination in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,4.62,184893,DB00564,Carbamazepine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.09,184894,DB00564,Carbamazepine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.47,184895,DB00564,Carbamazepine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.19,184896,DB00564,Carbamazepine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2,184897,DB00564,Carbamazepine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.85,184898,DB00564,Carbamazepine
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.74,184899,DB00564,Carbamazepine
,26094207,extraction recovery,"The extraction recovery was in the range of 78.3-88.4% for vortioxetine and 80.3% for carbamazepine (internal standard, IS).",An UPLC-MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26094207/),%,78.3-88.4,185572,DB00564,Carbamazepine
,26094207,extraction recovery,"The extraction recovery was in the range of 78.3-88.4% for vortioxetine and 80.3% for carbamazepine (internal standard, IS).",An UPLC-MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26094207/),%,80.3,185573,DB00564,Carbamazepine
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],"1,778",185596,DB00564,Carbamazepine
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],986,185597,DB00564,Carbamazepine
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],24.8,185598,DB00564,Carbamazepine
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],13.8,185599,DB00564,Carbamazepine
,9029743,clearance,"The clearance and volume of distribution of felbamate were 41.1 ml/h/kg and 908 ml/kg, respectively.",Population pharmacokinetics of felbamate in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029743/),[ml] / [h·kg],41.1,185907,DB00564,Carbamazepine
,9029743,volume of distribution,"The clearance and volume of distribution of felbamate were 41.1 ml/h/kg and 908 ml/kg, respectively.",Population pharmacokinetics of felbamate in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029743/),[ml] / [kg],908,185908,DB00564,Carbamazepine
,12504914,electroconvulsive threshold,"(2S,2R)-4-Methylglutamic acid (SYM 2081), a potent selective agonist of GluR5 and GluR6 kainate receptor subtypes, applied at the dose of 15.5 mg/kg, equal to its CD(16) value (i.e., a dose required to induce convulsions in 16% of mice), significantly decreased the electroconvulsive threshold from 7.0 to 5.8 mA.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),m,7.0,186820,DB00564,Carbamazepine
,12504914,electroconvulsive threshold,"(2S,2R)-4-Methylglutamic acid (SYM 2081), a potent selective agonist of GluR5 and GluR6 kainate receptor subtypes, applied at the dose of 15.5 mg/kg, equal to its CD(16) value (i.e., a dose required to induce convulsions in 16% of mice), significantly decreased the electroconvulsive threshold from 7.0 to 5.8 mA.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),m,5,186821,DB00564,Carbamazepine
,12504914,ED(50),"The respective ED(50) values were increased from 18.5 to 23.8 mg/kg for phenobarbital, and from 11.7 to 14.7 mg/kg for diphenylhydantoin.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),[mg] / [kg],18.5 to 23.8,186822,DB00564,Carbamazepine
,12504914,ED(50),"The respective ED(50) values were increased from 18.5 to 23.8 mg/kg for phenobarbital, and from 11.7 to 14.7 mg/kg for diphenylhydantoin.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),[mg] / [kg],11.7 to 14.7,186823,DB00564,Carbamazepine
,21079880,flow rate,Because of high column efficiency the mobile phase was pumped at a flow rate of 2.5 mL min(-1).,Liquid chromatographic high-throughput analysis of the new ultra-short acting hypnotic 'HIE-124' and its metabolite in mice serum using a monolithic silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079880/),[ml] / [min],2.5,186932,DB00564,Carbamazepine
,21079880,total run time,The total run time of the assay was 2 min.,Liquid chromatographic high-throughput analysis of the new ultra-short acting hypnotic 'HIE-124' and its metabolite in mice serum using a monolithic silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079880/),min,2,186933,DB00564,Carbamazepine
,21079880,limit of detection (LOD),"The limit of detection (LOD) for HIE-124 and its metabolite were 20 ng mL(-1) and 65 ng mL(-1), respectively.",Liquid chromatographic high-throughput analysis of the new ultra-short acting hypnotic 'HIE-124' and its metabolite in mice serum using a monolithic silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079880/),[ng] / [ml],20,186934,DB00564,Carbamazepine
,21079880,limit of detection (LOD),"The limit of detection (LOD) for HIE-124 and its metabolite were 20 ng mL(-1) and 65 ng mL(-1), respectively.",Liquid chromatographic high-throughput analysis of the new ultra-short acting hypnotic 'HIE-124' and its metabolite in mice serum using a monolithic silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079880/),[ng] / [ml],65,186935,DB00564,Carbamazepine
,16026556,CL/F,"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],2.1,186996,DB00564,Carbamazepine
,16026556,CL/F,"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],1.2,186997,DB00564,Carbamazepine
,16026556,CL(r),"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],1.1,186998,DB00564,Carbamazepine
,16026556,CL(r),"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],0.6,186999,DB00564,Carbamazepine
,9646011,elimination half-life,Peak concentration in serum is reached after 1 to 2 hours and the elimination half-life is between 1 and 3 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,1 and 3,187764,DB00564,Carbamazepine
,9646011,half-life,Concentrations of ALBSO are highly variable between individuals and it has a half-life of between 6 and 15 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,6 and 15,187765,DB00564,Carbamazepine
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],806,189197,DB00564,Carbamazepine
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],411,189198,DB00564,Carbamazepine
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],33.6,189199,DB00564,Carbamazepine
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],19.5,189200,DB00564,Carbamazepine
,2126946,Ng,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],33.6,189201,DB00564,Carbamazepine
,2126946,Ng,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],19.5,189202,DB00564,Carbamazepine
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],1163,189203,DB00564,Carbamazepine
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],672,189204,DB00564,Carbamazepine
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],22.9,189205,DB00564,Carbamazepine
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],13.8,189206,DB00564,Carbamazepine
,2126946,Ng,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],22.9,189207,DB00564,Carbamazepine
,2126946,Ng,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],13.8,189208,DB00564,Carbamazepine
,23147034,flow rate,"Chromatographic separation was conducted on an Ultimate C18 column with a mobile phase consisting of acetonitrile-water (containing 0.1% formic acid; 40:60, v/v) at a flow rate of 0.3 mL/min.",Determination of voriconazole in human plasma by HPLC-ESI-MS and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23147034/),[ml] / [min],0.3,189514,DB00564,Carbamazepine
,7649598,Cmax,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [ml],1.73,190591,DB00564,Carbamazepine
,7649598,Cmax,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [ml],0.94,190592,DB00564,Carbamazepine
,7649598,AUC o-t,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [h·ml],76.19,190593,DB00564,Carbamazepine
,7649598,AUC o-t,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [h·ml],52.66,190594,DB00564,Carbamazepine
,7649598,Tmax,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,5.60,190595,DB00564,Carbamazepine
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,16.80,190596,DB00564,Carbamazepine
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,44.88,190597,DB00564,Carbamazepine
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,125.07,190598,DB00564,Carbamazepine
,7649598,Vd,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[l] / [kg],2.19,190599,DB00564,Carbamazepine
,7649598,Vd,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[l] / [kg],3.85,190600,DB00564,Carbamazepine
,7649598,Cl,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[ml] / [min],34.07,190601,DB00564,Carbamazepine
,7649598,Cl,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[ml] / [min],25.26,190602,DB00564,Carbamazepine
,30793320,clearance,"Fentanyl clearance was significantly higher in the carbamazepine group compared to controls (mean ± SD: 20.1 ± 6.8 vs 13.2 ± 4.8 ml/min per kg, P < 0.05), and area under the plasma concentration curve (AUC) was significantly lower (150 ± 65 vs 233 ± 70 ng/ml × min, P < 0.02).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[ml] / [kg·min],20.1,190898,DB00564,Carbamazepine
,30793320,clearance,"Fentanyl clearance was significantly higher in the carbamazepine group compared to controls (mean ± SD: 20.1 ± 6.8 vs 13.2 ± 4.8 ml/min per kg, P < 0.05), and area under the plasma concentration curve (AUC) was significantly lower (150 ± 65 vs 233 ± 70 ng/ml × min, P < 0.02).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[ml] / [kg·min],13.2,190899,DB00564,Carbamazepine
,30793320,area under the plasma concentration curve (AUC),"Fentanyl clearance was significantly higher in the carbamazepine group compared to controls (mean ± SD: 20.1 ± 6.8 vs 13.2 ± 4.8 ml/min per kg, P < 0.05), and area under the plasma concentration curve (AUC) was significantly lower (150 ± 65 vs 233 ± 70 ng/ml × min, P < 0.02).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[ng] / [min·ml],150,190900,DB00564,Carbamazepine
,30793320,area under the plasma concentration curve (AUC),"Fentanyl clearance was significantly higher in the carbamazepine group compared to controls (mean ± SD: 20.1 ± 6.8 vs 13.2 ± 4.8 ml/min per kg, P < 0.05), and area under the plasma concentration curve (AUC) was significantly lower (150 ± 65 vs 233 ± 70 ng/ml × min, P < 0.02).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[ng] / [min·ml],233,190901,DB00564,Carbamazepine
,30793320,Volume of distribution,"Volume of distribution was larger in the carbamazepine group, but the difference was not statistically significant (5.4 ± 3.1 vs 3.6 ± 1.2 l/kg, P > 0.15).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[l] / [kg],5.4,190902,DB00564,Carbamazepine
,30793320,Volume of distribution,"Volume of distribution was larger in the carbamazepine group, but the difference was not statistically significant (5.4 ± 3.1 vs 3.6 ± 1.2 l/kg, P > 0.15).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[l] / [kg],3.6,190903,DB00564,Carbamazepine
>,12731458,bioavailability,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),%,95,192152,DB00564,Carbamazepine
,12731458,elimination half-life,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),h,7,192153,DB00564,Carbamazepine
,12731458,elimination half-life,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),h,6,192154,DB00564,Carbamazepine
,12731458,elimination half-life,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),h,10.5,192155,DB00564,Carbamazepine
,8756037,Relative bioavailabilities ((F)rel),"Relative bioavailabilities ((F)rel) of Temporal(R), Taver(R) and Carbamazepine Linocoln were 101.2%, 82.2% and 71.6% respectively, compared with Tegretol(R).",A comparative bioavailability of four Carbamazepine tablet formulations available in the Kenyan market. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756037/),%,101.2,192179,DB00564,Carbamazepine
,8756037,Relative bioavailabilities ((F)rel),"Relative bioavailabilities ((F)rel) of Temporal(R), Taver(R) and Carbamazepine Linocoln were 101.2%, 82.2% and 71.6% respectively, compared with Tegretol(R).",A comparative bioavailability of four Carbamazepine tablet formulations available in the Kenyan market. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756037/),%,82.2,192180,DB00564,Carbamazepine
,8756037,Relative bioavailabilities ((F)rel),"Relative bioavailabilities ((F)rel) of Temporal(R), Taver(R) and Carbamazepine Linocoln were 101.2%, 82.2% and 71.6% respectively, compared with Tegretol(R).",A comparative bioavailability of four Carbamazepine tablet formulations available in the Kenyan market. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756037/),%,71.6,192181,DB00564,Carbamazepine
,8756037,Percent drug content dissolved,"Percent drug content dissolved in vitro after I hour were 91.3%, 75.9% and 39.3% for Temporal(R), Taver(R) and Carbamazepine Lincoln, respectively.",A comparative bioavailability of four Carbamazepine tablet formulations available in the Kenyan market. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756037/),%,91.3,192182,DB00564,Carbamazepine
,8756037,Percent drug content dissolved,"Percent drug content dissolved in vitro after I hour were 91.3%, 75.9% and 39.3% for Temporal(R), Taver(R) and Carbamazepine Lincoln, respectively.",A comparative bioavailability of four Carbamazepine tablet formulations available in the Kenyan market. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756037/),%,75.9,192183,DB00564,Carbamazepine
,8756037,Percent drug content dissolved,"Percent drug content dissolved in vitro after I hour were 91.3%, 75.9% and 39.3% for Temporal(R), Taver(R) and Carbamazepine Lincoln, respectively.",A comparative bioavailability of four Carbamazepine tablet formulations available in the Kenyan market. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8756037/),%,39.3,192184,DB00564,Carbamazepine
,328018,half-life,After withdrawal of DPA the half-life was about 14 h in adult patients.,Preliminary observations on valproic acid kinetics in patients with epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/328018/),h,14,192230,DB00564,Carbamazepine
,10885584,absolute bioavailability,"The absolute bioavailability is approximately 50%, mainly because of gut wall and hepatic first-pass metabolism.",Clinical pharmacokinetics of mirtazapine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),%,50,193151,DB00564,Carbamazepine
,10885584,elimination half-life,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,20 to 40,193152,DB00564,Carbamazepine
,10885584,time to reach steady state,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),d,4 to 6,193153,DB00564,Carbamazepine
,10885584,Total body clearance,Total body clearance as determined from intravenous administration to young males amounts to 31 L/h.,Clinical pharmacokinetics of mirtazapine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),[l] / [h],31,193154,DB00564,Carbamazepine
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,18.0,193155,DB00564,Carbamazepine
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,9.9,193156,DB00564,Carbamazepine
,1139857,half-lives,Mean half-lives ranged from 31 to 35 hr.,Pharmacokinetics of carbamazepine in normal man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139857/),h,31 to 35,194105,DB00564,Carbamazepine
,20853465,total run time,"The total run time was 2.5 min and the elution of NTP, OH-NTP and IS occurred at 1.44, 1.28 and 1.39 min, respectively; this was achieved with a mobile phase consisting of 20 mm ammonium acetate : acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPURITY C(18) column.",Development and validation of a highly sensitive LC-MS/MS method for simultaneous quantitation of nortriptyline and 10-hydroxynortriptyline in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853465/),min,2.5,194957,DB00564,Carbamazepine
,20853465,flow rate,"The total run time was 2.5 min and the elution of NTP, OH-NTP and IS occurred at 1.44, 1.28 and 1.39 min, respectively; this was achieved with a mobile phase consisting of 20 mm ammonium acetate : acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPURITY C(18) column.",Development and validation of a highly sensitive LC-MS/MS method for simultaneous quantitation of nortriptyline and 10-hydroxynortriptyline in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853465/),[ml] / [min],0.50,194958,DB00564,Carbamazepine
,2384079,seizure rate,"On entry, the mean 14 day seizure rate was 2.5.",The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384079/),,2.5,196278,DB00564,Carbamazepine
,2384079,14,"On chewtabs mean 14 day rates were 2.4, 2.2, 2.4 and 2.7 after 2, 4, 8 and 12 weeks of treatment respectively.",The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384079/),,2.4,196279,DB00564,Carbamazepine
,2384079,14,"On chewtabs mean 14 day rates were 2.4, 2.2, 2.4 and 2.7 after 2, 4, 8 and 12 weeks of treatment respectively.",The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384079/),,2.2,196280,DB00564,Carbamazepine
,2384079,14,"On chewtabs mean 14 day rates were 2.4, 2.2, 2.4 and 2.7 after 2, 4, 8 and 12 weeks of treatment respectively.",The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384079/),,2.7,196281,DB00564,Carbamazepine
,2384079,rates,"On chewtabs mean 14 day rates were 2.4, 2.2, 2.4 and 2.7 after 2, 4, 8 and 12 weeks of treatment respectively.",The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384079/),,2.4,196282,DB00564,Carbamazepine
,2384079,rates,"On chewtabs mean 14 day rates were 2.4, 2.2, 2.4 and 2.7 after 2, 4, 8 and 12 weeks of treatment respectively.",The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384079/),,2.2,196283,DB00564,Carbamazepine
,2384079,rates,"On chewtabs mean 14 day rates were 2.4, 2.2, 2.4 and 2.7 after 2, 4, 8 and 12 weeks of treatment respectively.",The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384079/),,2.7,196284,DB00564,Carbamazepine
,2384079,steady state trough serum CBZ concentration,"On entry the mean steady state trough serum CBZ concentration was 35 mumols/l compared to 32, 31, 32 and 34 mumols/l after 2, 4, 8 and 12 weeks respectively.",The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384079/),[mumols] / [l],35,196285,DB00564,Carbamazepine
,2384079,steady state trough serum CBZ concentration,"On entry the mean steady state trough serum CBZ concentration was 35 mumols/l compared to 32, 31, 32 and 34 mumols/l after 2, 4, 8 and 12 weeks respectively.",The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384079/),[mumols] / [l],32,196286,DB00564,Carbamazepine
,2384079,steady state trough serum CBZ concentration,"On entry the mean steady state trough serum CBZ concentration was 35 mumols/l compared to 32, 31, 32 and 34 mumols/l after 2, 4, 8 and 12 weeks respectively.",The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384079/),[mumols] / [l],31,196287,DB00564,Carbamazepine
,2384079,steady state trough serum CBZ concentration,"On entry the mean steady state trough serum CBZ concentration was 35 mumols/l compared to 32, 31, 32 and 34 mumols/l after 2, 4, 8 and 12 weeks respectively.",The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384079/),[mumols] / [l],34,196288,DB00564,Carbamazepine
,16787802,peak value,The peak value of blood CBZ was comparable in the 2 groups: 33+/-3.46 mg/L (G1) vs 32.6+/-5.63 (G2) (P=.5); the requirement of mechanical ventilation was similar also (3 in each group).,Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16787802/),[mg] / [l],33,196511,DB00564,Carbamazepine
,16787802,peak value,The peak value of blood CBZ was comparable in the 2 groups: 33+/-3.46 mg/L (G1) vs 32.6+/-5.63 (G2) (P=.5); the requirement of mechanical ventilation was similar also (3 in each group).,Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16787802/),,32.6,196512,DB00564,Carbamazepine
,16787802,length of stay,The length of stay was also significantly decreased in the first group: 30.3+/-3.4 vs 39.7+/-7.3 hours in the second group (P=.000006).,Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16787802/),h,30.3,196513,DB00564,Carbamazepine
,16787802,length of stay,The length of stay was also significantly decreased in the first group: 30.3+/-3.4 vs 39.7+/-7.3 hours in the second group (P=.000006).,Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16787802/),h,39.7,196514,DB00564,Carbamazepine
,16787802,half-life,"Concurrently, we have noted a significant constant reduction of the half-life of CBZ from serum in the first group: 12.56+/-3.5 hours after multiple dose vs 27.88+/-7.36 hours after a simple dose (P=.0004).",Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16787802/),h,12.56,196515,DB00564,Carbamazepine
,16787802,half-life,"Concurrently, we have noted a significant constant reduction of the half-life of CBZ from serum in the first group: 12.56+/-3.5 hours after multiple dose vs 27.88+/-7.36 hours after a simple dose (P=.0004).",Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16787802/),h,27.88,196516,DB00564,Carbamazepine
,10996503,plasma concentrations,LTG dose of 369+/-236 mg per day (8.1+/-5.9 mg/kg per day) achieved LTG plasma concentrations of 6.8+/-3.3 microg/ml.,Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[μg] / [ml],6.8,196945,DB00564,Carbamazepine
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],0. 69,196946,DB00564,Carbamazepine
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],1.60,196947,DB00564,Carbamazepine
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],0.2,196948,DB00564,Carbamazepine
,17516704,apparent elimination half-life (t((1/2))),In plasma after a single oral administration of oxcarbazepine the mean apparent elimination half-life (t((1/2))) of MHD in adults was 8-9h.,Overview of the clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),h,8-9,197924,DB00564,Carbamazepine
,17516704,ki [inhibition constant],"In vitro, MHD inhibits the cytochrome P450 (CYP) 2C19 (ki [inhibition constant] = 88 micromol/L).",Overview of the clinical pharmacokinetics of oxcarbazepine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),[μM] / [l],88,197925,DB00564,Carbamazepine
,25700977,volume of distribution,"The mean values of volume of distribution and clearance of MHD in the patients were 14.2 L and 2.38 L h(-1), respectively.",Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700977/),l,14.2,198924,DB00564,Carbamazepine
,25700977,clearance,"The mean values of volume of distribution and clearance of MHD in the patients were 14.2 L and 2.38 L h(-1), respectively.",Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700977/),[l] / [h],2.38,198925,DB00564,Carbamazepine
greater,11499624,Recovery,Recovery for 2-hydroxyflutamide was greater than 91.4% and for internal standard was 93.6%.,Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499624/),%,91.4,199104,DB00564,Carbamazepine
,11499624,Recovery,Recovery for 2-hydroxyflutamide was greater than 91.4% and for internal standard was 93.6%.,Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499624/),%,93.6,199105,DB00564,Carbamazepine
,11499624,Cmax,"Analysis of 2-hydroxyflutamide concentrations in plasma samples from 16 healthy volunteers following oral administration of 250 mg of flutamide provided the following pharmacokinetic data (mean+/-SD): Cmax, 776 +/- 400 ng/ml; AUC(0-infinity), 5,368 +/- 2,689 ng h/ml; AUC(0-t) 5,005 +/- 2,605 ng h/ml; Tmax 2.6 +/- 1.6 h; elimination half-life, 5.2 +/- 2.0 h.",Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499624/),[ng] / [ml],776,199106,DB00564,Carbamazepine
,11499624,AUC(0-infinity),"Analysis of 2-hydroxyflutamide concentrations in plasma samples from 16 healthy volunteers following oral administration of 250 mg of flutamide provided the following pharmacokinetic data (mean+/-SD): Cmax, 776 +/- 400 ng/ml; AUC(0-infinity), 5,368 +/- 2,689 ng h/ml; AUC(0-t) 5,005 +/- 2,605 ng h/ml; Tmax 2.6 +/- 1.6 h; elimination half-life, 5.2 +/- 2.0 h.",Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499624/),[h·ng] / [ml],"5,368",199107,DB00564,Carbamazepine
,11499624,AUC(0-t),"Analysis of 2-hydroxyflutamide concentrations in plasma samples from 16 healthy volunteers following oral administration of 250 mg of flutamide provided the following pharmacokinetic data (mean+/-SD): Cmax, 776 +/- 400 ng/ml; AUC(0-infinity), 5,368 +/- 2,689 ng h/ml; AUC(0-t) 5,005 +/- 2,605 ng h/ml; Tmax 2.6 +/- 1.6 h; elimination half-life, 5.2 +/- 2.0 h.",Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499624/),[h·ng] / [ml],"5,005",199108,DB00564,Carbamazepine
,11499624,Tmax,"Analysis of 2-hydroxyflutamide concentrations in plasma samples from 16 healthy volunteers following oral administration of 250 mg of flutamide provided the following pharmacokinetic data (mean+/-SD): Cmax, 776 +/- 400 ng/ml; AUC(0-infinity), 5,368 +/- 2,689 ng h/ml; AUC(0-t) 5,005 +/- 2,605 ng h/ml; Tmax 2.6 +/- 1.6 h; elimination half-life, 5.2 +/- 2.0 h.",Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499624/),h,2.6,199109,DB00564,Carbamazepine
,11499624,elimination half-life,"Analysis of 2-hydroxyflutamide concentrations in plasma samples from 16 healthy volunteers following oral administration of 250 mg of flutamide provided the following pharmacokinetic data (mean+/-SD): Cmax, 776 +/- 400 ng/ml; AUC(0-infinity), 5,368 +/- 2,689 ng h/ml; AUC(0-t) 5,005 +/- 2,605 ng h/ml; Tmax 2.6 +/- 1.6 h; elimination half-life, 5.2 +/- 2.0 h.",Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499624/),h,5.2,199110,DB00564,Carbamazepine
,15496330,limit of detection,The limit of detection of ICA was 1.0 mg/L (S/N = 3) by UV detection at 270 nm.,Determination of icariin and metabolites in rat serum by capillary zone electrophoresis: rat pharmacokinetic studies after administration of icariin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496330/),[mg] / [l],1.0,199275,DB00564,Carbamazepine
,15496330,S/N,The limit of detection of ICA was 1.0 mg/L (S/N = 3) by UV detection at 270 nm.,Determination of icariin and metabolites in rat serum by capillary zone electrophoresis: rat pharmacokinetic studies after administration of icariin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496330/),,3,199276,DB00564,Carbamazepine
,12160664,time to fourth seizure,Remacemide hydrochloride showed a significantly ( P= 0.045) longer median time to fourth seizure compared with placebo (6.8 vs. 3.8 days).,"A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12160664/),d,6.8,199964,DB00564,Carbamazepine
,12160664,time to fourth seizure,Remacemide hydrochloride showed a significantly ( P= 0.045) longer median time to fourth seizure compared with placebo (6.8 vs. 3.8 days).,"A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12160664/),d,3.8,199965,DB00564,Carbamazepine
,16859057,area under the curve,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),[μg] / [h·ml],29.1,201975,DB00564,Carbamazepine
,16859057,area under the curve,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),[μg] / [h·ml],38.7,201976,DB00564,Carbamazepine
,16859057,half-life,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),[μg] / [h·ml],38.7,201977,DB00564,Carbamazepine
,16859057,half-life,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),h,7.7,201978,DB00564,Carbamazepine
,16859057,half-life,"In spinal cord-injured group, area under the curve and half-life were increased from 29.1 microg/mL.hr to 38.7 microg/mL.hr and from 7.7 hr to 14.1 hr as compared with the sham-lesioned control group, respectively.",The influence of experimental spinal cord injury on carbamazepine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859057/),h,14.1,201979,DB00564,Carbamazepine
,24512634,flow rate,The flow rate was set at 0.4 mL/min.,Gradient elution liquid chromatography mass spectrometry determination of acetylcorynoline in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512634/),[ml] / [min],0.4,202131,DB00564,Carbamazepine
,24512634,recoveries,3. Mean recoveries of acetylcorynoline in rat plasma were in the range of 72.3-87.6%.,Gradient elution liquid chromatography mass spectrometry determination of acetylcorynoline in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512634/),%,72.3-87.6,202132,DB00564,Carbamazepine
,24512634,Matrix effects,Matrix effects for acetylcorynoline were measured to be between 88.7% and 93.5%.,Gradient elution liquid chromatography mass spectrometry determination of acetylcorynoline in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512634/),%,88.7,202133,DB00564,Carbamazepine
,24512634,Matrix effects,Matrix effects for acetylcorynoline were measured to be between 88.7% and 93.5%.,Gradient elution liquid chromatography mass spectrometry determination of acetylcorynoline in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512634/),%,93.,202134,DB00564,Carbamazepine
,24925071,flow rate,"Chromatographic separation was carried out on an Acquity UPLC BEH C18 column using an isocratic mobile phase system composed of acetonitrile and water containing 1% formic acid (45:55, v/v) at a flow rate of 0.50 mL/min.",UPLC-MS/MS determination of voriconazole in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24925071/),[ml] / [min],0.50,202462,DB00564,Carbamazepine
,8846617,oral bioavailability,"Despite complete absorption, oral bioavailability in man is approximately 50% on account of first-pass hepatic metabolism.",Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,50,204181,DB00564,Carbamazepine
,8846617,terminal elimination half-life,Fluvoxamine shows a biphasic pattern of elimination with a mean terminal elimination half-life of 12 to 15 hours after a single oral dose; this is prolonged by 30 to 50% at steady-state.,Overview of the pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),h,12 to 15,204182,DB00564,Carbamazepine
,8846617,Plasma protein binding,Plasma protein binding of fluvoxamine (77%) is low compared with that of other SSRIs.,Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,77,204183,DB00564,Carbamazepine
,24974473,trough concentration,"As compared to VPA group, the combination of CBZ significantly (P < 0.01) decreased the trough concentration of VPA [VPA group, (69.5 +/- 28.8) microg x mL(-1); VPA+CBZ group, (46.3 +/- 25.6) microg x mL(-1)] and does-adjusted VPA trough concentration [VPA group, (4.89 +/- 2.21) microg x mL(-1) x mg(-1) x kg(-1); VPA+CBZ group, (3.14 +/- 1.74) microg x mL(-1) x mg(-1) x kg(-1)].",[Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974473/),[μg] / [ml],69.5,205250,DB00564,Carbamazepine
,24974473,trough concentration,"As compared to VPA group, the combination of CBZ significantly (P < 0.01) decreased the trough concentration of VPA [VPA group, (69.5 +/- 28.8) microg x mL(-1); VPA+CBZ group, (46.3 +/- 25.6) microg x mL(-1)] and does-adjusted VPA trough concentration [VPA group, (4.89 +/- 2.21) microg x mL(-1) x mg(-1) x kg(-1); VPA+CBZ group, (3.14 +/- 1.74) microg x mL(-1) x mg(-1) x kg(-1)].",[Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974473/),[μg] / [ml],46.3,205251,DB00564,Carbamazepine
,24974473,trough concentration,"As compared to VPA group, the combination of CBZ significantly (P < 0.01) decreased the trough concentration of VPA [VPA group, (69.5 +/- 28.8) microg x mL(-1); VPA+CBZ group, (46.3 +/- 25.6) microg x mL(-1)] and does-adjusted VPA trough concentration [VPA group, (4.89 +/- 2.21) microg x mL(-1) x mg(-1) x kg(-1); VPA+CBZ group, (3.14 +/- 1.74) microg x mL(-1) x mg(-1) x kg(-1)].",[Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974473/),[μg] / [kg·mg·ml],4.89,205252,DB00564,Carbamazepine
,24974473,trough concentration,"As compared to VPA group, the combination of CBZ significantly (P < 0.01) decreased the trough concentration of VPA [VPA group, (69.5 +/- 28.8) microg x mL(-1); VPA+CBZ group, (46.3 +/- 25.6) microg x mL(-1)] and does-adjusted VPA trough concentration [VPA group, (4.89 +/- 2.21) microg x mL(-1) x mg(-1) x kg(-1); VPA+CBZ group, (3.14 +/- 1.74) microg x mL(-1) x mg(-1) x kg(-1)].",[Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974473/),[μg] / [kg·mg·ml],3.14,205253,DB00564,Carbamazepine
,29981400,oral clearance (CL/F),"For the final PPK model, the oral clearance (CL/F) of VPA was estimated to be 0.259 L/h with IIV of 13.3%.",Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29981400/),[l] / [h],0.259,206493,DB00564,Carbamazepine
,8598183,area under the plasma concentration-time curve (AUC),"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[min·μg] / [ml],0.60,206565,DB00564,Carbamazepine
,8598183,area under the plasma concentration-time curve (AUC),"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[min·μg] / [ml],10.5,206566,DB00564,Carbamazepine
,8598183,peak midazolam concentration,"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[ng] / [ml],5.2,206567,DB00564,Carbamazepine
,8598183,peak midazolam concentration,"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[ng] / [ml],70.4,206568,DB00564,Carbamazepine
,8598183,elimination half-life (t l/2),The elimination half-life (t l/2) of midazolam was 1.3 +/- 0.2 h in patients and 3.1 +/- 0.1 h in controls (p < 0.001).,Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),h,1.3,206569,DB00564,Carbamazepine
,8598183,elimination half-life (t l/2),The elimination half-life (t l/2) of midazolam was 1.3 +/- 0.2 h in patients and 3.1 +/- 0.1 h in controls (p < 0.001).,Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),h,3.1,206570,DB00564,Carbamazepine
,10217343,terminal half-life (t1/2),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),h,2.2,206938,DB00564,Carbamazepine
,10217343,terminal half-life (t1/2),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),h,3.8,206939,DB00564,Carbamazepine
,10217343,clearance (CL),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),[l] / [h],7.8,206940,DB00564,Carbamazepine
,10217343,clearance (CL),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),[l] / [h],8.6,206941,DB00564,Carbamazepine
,10217343,Vd,The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),l,25,206942,DB00564,Carbamazepine
,10217343,Vd,The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),l,47,206943,DB00564,Carbamazepine
,10217343,Vd at steady state (V(ss)),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),,22.8,206944,DB00564,Carbamazepine
,10217343,Vd at steady state (V(ss)),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),,29.9,206945,DB00564,Carbamazepine
,10217343,absolute bioavailability,"After its oral administration to dogs, the absolute bioavailability was 78.4 +/- 20.9% for R(-)-MHD and 78.5 +/- 27.3% for S(+)-MHD; t1/2 was 2.7 +/- 0.6 hours for R(-)-MHD and 4.1 +/- 0.8 hours for S(+)-MHD.",Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),%,78.4,206946,DB00564,Carbamazepine
,10217343,absolute bioavailability,"After its oral administration to dogs, the absolute bioavailability was 78.4 +/- 20.9% for R(-)-MHD and 78.5 +/- 27.3% for S(+)-MHD; t1/2 was 2.7 +/- 0.6 hours for R(-)-MHD and 4.1 +/- 0.8 hours for S(+)-MHD.",Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),%,78.5,206947,DB00564,Carbamazepine
,10217343,t1/2,"After its oral administration to dogs, the absolute bioavailability was 78.4 +/- 20.9% for R(-)-MHD and 78.5 +/- 27.3% for S(+)-MHD; t1/2 was 2.7 +/- 0.6 hours for R(-)-MHD and 4.1 +/- 0.8 hours for S(+)-MHD.",Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),h,2.7,206948,DB00564,Carbamazepine
,10217343,t1/2,"After its oral administration to dogs, the absolute bioavailability was 78.4 +/- 20.9% for R(-)-MHD and 78.5 +/- 27.3% for S(+)-MHD; t1/2 was 2.7 +/- 0.6 hours for R(-)-MHD and 4.1 +/- 0.8 hours for S(+)-MHD.",Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),h,4.1,206949,DB00564,Carbamazepine
,23758485,"Cmax,ss","Mean eslicarbazepine Cmax,ss (in μm) following ESL QD (87.3) was 33.3% higher (p < 0.05) compared to ESL BID (65.5) and 82.1% higher (p < 0.05) compared to OXC BID (48.0).",Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23758485/),μm,87.3,207252,DB00564,Carbamazepine
,23758485,"area under the curve (AUC)ss,0-τ","The mean area under the curve (AUC)ss,0-τ (in μmol h/L) following the last dose of an 8-day repeated dosing was 1156.3, 1117.6, and 968.4 for ESL QD, ESL BID, and OXC BID, respectively.",Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23758485/),[h·μM] / [l],1156.3,207253,DB00564,Carbamazepine
,23758485,"area under the curve (AUC)ss,0-τ","The mean area under the curve (AUC)ss,0-τ (in μmol h/L) following the last dose of an 8-day repeated dosing was 1156.3, 1117.6, and 968.4 for ESL QD, ESL BID, and OXC BID, respectively.",Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23758485/),[h·μM] / [l],1117.6,207254,DB00564,Carbamazepine
,23758485,"area under the curve (AUC)ss,0-τ","The mean area under the curve (AUC)ss,0-τ (in μmol h/L) following the last dose of an 8-day repeated dosing was 1156.3, 1117.6, and 968.4 for ESL QD, ESL BID, and OXC BID, respectively.",Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23758485/),[h·μM] / [l],968.4,207255,DB00564,Carbamazepine
,30901732,m/z,"In the process of chromatographic separation, MRM transitions for WSJ-557 and carbamazepine (internal standard, IS) were m/z 316.1 → 260.0 and m/z 237.0 → 194.0, correspondingly.",A novel xanthine oxidase inhibitor WSJ-557 study on pharmacokinetics and tissue distribution in rats by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30901732/),,316.1,207383,DB00564,Carbamazepine
,30901732,m/z,"In the process of chromatographic separation, MRM transitions for WSJ-557 and carbamazepine (internal standard, IS) were m/z 316.1 → 260.0 and m/z 237.0 → 194.0, correspondingly.",A novel xanthine oxidase inhibitor WSJ-557 study on pharmacokinetics and tissue distribution in rats by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30901732/),,260.0,207384,DB00564,Carbamazepine
,30901732,m/z,"In the process of chromatographic separation, MRM transitions for WSJ-557 and carbamazepine (internal standard, IS) were m/z 316.1 → 260.0 and m/z 237.0 → 194.0, correspondingly.",A novel xanthine oxidase inhibitor WSJ-557 study on pharmacokinetics and tissue distribution in rats by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30901732/),,237.0,207385,DB00564,Carbamazepine
,30901732,m/z,"In the process of chromatographic separation, MRM transitions for WSJ-557 and carbamazepine (internal standard, IS) were m/z 316.1 → 260.0 and m/z 237.0 → 194.0, correspondingly.",A novel xanthine oxidase inhibitor WSJ-557 study on pharmacokinetics and tissue distribution in rats by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30901732/),,194.0,207386,DB00564,Carbamazepine
,30901732,absolute bioavailability (F),The average absolute bioavailability (F) of WSJ-557 was 6.48%.,A novel xanthine oxidase inhibitor WSJ-557 study on pharmacokinetics and tissue distribution in rats by UPLC-MS/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30901732/),%,6.48,207387,DB00564,Carbamazepine
,8787948,bioavailability,"After oral administration, zopiclone is rapidly absorbed, with a bioavailability of approximately 80%.",Clinical pharmacokinetics of zopiclone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787948/),%,80,207436,DB00564,Carbamazepine
,8787948,plasma protein binding,The plasma protein binding of zopiclone has been reported to be between 45 and 80%.,Clinical pharmacokinetics of zopiclone. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787948/),%,45 and 80,207437,DB00564,Carbamazepine
,8787948,terminal elimination half-life (t1/2z),The terminal elimination half-life (t1/2z) of zopiclone ranges from 3.5 to 6.5 hours.,Clinical pharmacokinetics of zopiclone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787948/),h,3.5 to 6.5,207438,DB00564,Carbamazepine
,22544712,flow rate,"The reconstituted samples were chromatographed on an Alltima HP C(18) column using an isocratic solvent mixture [acetonitrile-5 mm ammonium acetate (pH 4.5), 85:15 (v/v)] at a flow rate of 1.0 mL/min.",Simultaneous determination of sitagliptin and simvastatin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22544712/),[ml] / [min],1.0,207551,DB00564,Carbamazepine
,22544712,run time,A run time of 3.0 min for each sample made it possible to analyze more than 300 plasma samples per day.,Simultaneous determination of sitagliptin and simvastatin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22544712/),min,3.0,207552,DB00564,Carbamazepine
,2591466,plasma elimination half-life,"The plasma elimination half-life of oxcarbazepine appeared to lie in the range 1.0-2.5 h, and that of its 10-hydroxy metabolite averaged 8.4 h.",First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591466/),h,1.0-2.5,208126,DB00564,Carbamazepine
,2591466,plasma elimination half-life,"The plasma elimination half-life of oxcarbazepine appeared to lie in the range 1.0-2.5 h, and that of its 10-hydroxy metabolite averaged 8.4 h.",First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591466/),h,8.4,208127,DB00564,Carbamazepine
,2591466,apparent oral clearance,The apparent oral clearance of the parent drug (averaging 2.51.kg-1.h-1) was high enough to suggest substantial presystemic elimination.,First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591466/),1/[h·kg],2.51,208128,DB00564,Carbamazepine
,30327119,apparent clearance (CL/F),The population estimate of apparent clearance (CL/F) for a 70-kg person was 3.69 L/hr (RSE 6.9%).,Iron supplements in nursing home patients associated with reduced carbamazepine absorption. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327119/),[l] / [h],3.69,208712,DB00564,Carbamazepine
,3824425,elimination half-life,"During danazol coadministration, CBZ elimination half-life increased from a pretreatment value of 11 to 24.3 h.",Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3824425/),h,11,208827,DB00564,Carbamazepine
,3824425,elimination half-life,"During danazol coadministration, CBZ elimination half-life increased from a pretreatment value of 11 to 24.3 h.",Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3824425/),h,24,208828,DB00564,Carbamazepine
,3824425,plasma clearance,Carbamazepine plasma clearance decreased from 57.7 to 23.2 ml/h/kg.,Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3824425/),[ml] / [h·kg],57.7,208829,DB00564,Carbamazepine
,3824425,plasma clearance,Carbamazepine plasma clearance decreased from 57.7 to 23.2 ml/h/kg.,Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3824425/),[ml] / [h·kg],23.2,208830,DB00564,Carbamazepine
,20931788,extraction recoveries,"The extraction recoveries were 94.1%-105.3% and 85.8%-98.6%, respectively.",[Simultaneous determination of peimine and peiminine in rat plasma by LC-MS/MS and its application in the pharmacokinetic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931788/),%,94.1,209375,DB00564,Carbamazepine
,20931788,extraction recoveries,"The extraction recoveries were 94.1%-105.3% and 85.8%-98.6%, respectively.",[Simultaneous determination of peimine and peiminine in rat plasma by LC-MS/MS and its application in the pharmacokinetic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931788/),%,105,209376,DB00564,Carbamazepine
,20931788,extraction recoveries,"The extraction recoveries were 94.1%-105.3% and 85.8%-98.6%, respectively.",[Simultaneous determination of peimine and peiminine in rat plasma by LC-MS/MS and its application in the pharmacokinetic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931788/),%,85.8,209377,DB00564,Carbamazepine
,20931788,extraction recoveries,"The extraction recoveries were 94.1%-105.3% and 85.8%-98.6%, respectively.",[Simultaneous determination of peimine and peiminine in rat plasma by LC-MS/MS and its application in the pharmacokinetic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931788/),%,98,209378,DB00564,Carbamazepine
,19429015,"maximal concentration, C(max)","In vehicle pre-treated rats, hippocampal phenobarbital concentrations were lower in MP (maximal concentration, C(max): 6.0+/-0.6 microg ml(-1), p<0.05) than in C animals (C(max): 9.4+/-0.9 microg ml(-1)).",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],6.0,210613,DB00564,Carbamazepine
,19429015,C(max),"In vehicle pre-treated rats, hippocampal phenobarbital concentrations were lower in MP (maximal concentration, C(max): 6.0+/-0.6 microg ml(-1), p<0.05) than in C animals (C(max): 9.4+/-0.9 microg ml(-1)).",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],9.4,210614,DB00564,Carbamazepine
,19429015,C(max),Control rats pre-treated with nimodipine showed similar results (C(max): 10.7+/-0.6 microg ml(-1)) than those pre-treated with vehicle.,Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],10.7,210615,DB00564,Carbamazepine
,19429015,C(max),"Nimodipine pre-treatment in MP rats enhanced hippocampal phenobarbital concentrations (C(max): 10.2+/-1.0 microg ml(-1), p<0.05) as compared with vehicle pre-treatment.",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],10.2,210616,DB00564,Carbamazepine
,7614909,peak CBZ plasma levels,"With infusion of CBZ:HP beta CD 10 ml/min for 12-15 min, resulting in a CBZ dose of CBZ 5 mg/kg body weight, peak CBZ plasma levels of approximately 3.6 micrograms/ml were obtained.",New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl-beta-cyclodextrin: tolerability and pharmacokinetics after intravenous injection in comparison to a glycofurol-based formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614909/),[μg] / [ml],3.6,210755,DB00564,Carbamazepine
<,7614909,half-life (t1/2),This relatively low peak concentration is primarily due to the rapid elimination of CBZ in dogs [half-life (t1/2) < 1 h].,New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl-beta-cyclodextrin: tolerability and pharmacokinetics after intravenous injection in comparison to a glycofurol-based formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614909/),h,1,210756,DB00564,Carbamazepine
,19229380,clearance,"The typical mean value for carbamazepine clearance, estimated by the base model (without covariates), in our population was 3.43 l/h.",Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229380/),[l] / [h],3.43,211310,DB00564,Carbamazepine
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],21.7,211340,DB00564,Carbamazepine
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],10.1,211341,DB00564,Carbamazepine
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],29.8,211342,DB00564,Carbamazepine
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],62.12,211343,DB00564,Carbamazepine
,29342085,Cmax,"This model was subsequently extended to predict human brain morphine concentrations, and predicted a ROB Cmax of 21.7 ± 6.41 ng/mL when compared to ""better"" (10.1 ng/mL) or ""worse"" (29.8 ng/mL) brain tissue regions with a FC Cmax of 62.12 ± 17.32 ng/mL and a HC Cmax of 182.2 ± 51.2 ng/mL.",Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29342085/),[ng] / [ml],182.2,211344,DB00564,Carbamazepine
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],336,212367,DB00564,Carbamazepine
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],1202,212368,DB00564,Carbamazepine
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],293,212369,DB00564,Carbamazepine
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],117,212370,DB00564,Carbamazepine
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,2.5,212371,DB00564,Carbamazepine
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,1.6,212372,DB00564,Carbamazepine
,16918714,free fraction,"Mean total phenytoin concentration was 11.7 mg/l, free phenytoin 1.25 mg/l and phenytoin free fraction 0.107.","Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918714/),,0.107,212443,DB00564,Carbamazepine
,15730535,oral clearance (CL/F),Mean TPM oral clearance (CL/F) increased from 1.2 L/h (control) to 2.2 L/h after CBZ treatment.,Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),[l] / [h],1.2,212712,DB00564,Carbamazepine
,15730535,oral clearance (CL/F),Mean TPM oral clearance (CL/F) increased from 1.2 L/h (control) to 2.2 L/h after CBZ treatment.,Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),[l] / [h],2.2,212713,DB00564,Carbamazepine
,15730535,half-life,Mean TPM half-life decreased from 29 h to 19 h.,Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),h,29,212714,DB00564,Carbamazepine
,15730535,half-life,Mean TPM half-life decreased from 29 h to 19 h.,Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),h,19,212715,DB00564,Carbamazepine
,15730535,recovery,"Corresponding recovery values for 10-hydroxy-TPM (10-OH-TPM) were 1.2% and 1.8%, respectively.",Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),%,1.2,212716,DB00564,Carbamazepine
,15730535,recovery,"Corresponding recovery values for 10-hydroxy-TPM (10-OH-TPM) were 1.2% and 1.8%, respectively.",Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),%,1.8,212717,DB00564,Carbamazepine
,15730535,AUC,"The control AUC(metabolite)/AUC(drug) ratio for 2,3-diol-TPM and 10-OH-TPM were 1.5% and 0.6%, and they increased by threefold and twofold, respectively, after CBZ treatment.",Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),,0,212718,DB00564,Carbamazepine
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],23.25,213580,DB00564,Carbamazepine
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],16.82,213581,DB00564,Carbamazepine
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],259.3,213582,DB00564,Carbamazepine
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],189.7,213583,DB00564,Carbamazepine
,22281062,ED(50),"HMIPPS (25mg/kg) significantly potentiated the anticonvulsant action of valproate by reducing its ED(50) value from 259.3mg/kg to 210.6 mg/kg (P>0.05), but not that of phenobarbital, phenytoin and carbamazepine in the mouse maximal electroshock-induced seizure model.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],259.3,213584,DB00564,Carbamazepine
,22281062,ED(50),"HMIPPS (25mg/kg) significantly potentiated the anticonvulsant action of valproate by reducing its ED(50) value from 259.3mg/kg to 210.6 mg/kg (P>0.05), but not that of phenobarbital, phenytoin and carbamazepine in the mouse maximal electroshock-induced seizure model.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],210.6,213585,DB00564,Carbamazepine
,15372129,AUC(0-24),"Within-group comparisons, however, revealed a statistically significant increase in hypericin AUC(0-24) from a median of 119 (range 82-163 microg h/l) to 149 microg h/l (61-202 microg h/l) with cimetidine comedication and a decrease in pseudohypericin AUC(0-24) from a median of 51.0 (16.4-102.9 microg h/l) to 36.4 microg h/l (14.0-102.0 microg h/l) with carbamazepine comedication compared to the baseline pharmacokinetics in each group.",Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372129/),[h·μg] / [l],119,214072,DB00564,Carbamazepine
,15372129,AUC(0-24),"Within-group comparisons, however, revealed a statistically significant increase in hypericin AUC(0-24) from a median of 119 (range 82-163 microg h/l) to 149 microg h/l (61-202 microg h/l) with cimetidine comedication and a decrease in pseudohypericin AUC(0-24) from a median of 51.0 (16.4-102.9 microg h/l) to 36.4 microg h/l (14.0-102.0 microg h/l) with carbamazepine comedication compared to the baseline pharmacokinetics in each group.",Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372129/),[h·μg] / [l],149,214073,DB00564,Carbamazepine
,15372129,AUC(0-24),"Within-group comparisons, however, revealed a statistically significant increase in hypericin AUC(0-24) from a median of 119 (range 82-163 microg h/l) to 149 microg h/l (61-202 microg h/l) with cimetidine comedication and a decrease in pseudohypericin AUC(0-24) from a median of 51.0 (16.4-102.9 microg h/l) to 36.4 microg h/l (14.0-102.0 microg h/l) with carbamazepine comedication compared to the baseline pharmacokinetics in each group.",Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372129/),,51.0,214074,DB00564,Carbamazepine
,15372129,AUC(0-24),"Within-group comparisons, however, revealed a statistically significant increase in hypericin AUC(0-24) from a median of 119 (range 82-163 microg h/l) to 149 microg h/l (61-202 microg h/l) with cimetidine comedication and a decrease in pseudohypericin AUC(0-24) from a median of 51.0 (16.4-102.9 microg h/l) to 36.4 microg h/l (14.0-102.0 microg h/l) with carbamazepine comedication compared to the baseline pharmacokinetics in each group.",Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15372129/),[h·μg] / [l],36.4,214075,DB00564,Carbamazepine
,7153873,plasma clearance (CL),"The mean (+/- SD) of plasma clearance (CL), volume of distribution (V), and half-life (t 1/2) during the control period for EPO were 5.57 +/- 2.15 liters/hr, 7.48 +/- 2.50 liters and 0.95 +/- 0.16 hr, respectively.","Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153873/),[l] / [h],5.57,214654,DB00564,Carbamazepine
,7153873,volume of distribution (V),"The mean (+/- SD) of plasma clearance (CL), volume of distribution (V), and half-life (t 1/2) during the control period for EPO were 5.57 +/- 2.15 liters/hr, 7.48 +/- 2.50 liters and 0.95 +/- 0.16 hr, respectively.","Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153873/),l,7.48,214655,DB00564,Carbamazepine
,7153873,half-life (t 1/2),"The mean (+/- SD) of plasma clearance (CL), volume of distribution (V), and half-life (t 1/2) during the control period for EPO were 5.57 +/- 2.15 liters/hr, 7.48 +/- 2.50 liters and 0.95 +/- 0.16 hr, respectively.","Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153873/),h,0.95,214656,DB00564,Carbamazepine
,7153873,CL,"Subchronic administration of PB caused an increase in CL (8.23 +/- 2.03 liters/hr, p less than 0.05), a decrease in t 1/2 (0.67 +/- 0.09, p larger than 0.05 but less than 0.10), and no change in V.","Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153873/),[l] / [h],8.23,214657,DB00564,Carbamazepine
,7153873,t 1/2,"Subchronic administration of PB caused an increase in CL (8.23 +/- 2.03 liters/hr, p less than 0.05), a decrease in t 1/2 (0.67 +/- 0.09, p larger than 0.05 but less than 0.10), and no change in V.","Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153873/),,0.67,214658,DB00564,Carbamazepine
,33737678,trough,"For DRAE occurrence, the cut-off values of the MHD trough and AUC were 12.27 mg/L (specificity 0.570, sensitivity 0.643) and 698.5 mg h/L (specificity, sensitivity 0.571), respectively.",Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33737678/),[mg] / [l],12.27,214735,DB00564,Carbamazepine
,33737678,AUC,"For DRAE occurrence, the cut-off values of the MHD trough and AUC were 12.27 mg/L (specificity 0.570, sensitivity 0.643) and 698.5 mg h/L (specificity, sensitivity 0.571), respectively.",Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33737678/),[h·mg] / [l],698.5,214736,DB00564,Carbamazepine
,30267941,maximum tolerated dose,"Overall, 23/30 (76.7%) patients completed Study 231; 21/30 (70.0%) received perampanel ≥8 mg/day and 10/30 (33.3%) achieved a maximum tolerated dose of 12 mg/day.","Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30267941/),[mg] / [d],12,214934,DB00564,Carbamazepine
,30267941,plasma concentrations,Mean perampanel plasma concentrations were lower with concomitant carbamazepine vs non-inducers (152.7 ng/mL vs 389.4 ng/mL across perampanel groups); small patient numbers for non-inducers (n = 2) should be considered when interpreting these data.,"Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30267941/),[ng] / [ml],152.7,214935,DB00564,Carbamazepine
,30267941,plasma concentrations,Mean perampanel plasma concentrations were lower with concomitant carbamazepine vs non-inducers (152.7 ng/mL vs 389.4 ng/mL across perampanel groups); small patient numbers for non-inducers (n = 2) should be considered when interpreting these data.,"Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30267941/),[ng] / [ml],389.4,214936,DB00564,Carbamazepine
,28230619,apparent volume of distribution,"Based on a one-compartment model with first order absorption and elimination, the apparent volume of distribution was 105 L/70 kg, and the apparent clearance was allometrically related to the body weight as 2.25 L·h·70 kg without carbamazepine or phenytoin.",Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28230619/),[l] / [70·kg],105,214960,DB00564,Carbamazepine
,28230619,apparent clearance,Combination treatment with carbamazepine or phenytoin increased the apparent clearance to 3.51 L·h·70 kg.,Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28230619/),70·h·kg·l,3.51,214961,DB00564,Carbamazepine
,27003707,flow rate,"Chiral analysis in a run time of only 3 min was performed on an ACQUITY UPC(2) ™ Trefoil™ CEL2 column (3.0 × 150 mm, 2.5 μm) at 50 °C by isocratic elution with a mobile phase of supercritical carbon dioxide (purity ≥ 99.99%) and methanol (60:40, v/v) at a flow rate of 2.3 mL/min.",Development and validation of an enantioselective SFC-MS/MS method for simultaneous separation and quantification of oxcarbazepine and its chiral metabolites in beagle dog plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27003707/),[ml] / [min],2.3,215116,DB00564,Carbamazepine
up to,1743171,bioavailability,"Storage of carbamazepine (CBZ) and phenytoin (PHT) formulations in hot, humid conditions alters the dosage form and reduces bioavailability up to 50%.",Pharmacokinetic pitfalls of present antiepileptic medications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743171/),%,50,215613,DB00564,Carbamazepine
,19744012,Dose-normalized concentrations,Dose-normalized concentrations (mean +/- SD) of CBZ were 9.9 +/- 3.4 ng/mL/mg for CYP3A5 expressors and 13.1 +/- 4.5 ng/mL/mg for CYP3A5 non-expressors (P = 0.032).,Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19744012/),[ng] / [mg·ml],9.9,215952,DB00564,Carbamazepine
,19744012,Dose-normalized concentrations,Dose-normalized concentrations (mean +/- SD) of CBZ were 9.9 +/- 3.4 ng/mL/mg for CYP3A5 expressors and 13.1 +/- 4.5 ng/mL/mg for CYP3A5 non-expressors (P = 0.032).,Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19744012/),[ng] / [mg·ml],13.1,215953,DB00564,Carbamazepine
,19744012,oral clearance,"The oral clearance of CBZ was significantly higher in CYP3A5 non-expressors than that of CYP3A5 expressors (0.056 +/-0.017 L/h/kg vs. 0.040 +/- 0.014 L/h/kg, P = 0.004).",Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19744012/),[l] / [h·kg],0.056,215954,DB00564,Carbamazepine
,19744012,oral clearance,"The oral clearance of CBZ was significantly higher in CYP3A5 non-expressors than that of CYP3A5 expressors (0.056 +/-0.017 L/h/kg vs. 0.040 +/- 0.014 L/h/kg, P = 0.004).",Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19744012/),[l] / [h·kg],0.040,215955,DB00564,Carbamazepine
,30169477,apparent clearance (CL/F),"In the final model, apparent clearance (CL/F) of LTG was estimated to be 1.48 L/h; 500 mg valproic acid, oxcarbazepine, and UGT2B7-161TT genotype changed the CL/F by -46.2, +31.1, and -21.8%, respectively.",A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169477/),[l] / [h],1.48,216020,DB00564,Carbamazepine
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],16.7,216921,DB00564,Carbamazepine
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],8.9,216922,DB00564,Carbamazepine
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],9.9,216923,DB00564,Carbamazepine
,10463320,Plasma concentrations,Plasma concentrations of reduced bromperidol during itraconazole coadministration (3.6+/-2.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (1.8+/-1.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],3.6,216924,DB00564,Carbamazepine
,10463320,Plasma concentrations,Plasma concentrations of reduced bromperidol during itraconazole coadministration (3.6+/-2.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (1.8+/-1.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],1.8,216925,DB00564,Carbamazepine
,12217004,extraction ratio,"The extraction ratio was linearly related to time, and ranged 0.46-0.02.",Efficacy of charcoal hemoperfusion in massive carbamazepine poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12217004/),,0.46-0.02,218225,DB00564,Carbamazepine
,12217004,peak clearance,The peak clearance was 69 mL/min.,Efficacy of charcoal hemoperfusion in massive carbamazepine poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12217004/),[ml] / [min],69,218226,DB00564,Carbamazepine
,12217004,extraction ratio,"In our patient, this was equivalent to an extraction ratio of 0.2 at a flow rate of 150 mL/min.",Efficacy of charcoal hemoperfusion in massive carbamazepine poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12217004/),,0.2,218227,DB00564,Carbamazepine
,12217004,flow rate,"In our patient, this was equivalent to an extraction ratio of 0.2 at a flow rate of 150 mL/min.",Efficacy of charcoal hemoperfusion in massive carbamazepine poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12217004/),[ml] / [min],150,218228,DB00564,Carbamazepine
,27614256,flow rate,"Separation was achieved on a Waters ACQUITY UHPLC(®) HSS C18 column (2.1mm×50mm, 1.8μm) column with a gradient mobile phase consisting of acetonitrile-water (containing 0.1% formic acid) as mobile phase at a flow rate of 0.2mL/min.",Development and validation of a sensitive UHPLC-MS/MS method for quantitation of prucalopride in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27614256/),[ml] / [min],0.2,218257,DB00564,Carbamazepine
,27614256,m/z,"The monitored transitions were set at m/z 367.99→195.89 and m/z 236.97→194.04 for prucalopride and IS, respectively.",Development and validation of a sensitive UHPLC-MS/MS method for quantitation of prucalopride in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27614256/),,367.99,218258,DB00564,Carbamazepine
,27614256,m/z,"The monitored transitions were set at m/z 367.99→195.89 and m/z 236.97→194.04 for prucalopride and IS, respectively.",Development and validation of a sensitive UHPLC-MS/MS method for quantitation of prucalopride in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27614256/),,195.89,218259,DB00564,Carbamazepine
,27614256,m/z,"The monitored transitions were set at m/z 367.99→195.89 and m/z 236.97→194.04 for prucalopride and IS, respectively.",Development and validation of a sensitive UHPLC-MS/MS method for quantitation of prucalopride in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27614256/),,236.97,218260,DB00564,Carbamazepine
,27614256,m/z,"The monitored transitions were set at m/z 367.99→195.89 and m/z 236.97→194.04 for prucalopride and IS, respectively.",Development and validation of a sensitive UHPLC-MS/MS method for quantitation of prucalopride in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27614256/),,194.04,218261,DB00564,Carbamazepine
,27614256,Extraction recoveries,Extraction recoveries at three levels QC concentrations were in the range of 90.0-110.0% for prucalopride and 99.6% for IS.,Development and validation of a sensitive UHPLC-MS/MS method for quantitation of prucalopride in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27614256/),%,90.0-110.0,218262,DB00564,Carbamazepine
,27614256,Extraction recoveries,Extraction recoveries at three levels QC concentrations were in the range of 90.0-110.0% for prucalopride and 99.6% for IS.,Development and validation of a sensitive UHPLC-MS/MS method for quantitation of prucalopride in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27614256/),%,99.6,218263,DB00564,Carbamazepine
,29403761,flow rate,"The reconstituted samples were chromatographed on a Hypurity advance C18 column (50 mm×4.6 mm, 5 μm) using a mixture of acetonitrile-5 mM ammonium acetate buffer (pH-4.0) (50:50, v/v) as the mobile phase at a flow rate of 0.8 mL/min.",Simultaneous determination of telmisartan and amlodipine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403761/),[ml] / [min],0.8,219051,DB00564,Carbamazepine
,29403761,run time,A run time of 2.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Simultaneous determination of telmisartan and amlodipine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403761/),min,2.5,219052,DB00564,Carbamazepine
,6848300,Urinary recovery,"Urinary recovery of trans-CBZ-diol was 90 +/- 11% (mean +/- SD) of the dose, indicating almost complete absorption.","Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848300/),%,90,219863,DB00564,Carbamazepine
,6848300,elimination half-lifes (t 1/2s),Plasma kinetics of the epoxide fitted an open one-compartment model with elimination half-lifes (t 1/2s) of 6.1 +/- 0.9 hr.,"Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848300/),h,6.1,219864,DB00564,Carbamazepine
,6848300,Clearance,Clearance was 89 +/- 25 ml x kg-1 x hr-1.,"Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848300/),[ml] / [h·kg],89,219865,DB00564,Carbamazepine
,6848300,urinary excretion t 1/2,"The urinary excretion t 1/2 of the trans-CBZ-diol was 12.4 +/- 0.9 hr, which is longer (P less than 0.001) than the epoxide plasma t 1/2.","Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848300/),h,12.4,219866,DB00564,Carbamazepine
,6848300,t 1/2,"After 200 mg CBZ to the same subjects, plasma CBZ t 1/2 was 26.0 +/- 4.6 hr and clearance was 23.4 +/- 4.6 ml x kg -1 x hr -1.","Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848300/),h,26.0,219867,DB00564,Carbamazepine
,6848300,clearance,"After 200 mg CBZ to the same subjects, plasma CBZ t 1/2 was 26.0 +/- 4.6 hr and clearance was 23.4 +/- 4.6 ml x kg -1 x hr -1.","Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848300/),-1·-1·h·kg·ml,23.4,219868,DB00564,Carbamazepine
,25703948,total run time,The total run time was 2.0 min and the elution of acacetin was at 0.83 min.,Determination of acacetin in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25703948/),min,2.0,220061,DB00564,Carbamazepine
,25703948,elution,The total run time was 2.0 min and the elution of acacetin was at 0.83 min.,Determination of acacetin in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25703948/),min,0.83,220062,DB00564,Carbamazepine
,25703948,recovery,Mean recovery of acacetin in plasma was in the range of 78.4-85.2%.,Determination of acacetin in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25703948/),%,78.4-85.2,220063,DB00564,Carbamazepine
,7698101,half-life,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),h,7.2,220124,DB00564,Carbamazepine
,7698101,half-life,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),h,6.1,220125,DB00564,Carbamazepine
,7698101,apparent oral clearance,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),[ml] / [h·kg],110.8,220126,DB00564,Carbamazepine
,7698101,apparent oral clearance,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),[ml] / [h·kg],120.5,220127,DB00564,Carbamazepine
,7698101,apparent volume of distribution,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),[l] / [kg],1.08,220128,DB00564,Carbamazepine
,7698101,apparent volume of distribution,CBZ-E pharmacokinetic parameters in LTG-treated patients were found to be similar to those observed in controls (half-life: 7.2 +/- 1.6 vs 6.1 +/- 0.9 h; apparent oral clearance: 110.8 +/- 53.1 vs 120.5 +/- 29.9 ml/h/kg; apparent volume of distribution: 1.08 +/- 0.37 vs 1.04 +/- 0.25 l/kg respectively; means +/- s.d.).,"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7698101/),[l] / [kg],1.04,220129,DB00564,Carbamazepine
,2053116,plasma clearance,"Patients had a significantly higher plasma clearance of CBZ-E than the control group (mean values +/- SD = 220.2 +/- 63.5 versus 112.5 +/- 46.0 ml/h/kg, p less than 0.007) and a significantly shorter plasma half-life (mean values +/- SD = 4.3 +/- 1.0 versus 6.7 +/- 0.8 h, p less than 0.0015).","Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053116/),[ml] / [h·kg],220.2,220515,DB00564,Carbamazepine
,2053116,plasma clearance,"Patients had a significantly higher plasma clearance of CBZ-E than the control group (mean values +/- SD = 220.2 +/- 63.5 versus 112.5 +/- 46.0 ml/h/kg, p less than 0.007) and a significantly shorter plasma half-life (mean values +/- SD = 4.3 +/- 1.0 versus 6.7 +/- 0.8 h, p less than 0.0015).","Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053116/),[ml] / [h·kg],112.5,220516,DB00564,Carbamazepine
,2053116,plasma half-life,"Patients had a significantly higher plasma clearance of CBZ-E than the control group (mean values +/- SD = 220.2 +/- 63.5 versus 112.5 +/- 46.0 ml/h/kg, p less than 0.007) and a significantly shorter plasma half-life (mean values +/- SD = 4.3 +/- 1.0 versus 6.7 +/- 0.8 h, p less than 0.0015).","Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053116/),h,4.3,220517,DB00564,Carbamazepine
,2053116,plasma half-life,"Patients had a significantly higher plasma clearance of CBZ-E than the control group (mean values +/- SD = 220.2 +/- 63.5 versus 112.5 +/- 46.0 ml/h/kg, p less than 0.007) and a significantly shorter plasma half-life (mean values +/- SD = 4.3 +/- 1.0 versus 6.7 +/- 0.8 h, p less than 0.0015).","Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053116/),h,6.7,220518,DB00564,Carbamazepine
,27165568,total run time,"The total run time was 3.0 min, and the elution of apremilast was at 1.27 min.",Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27165568/),min,3.0,220752,DB00564,Carbamazepine
,27165568,elution,"The total run time was 3.0 min, and the elution of apremilast was at 1.27 min.",Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27165568/),min,1.27,220753,DB00564,Carbamazepine
,27165568,recovery,The mean recovery of apremilast in plasma was in the range of 83.2-87.5%.,Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27165568/),%,83.2-87.5,220754,DB00564,Carbamazepine
>,22102520,recoveries,"The recoveries of both I and II were always >60% with quantification limits (signal-to-noise ratio = 10) of 1.5 and 4.5 ng/mL for I and II, respectively.",Simultaneous quantification of centchroman and its 7-demethylated metabolite in rat dried blood spot samples using LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102520/),%,60,221206,DB00564,Carbamazepine
,22102520,recoveries,"The recoveries of both I and II were always >60% with quantification limits (signal-to-noise ratio = 10) of 1.5 and 4.5 ng/mL for I and II, respectively.",Simultaneous quantification of centchroman and its 7-demethylated metabolite in rat dried blood spot samples using LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102520/),[ng] / [ml],1.5,221207,DB00564,Carbamazepine
,22102520,signal-to-noise ratio,"The recoveries of both I and II were always >60% with quantification limits (signal-to-noise ratio = 10) of 1.5 and 4.5 ng/mL for I and II, respectively.",Simultaneous quantification of centchroman and its 7-demethylated metabolite in rat dried blood spot samples using LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102520/),[ng] / [ml],10,221208,DB00564,Carbamazepine
,22102520,signal-to-noise ratio,"The recoveries of both I and II were always >60% with quantification limits (signal-to-noise ratio = 10) of 1.5 and 4.5 ng/mL for I and II, respectively.",Simultaneous quantification of centchroman and its 7-demethylated metabolite in rat dried blood spot samples using LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102520/),[ng] / [ml],1.5,221209,DB00564,Carbamazepine
,22102520,signal-to-noise ratio,"The recoveries of both I and II were always >60% with quantification limits (signal-to-noise ratio = 10) of 1.5 and 4.5 ng/mL for I and II, respectively.",Simultaneous quantification of centchroman and its 7-demethylated metabolite in rat dried blood spot samples using LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102520/),[ng] / [ml],4.5,221210,DB00564,Carbamazepine
,3358884,bioavailability,"The bioavailability was reduced by colestipol 80%, by cholestyramine 95% and by activated charcoal 99.5%. 6. The interference with the gastrointestinal absorption of most of the basic drugs by colestipol and cholestyramine seems to be minimal.","Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358884/),%,80,223597,DB00564,Carbamazepine
,3358884,bioavailability,"The bioavailability was reduced by colestipol 80%, by cholestyramine 95% and by activated charcoal 99.5%. 6. The interference with the gastrointestinal absorption of most of the basic drugs by colestipol and cholestyramine seems to be minimal.","Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358884/),%,95,223598,DB00564,Carbamazepine
,3358884,bioavailability,"The bioavailability was reduced by colestipol 80%, by cholestyramine 95% and by activated charcoal 99.5%. 6. The interference with the gastrointestinal absorption of most of the basic drugs by colestipol and cholestyramine seems to be minimal.","Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358884/),%,99.5,223599,DB00564,Carbamazepine
,32047806,flow rate,"A mixture of acetonitrile-0.2% trifluoroacetic acid-water (48 : 10 : 42, V/V/V) was used as the mobile phase with a flow rate of 1.0 mL/min.",The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32047806/),[ml] / [min],1.0,224914,DB00564,Carbamazepine
,32047806,C max,"The C max of tadalafil in the control group and the experimental group was (725.89 ± 161.59) ng/mL and (1271.60 ± 179.31) ng/mL, t 1/2 was (9.28 ± 2.07) h and (11.70 ± 1.47) h, AUC (0-t) was (7399.61 ± 696.85) ng·h/mL and (9586.52 ± 2048.81) ng·h/mL, and AUC(0-∞) was (7995.50 ± 707.23) ng·h/mL and (10639.43 ± 2235.94) ng·h/mL, respectively.",The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32047806/),[ng] / [ml],725.89,224915,DB00564,Carbamazepine
,32047806,C max,"The C max of tadalafil in the control group and the experimental group was (725.89 ± 161.59) ng/mL and (1271.60 ± 179.31) ng/mL, t 1/2 was (9.28 ± 2.07) h and (11.70 ± 1.47) h, AUC (0-t) was (7399.61 ± 696.85) ng·h/mL and (9586.52 ± 2048.81) ng·h/mL, and AUC(0-∞) was (7995.50 ± 707.23) ng·h/mL and (10639.43 ± 2235.94) ng·h/mL, respectively.",The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32047806/),[ng] / [ml],1271.60,224916,DB00564,Carbamazepine
,32047806,t 1/2,"The C max of tadalafil in the control group and the experimental group was (725.89 ± 161.59) ng/mL and (1271.60 ± 179.31) ng/mL, t 1/2 was (9.28 ± 2.07) h and (11.70 ± 1.47) h, AUC (0-t) was (7399.61 ± 696.85) ng·h/mL and (9586.52 ± 2048.81) ng·h/mL, and AUC(0-∞) was (7995.50 ± 707.23) ng·h/mL and (10639.43 ± 2235.94) ng·h/mL, respectively.",The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32047806/),h,9.28,224917,DB00564,Carbamazepine
,32047806,t 1/2,"The C max of tadalafil in the control group and the experimental group was (725.89 ± 161.59) ng/mL and (1271.60 ± 179.31) ng/mL, t 1/2 was (9.28 ± 2.07) h and (11.70 ± 1.47) h, AUC (0-t) was (7399.61 ± 696.85) ng·h/mL and (9586.52 ± 2048.81) ng·h/mL, and AUC(0-∞) was (7995.50 ± 707.23) ng·h/mL and (10639.43 ± 2235.94) ng·h/mL, respectively.",The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32047806/),h,11.70,224918,DB00564,Carbamazepine
,32047806,AUC (0-t),"The C max of tadalafil in the control group and the experimental group was (725.89 ± 161.59) ng/mL and (1271.60 ± 179.31) ng/mL, t 1/2 was (9.28 ± 2.07) h and (11.70 ± 1.47) h, AUC (0-t) was (7399.61 ± 696.85) ng·h/mL and (9586.52 ± 2048.81) ng·h/mL, and AUC(0-∞) was (7995.50 ± 707.23) ng·h/mL and (10639.43 ± 2235.94) ng·h/mL, respectively.",The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32047806/),[h·ng] / [ml],7399.61,224919,DB00564,Carbamazepine
,32047806,AUC (0-t),"The C max of tadalafil in the control group and the experimental group was (725.89 ± 161.59) ng/mL and (1271.60 ± 179.31) ng/mL, t 1/2 was (9.28 ± 2.07) h and (11.70 ± 1.47) h, AUC (0-t) was (7399.61 ± 696.85) ng·h/mL and (9586.52 ± 2048.81) ng·h/mL, and AUC(0-∞) was (7995.50 ± 707.23) ng·h/mL and (10639.43 ± 2235.94) ng·h/mL, respectively.",The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32047806/),[h·ng] / [ml],9586.52,224920,DB00564,Carbamazepine
,32047806,AUC(0-∞),"The C max of tadalafil in the control group and the experimental group was (725.89 ± 161.59) ng/mL and (1271.60 ± 179.31) ng/mL, t 1/2 was (9.28 ± 2.07) h and (11.70 ± 1.47) h, AUC (0-t) was (7399.61 ± 696.85) ng·h/mL and (9586.52 ± 2048.81) ng·h/mL, and AUC(0-∞) was (7995.50 ± 707.23) ng·h/mL and (10639.43 ± 2235.94) ng·h/mL, respectively.",The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32047806/),[h·ng] / [ml],7995.50,224921,DB00564,Carbamazepine
,32047806,AUC(0-∞),"The C max of tadalafil in the control group and the experimental group was (725.89 ± 161.59) ng/mL and (1271.60 ± 179.31) ng/mL, t 1/2 was (9.28 ± 2.07) h and (11.70 ± 1.47) h, AUC (0-t) was (7399.61 ± 696.85) ng·h/mL and (9586.52 ± 2048.81) ng·h/mL, and AUC(0-∞) was (7995.50 ± 707.23) ng·h/mL and (10639.43 ± 2235.94) ng·h/mL, respectively.",The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32047806/),[h·ng] / [ml],10639.43,224922,DB00564,Carbamazepine
,34255318,total clearance,The population mean value of lamotrigine total clearance generated in the final model (with covariates) was 2.12 L/hr.,Population Pharmacokinetics Modeling of Lamotrigine in Jordanian Epileptic Patients Using Dried Blood Spot Sampling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34255318/),[l] / [h],2.12,226356,DB00564,Carbamazepine
,3992621,apparent mean half-life,CBZ in these studies disappeared from saliva with an apparent mean half-life of 21.0 +/- 4.8 min.,Fallacious results from measuring salivary carbamazepine concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3992621/),min,21.0,226983,DB00564,Carbamazepine
,15915352,area under the plasma concentration-time curve (AUC),Probenecid decreased the area under the plasma concentration-time curve (AUC) of CBZ from 1253.9 micromol h/l to 1020.7 micromol h/l (P < 0.001) while increasing that of CBZ-E from 137.6 micromol h/l to 183.5 micromol h/l (P = 0.033).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),[h·μM] / [l],1253.9,227490,DB00564,Carbamazepine
,15915352,area under the plasma concentration-time curve (AUC),Probenecid decreased the area under the plasma concentration-time curve (AUC) of CBZ from 1253.9 micromol h/l to 1020.7 micromol h/l (P < 0.001) while increasing that of CBZ-E from 137.6 micromol h/l to 183.5 micromol h/l (P = 0.033).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),[h·μM] / [l],1020.7,227491,DB00564,Carbamazepine
,15915352,area under the plasma concentration-time curve (AUC),Probenecid decreased the area under the plasma concentration-time curve (AUC) of CBZ from 1253.9 micromol h/l to 1020.7 micromol h/l (P < 0.001) while increasing that of CBZ-E from 137.6 micromol h/l to 183.5 micromol h/l (P = 0.033).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),[h·μM] / [l],137.6,227492,DB00564,Carbamazepine
,15915352,area under the plasma concentration-time curve (AUC),Probenecid decreased the area under the plasma concentration-time curve (AUC) of CBZ from 1253.9 micromol h/l to 1020.7 micromol h/l (P < 0.001) while increasing that of CBZ-E from 137.6 micromol h/l to 183.5 micromol h/l (P = 0.033).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),[h·μM] / [l],183.5,227493,DB00564,Carbamazepine
,15915352,AUC ratio,Probenecid increased the AUC ratio of CBZ-E/CBZ from 0.11 to 0.16 (P < 0.001).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),,0.11,227494,DB00564,Carbamazepine
,15915352,AUC ratio,Probenecid increased the AUC ratio of CBZ-E/CBZ from 0.11 to 0.16 (P < 0.001).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),,0.16,227495,DB00564,Carbamazepine
,14650359,bioavailability,Following oral administration the bioavailability of tramadol is high (70-90%) and with new slow release preparations twice daily administration enables effective pain control.,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),%,70-90,227851,DB00564,Carbamazepine
,14650359,plasma protein binding,Tramadol is characterised by low plasma protein binding (20%) and quite extensive tissue distribution (apparent volume of distribution about 3 l/kg).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),%,20,227852,DB00564,Carbamazepine
,14650359,apparent volume of distribution,Tramadol is characterised by low plasma protein binding (20%) and quite extensive tissue distribution (apparent volume of distribution about 3 l/kg).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),[l] / [kg],3,227853,DB00564,Carbamazepine
,14650359,Elimination half-lives,Elimination half-lives of the active agents range between 4.5 and 9.5 h and total plasma clearance of tramadol is moderately high (600 ml/min).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),h,4.5 and 9.5,227854,DB00564,Carbamazepine
,14650359,total plasma clearance,Elimination half-lives of the active agents range between 4.5 and 9.5 h and total plasma clearance of tramadol is moderately high (600 ml/min).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),[ml] / [min],600,227855,DB00564,Carbamazepine
,24264996,m,Mass transition of precursor ion → product ion pairs were monitored at m/z 823.4 → 313.1 for epimedin C and m/z 237.1 → 178.9 for carbamazepine (internal standard).,Pharmacokinetics and oral bioavailability of epimedin C after oral administration of epimedin C and Herba Epimedii extract in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24264996/),,823.4,227890,DB00564,Carbamazepine
,24264996,m/,Mass transition of precursor ion → product ion pairs were monitored at m/z 823.4 → 313.1 for epimedin C and m/z 237.1 → 178.9 for carbamazepine (internal standard).,Pharmacokinetics and oral bioavailability of epimedin C after oral administration of epimedin C and Herba Epimedii extract in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24264996/),,237.1,227891,DB00564,Carbamazepine
,24264996,m/,Mass transition of precursor ion → product ion pairs were monitored at m/z 823.4 → 313.1 for epimedin C and m/z 237.1 → 178.9 for carbamazepine (internal standard).,Pharmacokinetics and oral bioavailability of epimedin C after oral administration of epimedin C and Herba Epimedii extract in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24264996/),,178.9,227892,DB00564,Carbamazepine
,24264996,Oral bioavailabilities,"Oral bioavailabilities of epimedin C in the pure compound and in the Herba Epimedii were around 0.58% and 0.13%, respectively.",Pharmacokinetics and oral bioavailability of epimedin C after oral administration of epimedin C and Herba Epimedii extract in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24264996/),%,0.58,227893,DB00564,Carbamazepine
,24264996,Oral bioavailabilities,"Oral bioavailabilities of epimedin C in the pure compound and in the Herba Epimedii were around 0.58% and 0.13%, respectively.",Pharmacokinetics and oral bioavailability of epimedin C after oral administration of epimedin C and Herba Epimedii extract in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24264996/),%,0.13,227894,DB00564,Carbamazepine
,19370549,AUCs,"The AUCs of DIG with BBR (30 mg/kg, 100 mg/kg) were 133%, 170% (single) and 123%, 169% (2-week) of control, respectively.",Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19370549/),%,133,227895,DB00564,Carbamazepine
,19370549,AUCs,"The AUCs of DIG with BBR (30 mg/kg, 100 mg/kg) were 133%, 170% (single) and 123%, 169% (2-week) of control, respectively.",Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19370549/),%,170,227896,DB00564,Carbamazepine
,19370549,AUCs,"The AUCs of DIG with BBR (30 mg/kg, 100 mg/kg) were 133%, 170% (single) and 123%, 169% (2-week) of control, respectively.",Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19370549/),%,123,227897,DB00564,Carbamazepine
,19370549,AUCs,"The AUCs of DIG with BBR (30 mg/kg, 100 mg/kg) were 133%, 170% (single) and 123%, 169% (2-week) of control, respectively.",Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19370549/),%,169,227898,DB00564,Carbamazepine
,10390769,serum concentrations,"Mean serum concentrations of patients receiving CBZ were 8.2, 7.3 and 6.4 micrograms/ml for the 2, 4 and 6 hours samples, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],8.2,228745,DB00564,Carbamazepine
,10390769,serum concentrations,"Mean serum concentrations of patients receiving CBZ were 8.2, 7.3 and 6.4 micrograms/ml for the 2, 4 and 6 hours samples, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],7.3,228746,DB00564,Carbamazepine
,10390769,serum concentrations,"Mean serum concentrations of patients receiving CBZ were 8.2, 7.3 and 6.4 micrograms/ml for the 2, 4 and 6 hours samples, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],6.4,228747,DB00564,Carbamazepine
,10390769,serum concentrations,"Mean serum concentrations of CBZ in the group receiving CBZ + VAP were 7.8, 8.4 and 7.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],7.8,228748,DB00564,Carbamazepine
,10390769,serum concentrations,"Mean serum concentrations of CBZ in the group receiving CBZ + VAP were 7.8, 8.4 and 7.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],8.4,228749,DB00564,Carbamazepine
,10390769,serum concentrations,"Patients receiving VPA had mean serum concentrations of 92.8, 97.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],92.8,228750,DB00564,Carbamazepine
,10390769,serum concentrations,"Patients receiving VPA had mean serum concentrations of 92.8, 97.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],97.8,228751,DB00564,Carbamazepine
,10390769,serum concentrations,"Those receiving CBZ + VPA had serum concentrations of 69.1, 70.6 and 55.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),,69.1,228752,DB00564,Carbamazepine
,10390769,serum concentrations,"Those receiving CBZ + VPA had serum concentrations of 69.1, 70.6 and 55.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),,70.6,228753,DB00564,Carbamazepine
,10390769,serum concentrations,"Those receiving CBZ + VPA had serum concentrations of 69.1, 70.6 and 55.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),,55.8,228754,DB00564,Carbamazepine
,21366652,peak plasma concentrations (C(max)),"In the two periods of treatments, the mean peak plasma concentrations (C(max)) were 16·25 ng/mL (ivabradine alone) and 3·69 ng/mL (ivabradine after pretreatment with carbamazepine).",Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366652/),[ng] / [ml],16·25,228820,DB00564,Carbamazepine
,21366652,peak plasma concentrations (C(max)),"In the two periods of treatments, the mean peak plasma concentrations (C(max)) were 16·25 ng/mL (ivabradine alone) and 3·69 ng/mL (ivabradine after pretreatment with carbamazepine).",Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366652/),[ng] / [ml],3·69,228821,DB00564,Carbamazepine
,21366652,"time taken to reach C(max), t(max)","The time taken to reach C(max), t(max), were 0·97 and 1·14 h, respectively, and the total areas under the curve (AUC(0-∞)) were 52·49 and 10·33 ng h/mL, respectively.",Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366652/),h,0·97,228822,DB00564,Carbamazepine
,21366652,"time taken to reach C(max), t(max)","The time taken to reach C(max), t(max), were 0·97 and 1·14 h, respectively, and the total areas under the curve (AUC(0-∞)) were 52·49 and 10·33 ng h/mL, respectively.",Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366652/),h,1·14,228823,DB00564,Carbamazepine
,21366652,total areas under the curve (AUC(0-∞)),"The time taken to reach C(max), t(max), were 0·97 and 1·14 h, respectively, and the total areas under the curve (AUC(0-∞)) were 52·49 and 10·33 ng h/mL, respectively.",Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366652/),[h·ng] / [ml],52·49,228824,DB00564,Carbamazepine
,21366652,total areas under the curve (AUC(0-∞)),"The time taken to reach C(max), t(max), were 0·97 and 1·14 h, respectively, and the total areas under the curve (AUC(0-∞)) were 52·49 and 10·33 ng h/mL, respectively.",Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366652/),[h·ng] / [ml],10·33,228825,DB00564,Carbamazepine
,22312695,flow rate,"After addition of carbamazepine as internal standard (IS) and precipitation of protein with acetonitrile, the plasma samples were analyzed on an Agilent Zorbax SB-C18 (2.1 mm x 50 mm, 3.5 microm) column at 30 degrees C, with acetonitrile-0.1% formic acid as mobile phase at a flow rate of 0.4 mL min(-1).",Determination of bupropion and its main metabolite in rat plasma by LC-MS and its application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22312695/),[ml] / [min],0.4,229028,DB00564,Carbamazepine
,24887335,Ka,"The final PPK model of MHD was: Ka = 0.645 h⁻¹, V(L) = (11.3 + (age - 90.5) x 0.0282 + (TBW - 25.0) x 0.402) x e(0.0689), CL (L/h) = (0.557 + (DDPW - 20.8) x 0.00367 + (gender) x (-0.0636)) x e(0.120).",Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24887335/),h⁻¹,0.645,229938,DB00564,Carbamazepine
,2111769,terminal half-life (t1/2,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),h,6.3,230256,DB00564,Carbamazepine
,2111769,terminal half-life (t1/2,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),h,9.0,230257,DB00564,Carbamazepine
,2111769,clearance,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),[ml] / [h·kg],90.6,230258,DB00564,Carbamazepine
,2111769,clearance,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),[ml] / [h·kg],63.2,230259,DB00564,Carbamazepine
,2111769,apparent volume of distribution,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),[l] / [kg],0.82,230260,DB00564,Carbamazepine
,2111769,apparent volume of distribution,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),[l] / [kg],0.81,230261,DB00564,Carbamazepine
not exceed,3227056,peak levels,"In order to avoid adverse effects, peak levels should not exceed 12 (or even 10) mg/l.",Measuring plasma levels of carbamazepine. A pharmacokinetic study in patients with affective disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3227056/),[mg] / [l],12,230340,DB00564,Carbamazepine
,3227056,peak levels,"In order to avoid adverse effects, peak levels should not exceed 12 (or even 10) mg/l.",Measuring plasma levels of carbamazepine. A pharmacokinetic study in patients with affective disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3227056/),[mg] / [l],10,230341,DB00564,Carbamazepine
,21680153,apparent half-life,"The major compound in plasma was the active metabolite eslicarbazepine, which reached maximum concentrations (C(max)) 2h post-dose; thereafter, its plasma concentrations declined with a mean apparent half-life of 13, 14, and 20h in patients receiving ESL doses of 400, 800, and 1200mg once daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),h,13,230405,DB00564,Carbamazepine
,21680153,apparent half-life,"The major compound in plasma was the active metabolite eslicarbazepine, which reached maximum concentrations (C(max)) 2h post-dose; thereafter, its plasma concentrations declined with a mean apparent half-life of 13, 14, and 20h in patients receiving ESL doses of 400, 800, and 1200mg once daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),h,14,230406,DB00564,Carbamazepine
,21680153,apparent half-life,"The major compound in plasma was the active metabolite eslicarbazepine, which reached maximum concentrations (C(max)) 2h post-dose; thereafter, its plasma concentrations declined with a mean apparent half-life of 13, 14, and 20h in patients receiving ESL doses of 400, 800, and 1200mg once daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),h,20,230407,DB00564,Carbamazepine
,21680153,C(max),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μg] / [ml],9.7,230408,DB00564,Carbamazepine
,21680153,C(max),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μg] / [ml],15.5,230409,DB00564,Carbamazepine
,21680153,C(max),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μg] / [ml],23.0,230410,DB00564,Carbamazepine
,21680153,areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μgh] / [ml],132.5,230411,DB00564,Carbamazepine
,21680153,areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μgh] / [ml],205.4,230412,DB00564,Carbamazepine
,21680153,areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μgh] / [ml],336.1,230413,DB00564,Carbamazepine
,16599405,flow rate,"An aliquot of the supernatant (20 microL) is directly injected into an HPLC apparatus with methanol-phosphate buffer (0.01M, pH 3.0) (62:38, v/v) as the mobile phase at a flow rate of 1.0 mL/min.",Simple high-performance liquid chromatographic method for the determination of tetramethylpyrazine phosphate in very small volumes of dog plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599405/),[ml] / [min],1.0,230521,DB00564,Carbamazepine
,16599405,capacity factors,"The capacity factors are 1.48 for tetramethylpyrazine phosphate and 2.09 for carbamazepine, with a total run time of 10 min.",Simple high-performance liquid chromatographic method for the determination of tetramethylpyrazine phosphate in very small volumes of dog plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599405/),,1.48,230522,DB00564,Carbamazepine
,16599405,capacity factors,"The capacity factors are 1.48 for tetramethylpyrazine phosphate and 2.09 for carbamazepine, with a total run time of 10 min.",Simple high-performance liquid chromatographic method for the determination of tetramethylpyrazine phosphate in very small volumes of dog plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599405/),,2.09,230523,DB00564,Carbamazepine
,16599405,total run time,"The capacity factors are 1.48 for tetramethylpyrazine phosphate and 2.09 for carbamazepine, with a total run time of 10 min.",Simple high-performance liquid chromatographic method for the determination of tetramethylpyrazine phosphate in very small volumes of dog plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599405/),min,10,230524,DB00564,Carbamazepine
,16599405,limit of detection,The limit of detection is 0.05 microg/mL. Mean recoveries are 92.6-98.1%.,Simple high-performance liquid chromatographic method for the determination of tetramethylpyrazine phosphate in very small volumes of dog plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599405/),[μg] / [ml],0.05,230525,DB00564,Carbamazepine
,16599405,recoveries,The limit of detection is 0.05 microg/mL. Mean recoveries are 92.6-98.1%.,Simple high-performance liquid chromatographic method for the determination of tetramethylpyrazine phosphate in very small volumes of dog plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599405/),%,92.6-98.1,230526,DB00564,Carbamazepine
,26349052,AUC0-24,"As a result, the Cmax of imperialine was one-fold reduced and Tmax was two-fold prolonged, and the mean AUC0-24 was expressed as 89.581±21.243μgh/L, which showed that the oral bioavailability of imperialine was 2.46-fold improved.",A (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer)-dispersed sustained-release tablet for imperialine to simultaneously prolong the drug release and improve the oral bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349052/),[μgh] / [l],89.581,230700,DB00564,Carbamazepine
,26349052,diffusional coefficient,"By mathematically modeling and moment imaging of the drug release, Peppas equation was selected as the most fitted model for the sustained-release tablets with the diffusional coefficient in the range of 0.59-0.62, indicating the release of imperialine from the sustained-release tablets was an anomalous process involving polymer swelling, drug diffusion and matrix erosion.",A (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer)-dispersed sustained-release tablet for imperialine to simultaneously prolong the drug release and improve the oral bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349052/),,0.59-0.62,230701,DB00564,Carbamazepine
,1233232,plasma half-lives,The plasma half-lives of the drug were shorter in all patients after multiple doses (20.9 +/- 5.0 hours) than after the initial single dose (35.6 +/- 15.3 hours).,Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233232/),h,20.9,231217,DB00564,Carbamazepine
,1233232,plasma half-lives,The plasma half-lives of the drug were shorter in all patients after multiple doses (20.9 +/- 5.0 hours) than after the initial single dose (35.6 +/- 15.3 hours).,Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233232/),h,35.6,231218,DB00564,Carbamazepine
,1233232,maximal concentrations,"The calculated levels were higher (17.2+/-7.2 mug/ml) than the observed maximal concentrations (8.4+/-1.6 mug/ml on day 4), which were obtained 3-4 days after starting the multiple doses.",Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233232/),[μg] / [ml],8.4,231219,DB00564,Carbamazepine
,10613614,systemic clearance,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[ml] / [min],925,231628,DB00564,Carbamazepine
,10613614,systemic clearance,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[ml] / [min],569,231629,DB00564,Carbamazepine
,10613614,elimination half-life,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),h,12.7,231630,DB00564,Carbamazepine
,10613614,elimination half-life,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),h,19.4,231631,DB00564,Carbamazepine
,10613614,total area under the plasma concentration-time curve,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[h·ng] / [ml],37.3,231632,DB00564,Carbamazepine
,10613614,total area under the plasma concentration-time curve,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[h·ng] / [ml],65.1,231633,DB00564,Carbamazepine
up to,7936231,half-life,"Because of FNR's long half-life (up to 7 weeks), a parallel rather than crossover design was used.",Flunarizine for treatment of partial seizures: results of a concentration-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7936231/),weeks,7,232227,DB00564,Carbamazepine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],168.84,232536,DB00564,Carbamazepine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],98.12,232537,DB00564,Carbamazepine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],293.89,232538,DB00564,Carbamazepine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],221.85,232539,DB00564,Carbamazepine
,32737897,relative bioavailability,"Lower carbamazepine concentrations under KD were modelled as decreased relative bioavailability (44%), potentially related to decreased fraction absorbed (unexpected for this lipophilic drug), increased intestinal/hepatic metabolism and/or decreased protein-binding with KD.","Drug-drug and drug-food interactions in an infant with early-onset SCN2A epilepsy treated with carbamazepine, phenytoin and a ketogenic diet. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737897/),%,44,232721,DB00564,Carbamazepine
,1002351,plasma half-life,"The serum concentration, taken 2-hourly from 1600-0400 and at 0700 hr, showed the plasma half-life to be on the order of 10 hr, about one-third of that in normal volunteers.",The importance of individual pharmacokinetic data for treatment of epilepsy with carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1002351/),h,10,233092,DB00564,Carbamazepine
,1002351,half-life,"The half-life was about 5, 10, 10 and 20 hr.",The importance of individual pharmacokinetic data for treatment of epilepsy with carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1002351/),h,5,233093,DB00564,Carbamazepine
,1002351,half-life,"The half-life was about 5, 10, 10 and 20 hr.",The importance of individual pharmacokinetic data for treatment of epilepsy with carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1002351/),h,10,233094,DB00564,Carbamazepine
,1002351,half-life,"The half-life was about 5, 10, 10 and 20 hr.",The importance of individual pharmacokinetic data for treatment of epilepsy with carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1002351/),h,20,233095,DB00564,Carbamazepine
,29860181,flow rate,"Stereoselective separation was performed on CHIRALCEL OZ-RH column (150 mm × 4.6 mm i.d., 5 μm) with acetonitrile-water (10 mM ammonium acetate, 0.5% ammonia solution) (95:5, v/v) at a flow rate of 0.5 mL/min.",Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),[ml] / [min],0.5,233363,DB00564,Carbamazepine
,29860181,m/,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,409.1,233364,DB00564,Carbamazepine
,29860181,m/,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,238.0,233365,DB00564,Carbamazepine
,29860181,m/z,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,237.0,233366,DB00564,Carbamazepine
,29860181,m/z,Multiple reaction monitoring was selected with the transition of the m/z 409.1 → 238.0 for amlodipine enantiomers and m/z 237.0 → 194.1 for carbamazepine (IS) respectively.,Validated LC-MS/MS method for the determination of amlodipine enantiomers in rat plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29860181/),,194.1,233367,DB00564,Carbamazepine
,16600575,50% effective dose,"For example, in the proportion of 1:1 the theoretically calculated 50% effective dose for additivity (ED(50add)) was 138 mg/kg, while the experimentally derived ED(50) for the mixture (ED(50mix)) was 85.2 mg/kg.",Isobolographic analysis of interactions between losigamone and conventional antiepileptic drugs in the mouse maximal electroshock model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16600575/),,138,234359,DB00564,Carbamazepine
,16600575,ED(50),"For example, in the proportion of 1:1 the theoretically calculated 50% effective dose for additivity (ED(50add)) was 138 mg/kg, while the experimentally derived ED(50) for the mixture (ED(50mix)) was 85.2 mg/kg.",Isobolographic analysis of interactions between losigamone and conventional antiepileptic drugs in the mouse maximal electroshock model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16600575/),[mg] / [kg],85.2,234360,DB00564,Carbamazepine
,22246398,serum concentration,The mean ± SD serum concentration of OHC was 14.47 ± 8.28 μg/mL at a mean daily dose of 16.22 ± 7.99 mg/kg.,Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22246398/),[μg] / [ml],14.47,235025,DB00564,Carbamazepine
,23106522,half-life,"Zonisamide displays predictable, dose-dependent pharmacokinetics and has a half-life of ~60 h, allowing once- or twice-daily administration.","Zonisamide: its pharmacology, efficacy and safety in clinical trials. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106522/),h,60,236397,DB00564,Carbamazepine
,3621584,relative oral/intramuscular bioavailability,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),%,13,237079,DB00564,Carbamazepine
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.6,237080,DB00564,Carbamazepine
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.7,237081,DB00564,Carbamazepine
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.9,237082,DB00564,Carbamazepine
,29040230,concentration/dose (C/D) ratio,"The median concentration/dose (C/D) ratio of paliperidone was 16.1 (nmol/L)/(mg/d), with a 10-90 percentile range of 7.8-31.0 (nmol/L)/(mg/d).",Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29040230/),,16.1,237324,DB00564,Carbamazepine
,29040230,serum concentrations,"The median serum concentrations of paliperidone at the end of the dose interval were 31 nmol/L at an intramuscular dose of 50 mg/28 d, 53 nmol/L after a dose of 75 mg/28 d, 59 nmol/L after a dose of 100 mg/28 d, and 93 nmol/L after a dose of 150 mg/28 d.",Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29040230/),,31,237325,DB00564,Carbamazepine
,29040230,serum concentrations,"The median serum concentrations of paliperidone at the end of the dose interval were 31 nmol/L at an intramuscular dose of 50 mg/28 d, 53 nmol/L after a dose of 75 mg/28 d, 59 nmol/L after a dose of 100 mg/28 d, and 93 nmol/L after a dose of 150 mg/28 d.",Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29040230/),,53,237326,DB00564,Carbamazepine
,29040230,serum concentrations,"The median serum concentrations of paliperidone at the end of the dose interval were 31 nmol/L at an intramuscular dose of 50 mg/28 d, 53 nmol/L after a dose of 75 mg/28 d, 59 nmol/L after a dose of 100 mg/28 d, and 93 nmol/L after a dose of 150 mg/28 d.",Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29040230/),[nM] / [l],59,237327,DB00564,Carbamazepine
,29040230,serum concentrations,"The median serum concentrations of paliperidone at the end of the dose interval were 31 nmol/L at an intramuscular dose of 50 mg/28 d, 53 nmol/L after a dose of 75 mg/28 d, 59 nmol/L after a dose of 100 mg/28 d, and 93 nmol/L after a dose of 150 mg/28 d.",Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29040230/),[nM] / [l],93,237328,DB00564,Carbamazepine
,7082531,clearance,3 The mean (+/- s.d.) saliva CBZ clearance increased over the study period from 142 +/- 28 to 402 +/- 79 ml h -1 kg -1 (P less than 0.001) and the mean half-life decreased from 23.6 +/- 5.3 to 8.0 +/- 2.3 h (P less than 0.005).,Saliva carbamazepine levels in children before and during multiple dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082531/),-1·-1·h·kg·ml,142,237419,DB00564,Carbamazepine
,7082531,clearance,3 The mean (+/- s.d.) saliva CBZ clearance increased over the study period from 142 +/- 28 to 402 +/- 79 ml h -1 kg -1 (P less than 0.001) and the mean half-life decreased from 23.6 +/- 5.3 to 8.0 +/- 2.3 h (P less than 0.005).,Saliva carbamazepine levels in children before and during multiple dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082531/),-1·-1·h·kg·ml,402,237420,DB00564,Carbamazepine
,7082531,half-life,3 The mean (+/- s.d.) saliva CBZ clearance increased over the study period from 142 +/- 28 to 402 +/- 79 ml h -1 kg -1 (P less than 0.001) and the mean half-life decreased from 23.6 +/- 5.3 to 8.0 +/- 2.3 h (P less than 0.005).,Saliva carbamazepine levels in children before and during multiple dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082531/),h,23.6,237421,DB00564,Carbamazepine
,7082531,half-life,3 The mean (+/- s.d.) saliva CBZ clearance increased over the study period from 142 +/- 28 to 402 +/- 79 ml h -1 kg -1 (P less than 0.001) and the mean half-life decreased from 23.6 +/- 5.3 to 8.0 +/- 2.3 h (P less than 0.005).,Saliva carbamazepine levels in children before and during multiple dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082531/),h,8.0,237422,DB00564,Carbamazepine
,7082531,apparent volume of distribution,"The mean apparent volume of distribution after the first dose, 4.72 +/- 0.84 1 kg -1, was similar to that after 5 weeks treatment, 4.66 +/- 1.68 1 kg -1.",Saliva carbamazepine levels in children before and during multiple dosing. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082531/),-1·1·kg,4.72,237423,DB00564,Carbamazepine
,7082531,apparent volume of distribution,"The mean apparent volume of distribution after the first dose, 4.72 +/- 0.84 1 kg -1, was similar to that after 5 weeks treatment, 4.66 +/- 1.68 1 kg -1.",Saliva carbamazepine levels in children before and during multiple dosing. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082531/),-1·1·kg,4.66,237424,DB00564,Carbamazepine
,23480152,terminal half-life (t½ ),"The terminal half-life (t½ ) in humans is 105 h; however, in the presence of a strong CYP3A4 inducer (such as carbamazepine), the t½ can be reduced.","Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23480152/),h,105,237689,DB00564,Carbamazepine
,2618723,flow rate,Separation of CBZ and ECBZ was achieved by reversed phase chromatography using a mobile phase consisting of methanol-water (1:1) at flow rate of 0.8 ml/min on a 5 microns YWG C-18 column.,[Simultaneous determination of carbamazepine and its active metabolite in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618723/),[ml] / [min],0.8,240758,DB00564,Carbamazepine
,2618723,recoveries,The recoveries of CBZ and ECBZ were found to be 99.7% +/- 2.45 and 97.3% +/- 4.20 respectively.,[Simultaneous determination of carbamazepine and its active metabolite in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618723/),%,99.7,240759,DB00564,Carbamazepine
,2618723,recoveries,The recoveries of CBZ and ECBZ were found to be 99.7% +/- 2.45 and 97.3% +/- 4.20 respectively.,[Simultaneous determination of carbamazepine and its active metabolite in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618723/),%,97.3,240760,DB00564,Carbamazepine
,10197296,apparent oral clearance,The population mean apparent oral clearance of lamotrigine in adult patients receiving one concomitant enzyme-inducing antiepileptic drug and not valproic acid was estimated to be 1 mL/min/kg.,Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10197296/),[ml] / [kg·min],1,241375,DB00564,Carbamazepine
,10778658,Cmax,"The mean Cmax, Tmax, t1/2 and AUC for formulation A were: 1.67 +/- 0.26 mcg/mL, 24 +/- 0 hr, 47.8 +/- 9.7 hr and 136.7 +/- 25.4 mcg/ml.",Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778658/),[mcg] / [ml],1.67,241878,DB00564,Carbamazepine
,10778658,Tmax,"The mean Cmax, Tmax, t1/2 and AUC for formulation A were: 1.67 +/- 0.26 mcg/mL, 24 +/- 0 hr, 47.8 +/- 9.7 hr and 136.7 +/- 25.4 mcg/ml.",Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778658/),h,24,241879,DB00564,Carbamazepine
,10778658,Tmax,"The mean Cmax, Tmax, t1/2 and AUC for formulation A were: 1.67 +/- 0.26 mcg/mL, 24 +/- 0 hr, 47.8 +/- 9.7 hr and 136.7 +/- 25.4 mcg/ml.",Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778658/),h,47.8,241880,DB00564,Carbamazepine
,10778658,t1/2,"The mean Cmax, Tmax, t1/2 and AUC for formulation A were: 1.67 +/- 0.26 mcg/mL, 24 +/- 0 hr, 47.8 +/- 9.7 hr and 136.7 +/- 25.4 mcg/ml.",Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778658/),h,24,241881,DB00564,Carbamazepine
,10778658,AUC,"The mean Cmax, Tmax, t1/2 and AUC for formulation A were: 1.67 +/- 0.26 mcg/mL, 24 +/- 0 hr, 47.8 +/- 9.7 hr and 136.7 +/- 25.4 mcg/ml.",Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778658/),[mcg] / [ml],136.7,241882,DB00564,Carbamazepine
,16403497,effective dose (ED50),"Moreover, 2-PMPA administered i.p. at a constant dose of 150 mg/kg (the dose increasing the threshold for electroconvulsions) enhanced significantly the anticonvulsant action of valproate, by reducing its median effective dose (ED50) from 281.4 to 230.1 mg/kg (P<0.05).",2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16403497/),[mg] / [kg],281.4,243510,DB00564,Carbamazepine
,16403497,effective dose (ED50),"Moreover, 2-PMPA administered i.p. at a constant dose of 150 mg/kg (the dose increasing the threshold for electroconvulsions) enhanced significantly the anticonvulsant action of valproate, by reducing its median effective dose (ED50) from 281.4 to 230.1 mg/kg (P<0.05).",2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16403497/),[mg] / [kg],230.1,243511,DB00564,Carbamazepine
,2497766,plasma clearance,"2. After CBZ administration, mean VPA plasma clearance increased from 0.90 +/- 0.18 s.d. to 1.26 +/- 0.24 l h-1 (P less than 0.05) as did clearance of free VPA (20.8 +/- 7.6 to 37.0 +/- 13.6 l h-1).",The effect of carbamazepine on valproic acid disposition in adult volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[l] / [h],0.90,243609,DB00564,Carbamazepine
,2497766,plasma clearance,"2. After CBZ administration, mean VPA plasma clearance increased from 0.90 +/- 0.18 s.d. to 1.26 +/- 0.24 l h-1 (P less than 0.05) as did clearance of free VPA (20.8 +/- 7.6 to 37.0 +/- 13.6 l h-1).",The effect of carbamazepine on valproic acid disposition in adult volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[l] / [h],1.26,243610,DB00564,Carbamazepine
,2497766,clearance,"2. After CBZ administration, mean VPA plasma clearance increased from 0.90 +/- 0.18 s.d. to 1.26 +/- 0.24 l h-1 (P less than 0.05) as did clearance of free VPA (20.8 +/- 7.6 to 37.0 +/- 13.6 l h-1).",The effect of carbamazepine on valproic acid disposition in adult volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[l] / [h],20.8,243611,DB00564,Carbamazepine
,2497766,clearance,"2. After CBZ administration, mean VPA plasma clearance increased from 0.90 +/- 0.18 s.d. to 1.26 +/- 0.24 l h-1 (P less than 0.05) as did clearance of free VPA (20.8 +/- 7.6 to 37.0 +/- 13.6 l h-1).",The effect of carbamazepine on valproic acid disposition in adult volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[l] / [h],37.0,243612,DB00564,Carbamazepine
,2497766,elimination rate constant,Mean VPA elimination rate constant increased from 0.051 +/- 0.011 to 0.067 +/- 0.011 h-1 (P less than 0.05) after CBZ administration.,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),1/[h],0.051,243613,DB00564,Carbamazepine
,2497766,elimination rate constant,Mean VPA elimination rate constant increased from 0.051 +/- 0.011 to 0.067 +/- 0.011 h-1 (P less than 0.05) after CBZ administration.,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),1/[h],0.067,243614,DB00564,Carbamazepine
,2497766,area under the serum concentration vs time curve,3. Mean area under the serum concentration vs time curve decreased from 675.0 +/- 130.5 to 475.7 +/- 75.7 mg l-1 h (P less than 0.05) after CBZ administration.,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[h·mg] / [l],675.0,243615,DB00564,Carbamazepine
,2497766,area under the serum concentration vs time curve,3. Mean area under the serum concentration vs time curve decreased from 675.0 +/- 130.5 to 475.7 +/- 75.7 mg l-1 h (P less than 0.05) after CBZ administration.,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[h·mg] / [l],475.7,243616,DB00564,Carbamazepine
,2497766,half-life,Mean serum VPA half-life decreased from 14.0 +/- 2.4 to 10.6 +/- 1.4 h (P less than 0.05).,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),h,14.0,243617,DB00564,Carbamazepine
,2497766,half-life,Mean serum VPA half-life decreased from 14.0 +/- 2.4 to 10.6 +/- 1.4 h (P less than 0.05).,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),h,10.6,243618,DB00564,Carbamazepine
,2497766,trough concentrations,Mean serum VPA trough concentrations decreased from 44.0 +/- 16.7 to 27.0 +/- 10.4 micrograms ml-1 (P less than 0.05).,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[μg] / [ml],44.0,243619,DB00564,Carbamazepine
,2497766,trough concentrations,Mean serum VPA trough concentrations decreased from 44.0 +/- 16.7 to 27.0 +/- 10.4 micrograms ml-1 (P less than 0.05).,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[μg] / [ml],27.0,243620,DB00564,Carbamazepine
,17538173,MTD,The MTD was 130 mg/m2 every 3 weeks.,Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538173/),[mg] / [m2],130,244250,DB00564,Carbamazepine
,17538173,clearance rate,"At the MTD, the median clearance rate of ultrafiltrable platinum was 9.7 L/h/m2 (range, 6.5 to 15.5 L/h/m2).",Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538173/),[l] / [h·m2],9.7,244251,DB00564,Carbamazepine
,24342894,clearance,"Therapeutic drug monitoring of carbamazepine was carried out, and a slow carbamazepine clearance of 1.45 L·h⁻¹ per 70 kg was observed.",Slow carbamazepine clearance in a nonadherent Malay woman with epilepsy and thyrotoxicosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342894/),[h⁻¹·l] / [70·kg],1.45,244420,DB00564,Carbamazepine
,16600452,peak plasma concentrations,"Before carbamazepine coadministration, the peak plasma concentrations+/-SD of perospirone and ID-15036 were 4.0+/-4.3 and 11.7+/-7.1 ng/ml, respectively.",Effect of carbamazepine on the single oral dose pharmacokinetics of perospirone and its active metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16600452/),[ng] / [ml],4.0,244893,DB00564,Carbamazepine
,16600452,peak plasma concentrations,"Before carbamazepine coadministration, the peak plasma concentrations+/-SD of perospirone and ID-15036 were 4.0+/-4.3 and 11.7+/-7.1 ng/ml, respectively.",Effect of carbamazepine on the single oral dose pharmacokinetics of perospirone and its active metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16600452/),[ng] / [ml],11.7,244894,DB00564,Carbamazepine
,31364202,50% effective dose (ED50 ),"In the MES and PTZ experiments, the 50% effective dose (ED50 ) values of compound 6c were 9.5 and 20.5 mg/kg, respectively.","Synthesis and evaluation of anticonvulsant activities of 7-phenyl-4,5,6,7-tetrahydrothieno[3,2-b ]pyridine derivatives. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364202/),[mg] / [kg],9.5,245130,DB00564,Carbamazepine
,31364202,50% effective dose (ED50 ),"In the MES and PTZ experiments, the 50% effective dose (ED50 ) values of compound 6c were 9.5 and 20.5 mg/kg, respectively.","Synthesis and evaluation of anticonvulsant activities of 7-phenyl-4,5,6,7-tetrahydrothieno[3,2-b ]pyridine derivatives. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31364202/),[mg] / [kg],20.5,245131,DB00564,Carbamazepine
,10368079,areas under the plasma concentration curves (AUC(0-24h,"Compared with placebo, areas under the plasma concentration curves (AUC(0-24h, geometric means) decreased by 47% for both EE (from 1,677 to 886 pg.h/ml; p < 0.01) and LN (from 137 to 73 ng.h/ml; p < 0.01), during OCBZ treatment.",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[h·pg] / [ml],1,245147,DB00564,Carbamazepine
,10368079,areas under the plasma concentration curves (AUC(0-24h,"Compared with placebo, areas under the plasma concentration curves (AUC(0-24h, geometric means) decreased by 47% for both EE (from 1,677 to 886 pg.h/ml; p < 0.01) and LN (from 137 to 73 ng.h/ml; p < 0.01), during OCBZ treatment.",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[h·ng] / [ml],137,245148,DB00564,Carbamazepine
,10368079,Peak plasma EE concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[pg] / [ml],180,245149,DB00564,Carbamazepine
,10368079,Peak plasma EE concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[pg] / [ml],117,245150,DB00564,Carbamazepine
,10368079,peak plasma LN concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[ng] / [ml],10.2,245151,DB00564,Carbamazepine
,10368079,peak plasma LN concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[ng] / [ml],7.7,245152,DB00564,Carbamazepine
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,13,245153,DB00564,Carbamazepine
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,28.8,245154,DB00564,Carbamazepine
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,15,245155,DB00564,Carbamazepine
,6677873,Fetal/maternal,Fetal/maternal serum concentration ratios at birth were 0.78 +/- 0.14 (n = 5) for CBZ and 0.75 +/- 0.09 (n = 5) for CBZE .,"Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677873/),,0.78,246330,DB00564,Carbamazepine
,6677873,Fetal/maternal,Fetal/maternal serum concentration ratios at birth were 0.78 +/- 0.14 (n = 5) for CBZ and 0.75 +/- 0.09 (n = 5) for CBZE .,"Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677873/),,0.75,246331,DB00564,Carbamazepine
,6677873,serum concentration ratios,Fetal/maternal serum concentration ratios at birth were 0.78 +/- 0.14 (n = 5) for CBZ and 0.75 +/- 0.09 (n = 5) for CBZE .,"Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677873/),,0.78,246332,DB00564,Carbamazepine
,6677873,serum concentration ratios,Fetal/maternal serum concentration ratios at birth were 0.78 +/- 0.14 (n = 5) for CBZ and 0.75 +/- 0.09 (n = 5) for CBZE .,"Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677873/),,0.75,246333,DB00564,Carbamazepine
,6677873,half-lives,"Neonatal half-lives were 28 +/- 11 hours (n = 4) for CBZ and 20 and 24 hours (n = 2) for CBZE . maternal milk/serum concentration ratios of CBZ and CBZE were 0.39 +/- 0.22 (N = 11) and 0.49 +/- 0.28 (n = 6), respectively.","Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677873/),h,28,246334,DB00564,Carbamazepine
,6677873,half-lives,"Neonatal half-lives were 28 +/- 11 hours (n = 4) for CBZ and 20 and 24 hours (n = 2) for CBZE . maternal milk/serum concentration ratios of CBZ and CBZE were 0.39 +/- 0.22 (N = 11) and 0.49 +/- 0.28 (n = 6), respectively.","Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677873/),h,20,246335,DB00564,Carbamazepine
,6677873,half-lives,"Neonatal half-lives were 28 +/- 11 hours (n = 4) for CBZ and 20 and 24 hours (n = 2) for CBZE . maternal milk/serum concentration ratios of CBZ and CBZE were 0.39 +/- 0.22 (N = 11) and 0.49 +/- 0.28 (n = 6), respectively.","Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677873/),h,24,246336,DB00564,Carbamazepine
,6677873,maternal milk/serum concentration ratios,"Neonatal half-lives were 28 +/- 11 hours (n = 4) for CBZ and 20 and 24 hours (n = 2) for CBZE . maternal milk/serum concentration ratios of CBZ and CBZE were 0.39 +/- 0.22 (N = 11) and 0.49 +/- 0.28 (n = 6), respectively.","Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677873/),,0.39,246337,DB00564,Carbamazepine
,6677873,maternal milk/serum concentration ratios,"Neonatal half-lives were 28 +/- 11 hours (n = 4) for CBZ and 20 and 24 hours (n = 2) for CBZE . maternal milk/serum concentration ratios of CBZ and CBZE were 0.39 +/- 0.22 (N = 11) and 0.49 +/- 0.28 (n = 6), respectively.","Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677873/),,0.49,246338,DB00564,Carbamazepine
,6677873,steady-state CBZ serum levels,"The steady-state CBZ serum levels of nursed infants were about 1.0 micrograms/ml in all cases but one, where a maximum concentration of 4.7 micrograms/ml was reached.","Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677873/),[μg] / [ml],1.0,246339,DB00564,Carbamazepine
,6677873,maximum concentration,"The steady-state CBZ serum levels of nursed infants were about 1.0 micrograms/ml in all cases but one, where a maximum concentration of 4.7 micrograms/ml was reached.","Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6677873/),[μg] / [ml],4.7,246340,DB00564,Carbamazepine
,17433925,elimination half-life,The elimination half-life for the entire patient population was approximately twofold longer than the value reported in the product labeling (40-50 h vs 22 h).,Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433925/),h,40-50,246570,DB00564,Carbamazepine
,17433925,elimination half-life,The elimination half-life for the entire patient population was approximately twofold longer than the value reported in the product labeling (40-50 h vs 22 h).,Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433925/),h,22,246571,DB00564,Carbamazepine
,17433925,elimination half-life,"Preliminary results from 67 patients on CBZ therapy (14 elderly, mean age 70 years; 53 younger adults, mean age 41 years) showed no apparent difference between elderly and adult patients in any parameter; however, the mean CBZ elimination half-life for the combined groups (21 h) was longer than previous estimates.",Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433925/),h,21,246572,DB00564,Carbamazepine
,24452521,flow rate,"Chromatographic separation was carried out on an Acquity UPLC BEH C18 column using an isocratic mobile phase system composed of acetonitrile and 1% formic acid in water (33:67, v/v) at a flow rate of 0.45 mL/min.",UPLC-MS/MS determination of phentolamine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24452521/),[ml] / [min],0.45,247016,DB00564,Carbamazepine
,24452521,m/z,"The MRM transitions of m/z 282.1 → 212.0 and m/z 237.1 → 194.2 were used to quantify for phentolamine and carbamazepine (internal standard, IS), respectively.",UPLC-MS/MS determination of phentolamine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24452521/),,237.,247017,DB00564,Carbamazepine
,24452521,m/z,"The MRM transitions of m/z 282.1 → 212.0 and m/z 237.1 → 194.2 were used to quantify for phentolamine and carbamazepine (internal standard, IS), respectively.",UPLC-MS/MS determination of phentolamine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24452521/),,194.2,247018,DB00564,Carbamazepine
,25378280,flow rate,"After a single-step protein precipitation by acetonitrile, CSB-INH and IS were separated on an Acquity BEH(TM) C18 column (50 × 2.1 mm, 1.7 µm) under an isocratic mobile phase, consisting of acetonitrile: 10 mM ammonium acetate (95:5, v/v), at a flow rate of 0.3 mL/min.",Development and validation of UHPLC-MS/MS assay for rapid determination of a carvone Schiff base of isoniazid (CSB-INH) in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378280/),[ml] / [min],0.3,248744,DB00564,Carbamazepine
,25378280,m/z,The precursor to product ion transitions were set at m/z 270.08 → 79.93 for CSB-INH and m/z 237.00 → 178.97 for IS.,Development and validation of UHPLC-MS/MS assay for rapid determination of a carvone Schiff base of isoniazid (CSB-INH) in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378280/),,270.08,248745,DB00564,Carbamazepine
,25378280,m/z,The precursor to product ion transitions were set at m/z 270.08 → 79.93 for CSB-INH and m/z 237.00 → 178.97 for IS.,Development and validation of UHPLC-MS/MS assay for rapid determination of a carvone Schiff base of isoniazid (CSB-INH) in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378280/),,79.93,248746,DB00564,Carbamazepine
,25378280,m/z,The precursor to product ion transitions were set at m/z 270.08 → 79.93 for CSB-INH and m/z 237.00 → 178.97 for IS.,Development and validation of UHPLC-MS/MS assay for rapid determination of a carvone Schiff base of isoniazid (CSB-INH) in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378280/),,237.00,248747,DB00564,Carbamazepine
,25378280,m/z,The precursor to product ion transitions were set at m/z 270.08 → 79.93 for CSB-INH and m/z 237.00 → 178.97 for IS.,Development and validation of UHPLC-MS/MS assay for rapid determination of a carvone Schiff base of isoniazid (CSB-INH) in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378280/),,178.97,248748,DB00564,Carbamazepine
,17199019,half-life,Human pharmacology studies have shown that brivaracetam has a half-life of 8 h and nearly complete bioavailability.,Brivaracetam (UCB 34714). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17199019/),h,8,248873,DB00564,Carbamazepine
,1855347,area under the concentration-time curve,Addition of fluoxetine resulted in a significant increase in the area under the concentration-time curve of carbamazepine (105.93 +/- 18.05 micrograms/ml.hr versus 134.97 +/- 12.15 micrograms/ml.hr; t = 3.284; df = 5; p = 0.022) and CBZE (11.6 +/- 1.93 micrograms/ml.hr versus 15.2 +/- 2.4 micrograms/ml.hr; t = 2.805; df = 5; p = 0.038).,Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[μg] / [h·ml],105.93,248946,DB00564,Carbamazepine
,1855347,area under the concentration-time curve,Addition of fluoxetine resulted in a significant increase in the area under the concentration-time curve of carbamazepine (105.93 +/- 18.05 micrograms/ml.hr versus 134.97 +/- 12.15 micrograms/ml.hr; t = 3.284; df = 5; p = 0.022) and CBZE (11.6 +/- 1.93 micrograms/ml.hr versus 15.2 +/- 2.4 micrograms/ml.hr; t = 2.805; df = 5; p = 0.038).,Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[μg] / [h·ml],134.97,248947,DB00564,Carbamazepine
,1855347,area under the concentration-time curve,Addition of fluoxetine resulted in a significant increase in the area under the concentration-time curve of carbamazepine (105.93 +/- 18.05 micrograms/ml.hr versus 134.97 +/- 12.15 micrograms/ml.hr; t = 3.284; df = 5; p = 0.022) and CBZE (11.6 +/- 1.93 micrograms/ml.hr versus 15.2 +/- 2.4 micrograms/ml.hr; t = 2.805; df = 5; p = 0.038).,Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[μg] / [h·ml],11.6,248948,DB00564,Carbamazepine
,1855347,area under the concentration-time curve,Addition of fluoxetine resulted in a significant increase in the area under the concentration-time curve of carbamazepine (105.93 +/- 18.05 micrograms/ml.hr versus 134.97 +/- 12.15 micrograms/ml.hr; t = 3.284; df = 5; p = 0.022) and CBZE (11.6 +/- 1.93 micrograms/ml.hr versus 15.2 +/- 2.4 micrograms/ml.hr; t = 2.805; df = 5; p = 0.038).,Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[μg] / [h·ml],15.2,248949,DB00564,Carbamazepine
,1855347,oral,"Both oral and intrinsic clearance of carbamazepine was decreased significantly on fluoxetine addition (3.87 +/- 0.68 L/hr versus 2.98 +/- 0.26 L/hr; t = 3.025; df = 5; p = 0.029 and 17.90 +/- 4.9 L/hr versus 11.92 +/- 1.4 L/hr; t = 3.037; df = 5; p = 0.029, respectively).",Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[l] / [h],3.87,248950,DB00564,Carbamazepine
,1855347,intrinsic clearance,"Both oral and intrinsic clearance of carbamazepine was decreased significantly on fluoxetine addition (3.87 +/- 0.68 L/hr versus 2.98 +/- 0.26 L/hr; t = 3.025; df = 5; p = 0.029 and 17.90 +/- 4.9 L/hr versus 11.92 +/- 1.4 L/hr; t = 3.037; df = 5; p = 0.029, respectively).",Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[l] / [h],2.98,248951,DB00564,Carbamazepine
,1855347,intrinsic clearance,"Both oral and intrinsic clearance of carbamazepine was decreased significantly on fluoxetine addition (3.87 +/- 0.68 L/hr versus 2.98 +/- 0.26 L/hr; t = 3.025; df = 5; p = 0.029 and 17.90 +/- 4.9 L/hr versus 11.92 +/- 1.4 L/hr; t = 3.037; df = 5; p = 0.029, respectively).",Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[l] / [h],17.90,248952,DB00564,Carbamazepine
,1855347,intrinsic clearance,"Both oral and intrinsic clearance of carbamazepine was decreased significantly on fluoxetine addition (3.87 +/- 0.68 L/hr versus 2.98 +/- 0.26 L/hr; t = 3.025; df = 5; p = 0.029 and 17.90 +/- 4.9 L/hr versus 11.92 +/- 1.4 L/hr; t = 3.037; df = 5; p = 0.029, respectively).",Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[l] / [h],11.92,248953,DB00564,Carbamazepine
,25380628,CL/F,Typical value of PB CL/F for final model was estimated at 0.314 l/h.,Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25380628/),[l] / [h],0.314,249519,DB00564,Carbamazepine
,9578000,Css,Twenty-five patients taking phenytoin (PHT) and/ or phenobarbital (PB) and/or primidone (PRM) underwent a rapid switchover to CBZ following a 10 mg/kg single-dose kinetic study (day 1) which allowed calculation of a maintenance dose necessary to yield a mean Css of 10.2 (+/-2.2) mg/l.,Rapid switchover to carbamazepine using pharmacokinetic parameters. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578000/),[mg] / [l],10.2,249787,DB00564,Carbamazepine
,9578000,Css,"All patients completed the switchover to CBZ within a mean time period of 6 days (+/-2), reaching a mean maintenance dose of 1,639 mg/day (+/-370) which yielded a mean Css of 11.3 (+/-3.2) mg/l.",Rapid switchover to carbamazepine using pharmacokinetic parameters. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578000/),[mg] / [l],11.3,249788,DB00564,Carbamazepine
,22612290,"half-life (t(1/2,eff) )","After ESL oral administration, the effective half-life (t(1/2,eff) ) of eslicarbazepine was 20-24 h, which is approximately two times longer than its terminal half-life (t(1/2)).",Pharmacokinetics and drug interactions of eslicarbazepine acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612290/),h,20-24,249977,DB00564,Carbamazepine
,32959332,stability constant,Phase solubility studies of CBZ at different molar concentrations of beta-cyclodextrin (β-CD) and hydroxypropyl beta-cyclodextrin (HP-β-CD) indicated AL-type solubility profile with stability constants of 574 M-1 and 899 M-1 for β-CD and HP-β-CD.,Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959332/),1/[M],574,250310,DB00564,Carbamazepine
,32959332,stability constant,Phase solubility studies of CBZ at different molar concentrations of beta-cyclodextrin (β-CD) and hydroxypropyl beta-cyclodextrin (HP-β-CD) indicated AL-type solubility profile with stability constants of 574 M-1 and 899 M-1 for β-CD and HP-β-CD.,Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959332/),1/[M],899,250311,DB00564,Carbamazepine
,32959332,solubility,CBP-4 and CHP-2 showed a solubility of 4.27 ± 0.09 mg/mL and 6.39 ± 0.09 mg/mL as compared to plain CBZ (0.140 ± 0.007 mg/mL).,Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959332/),[mg] / [ml],4.27,250312,DB00564,Carbamazepine
,32959332,solubility,CBP-4 and CHP-2 showed a solubility of 4.27 ± 0.09 mg/mL and 6.39 ± 0.09 mg/mL as compared to plain CBZ (0.140 ± 0.007 mg/mL).,Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959332/),[mg] / [ml],6.39,250313,DB00564,Carbamazepine
,32959332,solubility,CBP-4 and CHP-2 showed a solubility of 4.27 ± 0.09 mg/mL and 6.39 ± 0.09 mg/mL as compared to plain CBZ (0.140 ± 0.007 mg/mL).,Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959332/),[mg] / [ml],0.140,250314,DB00564,Carbamazepine
,32959332,release,Drug release studies indicated highest release of CBZ from CHP-2 (98.69 ± 2.96%) compared to CBP-4 (82.64 ± 2.45%) and plain drug (13.47 ± 0.54%).,Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959332/),%,98.69,250315,DB00564,Carbamazepine
,32959332,release,Drug release studies indicated highest release of CBZ from CHP-2 (98.69 ± 2.96%) compared to CBP-4 (82.64 ± 2.45%) and plain drug (13.47 ± 0.54%).,Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959332/),%,82.64,250316,DB00564,Carbamazepine
,32959332,release,Drug release studies indicated highest release of CBZ from CHP-2 (98.69 ± 2.96%) compared to CBP-4 (82.64 ± 2.45%) and plain drug (13.47 ± 0.54%).,Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959332/),%,13.47,250317,DB00564,Carbamazepine
,9234869,Recovery,Recovery from plasma averaged 88%.,High-performance liquid chromatographic assay for thiopental in human plasma. Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234869/),%,88,250568,DB00564,Carbamazepine
at,9234869,Percent recovery,Percent recovery was at least 93%.,High-performance liquid chromatographic assay for thiopental in human plasma. Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234869/),%,93,250569,DB00564,Carbamazepine
,23558601,Tmax,The Tmax and Cmax values of 97/63 were 1.75±0.77 h and 862±306 ng/mL in male rats whereas in female rats they were 5.45±0.76 h and 662.75±95.09 ng/mL after a single dose of 97/78 alone.,Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),h,1.75,251578,DB00564,Carbamazepine
,23558601,Tmax,The Tmax and Cmax values of 97/63 were 1.75±0.77 h and 862±306 ng/mL in male rats whereas in female rats they were 5.45±0.76 h and 662.75±95.09 ng/mL after a single dose of 97/78 alone.,Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),h,5.45,251579,DB00564,Carbamazepine
,23558601,Cmax,The Tmax and Cmax values of 97/63 were 1.75±0.77 h and 862±306 ng/mL in male rats whereas in female rats they were 5.45±0.76 h and 662.75±95.09 ng/mL after a single dose of 97/78 alone.,Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),[ng] / [ml],862,251580,DB00564,Carbamazepine
,23558601,Cmax,The Tmax and Cmax values of 97/63 were 1.75±0.77 h and 862±306 ng/mL in male rats whereas in female rats they were 5.45±0.76 h and 662.75±95.09 ng/mL after a single dose of 97/78 alone.,Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),[ng] / [ml],662.75,251581,DB00564,Carbamazepine
,23558601,Tmax,"However, following coadministration of 97/78 and carbamazepine, the values for Tmax and Cmax were 1.06±0.16 h and 533±153 ng/mL in male rats and 2.23±1.93 h and 636.5±112.4 ng/mL in female rats.",Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),h,1.06,251582,DB00564,Carbamazepine
,23558601,Tmax,"However, following coadministration of 97/78 and carbamazepine, the values for Tmax and Cmax were 1.06±0.16 h and 533±153 ng/mL in male rats and 2.23±1.93 h and 636.5±112.4 ng/mL in female rats.",Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),h,2.23,251583,DB00564,Carbamazepine
,23558601,Cmax,"However, following coadministration of 97/78 and carbamazepine, the values for Tmax and Cmax were 1.06±0.16 h and 533±153 ng/mL in male rats and 2.23±1.93 h and 636.5±112.4 ng/mL in female rats.",Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),[ng] / [ml],533,251584,DB00564,Carbamazepine
,23558601,Cmax,"However, following coadministration of 97/78 and carbamazepine, the values for Tmax and Cmax were 1.06±0.16 h and 533±153 ng/mL in male rats and 2.23±1.93 h and 636.5±112.4 ng/mL in female rats.",Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),[ng] / [ml],636.5,251585,DB00564,Carbamazepine
,23558601,half life,"The half life of 97/63 following a single oral dose of 97/78 or coadministration with carbamazepine to male rats was 6.98±0.63 h and 6.64±0.54 h, respectively; the values in female rats were 7.5±0.5 h and 5.48±0.37 h.",Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),h,6.98,251586,DB00564,Carbamazepine
,23558601,half life,"The half life of 97/63 following a single oral dose of 97/78 or coadministration with carbamazepine to male rats was 6.98±0.63 h and 6.64±0.54 h, respectively; the values in female rats were 7.5±0.5 h and 5.48±0.37 h.",Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),h,6.64,251587,DB00564,Carbamazepine
,23558601,half life,"The half life of 97/63 following a single oral dose of 97/78 or coadministration with carbamazepine to male rats was 6.98±0.63 h and 6.64±0.54 h, respectively; the values in female rats were 7.5±0.5 h and 5.48±0.37 h.",Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),h,7.5,251588,DB00564,Carbamazepine
,23558601,half life,"The half life of 97/63 following a single oral dose of 97/78 or coadministration with carbamazepine to male rats was 6.98±0.63 h and 6.64±0.54 h, respectively; the values in female rats were 7.5±0.5 h and 5.48±0.37 h.",Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23558601/),h,5.48,251589,DB00564,Carbamazepine
,24366214,recoveries,Mean recoveries of CUDC-101 in rat plasma were in the range of 84.0-90.5%.,Determination of CUDC-101 in rat plasma by liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24366214/),%,84.0-90.5,251738,DB00564,Carbamazepine
,6650125,Tmax,The time-concentration curves showed a median Tmax of 8 h followed by a plateau until 24 h indicating saturable kinetic processes.,"Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650125/),h,8,251989,DB00564,Carbamazepine
,6650125,half-life,"The half-life of 10-OH-carbazepine in saliva, 13.8 +/- 3.7 (SD) h, was significantly shorter than in serum, 19.3 +/- 6.2 (SD) h.","Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650125/),h,13.8,251990,DB00564,Carbamazepine
,6650125,half-life,"The half-life of 10-OH-carbazepine in saliva, 13.8 +/- 3.7 (SD) h, was significantly shorter than in serum, 19.3 +/- 6.2 (SD) h.","Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650125/),h,19.3,251991,DB00564,Carbamazepine
,16390352,plasma C(max),"In the clinical studies, ketoconazole increased mean quetiapine plasma C(max) by 3.35-fold, from 45 to 150 ng ml(-1) (mean C(max) ratio 90% CI 2.51, 4.47) and decreased its clearance (Cl/F) by 84%, from 138 to 22 l h(-1) (mean ratio 90% CI 0.13, 0.20).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[ng] / [ml],45 to 150,252117,DB00564,Carbamazepine
,16390352,clearance (Cl/F),"In the clinical studies, ketoconazole increased mean quetiapine plasma C(max) by 3.35-fold, from 45 to 150 ng ml(-1) (mean C(max) ratio 90% CI 2.51, 4.47) and decreased its clearance (Cl/F) by 84%, from 138 to 22 l h(-1) (mean ratio 90% CI 0.13, 0.20).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[l] / [h],138 to 22,252118,DB00564,Carbamazepine
,16390352,plasma C(max),"Carbamazepine decreased quetiapine plasma C(max) by 80%, from 1042 to 205 ng ml(-1) (mean C(max) ratio 90% CI 0.14, 0.28) and increased its clearance 7.5-fold, from 65 to 483 l h(-1) (mean ratio 90% CI 6.04, 9.28).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[ng] / [ml],1042 to 205,252119,DB00564,Carbamazepine
,16390352,clearance,"Carbamazepine decreased quetiapine plasma C(max) by 80%, from 1042 to 205 ng ml(-1) (mean C(max) ratio 90% CI 0.14, 0.28) and increased its clearance 7.5-fold, from 65 to 483 l h(-1) (mean ratio 90% CI 6.04, 9.28).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[l] / [h],65 to 483,252120,DB00564,Carbamazepine
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.36,252731,DB00564,Carbamazepine
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.23,252732,DB00564,Carbamazepine
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.24,252733,DB00564,Carbamazepine
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.34,252734,DB00564,Carbamazepine
,23996245,clearance,"The typical clearance for CBZ was estimated to be 5.85 and 5.68 L/h from plasma and DBS concentrations, respectively.",Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996245/),[l] / [h],5.85,252948,DB00564,Carbamazepine
,23996245,clearance,"The typical clearance for CBZ was estimated to be 5.85 and 5.68 L/h from plasma and DBS concentrations, respectively.",Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996245/),[l] / [h],5.68,252949,DB00564,Carbamazepine
,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,253,254137,DB00564,Carbamazepine
>,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,208,254138,DB00564,Carbamazepine
,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,255,254139,DB00564,Carbamazepine
>,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,194,254140,DB00564,Carbamazepine
>,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,247,254141,DB00564,Carbamazepine
>,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,204,254142,DB00564,Carbamazepine
,18027989,objective response rate,"In 50 patients with measurable disease, the objective response rate was 60%, with complete responses in 6% of patients.",Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027989/),%,60,255193,DB00564,Carbamazepine
,18027989,AUC,"Cyclophosphamide exposure (the AUC) was significantly higher in patients with at least stable disease (n = 44) than in patients with progressive disease (n = 6; 945 micromol . h/L [95% CI 889, 1001] vs 602 micromol . h/L [95% CI 379, 825], p = 0.0002).",Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027989/),[h·μM] / [l],;,255194,DB00564,Carbamazepine
,18027989,AUC,"Cyclophosphamide exposure (the AUC) was significantly higher in patients with at least stable disease (n = 44) than in patients with progressive disease (n = 6; 945 micromol . h/L [95% CI 889, 1001] vs 602 micromol . h/L [95% CI 379, 825], p = 0.0002).",Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027989/),[h·μM] / [l],945,255195,DB00564,Carbamazepine
,18027989,AUC,"Cyclophosphamide exposure (the AUC) was significantly higher in patients with at least stable disease (n = 44) than in patients with progressive disease (n = 6; 945 micromol . h/L [95% CI 889, 1001] vs 602 micromol . h/L [95% CI 379, 825], p = 0.0002).",Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027989/),[h·μM] / [l],602,255196,DB00564,Carbamazepine
,11497340,clearance (CL,"The population estimates for clearance (CL; modelled independently of dose) and volume of distribution were 13.2 +/- 0.6 l/h and 525 +/- 44 1, respectively.",Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11497340/),[l] / [h],13.2,255727,DB00564,Carbamazepine
,11497340,volume of distribution,"The population estimates for clearance (CL; modelled independently of dose) and volume of distribution were 13.2 +/- 0.6 l/h and 525 +/- 44 1, respectively.",Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11497340/),1,525,255728,DB00564,Carbamazepine
,19493706,m,"The analytes and carbamazepine (internal standard, I.S.) were monitored in a selected-ion reaction (SIR) mode with a positive electrospray ionization (ESI) interface by the following ions: m/z 417.2 for puerarin, m/z 255.2 for daidzein, m/z 271.0 for baicalin, m/z 461.0 for wogonoside, m/z 441.0 for liquiritin and m/z 237.2 for carbamazepine (I.S.), respectively.","Simultaneous determination of puerarin, daidzein, baicalin, wogonoside and liquiritin of GegenQinlian decoction in rat plasma by ultra-performance liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493706/),,417.2,255912,DB00564,Carbamazepine
,19493706,m/,"The analytes and carbamazepine (internal standard, I.S.) were monitored in a selected-ion reaction (SIR) mode with a positive electrospray ionization (ESI) interface by the following ions: m/z 417.2 for puerarin, m/z 255.2 for daidzein, m/z 271.0 for baicalin, m/z 461.0 for wogonoside, m/z 441.0 for liquiritin and m/z 237.2 for carbamazepine (I.S.), respectively.","Simultaneous determination of puerarin, daidzein, baicalin, wogonoside and liquiritin of GegenQinlian decoction in rat plasma by ultra-performance liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493706/),,255.2,255913,DB00564,Carbamazepine
,19493706,m/z,"The analytes and carbamazepine (internal standard, I.S.) were monitored in a selected-ion reaction (SIR) mode with a positive electrospray ionization (ESI) interface by the following ions: m/z 417.2 for puerarin, m/z 255.2 for daidzein, m/z 271.0 for baicalin, m/z 461.0 for wogonoside, m/z 441.0 for liquiritin and m/z 237.2 for carbamazepine (I.S.), respectively.","Simultaneous determination of puerarin, daidzein, baicalin, wogonoside and liquiritin of GegenQinlian decoction in rat plasma by ultra-performance liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493706/),,271.0,255914,DB00564,Carbamazepine
,19493706,m/z,"The analytes and carbamazepine (internal standard, I.S.) were monitored in a selected-ion reaction (SIR) mode with a positive electrospray ionization (ESI) interface by the following ions: m/z 417.2 for puerarin, m/z 255.2 for daidzein, m/z 271.0 for baicalin, m/z 461.0 for wogonoside, m/z 441.0 for liquiritin and m/z 237.2 for carbamazepine (I.S.), respectively.","Simultaneous determination of puerarin, daidzein, baicalin, wogonoside and liquiritin of GegenQinlian decoction in rat plasma by ultra-performance liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493706/),,461.0,255915,DB00564,Carbamazepine
,19493706,m/,"The analytes and carbamazepine (internal standard, I.S.) were monitored in a selected-ion reaction (SIR) mode with a positive electrospray ionization (ESI) interface by the following ions: m/z 417.2 for puerarin, m/z 255.2 for daidzein, m/z 271.0 for baicalin, m/z 461.0 for wogonoside, m/z 441.0 for liquiritin and m/z 237.2 for carbamazepine (I.S.), respectively.","Simultaneous determination of puerarin, daidzein, baicalin, wogonoside and liquiritin of GegenQinlian decoction in rat plasma by ultra-performance liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493706/),,441.0,255916,DB00564,Carbamazepine
,19493706,extraction recoveries,"The extraction recoveries were on average 79.8% for puerarin, 90.8% for daidzein, 74.4% for baicalin, 70.2% for wogonoside and 84.7% for liquiritin.","Simultaneous determination of puerarin, daidzein, baicalin, wogonoside and liquiritin of GegenQinlian decoction in rat plasma by ultra-performance liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493706/),%,79.8,255917,DB00564,Carbamazepine
,19493706,extraction recoveries,"The extraction recoveries were on average 79.8% for puerarin, 90.8% for daidzein, 74.4% for baicalin, 70.2% for wogonoside and 84.7% for liquiritin.","Simultaneous determination of puerarin, daidzein, baicalin, wogonoside and liquiritin of GegenQinlian decoction in rat plasma by ultra-performance liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493706/),%,90.8,255918,DB00564,Carbamazepine
,19493706,extraction recoveries,"The extraction recoveries were on average 79.8% for puerarin, 90.8% for daidzein, 74.4% for baicalin, 70.2% for wogonoside and 84.7% for liquiritin.","Simultaneous determination of puerarin, daidzein, baicalin, wogonoside and liquiritin of GegenQinlian decoction in rat plasma by ultra-performance liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493706/),%,74.4,255919,DB00564,Carbamazepine
,19493706,extraction recoveries,"The extraction recoveries were on average 79.8% for puerarin, 90.8% for daidzein, 74.4% for baicalin, 70.2% for wogonoside and 84.7% for liquiritin.","Simultaneous determination of puerarin, daidzein, baicalin, wogonoside and liquiritin of GegenQinlian decoction in rat plasma by ultra-performance liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493706/),%,70.2,255920,DB00564,Carbamazepine
,19493706,extraction recoveries,"The extraction recoveries were on average 79.8% for puerarin, 90.8% for daidzein, 74.4% for baicalin, 70.2% for wogonoside and 84.7% for liquiritin.","Simultaneous determination of puerarin, daidzein, baicalin, wogonoside and liquiritin of GegenQinlian decoction in rat plasma by ultra-performance liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493706/),%,84.7,255921,DB00564,Carbamazepine
,18605233,Cmax,"Pharmacokinetic parameters were: Cmax 6.51 +/- 1.32 and 6.63 +/- 0.95 microg/mL, tmax 3.55 +/- 0.98 and 1.82 +/- 0.59 hr, AUC 66.61 +/- 28.16 and 73.54 +/- 15.35 microg x h/mL and t1/2 7.16 +/- 2.55 and 5.80 +/- 1.37 hr.",Kainic acid does not modify the oral pharmacokinetics of carbamazepine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605233/),[μg] / [ml],6.51,256200,DB00564,Carbamazepine
,18605233,Cmax,"Pharmacokinetic parameters were: Cmax 6.51 +/- 1.32 and 6.63 +/- 0.95 microg/mL, tmax 3.55 +/- 0.98 and 1.82 +/- 0.59 hr, AUC 66.61 +/- 28.16 and 73.54 +/- 15.35 microg x h/mL and t1/2 7.16 +/- 2.55 and 5.80 +/- 1.37 hr.",Kainic acid does not modify the oral pharmacokinetics of carbamazepine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605233/),[μg] / [ml],6.63,256201,DB00564,Carbamazepine
,18605233,tmax,"Pharmacokinetic parameters were: Cmax 6.51 +/- 1.32 and 6.63 +/- 0.95 microg/mL, tmax 3.55 +/- 0.98 and 1.82 +/- 0.59 hr, AUC 66.61 +/- 28.16 and 73.54 +/- 15.35 microg x h/mL and t1/2 7.16 +/- 2.55 and 5.80 +/- 1.37 hr.",Kainic acid does not modify the oral pharmacokinetics of carbamazepine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605233/),h,3.55,256202,DB00564,Carbamazepine
,18605233,tmax,"Pharmacokinetic parameters were: Cmax 6.51 +/- 1.32 and 6.63 +/- 0.95 microg/mL, tmax 3.55 +/- 0.98 and 1.82 +/- 0.59 hr, AUC 66.61 +/- 28.16 and 73.54 +/- 15.35 microg x h/mL and t1/2 7.16 +/- 2.55 and 5.80 +/- 1.37 hr.",Kainic acid does not modify the oral pharmacokinetics of carbamazepine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605233/),h,1.82,256203,DB00564,Carbamazepine
,18605233,AUC,"Pharmacokinetic parameters were: Cmax 6.51 +/- 1.32 and 6.63 +/- 0.95 microg/mL, tmax 3.55 +/- 0.98 and 1.82 +/- 0.59 hr, AUC 66.61 +/- 28.16 and 73.54 +/- 15.35 microg x h/mL and t1/2 7.16 +/- 2.55 and 5.80 +/- 1.37 hr.",Kainic acid does not modify the oral pharmacokinetics of carbamazepine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605233/),[h·μg] / [ml],66.61,256204,DB00564,Carbamazepine
,18605233,AUC,"Pharmacokinetic parameters were: Cmax 6.51 +/- 1.32 and 6.63 +/- 0.95 microg/mL, tmax 3.55 +/- 0.98 and 1.82 +/- 0.59 hr, AUC 66.61 +/- 28.16 and 73.54 +/- 15.35 microg x h/mL and t1/2 7.16 +/- 2.55 and 5.80 +/- 1.37 hr.",Kainic acid does not modify the oral pharmacokinetics of carbamazepine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605233/),[h·μg] / [ml],73.54,256205,DB00564,Carbamazepine
,18605233,t1/2,"Pharmacokinetic parameters were: Cmax 6.51 +/- 1.32 and 6.63 +/- 0.95 microg/mL, tmax 3.55 +/- 0.98 and 1.82 +/- 0.59 hr, AUC 66.61 +/- 28.16 and 73.54 +/- 15.35 microg x h/mL and t1/2 7.16 +/- 2.55 and 5.80 +/- 1.37 hr.",Kainic acid does not modify the oral pharmacokinetics of carbamazepine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605233/),h,7.16,256206,DB00564,Carbamazepine
,18605233,t1/2,"Pharmacokinetic parameters were: Cmax 6.51 +/- 1.32 and 6.63 +/- 0.95 microg/mL, tmax 3.55 +/- 0.98 and 1.82 +/- 0.59 hr, AUC 66.61 +/- 28.16 and 73.54 +/- 15.35 microg x h/mL and t1/2 7.16 +/- 2.55 and 5.80 +/- 1.37 hr.",Kainic acid does not modify the oral pharmacokinetics of carbamazepine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605233/),h,5.80,256207,DB00564,Carbamazepine
,22472186,flow rate,"The chromatographic separation was achieved on a Zorbax SB-C(18) column (100 mm × 2.1 mm, 3.5 μm) with an isocratic elution system comprised of acetonitrile and 0.3% aqueous acetic acid at a flow rate of 0.3 ml/min.",Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472186/),[ml] / [min],0.3,258341,DB00564,Carbamazepine
less,22472186,penetration ratio,"The brain distribution studies showed that the brain distribution of FLZ was limited with the penetration ratio less than 0.1 in rats, with no target effect in the seven collected regions.",Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472186/),,0.1,258342,DB00564,Carbamazepine
,12472982,trough concentrations,"Mean trough concentrations were 7.9 +/- 1.4 microg/mL with carbamazepine alone, and 6.5 +/- 2.0 microg/mL with carbamazepine-vigabatrin association (P < 0.03).",Effect of vigabatrin on the pharmacokinetics of carbamazepine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472982/),[μg] / [ml],7.9,259211,DB00564,Carbamazepine
,12472982,trough concentrations,"Mean trough concentrations were 7.9 +/- 1.4 microg/mL with carbamazepine alone, and 6.5 +/- 2.0 microg/mL with carbamazepine-vigabatrin association (P < 0.03).",Effect of vigabatrin on the pharmacokinetics of carbamazepine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472982/),[μg] / [ml],6.5,259212,DB00564,Carbamazepine
,12472982,level/dose ratio (L/D),The mean values of pharmacokinetic parameters were: level/dose ratio (L/D) = 0.59 +/- 0.20 vs.,Effect of vigabatrin on the pharmacokinetics of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472982/),,0.59,259213,DB00564,Carbamazepine
,12472982,plasma clearance (Cl),"0.45 +/- 0.15 (P < 0.05) and plasma clearance (Cl) = 78.5 +/- 25.8 vs. 105.8 +/- 38.9 mL/h/kg (P < 0.05), with carbamazepine alone and carbamazepine-vigabatrin combination, respectively.",Effect of vigabatrin on the pharmacokinetics of carbamazepine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472982/),[ml] / [h·kg],78.5,259214,DB00564,Carbamazepine
,12472982,plasma clearance (Cl),"0.45 +/- 0.15 (P < 0.05) and plasma clearance (Cl) = 78.5 +/- 25.8 vs. 105.8 +/- 38.9 mL/h/kg (P < 0.05), with carbamazepine alone and carbamazepine-vigabatrin combination, respectively.",Effect of vigabatrin on the pharmacokinetics of carbamazepine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472982/),[ml] / [h·kg],105.8,259215,DB00564,Carbamazepine
,24571554,clearance,Mean study population value of LTG clearance estimated by the final model was 3.17 l/h.,Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],3.17,259257,DB00564,Carbamazepine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],4.02,259258,DB00564,Carbamazepine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],3.03,259259,DB00564,Carbamazepine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],4.95,259260,DB00564,Carbamazepine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],4.15,259261,DB00564,Carbamazepine
,24571554,clearance,"No influence of OC was found in LTG-VPA combination (clearance with OC 0.99±0.16 l/h, OC-free week 0.90±0.15 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],0.99,259262,DB00564,Carbamazepine
,24571554,clearance,"No influence of OC was found in LTG-VPA combination (clearance with OC 0.99±0.16 l/h, OC-free week 0.90±0.15 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],0.90,259263,DB00564,Carbamazepine
,346287,elimination half-life,"After single oral doses of carbamazepine, the absorption is fairly complete and the elimination half-life is about 35 hours (range 18 to 65 hours).",Clinical pharmacokinetics of carbamazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/346287/),h,35,260413,DB00564,Carbamazepine
,346287,half-life,"During multiple dosing, the half-life is decreased to 10-20 hours, probably due to autoinduction of the oxidative metabolism of the drug.",Clinical pharmacokinetics of carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346287/),h,10-20,260414,DB00564,Carbamazepine
,346287,plasma protein binding,The plasma protein binding of the metabolite is about 50% compared with about 75% for the parent drug.,Clinical pharmacokinetics of carbamazepine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346287/),%,50,260415,DB00564,Carbamazepine
,346287,plasma protein binding,The plasma protein binding of the metabolite is about 50% compared with about 75% for the parent drug.,Clinical pharmacokinetics of carbamazepine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346287/),%,75,260416,DB00564,Carbamazepine
,346287,plasma half-lives,"In newborns exposed to the drug during fetal life, the plasma half-lives were relatively short (8.2 to 28.1 hours) indicating an induction of carbamazepine metabolism during gestation.",Clinical pharmacokinetics of carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346287/),h,8.2 to 28.1,260417,DB00564,Carbamazepine
,8422853,plasma CBZ,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],5.28,260613,DB00564,Carbamazepine
,8422853,plasma CBZ,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],5.36,260614,DB00564,Carbamazepine
,8422853,plasma CBZ,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],3.16,260615,DB00564,Carbamazepine
,8422853,plasma CBZ,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],3.00,260616,DB00564,Carbamazepine
,8422853,concentrations,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],5.28,260617,DB00564,Carbamazepine
,8422853,concentrations,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],5.36,260618,DB00564,Carbamazepine
,8422853,concentrations,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],3.16,260619,DB00564,Carbamazepine
,8422853,concentrations,"During the controlled study, mean plasma CBZ concentrations at 2 and 6.5 h after the 600-mg dose were 5.28 and 5.36 micrograms/ml; after LTG 300 mg, they were 3.16 and 3.00 micrograms/ml.",Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422853/),[μg] / [ml],3.00,260620,DB00564,Carbamazepine
,15519127,Ki,"The estimated Ki for zonisamide inhibition of CYP3A4 was 1076 microM, 12 times higher than typical unbound therapeutic serum zonisamide concentrations.",Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519127/),μM,1076,260946,DB00564,Carbamazepine
,15519127,t1/2,"The observed mean zonisamide t1/2 (36.3h), relative to approximately 65 h reported in subjects on zonisamide monotherapy, reflects known CYP3A4 induction by carbamazepine.",Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519127/),h,36.3,260947,DB00564,Carbamazepine
,15519127,t1/2,"The observed mean zonisamide t1/2 (36.3h), relative to approximately 65 h reported in subjects on zonisamide monotherapy, reflects known CYP3A4 induction by carbamazepine.",Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519127/),h,65,260948,DB00564,Carbamazepine
,18248517,Terminal half-life,Terminal half-life in plasma ranged from 159 min.,Seromucosal transport of intravenously administered carbamazepine is not enhanced by oral doses of activated charcoal in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18248517/),min,159,261748,DB00564,Carbamazepine
,18248517,area under the curve,"Correspondingly, the area under the curve did not vary significantly and ranged between 1.13 and 1.41 g/min./l (P = 0.378).",Seromucosal transport of intravenously administered carbamazepine is not enhanced by oral doses of activated charcoal in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18248517/),[g] / [·l·min],1.13 and 1.41,261749,DB00564,Carbamazepine
,18248517,Excretion,Excretion of carbamazepine and metabolites into urine varied between 3% and 6% of dose within all groups and showed close correlation with diuresis.,Seromucosal transport of intravenously administered carbamazepine is not enhanced by oral doses of activated charcoal in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18248517/),%,3,261750,DB00564,Carbamazepine
,18248517,Excretion,Excretion of carbamazepine and metabolites into urine varied between 3% and 6% of dose within all groups and showed close correlation with diuresis.,Seromucosal transport of intravenously administered carbamazepine is not enhanced by oral doses of activated charcoal in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18248517/),%,6,261751,DB00564,Carbamazepine
,20643590,m/,"The following ions: m/z 447 for baicalin, m/z 461 for wogonoside and m/z 237 for the I.S. were used for quantitative determination.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,461,263955,DB00564,Carbamazepine
,20643590,signal-to-noise ratio,The lower limit of detection (LLOD) based on a signal-to-noise ratio of 2 was 0.06155microg mL(-1) for baicalin and 0.04416microg mL(-1) for wogonoside.,Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),[μg] / [ml],2,263956,DB00564,Carbamazepine
,20643590,signal-to-noise ratio,The lower limit of detection (LLOD) based on a signal-to-noise ratio of 2 was 0.06155microg mL(-1) for baicalin and 0.04416microg mL(-1) for wogonoside.,Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),[μg] / [ml],0.06155,263957,DB00564,Carbamazepine
,20643590,signal-to-noise ratio,The lower limit of detection (LLOD) based on a signal-to-noise ratio of 2 was 0.06155microg mL(-1) for baicalin and 0.04416microg mL(-1) for wogonoside.,Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),[μg] / [ml],0.04416,263958,DB00564,Carbamazepine
,20643590,extraction recovery,The extraction recovery at three QC concentrations ranged from 74.7 to 86.0% for baicalin and from 71.3 to 83.7% for wogonoside.,Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),%,74.7 to 86.0,263959,DB00564,Carbamazepine
,20643590,extraction recovery,The extraction recovery at three QC concentrations ranged from 74.7 to 86.0% for baicalin and from 71.3 to 83.7% for wogonoside.,Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),%,71.3 to 83.7,263960,DB00564,Carbamazepine
,20643590,t(1/2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of baicalin was 3.60+/-0.90 and 5.64+/-1.67, the C(max1) was 1.64+/-0.99 and 5.66+/-2.02, the t(max1) was 0.13+/-0.05 and 0.20+/-0.07, the C(max2) was 2.43+/-0.46 and 3.18+/-1.66, and the t(max2) were 6.40+/-1.67 and 5.66+/-2.02, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,3.60,263961,DB00564,Carbamazepine
,20643590,t(1/2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of baicalin was 3.60+/-0.90 and 5.64+/-1.67, the C(max1) was 1.64+/-0.99 and 5.66+/-2.02, the t(max1) was 0.13+/-0.05 and 0.20+/-0.07, the C(max2) was 2.43+/-0.46 and 3.18+/-1.66, and the t(max2) were 6.40+/-1.67 and 5.66+/-2.02, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,5.64,263962,DB00564,Carbamazepine
,20643590,C(max1),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of baicalin was 3.60+/-0.90 and 5.64+/-1.67, the C(max1) was 1.64+/-0.99 and 5.66+/-2.02, the t(max1) was 0.13+/-0.05 and 0.20+/-0.07, the C(max2) was 2.43+/-0.46 and 3.18+/-1.66, and the t(max2) were 6.40+/-1.67 and 5.66+/-2.02, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,1.64,263963,DB00564,Carbamazepine
,20643590,C(max1),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of baicalin was 3.60+/-0.90 and 5.64+/-1.67, the C(max1) was 1.64+/-0.99 and 5.66+/-2.02, the t(max1) was 0.13+/-0.05 and 0.20+/-0.07, the C(max2) was 2.43+/-0.46 and 3.18+/-1.66, and the t(max2) were 6.40+/-1.67 and 5.66+/-2.02, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,5.66,263964,DB00564,Carbamazepine
,20643590,t(max1),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of baicalin was 3.60+/-0.90 and 5.64+/-1.67, the C(max1) was 1.64+/-0.99 and 5.66+/-2.02, the t(max1) was 0.13+/-0.05 and 0.20+/-0.07, the C(max2) was 2.43+/-0.46 and 3.18+/-1.66, and the t(max2) were 6.40+/-1.67 and 5.66+/-2.02, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,0.13,263965,DB00564,Carbamazepine
,20643590,t(max1),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of baicalin was 3.60+/-0.90 and 5.64+/-1.67, the C(max1) was 1.64+/-0.99 and 5.66+/-2.02, the t(max1) was 0.13+/-0.05 and 0.20+/-0.07, the C(max2) was 2.43+/-0.46 and 3.18+/-1.66, and the t(max2) were 6.40+/-1.67 and 5.66+/-2.02, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,0.20,263966,DB00564,Carbamazepine
,20643590,C(max2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of baicalin was 3.60+/-0.90 and 5.64+/-1.67, the C(max1) was 1.64+/-0.99 and 5.66+/-2.02, the t(max1) was 0.13+/-0.05 and 0.20+/-0.07, the C(max2) was 2.43+/-0.46 and 3.18+/-1.66, and the t(max2) were 6.40+/-1.67 and 5.66+/-2.02, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,2.43,263967,DB00564,Carbamazepine
,20643590,C(max2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of baicalin was 3.60+/-0.90 and 5.64+/-1.67, the C(max1) was 1.64+/-0.99 and 5.66+/-2.02, the t(max1) was 0.13+/-0.05 and 0.20+/-0.07, the C(max2) was 2.43+/-0.46 and 3.18+/-1.66, and the t(max2) were 6.40+/-1.67 and 5.66+/-2.02, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,3.18,263968,DB00564,Carbamazepine
,20643590,t(max2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of baicalin was 3.60+/-0.90 and 5.64+/-1.67, the C(max1) was 1.64+/-0.99 and 5.66+/-2.02, the t(max1) was 0.13+/-0.05 and 0.20+/-0.07, the C(max2) was 2.43+/-0.46 and 3.18+/-1.66, and the t(max2) were 6.40+/-1.67 and 5.66+/-2.02, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,6.40,263969,DB00564,Carbamazepine
,20643590,t(max2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of baicalin was 3.60+/-0.90 and 5.64+/-1.67, the C(max1) was 1.64+/-0.99 and 5.66+/-2.02, the t(max1) was 0.13+/-0.05 and 0.20+/-0.07, the C(max2) was 2.43+/-0.46 and 3.18+/-1.66, and the t(max2) were 6.40+/-1.67 and 5.66+/-2.02, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,5.66,263970,DB00564,Carbamazepine
,20643590,t(1/2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of wogonoside was 4.97+/-1.68 and 7.71+/-1.55, the C(max1) was 1.39+/-0.83 and 1.45+/-0.37, the t(max1) was 0.21+/-0.20 and 0.17+/-0.01, the C(max2) was 1.90+/-0.55 and 1.42+/-0.70, and the t(max2) was 5.60+/-1.67 and 5.20+/-1.79, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,4.97,263971,DB00564,Carbamazepine
,20643590,t(1/2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of wogonoside was 4.97+/-1.68 and 7.71+/-1.55, the C(max1) was 1.39+/-0.83 and 1.45+/-0.37, the t(max1) was 0.21+/-0.20 and 0.17+/-0.01, the C(max2) was 1.90+/-0.55 and 1.42+/-0.70, and the t(max2) was 5.60+/-1.67 and 5.20+/-1.79, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,7.71,263972,DB00564,Carbamazepine
,20643590,C(max1),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of wogonoside was 4.97+/-1.68 and 7.71+/-1.55, the C(max1) was 1.39+/-0.83 and 1.45+/-0.37, the t(max1) was 0.21+/-0.20 and 0.17+/-0.01, the C(max2) was 1.90+/-0.55 and 1.42+/-0.70, and the t(max2) was 5.60+/-1.67 and 5.20+/-1.79, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,1.39,263973,DB00564,Carbamazepine
,20643590,C(max1),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of wogonoside was 4.97+/-1.68 and 7.71+/-1.55, the C(max1) was 1.39+/-0.83 and 1.45+/-0.37, the t(max1) was 0.21+/-0.20 and 0.17+/-0.01, the C(max2) was 1.90+/-0.55 and 1.42+/-0.70, and the t(max2) was 5.60+/-1.67 and 5.20+/-1.79, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,1.45,263974,DB00564,Carbamazepine
,20643590,t(max1),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of wogonoside was 4.97+/-1.68 and 7.71+/-1.55, the C(max1) was 1.39+/-0.83 and 1.45+/-0.37, the t(max1) was 0.21+/-0.20 and 0.17+/-0.01, the C(max2) was 1.90+/-0.55 and 1.42+/-0.70, and the t(max2) was 5.60+/-1.67 and 5.20+/-1.79, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,0.21,263975,DB00564,Carbamazepine
,20643590,t(max1),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of wogonoside was 4.97+/-1.68 and 7.71+/-1.55, the C(max1) was 1.39+/-0.83 and 1.45+/-0.37, the t(max1) was 0.21+/-0.20 and 0.17+/-0.01, the C(max2) was 1.90+/-0.55 and 1.42+/-0.70, and the t(max2) was 5.60+/-1.67 and 5.20+/-1.79, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,0.17,263976,DB00564,Carbamazepine
,20643590,C(max2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of wogonoside was 4.97+/-1.68 and 7.71+/-1.55, the C(max1) was 1.39+/-0.83 and 1.45+/-0.37, the t(max1) was 0.21+/-0.20 and 0.17+/-0.01, the C(max2) was 1.90+/-0.55 and 1.42+/-0.70, and the t(max2) was 5.60+/-1.67 and 5.20+/-1.79, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,1.90,263977,DB00564,Carbamazepine
,20643590,C(max2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of wogonoside was 4.97+/-1.68 and 7.71+/-1.55, the C(max1) was 1.39+/-0.83 and 1.45+/-0.37, the t(max1) was 0.21+/-0.20 and 0.17+/-0.01, the C(max2) was 1.90+/-0.55 and 1.42+/-0.70, and the t(max2) was 5.60+/-1.67 and 5.20+/-1.79, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,1.42,263978,DB00564,Carbamazepine
,20643590,t(max2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of wogonoside was 4.97+/-1.68 and 7.71+/-1.55, the C(max1) was 1.39+/-0.83 and 1.45+/-0.37, the t(max1) was 0.21+/-0.20 and 0.17+/-0.01, the C(max2) was 1.90+/-0.55 and 1.42+/-0.70, and the t(max2) was 5.60+/-1.67 and 5.20+/-1.79, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,5.60,263979,DB00564,Carbamazepine
,20643590,t(max2),"Following oral administration of Xiaochaihu Tang and Radix scutellariae extract, the t(1/2) of wogonoside was 4.97+/-1.68 and 7.71+/-1.55, the C(max1) was 1.39+/-0.83 and 1.45+/-0.37, the t(max1) was 0.21+/-0.20 and 0.17+/-0.01, the C(max2) was 1.90+/-0.55 and 1.42+/-0.70, and the t(max2) was 5.60+/-1.67 and 5.20+/-1.79, respectively.",Comparative pharmacokinetics of baicalin and wogonoside by liquid chromatography-mass spectrometry after oral administration of Xiaochaihu Tang and Radix scutellariae extract to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20643590/),,5.20,263980,DB00564,Carbamazepine
,22886904,flow rate,"The chromatographic resolution was achieved on a Hypurity Advance C(18) column using an isocratic mobile phase consisting of 5 mm ammonium acetate-acetonitrile (15:85, v/v) at flow rate of 1.0 mL/min.",Sensitive LC-MS/MS-ESI method for simultaneous determination of nifedipine and atenolol in human plasma and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22886904/),[ml] / [min],1.0,264261,DB00564,Carbamazepine
,22886904,total run time of analysis,"The total run time of analysis was 2 min and elution of NF, AT and IS occurred at 0.79, 1.04 and 0.76 min, respectively.",Sensitive LC-MS/MS-ESI method for simultaneous determination of nifedipine and atenolol in human plasma and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22886904/),min,2,264262,DB00564,Carbamazepine
,3760062,flow-rate,"Separation of CBZ and CBZ-EP was achieved by reversed-phase chromatography, using a mobile phase consisting of acetonitrile-methanol-water (19:37:44) at a flow-rate of 1.8 ml/min in conjunction with a Nova-Pak C18 column.","High-performance liquid chromatographic determination of carbamazepine and carbamazepine 10,11-epoxide in plasma and saliva following solid-phase sample extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760062/),[ml] / [min],1.8,266111,DB00564,Carbamazepine
,31463480,m/z,The target fragment ions were m/z 391.3 → 161.3 for flibanserin and m/z 237.1 → 194 for carbamazepine (IS).,A rapid and sensitive UPLC-MS/MS method for the determination of flibanserin in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463480/),,391.3,266630,DB00564,Carbamazepine
,31463480,m/z,The target fragment ions were m/z 391.3 → 161.3 for flibanserin and m/z 237.1 → 194 for carbamazepine (IS).,A rapid and sensitive UPLC-MS/MS method for the determination of flibanserin in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463480/),,161.3,266631,DB00564,Carbamazepine
,31463480,m/z,The target fragment ions were m/z 391.3 → 161.3 for flibanserin and m/z 237.1 → 194 for carbamazepine (IS).,A rapid and sensitive UPLC-MS/MS method for the determination of flibanserin in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463480/),,237.1,266632,DB00564,Carbamazepine
,31463480,m/z,The target fragment ions were m/z 391.3 → 161.3 for flibanserin and m/z 237.1 → 194 for carbamazepine (IS).,A rapid and sensitive UPLC-MS/MS method for the determination of flibanserin in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463480/),,194,266633,DB00564,Carbamazepine
,31463480,extraction recovery,The extraction recovery of flibanserin was in the range of 91.5-95.8%.,A rapid and sensitive UPLC-MS/MS method for the determination of flibanserin in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463480/),%,91.5-95.8,266634,DB00564,Carbamazepine
,26942940,clearances,"The clearances achieved for CBZE (mean = 25.2, range 17.7-42.6 mL/min) exceeded that for CBZ (mean = 18.1, range 12.7-28.7 mL/min).","Carbamazepine and carbamazepine-10,11-epoxide clearance measurements during continuous venovenous hemofiltration in a massive overdose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26942940/),[ml] / [min],25.2,267060,DB00564,Carbamazepine
,26942940,clearances,"The clearances achieved for CBZE (mean = 25.2, range 17.7-42.6 mL/min) exceeded that for CBZ (mean = 18.1, range 12.7-28.7 mL/min).","Carbamazepine and carbamazepine-10,11-epoxide clearance measurements during continuous venovenous hemofiltration in a massive overdose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26942940/),[ml] / [min],18.1,267061,DB00564,Carbamazepine
,2498074,relative bioavailability,The relative bioavailability of CBZ suspension with enteral feeding administration was 90.1% of that during fasting.,Effects of enteral tube feeding on the absorption and pharmacokinetic profile of carbamazepine suspension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498074/),%,90.1,267153,DB00564,Carbamazepine
,25010713,total run time,The total run time was 1.60 min and the elution of avicularin was at 1.20 min.,UPLC-MS/MS method for determination of avicularin in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25010713/),min,1.60,268535,DB00564,Carbamazepine
,25010713,elution,The total run time was 1.60 min and the elution of avicularin was at 1.20 min.,UPLC-MS/MS method for determination of avicularin in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25010713/),min,1.20,268536,DB00564,Carbamazepine
,25010713,recovery,Mean recovery of avicularin in plasma was in the range of 84.2-89.5%.,UPLC-MS/MS method for determination of avicularin in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25010713/),%,84.2-89.5,268537,DB00564,Carbamazepine
,16175133,m/z,The m/z transitions 316-->182 (bromazepam) and 237-->194 (carbamazepine) were used for quantification.,On-line solid-phase extraction coupled with high-performance liquid chromatography and tandem mass spectrometry (SPE-HPLC-MS-MS) for quantification of bromazepam in human plasma: an automated method for bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175133/),,316,268963,DB00564,Carbamazepine
,16175133,m/z,The m/z transitions 316-->182 (bromazepam) and 237-->194 (carbamazepine) were used for quantification.,On-line solid-phase extraction coupled with high-performance liquid chromatography and tandem mass spectrometry (SPE-HPLC-MS-MS) for quantification of bromazepam in human plasma: an automated method for bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175133/),,182,268964,DB00564,Carbamazepine
,16175133,m/z,The m/z transitions 316-->182 (bromazepam) and 237-->194 (carbamazepine) were used for quantification.,On-line solid-phase extraction coupled with high-performance liquid chromatography and tandem mass spectrometry (SPE-HPLC-MS-MS) for quantification of bromazepam in human plasma: an automated method for bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175133/),,237,268965,DB00564,Carbamazepine
,16175133,m/z,The m/z transitions 316-->182 (bromazepam) and 237-->194 (carbamazepine) were used for quantification.,On-line solid-phase extraction coupled with high-performance liquid chromatography and tandem mass spectrometry (SPE-HPLC-MS-MS) for quantification of bromazepam in human plasma: an automated method for bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175133/),,194,268966,DB00564,Carbamazepine
,16175133,retention times,"The retention times of bromazepam and carbamazepine were 2.6 and 3.2 minutes, respectively.",On-line solid-phase extraction coupled with high-performance liquid chromatography and tandem mass spectrometry (SPE-HPLC-MS-MS) for quantification of bromazepam in human plasma: an automated method for bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175133/),min,2.6,268967,DB00564,Carbamazepine
,16175133,retention times,"The retention times of bromazepam and carbamazepine were 2.6 and 3.2 minutes, respectively.",On-line solid-phase extraction coupled with high-performance liquid chromatography and tandem mass spectrometry (SPE-HPLC-MS-MS) for quantification of bromazepam in human plasma: an automated method for bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175133/),min,3.2,268968,DB00564,Carbamazepine
,1352988,half-life,"During VCD treatment, the half-life of CBZ-E was prolonged significantly compared with control (19.7 +/- 6.7 h vs 6.9 +/- 2.0 h, means +/- s.d., P less than 0.01), and its oral clearance decreased four-fold (from 109.6 +/- 30.7 to 28.8 +/- 11.1 ml h-1 kg-1, P less than 0.01).","Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352988/),h,19.7,269549,DB00564,Carbamazepine
,1352988,half-life,"During VCD treatment, the half-life of CBZ-E was prolonged significantly compared with control (19.7 +/- 6.7 h vs 6.9 +/- 2.0 h, means +/- s.d., P less than 0.01), and its oral clearance decreased four-fold (from 109.6 +/- 30.7 to 28.8 +/- 11.1 ml h-1 kg-1, P less than 0.01).","Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352988/),h,6.9,269550,DB00564,Carbamazepine
,1352988,oral clearance,"During VCD treatment, the half-life of CBZ-E was prolonged significantly compared with control (19.7 +/- 6.7 h vs 6.9 +/- 2.0 h, means +/- s.d., P less than 0.01), and its oral clearance decreased four-fold (from 109.6 +/- 30.7 to 28.8 +/- 11.1 ml h-1 kg-1, P less than 0.01).","Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352988/),[ml] / [h·kg],109.6,269551,DB00564,Carbamazepine
,1352988,oral clearance,"During VCD treatment, the half-life of CBZ-E was prolonged significantly compared with control (19.7 +/- 6.7 h vs 6.9 +/- 2.0 h, means +/- s.d., P less than 0.01), and its oral clearance decreased four-fold (from 109.6 +/- 30.7 to 28.8 +/- 11.1 ml h-1 kg-1, P less than 0.01).","Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352988/),[ml] / [h·kg],28.8,269552,DB00564,Carbamazepine
,3082590,AUC,Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4).,The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[pg] / [h·ml],880,269574,DB00564,Carbamazepine
,3082590,AUC,Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4).,The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[ng] / [h·ml],29.1,269575,DB00564,Carbamazepine
,3082590,AUC,"Between two and four months after sodium valproate therapy the mean AUC figures had not changed significantly, the figure for EE2 being 977 +/- 130 pg/ml X h and for levonorgestrel 29.2 +/- 1.9 ng/ml X h (p greater than or equal to 0.1 in each case).",The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[pg] / [h·ml],977,269576,DB00564,Carbamazepine
,3082590,AUC,"Between two and four months after sodium valproate therapy the mean AUC figures had not changed significantly, the figure for EE2 being 977 +/- 130 pg/ml X h and for levonorgestrel 29.2 +/- 1.9 ng/ml X h (p greater than or equal to 0.1 in each case).",The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[ng] / [h·ml],29.2,269577,DB00564,Carbamazepine
,7993989,areas under the plasma concentration-time curves (AUC),"Mean (+/- SD) areas under the plasma concentration-time curves (AUC) of the major component in plasma, the active monohydroxy metabolite (MHD), which is responsible for the therapeutic effect in man, were 672 (25) mumol L-1 h when given to the fasted volunteers and 780 (31) mumol L-1 h (p = 0.042) when given after a substantial breakfast.",The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7993989/),[h·μM] / [l],672,269580,DB00564,Carbamazepine
,7993989,areas under the plasma concentration-time curves (AUC),"Mean (+/- SD) areas under the plasma concentration-time curves (AUC) of the major component in plasma, the active monohydroxy metabolite (MHD), which is responsible for the therapeutic effect in man, were 672 (25) mumol L-1 h when given to the fasted volunteers and 780 (31) mumol L-1 h (p = 0.042) when given after a substantial breakfast.",The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7993989/),[h·μM] / [l],780,269581,DB00564,Carbamazepine
,7993989,maximum concentrations (Cmax),Mean (+/- SD) maximum concentrations (Cmax) were 25.5 (4.8) mumol L-1 when given to the fasted volunteers and 31.4 (5.3) mumol L-1 (p = 0.025) when given after breakfast.,The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7993989/),[μM] / [l],25.5,269582,DB00564,Carbamazepine
,7993989,maximum concentrations (Cmax),Mean (+/- SD) maximum concentrations (Cmax) were 25.5 (4.8) mumol L-1 when given to the fasted volunteers and 31.4 (5.3) mumol L-1 (p = 0.025) when given after breakfast.,The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7993989/),[μM] / [l],31.4,269583,DB00564,Carbamazepine
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,36.4,269758,DB00564,Carbamazepine
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,54.2,269759,DB00564,Carbamazepine
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,27.1,269760,DB00564,Carbamazepine
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,35.8,269761,DB00564,Carbamazepine
,11253616,Absorption rate constant,The population model was: Clearance (Lhr-1) = ((2.24 x Surface area (m2)) + (0.047 x Dose (mg.kg-1)); Volume of distribution (L) = 0.37 x weight (kg); Absorption rate constant = 0.013 (hr-1).,"Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11253616/),1/[h],0.013,270313,DB00564,Carbamazepine
,32276090,bioavailability,"Likewise, the studied formulation allowed complete bioavailability in-vivo with the three lower doses, while the same formulation allowed only 76% and 42% bioavailability for the 100 and 200 mg/kg doses, respectively.","The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with a cosolvent-based formulation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32276090/),%,76,270410,DB00564,Carbamazepine
,32276090,bioavailability,"Likewise, the studied formulation allowed complete bioavailability in-vivo with the three lower doses, while the same formulation allowed only 76% and 42% bioavailability for the 100 and 200 mg/kg doses, respectively.","The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with a cosolvent-based formulation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32276090/),%,42,270411,DB00564,Carbamazepine
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB00564,Carbamazepine
,8547729,Varea/F,"Carbamazepine Varea/F and t1/2 were significantly greater in group A than in group B (98.4 +/- 26.9 vs. 60.7 +/- 8.5 L, respectively, p < 0.001; and 59.4 +/- 14.7 vs. 31.0 +/- 5.0 h, respectively, p < 0.001), but its Clpo/F was reduced only slightly in obese as compared with lean subjects (19.8 +/- 5.2 vs. 23.0 +/- 4.6 mL/min, respectively, p = 0.07).",Carbamazepine pharmacokinetics in obese and lean subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547729/),l,98.4,272109,DB00564,Carbamazepine
,8547729,Varea/F,"Carbamazepine Varea/F and t1/2 were significantly greater in group A than in group B (98.4 +/- 26.9 vs. 60.7 +/- 8.5 L, respectively, p < 0.001; and 59.4 +/- 14.7 vs. 31.0 +/- 5.0 h, respectively, p < 0.001), but its Clpo/F was reduced only slightly in obese as compared with lean subjects (19.8 +/- 5.2 vs. 23.0 +/- 4.6 mL/min, respectively, p = 0.07).",Carbamazepine pharmacokinetics in obese and lean subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547729/),l,60.7,272110,DB00564,Carbamazepine
,8547729,t1/2,"Carbamazepine Varea/F and t1/2 were significantly greater in group A than in group B (98.4 +/- 26.9 vs. 60.7 +/- 8.5 L, respectively, p < 0.001; and 59.4 +/- 14.7 vs. 31.0 +/- 5.0 h, respectively, p < 0.001), but its Clpo/F was reduced only slightly in obese as compared with lean subjects (19.8 +/- 5.2 vs. 23.0 +/- 4.6 mL/min, respectively, p = 0.07).",Carbamazepine pharmacokinetics in obese and lean subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547729/),l,60.7,272111,DB00564,Carbamazepine
,8547729,t1/2,"Carbamazepine Varea/F and t1/2 were significantly greater in group A than in group B (98.4 +/- 26.9 vs. 60.7 +/- 8.5 L, respectively, p < 0.001; and 59.4 +/- 14.7 vs. 31.0 +/- 5.0 h, respectively, p < 0.001), but its Clpo/F was reduced only slightly in obese as compared with lean subjects (19.8 +/- 5.2 vs. 23.0 +/- 4.6 mL/min, respectively, p = 0.07).",Carbamazepine pharmacokinetics in obese and lean subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547729/),h,59.4,272112,DB00564,Carbamazepine
,8547729,t1/2,"Carbamazepine Varea/F and t1/2 were significantly greater in group A than in group B (98.4 +/- 26.9 vs. 60.7 +/- 8.5 L, respectively, p < 0.001; and 59.4 +/- 14.7 vs. 31.0 +/- 5.0 h, respectively, p < 0.001), but its Clpo/F was reduced only slightly in obese as compared with lean subjects (19.8 +/- 5.2 vs. 23.0 +/- 4.6 mL/min, respectively, p = 0.07).",Carbamazepine pharmacokinetics in obese and lean subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547729/),h,31.0,272113,DB00564,Carbamazepine
,8547729,Clpo/F,"Carbamazepine Varea/F and t1/2 were significantly greater in group A than in group B (98.4 +/- 26.9 vs. 60.7 +/- 8.5 L, respectively, p < 0.001; and 59.4 +/- 14.7 vs. 31.0 +/- 5.0 h, respectively, p < 0.001), but its Clpo/F was reduced only slightly in obese as compared with lean subjects (19.8 +/- 5.2 vs. 23.0 +/- 4.6 mL/min, respectively, p = 0.07).",Carbamazepine pharmacokinetics in obese and lean subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547729/),[ml] / [min],19.8,272114,DB00564,Carbamazepine
,8547729,Clpo/F,"Carbamazepine Varea/F and t1/2 were significantly greater in group A than in group B (98.4 +/- 26.9 vs. 60.7 +/- 8.5 L, respectively, p < 0.001; and 59.4 +/- 14.7 vs. 31.0 +/- 5.0 h, respectively, p < 0.001), but its Clpo/F was reduced only slightly in obese as compared with lean subjects (19.8 +/- 5.2 vs. 23.0 +/- 4.6 mL/min, respectively, p = 0.07).",Carbamazepine pharmacokinetics in obese and lean subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547729/),[ml] / [min],23.0,272115,DB00564,Carbamazepine
,8547729,Clpo/F,"Correction for IBW yielded similar results for Varea/F and t1/2, but Clpo/F per kg of IBW was significantly smaller in the obese than in the lean subjects (0.32 +/- 0.07 vs. 0.39 +/- 0.06 mL/min/kg of IBW, respectively, p < 0.02).",Carbamazepine pharmacokinetics in obese and lean subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547729/),[ml] / [kg·min],0.32,272116,DB00564,Carbamazepine
,8547729,Clpo/F,"Correction for IBW yielded similar results for Varea/F and t1/2, but Clpo/F per kg of IBW was significantly smaller in the obese than in the lean subjects (0.32 +/- 0.07 vs. 0.39 +/- 0.06 mL/min/kg of IBW, respectively, p < 0.02).",Carbamazepine pharmacokinetics in obese and lean subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547729/),[ml] / [kg·min],0.39,272117,DB00564,Carbamazepine
,10217336,concentration/dose (C/D) ratio,"In 20 patients in monotherapy, the concentration/dose (C/D) ratio was 65 (range: 50-84) nmol/L/mg (mean and 95% confidence interval, antilog from lognormal distribution).",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],65,272553,DB00564,Carbamazepine
less,10217336,C/D ratio,"In 37 patients with concomitant carbamazepine treatment, the C/D ratio was less than half that of the patients in monotherapy; 31 (2146) nmol/L/mg, and in 14 patients with phenytoin, it was even lower; 17 (13-23) nmol/L/mg.",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],31,272554,DB00564,Carbamazepine
,10217336,C/D ratio,"In 37 patients with concomitant carbamazepine treatment, the C/D ratio was less than half that of the patients in monotherapy; 31 (2146) nmol/L/mg, and in 14 patients with phenytoin, it was even lower; 17 (13-23) nmol/L/mg.",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],17,272555,DB00564,Carbamazepine
,10217336,C/D,Valproic acid significantly increased the C/D to 251 (200-320) nmol/L/mg in 13 patients.,Lamotrigine drug interactions in a TDM material. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],251,272556,DB00564,Carbamazepine
,24327551,flow rate,"Samples were separated on a Waters Acquity UPLC BEH C18 column (1.7 µm, 2.1 × 100 mm) with a gradient mobile phase consisted of 60:40 going to 40:60 (v/v) water-acetonitrile at a flow rate of 0.5 mL/min.","Quantification of carbamazepine and its 10,11-epoxide metabolite in rat plasma by UPLC-UV and application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24327551/),[ml] / [min],0.5,272646,DB00564,Carbamazepine
,24327551,total run time,"The total run time was as low as 6 min, representing a significant improvement in comparison to existing methods.","Quantification of carbamazepine and its 10,11-epoxide metabolite in rat plasma by UPLC-UV and application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24327551/),min,6,272647,DB00564,Carbamazepine
,11981236,Steady-state plasma concentrations,"Steady-state plasma concentrations of CBZ increased from 6.67 +/- 0.41 microg/mL at baseline to 7.37 +/- 0.59 microg/mL (p < 0.01) at T1, to 7.95 +/- 0.47 microg/mL (p < 0.0001) at T2.",Carbamazepine-risperidone interactions in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981236/),[μg] / [ml],6.67,273418,DB00564,Carbamazepine
,11981236,Steady-state plasma concentrations,"Steady-state plasma concentrations of CBZ increased from 6.67 +/- 0.41 microg/mL at baseline to 7.37 +/- 0.59 microg/mL (p < 0.01) at T1, to 7.95 +/- 0.47 microg/mL (p < 0.0001) at T2.",Carbamazepine-risperidone interactions in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981236/),[μg] / [ml],7.37,273419,DB00564,Carbamazepine
,11981236,Steady-state plasma concentrations,"Steady-state plasma concentrations of CBZ increased from 6.67 +/- 0.41 microg/mL at baseline to 7.37 +/- 0.59 microg/mL (p < 0.01) at T1, to 7.95 +/- 0.47 microg/mL (p < 0.0001) at T2.",Carbamazepine-risperidone interactions in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981236/),[μg] / [ml],7.95,273420,DB00564,Carbamazepine
